

**The 2016 “Research on Drug Evidence” Report**  
**[From the 18th ICPO / INTERPOL Forensic Science Symposium]**

**Robert F. X. Klein**  
U.S. Department of Justice  
Drug Enforcement Administration  
Special Testing and Research Laboratory  
22624 Dulles Summit Court  
Dulles, VA 20166  
[dea-microgram@usdoj.gov]

**ABSTRACT:** A reprint of the 2016 “Research on Drug Evidence” Report (a review) is provided.

**KEYWORDS:** INTERPOL, Illicit Drugs, Controlled Substances, Forensic Chemistry.

**Important Information:**

Presented at the 18th ICPO / INTERPOL Forensic Science Symposium, Lyon, France, October 11 - 13, 2016.

Authorized Reprint. Copyright INTERPOL. All rights reserved. May not be reprinted without express permission from INTERPOL.

For pertinent background, see: Klein RFX. ICPO / INTERPOL Forensic Science Symposia, 1995 - 2016. “Research on Drug Evidence”. Prefacing Remarks (and a Request for Information). *Microgram Journal* 2016;13(1-4):1-3.

The "General Overview" (Talking Paper) was removed from this reprint (Editor's discretion).

This reprint is derived from the original electronic document, and is not an image of the best available hard copy (as was utilized for the 1995 and 1998 reports). For this reason, the pagination in the Proceedings is not retained in this reprint, some minor reformatting was done to eliminate deadspace, and all widow and orphan lines were left as is.

# Research on Drug Evidence

July 1, 2013 - June 30, 2016

Presented by: Jeffrey H. Comparin

Prepared by: Robert F.X. Klein

U.S. Department of Justice  
Drug Enforcement Administration

Office of Forensic Sciences  
8701 Morrissette Drive  
Springfield, VA 22152 USA

(Coordinating Office)

and

Special Testing and Research Laboratory  
22624 Dulles Summit Court  
Dulles, VA 20166 USA

(Coordinating Laboratory)

Eighteenth ICPO - INTERPOL  
Forensic Sciences Symposium  
October 2016

Lyon, France

## Table of Contents

General Overview (Talking Paper) - **[Removed at the Editor's Discretion]**

### **1. Routine and Improved Analyses of Abused Substances**

1.A - Individual Compounds or Substances

1.B - Individual Natural Products Containing Abused Substances

1.C - Common Groups or Classes of Compounds or Substances

1.D - Synthetic Cannabinoids and Cannabimimetics

1.E - Polydrug A: Mixed or Unrelated Named Compounds or Substances

### **2. Instrument Focus**

2.A - Polydrug B: Mixed or Unrelated Groups of Compounds or Substances

2.B - New and/or Improved Instrumental Techniques

### **3. Miscellaneous Topics**

#### Preface Notes:

1. With the exception of synthetic cannabinoids and cannabimimetics, all references are subdivided by individual drug, drug group/class, or general topic, then chronologically (year only) within each subsection, then alphabetically by first author within each year. Synthetic cannabinoids and cannabimimetics are in a separate category (1.D), and are subdivided as individual compounds, groups of compounds, and finally as groups with other drugs.

2. Many citations included in this report are dated prior to July 1, 2013, because they had not yet been abstracted prior to the 2013 report. In addition, many of the references in this report are cited as "Ahead of Print;" because their actual publication citation was never subsequently published in Chemical Abstracts. For this reason, the year listed with "Ahead of Print" may not reflect the actual year of publication; however, the rest of the citation will remain the same, allowing the full citation to be easily found by Internet searching.

3. All citations are formatted in accordance with *Uniform Requirements for Manuscripts Submitted to Biomedical Journals*, except that journal names are not abbreviated.

4. In contrast to recent reports, no restricted articles are cited in this report.

5. A small number of citations are bolded, reflecting topics judged to be of notable importance. **[Bolding removed at the Editor's Discretion]**

## 1. Routine and Improved Analyses of Abused Substances

Improved methods of analysis, i.e., faster, more discriminatory, more sensitive, less costly, etc., are needed for all abused substances. Additionally, standard analytical data are required for previously unknown or rarely encountered substances and/or new "designer drugs."

Drug seizures and clandestine laboratory operations are continuously monitored to provide a comprehensive overview of new developments. Ongoing research in the forensic community, as well as in the general fields of analytical chemistry and toxicology, provide new and/or improved methods of analysis for abused substances. Reports providing standard analytical data for new drugs of abuse and/or improved analytical protocols for known drugs of abuse are generated for the forensic and enforcement communities.

1.A - Individual Compounds or Substances

1.B - Individual Natural Products Containing Abused Substances

1.C - Common Groups or Classes of Compounds or Substances

1.D - Synthetic Cannabinoids and Cannabimimetics

1.E - Mixed or Unrelated Individual (Named) Compounds or Substances

-----

**1.A - Individual Compounds or Substances** (except individual synthetic cannabinoids and cannabimimetics, which are compiled under 1.D)

**Alprazolam: 2014** by UV/Vis after derivatization with DDQ (1); **2015** as a contaminant in "natural waters" by adsorptive cathodic stripping voltammetry (2);

**2-Amino-1-(4-bromo-2, 5-dimethoxyphenyl)ethan-1-one (bk-2C-B): 2015** characterization by GC/MS (with and without derivatization with 2,2,2-trichloroethyl chloroformate), LC/HRMS, and NMR (3); synthesis and identification of bk-2C-B by NMR, GC, LC, and HR-MS (4);

**5-(2-Aminopropyl)indole (5-IT): 2015** an overview (5);

**Amphetamine: 2013** impurity profile of amphetamine produced from APAAN (6); **2014** identification of 4,6-dimethyl-3,5-diphenylpyridin-2-one as a route specific byproduct for amphetamine synthesized by the APAAN to P2P, Leuckart route (7); **2015** determination of relative enantiomer migration order using racemic amphetamine (8); **2016** impurity profiling of P2P-derived amphetamine; identification and characterization of the by-products from the APAAN and alpha-methylstyrene routes to P2P and their respective impurities following

Leuckart reduction (9);

**Barbital**: 2013 determination by RP-HPLC (10);

**Benzphetamine**: 2014 production and impurity profiling of benzphetamine HCl (11);

**1-Benzylpiperazine (BZP)**: 2013 a review (social focus, but includes "analytical methodologies for the identification of BZP in forensic settings") (12); 2015 determination of the isotopic makeup of BZP synthesized from 3 different sources by IRMS (13);

**4-Bromo-2,5-dimethoxyamphetamine**: 2015 by LC-MS/MS (14);

**2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe)**: 2015 by HP-TLC (15); a review (16);

**Buphedrone (2-(Methylamino)-1-phenylbutan-1-one)**: 2013 characterization with GC/MS, HPLC-DAD, and LC-MS/MS (17);

**Buprenorphine**: 2016 abuse and diversion of the buprenorphine transdermal delivery system (18);

**Camfetamine (N-Methyl-3-phenyl-norbornan-2-amine)**: 2014 an overview (19);

**Chloral Hydrate**: 2015 detection of chloral hydrate adulteration in alcoholic beverages (20);

**2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe)**: 2013 characterization by GC-EI-MS (with and without derivatization with TFAA), LC-ESI-QTOF-MS, FTIR, and NMR (21); 2014 an overview (22);

**4-Chloromethcathinone (Clephedrone)**: 2014 characterization by GC/MS, NMR, GC, and CE (23);

**Cocaine**: 2012 rapid separation and characterization of cocaine and various cutting agents by differential mobility spectrometry-MS (24); optical detection using a highly specific triple-fragment aptamer (25); 2013 by electrochemical determination (26); by GC/FID (27); determination on circulated banknotes by CE with UV detection (28); separation of cocaine and phenyltetrahydroimidazothiazole mixtures (29); profiling of cocaine seized in Naples, Italy, by 1H-NMR (30); analysis by GC/MS, ATR/FTIR, and chemometric methods (31); detection of contamination of Brazilian currency by HPLC/UV (32); detection of hygrine and cuscohygrine as

possible markers (to distinguish coca chewing from cocaine abuse) by GC/MS (33); fluorescent sensing of cocaine based on a structure switching aptamer, gold nanoparticles, and graphene oxide (34); comparative analysis of solvent impurity profiles obtained by HS-GC/MS (35); detection by a fluorescent biosensing system (36); **2014** IMS evaluation of cocaine occupational exposure in forensic laboratories (37); electrochemical detection using disposable sensors (38); determination of levamisole and tetramisole in cocaine by enantioselective HPLC with circular dichroism detection (39); the stability of cocaine and its metabolites in municipal wastewater (presents the case for using metabolite consolidation to monitor cocaine utilization) (40); impurity profiling of cocaine seized by the Brazilian Federal Police in 2009-2012 (41); determination of cocaine, benzoic acid, benzoylecgonine, caffeine, lidocaine, phenacetin, benzocaine, and diltiazem by HPLC/DAD (42); analysis of "crack" by Scotts color testing, TLC, GC/FID, and GC/MS (43); quantification by IR and PLSR (44); detection by microfluidic paper sensors (45); determination of the isomeric truxillines in illicit cocaine via CGC/FID and their use and implication in the determination of cocaine origin and trafficking routes (46); a bio-inspired solid phase extraction sorbent material for cocaine (47); radiographic (CT) features of intracorporeally smuggled (body-carried) liquid cocaine versus solid cocaine (48); determination of cocaine, its metabolites, and its pyrolytic products by LC-MS using a chemometric approach (49); determination by diffuse reflectance measurements in the near IR (50); colorimetric detection with aptamer-gold nanoparticle conjugates coupled to an android-based color analysis (51); qualitative analysis by DESI-MS (52); the evaluation of trace cocaine on banknotes (53); novel optical fibre-based cocaine sensors (54); a study of the inclusion complex between p-sulfonated calix[4]arene with cocaine HCl by fluorescence and <sup>1</sup>H NMR (55); **2015** determination of cocaine on Brazilian banknotes (analytical methodology not identified in the abstract) (56); multicriteria FTIR/ATR wavenumber selection to differentiate cocaine base versus HCl (57); an electroanalytical method for the quantification of aminopyrine in cocaine (58); chemical profiling of cocaine seizures in Finland by GC/MS (59); comparison of canine detection of methyl benzoate released from 4 different species of snapdragon versus actual cocaine (60); differentiation of South American crack and domestic (US-produced) crack cocaine via HS-GC/MS (61); the influence of medium and elicitors on the production of cocaine, amino acids, and phytohormones by *Erythroxylum coca calli* (62); a study of the inclusion behavior of p-sulfonated calix [4,6,8] arene with cocaine HCl by fluorescence and <sup>1</sup>H NMR (63); a discussion of levamisole in cocaine preparations (64); quantification of cocaine and adulterants by IR and PLSR (65); determination of cocaine in creek water via SPE with subsequent analyses by either HPLC or GC (66); quantification of cocaine, caffeine, 4-dimethylaminoantipyrine, levamisole, lidocaine, and phenacetin by GC/NPD (67); copper thiocyanato complexes and cocaine (a case of "black cocaine") (68); chemical profiling of cocaine in Brazil from 2010 to 2013, a discussion of the increase in aminopyrine in cocaine (analytical methodology not identified in the abstract) (69); HS-GC-MS analysis of South American commercial solvents to monitor their use in the illicit conversion of cocaine base to HCl (70); profiling cocaine and some

common adulterants by FTIR/ATR (71); a review of nanomaterial-based cocaine aptasensors (72); profiling of cocaine by FTIR/ATR, GC/MS, and HS-GC/MS determination of minor alkaloids and residual solvents (73); ultra-high frequency piezoelectric aptasensor for the label-free detection of cocaine (74); identification of different forms of cocaine and substances used in adulteration using NIR Raman spectroscopy and infrared absorption spectroscopy (75); determination of cocaine, its main metabolites, and its pyrolytic products by HPLC-UV-CAD (76); voltammetric determination of cocaine using carbon screen printed electrodes chemically modified with uranyl Schiff base films (77); optical fibre fluorescent chemical probes for the detection of cocaine (78); **2016** detection and unambiguous identification of traces of cocaine on Euro banknotes using FAPA-MS (79); analysis of cocaine and its adulterants by TLC coupled to paper spray ionization MS (80); fast on-site screening of cocaine with a wearable fingertip sensor based on voltammetry (81); geographically sourcing cocaine's origin by delineation of 19 major coca growing regions in South America (82); determination of cocaine, diltiazem, benzocaine, levamisole, caffeine, phenacetin, lidocaine, and dipyrone by LC/DAD (83); use of a small-molecule-dependent split aptamer assembly for detn. of cocaine (84); detection by a fluorescence immunoassay (85); use of a key aptamer structure-switching mechanism for the ultrahigh frequency detection of cocaine (86); the stability of cocaine impurity profiles during 12 months of storage, by GC/MS and HS-GC-MS (87); removal of benzoylecgonine in water matrices by UV254/H<sub>2</sub>O<sub>2</sub> processing using a flow microcapillary film array photoreactor (88); determination of procaine in cocaine by a paper-based device coupling electrochemical sample pretreatment and colorimetric detection (89); polarographic determination of the stability constant of the complex formed between cocaine and cobalt thiocyanate (90); detection by a electrochemical aptasensor (91); a fluorescent aptasensor for cocaine based on a G-quadruplex and ruthenium polypyridyl complex molecular light switch (92);

**Clobazam (7-chloro-1-methyl-5-phenyl-1,5-dihydrobenzo[1,4]diazepine-2,4-dione):** **2015** the dynamic behavior of clobazam on HPLC chiral stationary phases (93); **2016** spectroscopic and quantum chemical studies of the molecular geometry, frontier molecular orbital, NLO, and NBO analysis of clobazam (94);

**Codeine:** **2013** detection using a label-free electrochemical biosensor based on a DNA aptamer (95); **2014** a rapid colorimetric method for the detection of codeine sulphate using unmodified gold nanoprobe (96); analysis of codeine phosphate sustained release capsules by HPLC (97); **2015** development of an abuse- and alcohol-resistant formulation of codeine phosphate (98); **2016** photocatalytic degrdn. of codeine by UV-irradiated TiO<sub>2</sub> (99);

**Deschloroketamine (2-Methylamino-2-phenylcyclohexanone):** **2016** characterization of deschloroketamine by GC/MS, LC/HRMS, MS/MS, and NMR (100);

**Desomorphine ("Krokodil")**: 2014 a review (101); 2015 an overview and review (102); analysis by TLC, UV/Vis, <sup>1</sup>H NMR, and FTIR (103);

**Diazepam**: 2015 differentiation of licit and illicit diazepam tablets by DSC (104); 2016 determination of the compatibility between diazepam and tablet excipients by DSC, thermogravimetry, and IR (105);

**3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700)**: 2016 the first reported fatality associated with U-47700 (and implications for forensic analysis) (106);

**1-(2,3-Dihydro-1H-inden-5-yl)-2-phenyl-2-(pyrrolidin-1-yl)-ethanone ("IndapYROphenidone")**: 2015 characterization by GC/MS, LC-HRMS, NMR, and X-ray crystallography (107);

**Diltiazem**: 2015 analytical characterization of two new related impurities of diltiazem (2-(4-methoxyphenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate and 2-(4-methoxyphenyl)-4-oxo-5-vinyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate) by HRMS and NMR (108);

**1-(3,4-Dimethoxyphenyl)-2-(ethylamino)pentan-1-one (DL-4662)**: 2015 characterization by NMR, GC/MS, and HPLC (109);

**4,4'-Dimethylaminorex (4,4'-DMAR)**: 2015 chemistry, pharmacology, and toxicology (110); an overview (111);

**1,3-Dimethylamylamine (DMAA)**: 2014 determination by <sup>1</sup>H NMR (112); 2015 identification by DART-QTOF-MS (113);

**1,3-Dimethylbutylamine (DMBA)**: 2015 identification in dietary supplements by UHPLC/MS (114);

**N,N-Dimethyltryptamine (DMT)**: 2014 conformational, spectroscopic and nonlinear optical properties (a theoretical study) (115); a review (also presenting the results of a global survey) (116);

**Eszopiclone**: 2013 determination by UHPLC and HPLC (117);

**N-Ethyl-alpha-ethylphenethylamine**: 2013 characterization by GC/MS, LC-TOFMS, and 1D- and 2D-NMR (118);

**2-(Ethylamino)-1-(4-methylphenyl)-1-pentanone (4-MEAP):** 2015 analysis by GC/MS, NMR, and LC/EIS (119);

**Ethylone (3,4-Methylenedioxy-N-ethylcathinone):** 2015 synthesis and characterization of two conformational polymorphs of ethylone HCl by FTIR, FT-Raman, powder XRD, GC-MS, ESI-MS/MS and NMR (13C CPMAS, 1H, 13C) (120);

**Etizolam:** 2014 synthesis (121);

**Fenethylamine:** 2016 a review (122);

**Fentanyl:** 2012 impurity profiling of illicit fentanyl using UHPLC-MS/MS (123); 2015 discussion of a case of abuse via extn. of fentanyl from transdermal patches (124); organic and inorganic impurity profiling of fentanyl produced by 6 different methods, using GC-MS, LC-MS, and ICP-MS (125); 2016 impurity profiling using multivariate statistical analysis of orthogonal mass spectral data (includes GC/MS, LC-MS/MS-TOF, and ICPMS) (126);

**Flephedrone:** 2015 characterization by 1H, 13C, 15N HMBC, and 19F NMR (127);

**Flubromazepam:** 2013 characterization by NMR, GC/MS, LC-MS/MS, and LC-QTOF-MS (128);

**Flunitrazepam:** 2013 electroanalytical sensing using screen-printed graphite electrodes (129); 2014 electroanalytical sensing using electrogenerated chemiluminescence (130); 2015 novel reductive-reductive mode electrochemical detection by HPLC with dual electrode detection (131); 2016 detection in beverages using portable Raman (132);

**6-Fluoro-3,4-methylenedioxyamphetamine:** 2015 crystal structure (133);

**4'-Fluoro- $\alpha$ -pyrrolidinobutyrophenone (4F-PBP):** 2015 structural characterization by 1H, 13C, 19F NMR, and MS (134);

**Heroin:** 2012 a review of crystal water in heroin HCl standard (135); 2013 high resolution impurity profiling by UHPLC (136); determination of heroin, morphine, 6-MAM, codeine, and 6-acetylcodeine drug samples using HPLC with "parallel segmented flow," which enables the simultaneous use of UV-absorbance, tris(2,2'-bipyridine)ruthenium(III) chemiluminescence, and permanganate chemiluminescence (137); 2014 determination of heroin, 6-acetylmorphine, acetylcodeine, morphine, noscapine, papaverine, caffeine, acetaminophen, lactose, lidocaine, mannitol, and piracetam by 1H NMR and 2D DOSY 1H NMR (138); comparison of quantitation

of illicit heroin HCl samples obtained by quantitative NMR versus results obtained by CE (139); an overview of the detection of heroin (140); inorganic impurity profiling and classification of illicit heroin by ICP-MS (141); **2015** acetaminophen, caffeine, diazepam, phenobarbital, and alprazolam in heroin by GC/MS (142); characterization and origin of the 'B' and 'C' compounds in the acid/neutral forensic signatures of heroin (143); classification of illicit heroin by UPLC-Q-TOF analysis of acidic and neutral manufacturing impurities (144); **2016** site- and species-specific hydrolysis rates of heroin to the mono-acetylmorphines (145);

**Human Growth Hormone (HGH) (and related substances):** **2014** identification of the growth hormone-releasing hormone analogue [Pro1, Val14]-hGHRH in a confiscated product (146); identification and quantification of GHRP-2 by NMR and MS (147); **2015** quantification of HGH by isotope dilution-HPLC/MS (148);

**Hydrocodone:** **2014** synthesis from thebaine in six steps (149); **2015** wastewater effluent hydrocodone concentrations as an indicator of a drug disposal program success (analytical methodology not identified in the abstract) (150);

**Hydromorphone:** **2016** two orthorhombic polymorphs of hydromorphone (151);

**gamma-Hydroxybutyric Acid (GHB) (also gamma-Butyrolactone (GBL), 1,4-Butanediol (BD), and Tetrahydrofuran (THF)):** **2013** a comprehensive study of the worldwide distribution of GBL using internet monitoring, comparison of packaging, and carbon isotopic measurements (152); detection of GHB, GBL, and BD in dietary supplements and foods, by GC/MS (using isotopologues for quantitation) (153); development of a fluorescent sensor for GBL (154); **2014** a review of the relative risks of GHB and GBL (155); development of a fluorescent sensor for GHB (156); **2015** analysis of GBL and 1,4-BD by chemical ionization-ion trap-GC/MS (157); **2016** comparative study of GHB and other derivative compounds (GBL, butyric acid, and succinic acid) by spectroelectrochemistry Raman on platinum surface (158); detection of BD in spiked drinks (analytical methodology not provided in the abstract) (159);

**Ibogaine:** **2013** determination by GC-MS/MS (160);

**2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine (25I-NBMD):** **2013** characterization by LC, ESI-QTOFMS, GC/MS, and MS/MS (161);

**Ketamine:** **2012** a simple color testing reagent for screening (162); **2013** screening in orange juice by TLC (163); a review of O-chlorophenyl cyclopentyl ketone (the precursor for ketamine) (164); **2014** wearable devices based on ionic liquid-based SPME for the environmental monitoring of ketamine (165); estimation by UV/Vis (166); electroanalytical sensing using

electrogenerated chemiluminescence (167); a review (168);

**Lisdexamfetamine Dimesylate**: 2012 synthesis and characterization by FT-IR, NMR, ESI-TOF/MS, GC-MS, and HPLC (169);

**Lysergic Acid Diethylamide (LSD)**: 2014 determination by adsorptive stripping voltammetry (170);

**Mephedrone (4-Methylmethcathinone)**: 2013 by SERS with a portable Raman (171); 2014 a study of phase transformations (to minimize transitions between polymorphic forms during storage) (172); use of mephedrone as a exemplar in an interpretative spectroscopy exercise in a second-year bioscience program (173); analysis of purity and cutting agents in street-level samples from South Wales collected between Nov. 2011 and March 2013, by FTIR (4-fluoromethcathinone and 4-methylethcathinone were also found) (174); structures of mephedrone hydrogen sulfate and its polymorphs under ambient and high pressure conditions (175); 2015 computational studies on molecular structure and interpretation of vibrational spectra, thermodynamical and HOMO-LUMO analyses of mephedrone using density functional theory and ab initio methods (176); spectrophotometric determination (177); identification of 1,2,3,5-tetramethyl-4-(4-methylphenyl)-1H-imidazol-3-ium salt (TMMPI), formed during the synthesis of mephedrone (analysis by GC/MS, LC/MS, NMR, and crystal structure determination (178); 2016 detection via an anthracene molecular probe (by NMR) (179);

**Methamphetamine**: 2012 analysis of the enantiomeric makeup of methamphetamine in OTC inhalers (also includes a toxicology study) (180); fates of precursors and byproducts in soil from the Leuckardt, Nagai, and dissolving metal reductive syntheses of methamphetamine (181); evaluation of the effects of synthesis conditions on the  $\delta^{13}\text{C}$ ,  $\delta^{15}\text{N}$ , and  $\delta^2\text{H}$  stable isotope ratio values of methamphetamine (182); 2013 detection of pharmaceutical impurities in methamphetamine by GC/FID and GC/MS (183); rapid quantitation of methamphetamine by FTIR/ATR and Chemometrics (184); impurity profiling by CE using a highly sulfated gamma-cyclodextrin as a chiral selector (includes methamphetamine, amphetamine, ephedrine, pseudoephedrine, norephedrine, and norpseudoephedrine) (185); screening of methamphetamine, pseudoephedrine, and ephedrine by a portable lab-on-a-chip instrument (186); quantitation of airborne methamphetamine by SPME and GC/MS (187); detection in indoor air using dynamic SPME followed by GC/MS (188); elemental profiling of methamphetamine using ICPMS (189); influence of precursor solvent extraction on stable isotope signatures of methamphetamine prepared from OTC pharmaceuticals using the Moscow and hypophosphorous syntheses (190); stable isotope analysis of methamphetamine, to help determine precursors (191); molecular fluorescence spectroscopy of methamphetamine in methanol (192); rapid, nondestructive screening test for methamphetamine in clandestine laboratory liquids by Raman (193); impurity

profiling of methamphetamine synthesized from P2P prepared from phenylacetic acid or its esters (194); terahertz spectra of methamphetamine HCl (195); **2014** differentiation of ephedrine and pseudoephedrine based methamphetamine samples by 2D-HPLC (196); determination of methamphetamine in sewers using a Polar Organic Chemical Integrative Sampler followed by HPLC-MS/MS (197); real time quantitative (Simon) colourimetric test for methamphetamine detection using digital and mobile phone technology (198); a review of methamphetamine profiling (199); use of IRMS for methamphetamine profiling (comparison of ephedrine and pseudoephedrine-based samples to P2P-based samples) (200); use of 10-ethylacridine-2-sulfonyl chloride for detection of methamphetamine (201); **2015** "amine-rich carbon nanodots" as a fluorescence probe for methamphetamine precursors (202); photocatalytic degradation of methamphetamine in wastewater by UV/TiO<sub>2</sub> (203); use of methamphetamine impurity profiling for intelligence gathering (204); detection by a fluorescence nanosensor (with comparison with HPLC) (205); identification of trans-N-methyl-4-methyl-5-phenyl-4-penten-2-amine HCl as an impurity in methamphetamine synthesized via reductive amination of P2P made from phenylacetic acid/lead (II) acetate (206); enantiomeric profiling of methamphetamine by LC-MS-MS (207); **2016** determination of the synthetic routes of methamphetamine using GC-MS and multivariate analysis (208); demethylation of methamphetamine by UV treatment at wastewater treatment plants (209); detection of trace methamphetamine by dual-mode plasmonic naked-eye colorimetry and a SERS sensor with a handheld Raman spectrometer (210);

**Methaqualone:** **2013** simultaneous determination of methaqualone, saccharin, paracetamol, and phenacetin in illicit drug samples by HPLC (211);

**Methcathinone:** **2012** detection by HPLC (212); **2013** qualitative and quantitative analysis by LC/MS/MS (213); quantitative analysis by GC/MS (214);

**Methiopropamine:** **2015** indirect electrochemical detection of methiopropamine (MPA) and 2-aminoindane (2-AI) by Raman spectroscopy, presumptive (color) testing, HPLC, and electrochemical analysis (this mixture was referred to as "synthacaine") (215); by selective reagent ionisation-TOF-MS for analysis of a mixture of methiopropamine and benzocaine (also referred to as "synthacaine") (216);

**Methoxetamine:** **2013** by GC-MS and <sup>1</sup>H- and <sup>13</sup>C-NMR (217); **2014** a review (218);

**2-Methoxydiphenidine (2-MXP):** **2015** synthesis and characterization (includes the positional isomers; toxicological focus) (219);

**para-Methyl-4-methylaminorex:** **2014** an overview of deaths from use (220);

**3,4-Methylenedioxy-N-benzyl cathinone (BMDP):** 2013 characterization by LC/high res QTOF-MS, EI-MS, IR, and 1D- and 2D- 1H- and 13C-NMR (221);

**3,4-Methylenedioxymethamphetamine (MDMA):** 2013 enantiomeric purification by batch chromatography with a cyclodextrin chiral selector (222); use of organic and inorganic impurities in MDMA for comparative analyses (223); impurity profiles of MDMA synthesized by different routes or by variations in the same routes, by GC/MS and GCxGC-TOF-MS (224); 2014 the effects of extn. procedure and GC temp. programming on MDMA impurity profiles (225); by voltammetry (226); 2015 analysis by direct laser ablation with TOFMS (227); compression studies (228); impurity profiling of MDMA synthesised from catechol (229); chemiluminescence detection of MDMA in street drug samples (230);

**3,4-Methylenedioxy-4-methylaminorex (MDMAR):** 2015 synthesis of the cis- and trans-isomers, with characterization by "chromatographic, spectroscopic, mass spectrometry, and crystal structure analysis" (231);

**Methylenedioxypyrovalerone (MDPV):** 2013 injection of MDPV among needle exchange program participants in Hungary (232); 2014 a review, including sepn. and analysis by TLC, GC/MS, HPLC, and LC/MS (233); analysis by GC/MS and LC/MS (234); a review (235); see also phencyclidine (below) for a related citation;

**4-Methylethcathinone (4-MEC):** 2013 by GC/MS, HPLC-DAD, and LC-MS/MS (236);

**Methylhexaneamine:** 2013 by GC/HR-TOFMS with soft ionization (237);

**β-Methylphenylethylamine (BMPEA):** 2015 by LC-QTOF-MS (238);

**4-Methylthioamphetamine (4-MTA):** 2012 identification of common impurities found in 4-MTA produced by the reductive amination and nitropropene routes (239); identification and synthesis of by-products found in 4-MTA produced by the Leuckart method (240);

**Mianserin (a psychoactive tetracyclic antidepressant):** 2012 by TLC, color testing, and UV (241);

**Midazolam:** 2015 a review of published, validated methods for determination of midazolam in pharmaceuticals (242);

**Morphine:** 2013 evaluation of stationary phases based on silica hydride, using morphine as the model compound (243); determination in compound liquorice tablets by HPLC with online SPE

(244); **2014** detection using electroactive polymers (245); 271 highly sensitive detection based on molecular imprinting polymers using surface plasmon resonance (246); determination in pharmaceutical samples by kinetic spectrophotometry (247); conformational complexity of morphine and morphinum in the gas phase and in water (a DFT and MP2 study) (248); degradation of morphine in opium poppy processing waste composting (249); **2015** "fingerprinting" using chromatographic purity profiling and multivariate data analysis (250); a study of the stability of morphine sulfate orally disintegrating tablets (analytical methodology not identified in the abstract) (251); a review of sugar derivatives of morphine (252); **2016** a structural and computational study (to determine morphine's mechanism of action as an antioxidant) (253); photostability of 6-MAM and morphine exposed to controlled UV irradiation in water and methanol (254); characterization and origin differentiation of morphine base, HCl, and sulfate (and other unspecified "morphine derivatives") by DSC/TG and FTIR (255); detection using cathodically electropolymerized, molecularly imprinted poly(p-aminostyrene) films (256); determination in pharmaceutical products by on-line SPE and HPLC (257);

**Oripavine:** **2014** a review of the chemistry of oripavine and its derivatives (258);

**Oxycodone:** **2013** analysis of oxycodone/acetaminophen tablets by HPLC (259); a study on the effectiveness of reformulated (abuse deterrent) oxycodone tablets (260); **2014** a review (261); the impact of a reformulation of extended-release oxycodone designed to deter abuse in a group of prescription opioid abusers (262); reductions in reported deaths following the introduction of extended-release oxycodone with an abuse-deterrent formulation (263); **2015** impact of the introduction of an abuse-deterrent sustained-release formulation in Australia (264); an overview of the level and methods of tampering with a tamper-resistant formulation (265); **2016** evaluation of the tamper-resistant properties of biphasic immediate-release / extended-release oxycodone/acetaminophen tablets (266);

**Phenazepam:** **2012** analysis of phenazepam by GC/MS and LC-MS/MS (267);

**Phencyclidine (PCP):** **2013** false-positive PCP immunoassay caused by MDPV (268);

**Phenobarbital:** **2014** detection by an electrochemical sensor based on molecular imprinted polymer (269); detection by an electrochemical sensor based on molecular imprinted technique and electropolymerization membrane (270); characterization of the monosolvates between phenobarbital and acetonitrile, nitromethane, dichloromethane, and 1,4-dioxane by single-crystal and powder X-ray diffraction, thermoanal. methods, FTIR, Raman, and solid-state NMR (271); **2015** simultaneous determination of phenobarbital and aspirin by HPLC (272); **2016** a study of polymorphism of phenobarbital by structural, thermal, and VT-Raman spectroscopy (273);

**Phenyl Acetyl Carbinol (L-PAC and R-PAC):** 2014 isolation/selection of the best yeast culture and its metabolic control for the biotransformation of benzaldehyde to 1-hydroxy-1-phenyl-2-propanone (274); use of substituted benzaldehydes for the manuf. of substituted L-PAC analogs (which were subjected to reductive amination to give the corresponding substituted pseudoephedrine/ephedrine analog, which were then either reduced or oxidized to produce the corresponding methamphetamine or methcathinone analogs) (275); 2015 biosynthesis of R-PAC in [BMIM][PF6]/aqueous biphasic system using *Saccharomyces cerevisiae* (276);

**Phenyl-2-propanone (P2P, Phenylacetone):** 2016 a detailed analysis of the impurities formed when P2P is synthesized via an aldol condensation of benzaldehyde and Me Et ketone (MEK), followed by a Baeyer-Villiger reaction, followed by ester hydrolysis (route specific markers for this synthesis include 3-methyl-4-phenyl-3-buten-2-one, 2-methyl-1,5-diphenylpenta-1,4-diene-3-one, 2-(methylamino)-3-methyl-4-phenyl-3-butene, 2-(methylamino)-3-methyl-4-phenylbutane, and 1-(methylamino)-2-methyl-1,5-diphenylpenta-4-ene-3-one) (277);

**Pregabalin:** 2016 a literature review (278);

**Pyrazolam (8-Bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine):** 2013 characterization by GC/MS, LC-MS/MS, LC-QTOFMS, and NMR (also includes a toxicology study) (279);

**alpha-Pyrrolidinopentiophenone (alpha-PVP):** 2013 thermal degradation during GC/MS analysis (280); 2016 structure by crystallography (281);

**Scopolamine:** 2013 detection in spiked samples by portable CE with contactless conductivity detection (282);

**Sibutramine:** 2012 quantitative determination in adulterated herbal slimming formulations by TLC-image analysis and TLC-densitometry (Dragendorff reagent was used for spot detection) (283); 2013 detection of illicit adulteration of botanical food supplements, by color tests, TLC, HPLC-DAD, MS, and NMR (284); 2015 detection and quantitation in herbal medicines by NIR (285);

**Testosterone:** 2014 stable carbon isotope ratio profiling of illicit preparations (by GC-IRMS) (286); 2016 screening for in aquatic environments by DART-MS (287);

**Tianeptine:** 2016 identification by "a multi-pronged analysis approach" (not detailed in the abstract) (288);

**Tramadol**: 2014 a survey of abuse of tramadol in the U.K. (289);

**1-(3-(Trifluoromethyl)phenyl)piperazine (TFMPP)**: 2014 an FTIR, FT-Raman, UV/Vis, and DFT quantum chemical study (290);

**Zolpidem**: 2014 development of modified-release tablets of zolpidem tartrate (291);

**Zopiclone (see also Eszopiclone)**: 2015 quantitative determination of zopiclone and its impurity by four different spectrophotometric methods (292); quantitative determination of zopiclone and its impurity by HPTLC (293).

-----

### **1.B - Individual Natural Products Containing Abused Substances (except natural products laced with synthetic cannabinoids and/or cannabimimetics)**

**Overviews and/or Reviews**: 2013 an overview of the hallucinogenic plant and fungal species naturally growing in Mediterranean countries (including *Phalaris aquatica*, *Peganum harmala*, *Mandragora officinarum*, *Hyoscyamus niger*, *Atropa belladonna*, *Datura stramonium*, *Cannabis sativa*, *Psilocybe semilanceata*, and *Amanita muscaria*) (294); 2014 natural products as lead structures for the synthesis of "smart" and "recreational" drugs (295); comprehensive comparison of different MS techniques for the detection, identification, and characterization of bioactive substances in herbal materials, including saponins, alkaloid, tropane alkaloids, lycopodium alkaloids, phenethylisoquinoline alkaloids, benzyltetrahydroisoquinolines, morphine, berberine, dauricine, quinolines, flavonoids, flavones, flavanols, anthocyanidins, etc. (296); a review, covering kava, kratom, *Salvia divinorum*, bufotenine, glaucine, betel, pituri, lettuce opium, and kanna (297);

**Ayahuasca**: 2015 quantitative determination of the alkaloids in *Tetrapteryx mucronata* (a plant occasionally used in Ayahuasca preparation) by HPLC-ESIMS/MS (bufotenine, 5-methoxy-N-methyltryptamine, 5-methoxybufotenine, and 2-methyl-6-methoxy-1,2,3,4-tetrahydro- $\beta$ -carboline were identified) (298); 2016 analysis by DART-HRMS (299);

**Betel (*Piper betle* Linn)**: 2013 an overview of its phytochemistry, pharmacological profile, and therapeutic uses (300);

**Coca (*Erythroxylum*)**: 2012 identification using DNA analysis (301); 2014 chemosystematic identification of 15 new cocaine-bearing *Erythroxylum* cultigens grown in Colombia for illicit cocaine production (302); selection and validation of reference genes for quantitative gene

expression studies (303);

**Damiana (*Turnera diffusa*):** 2013 identification and discrimination of damiana in herbal blends by GCxGC (304);

**Datura stramonium (Jimson weed, Angel Trumpet):** 2013 isolation of (3R,5R,7Z)-3-hydroxy-5-dec-7-enolide, (R)-tuberolactone, daturadiol, monolinoleoyl glycerol, linoleic acid, and lutein from *Datura stramonium* (analytical methodology not identified in the abstract) (305); a review, including testing methods for *Flos daturae* (306); 2014 a review of the use of *Datura* for poisoning (307); 2015 analysis of phytochemical alkaloids in *Datura stramonium* by GC/MS (308); DNA molecular identification of *Datura* medicinal plants using ITS2 barcode sequence (309); determination of hyoscyamine and scopolamine in *Datura stramonium* by HPLC (310); fingerprint analysis of *Daturae flos* using rapid resolution LC-ESI-MS (311);

**Ephedra:** 2013 determination of ephedrine and pseudoephedrine in *Herba ephedrae* from different habitats and species by HPLC (312); a review and overview, covering the past 10 years (313); optimum conditions for extracting ephedrine from *Ephedra sinica* by response surface methodology (based on HPLC analyses) (314); 2014 correlation between the main alkaloid contents and the powder fractions of pulverized *Ephedra sinica* (analysis by HPLC) (315); 2015 determination of the total alkaloids content, total phenolics content, and total flavonoids content, and determine their relationship in dry herb of *Ephedra major*, *Ephedra distachya* subsp. *helvetica*, *Ephedra monosperma*, *Ephedra fragilis*, *Ephedra foeminea*, *Ephedra alata*, *Ephedra altissima*, and *Ephedra foliata*, by UHPLC/UV (316); the influence of genetic factors on the ephedrine alkaloid composition ratio in ephedra (317); identification and determination of biogenic amines in *Ephedrae herba* by RP-HPLC with precolumn derivatization (318);

**Hawaiian Baby Woodrose (*Argyrea nervosa*):** 2015 determination of its alkaloid composition (319);

**Khat (*Catha edulis*):** 2012 determination of of cathinone, cathine, and phenylpropanolamine in khat by GC/MS and GC/FID (320); 2013 evaluation of the effect of various drying techniques on the levels of cathinone in khat (321); optimized GC analysis for cathine, phenylpropanolamine, and cathinone in khat following derivatization with MSTFA (322); analysis by CE (323); 2015 isolation of kaempferol, quercetin, and myricetin skeletons from khat, with structural analysis by <sup>1</sup>H and <sup>13</sup>C NMR, and UV (sugars determined by TLC after acid hydrolysis) (324); use of cation-exchange solid-phase and liquid-liquid extraction for the determination of khat alkaloids by reversed phase HPLC-DAD (325); rapid differentiation of khat using single point and imaging vibrational spectroscopy (326); use of a (-)-norephedrine-based molecularly imprinted polymer for the solid-phase extraction of psychoactive phenylpropylamino alkaloids from khat (327); a

review (328); a review (329);

**Kratom (*Mitragynine speciosa*): 2013** by microscopy, TLC, and HPLC (330); by HPLC/DAD (331); **2014** by DART-MS (332); quantification of mitragynine in Kratom by an indirect competitive enzyme-linked immunosorbent assay (333); identification of mitragynine and O-desmethyltramadol in kratom (analytical method not identified in the abstract) (334); comparison of GC/MS, SFC with DAD, and HPLC with MS and DAD for detection of mitragynine and other indole and oxindole alkaloids in kratom (335); **2015** identification and characterization of indole and oxindole alkaloids in kratom using LC-accurate-QTOF-MS (336); a review (337); a review of its phytochemistry (338); detection of mitragynine and its analogs (analytical method not identified in the abstract) (339); a review of the chemistry of mitragynine alkaloids (340); the chemistry of the mitragynines (341); an overview and review (342); an overview of the physicochemical properties of mitragynine (includes UV and HPLC analyses) (343); **2016** monitoring the mis-use of kratom in sports (344); a review (345); extraction of mitragynine from kratom (346);

**Marijuana and Hemp (*Cannabis sativa*) and associated Phytocannabinoids: 2012**

comparison of bulk and compound-specific  $\delta^{13}\text{C}$  isotope ratio analyses for the discrimination of marijuana samples (347); effects of electrical lighting power and irradiance on indoor-grown marijuana potency and yield (348); of THC in marijuana, by HPLC (349); **2013** effects of cultural conditions on the hemp fibres (350); of marijuana extracts by HPLC/UV following cloud point extraction (351); chemical profiling of different hashish seizures by GC/MS and statistical methodology (7 cannabinoids were profiled; analytical methodology not identified in the abstract) (352); production, characterization, and application of hemp essential oil (353); optimisation and characterisation of marijuana extracts obtained by supercritical fluid extraction, focused ultrasound extraction, and retention time locking GC/MS (354); by laser-ablation-ICPMS - a review, covering many other applications (355); a study of marijuana potency from the 1970s to the 2000s (356); supercritical CO<sub>2</sub> extraction of cannabis seed oil (and its fatty acid composition analysis) (357); use of ultrasound to extract flavanoids from cannabis (with analysis by UV) (358); determination of cannabidiol in "hemp food" by UHPLC-MS/MS (359); potency survey in the Venice, Italy area from 2010-2012 (360); **2014** identification and quantification of cannabinoids in cannabis by HPLC/MS (361); cold pressing and supercritical CO<sub>2</sub> extraction of hemp seed oil (362); simultaneous quantification of THC, THC-Acid-A, CBN, and CBD in seized drugs by HPLC/DAD (363); a surface plasmon resonance-based method for detection and determination of cannabinoids (THC, CBD, and CBN) in hashish, using silver nanoparticles (364); variation in mineral composition in the leaves, bark and core of 5 fibre hemp cultivars (365); comparison of 2 different conventional working electrodes for detection of THC using square-wave voltammetry (366); Bayesian classification criterion for discriminating between drug type (illegal) and fiber type (legal) cannabis at an early stage of the growth (367); analysis of

marijuana samples of varying age by the Duquenois-Levine color test (368); variation in preliminary phytochemical screening of cannabis leaf, stem and root (369); separation of aroma compounds from industrial hemp by supercritical CO<sub>2</sub> extraction and on-line fractionation (370); fast fingerprinting of cannabinoid markers by laser desorption ionization using silica plate extraction (371); elucidation of the Duquenois-Levine chromophore (372); the kinetics and thermodynamics of hempseed oil extraction by n-hexane (373); evaluation of fatty acid profile, antioxidant capacity and metabolic content of cannabinoid-free cannabis grown in the Po valley, Italy (374); identification of 5,5-dimethyl-1-vinylbicyclo[2.1.1]hexane as a volatile marker of hashish (375); analytical and phytochemical characterization of the unsaponifiable fraction of cannabis seed oil (376); resolution of co-eluting compounds of cannabis comprehensive 2D-GC/MS with Multivariate Curve Resolution-Alternating Least Squares (377); metals and organic compounds in the biosynthesis of cannabinoids - a chemometric approach to correlating the metal content in the different parts of cannabis with the soils where plants were cultivated (and with their cannabinoids content) (378); synthesis of all 4 stereoisomers of THC (379); understanding cultivar-specificity and soil determinants of the cannabis microbiome (includes descriptions of the endorhiza-, rhizosphere-, and bulk soil-assocd. microbiome of 5 distinct cannabis cultivars) (380); cannabis potency in the Venice area (Italy) (2013 update) (381); extraction of flavonoids from cannabis by ultrasound (and its scavenging activity towards the DPPH radical) (382); **2015** minor oxygenated cannabinoids (9 $\alpha$ -hydroxyhexahydrocannabinol, 7-oxo-9 $\alpha$ -hydroxyhexahydrocannabinol, 10 $\alpha$ -hydroxyhexahydrocannabinol, 10 $\alpha$ -Rhydroxyhexahydrocannabinol,  $\Delta$ 9-THC aldehyde A, 8-oxo- $\Delta$ 9-THC, 10 $\alpha$ -hydroxy-10-oxo- $\Delta$ 8-THC, 9 $\alpha$ -hydroxy-10-oxo- $\Delta$ 6a,10a-THC, and 1'S-hydroxycannabinol) from high potency cannabis (structural elucidation was accomplished by 1D and 2D NMR, HRMS, and GC/MS) (383); supercritical CO<sub>2</sub> extraction of hemp seed oil (384); ab initio quantum mechanical calculations on THC (385); fatty acid composition, and oxidation stability of the hempseed oil from 4 cannabis cultivars (386); determination of the conformation of THC by linear and nonlinear CD (387); using compact mass spectrometry for detection and quantification of cannabinoids in cannabis (388); potential oil yield, evaluation of elemental profiling methods, including laser-induced breakdown spectroscopy, ICP-MS, LA-ICP-MS, and  $\mu$ XRF for the differentiation of cannabis grown in different nutrient solutions (389); quality analysis of cannabis seed oils extracted by the hot-pressing method, the cold-pressing method, or by an aq. enzymic method (390); analysis of cannabinoids and terpenes in cannabis by HPLC/DAD and GC/FID (391); synthesis of THC and related derivatives via a Diels-Alder route (392); isobaric drug analyses of THC and CBD by DART and hydrogen/deuterium exchange (393); molecular imaging of cannabis leaf tissue with MeV-SIMS (394); analysis of marijuana by LC techniques (a literature survey 1990 - 2015) (395); review of marijuana testing rules in Colorado, methods used for testing, and test results (396); increasing sample throughput of cannabis analyses by using a highly selective stationary phase combined with superficially porous particle technol. for HPLC and LC-MS/MS (includes comparison versus UHPLC) (397); screening of cannabinoids in

industrial-grade hemp using 2D-LC with chemiluminescence detection (398); use of <sup>1</sup>H NMR and HPLC/DAD to determine cannabis chemotype, extract profiling, and specification (399); the relationship between cannabinoid content and composition of fatty acids in hempseed oils (400); characterization of the smell of marijuana by SPME with multidimensional GC/MS (401); analysis of residual solvents in cannabis extracts by GC (402); an overview of recent improvements in chromatography for analysis of marijuana (403); determination of the relative percentage distribution of THCA and  $\Delta^9$ -THC in herbal cannabis seized in Austria - impact of different storage temperatures on stability (404); feasibility of facile quantification of cannabinoid content in cannabis to discriminate drug- from fiber-type cannabis in the field (405); cannabinoid dose and label accuracy in marijuana edibles (406); determination of THC, CBD, and CBN by GC/MS (focus on athletic doping) (407); differences in the extraction of THC, THCA, and CBN from cannabis by long-lasting liq. extn. in a Soxhlet app. versus pressurized liq. extn. (408); improving quality control methods for extracting cannabis by flash chromatography (409); determination of selected metals in leaves of cannabis by flame AA (410); simultaneous extraction of total flavonoids and total phenolic compounds from hemp (411); **2016** evolution of 8 cannabinoids and 23 terpenes during the growth of cannabis plants from different chemotypes (412); comparison of new and traditional fiber hemp cultivars (stem, bark, and core yield, and chemical composition) (413); heated headspace SPME of marijuana for chemical testing (414); rapid quantitative chemical analysis of cannabinoids in seized cannabis using heated HS-SPME and GC/MS (415); qual. and quant. detn. of CBDA, CBD, CBN, THC and THC-A in "cannabis-based medicinal exts." by HPLC/UV and HPLC-ESI-QTOF-MS (416); report from a Colorado private laboratory on regional cannabis potency (THC, CBD, CBN, THCA, CBDA, THCV, CBDV, CBG, and CBC) by UHPLC analysis (417); potency trends in confiscated cannabis (includes analytical methods; time frame not indicated in the abstract) (418); changes in cannabis potency (focusing on THC and CBD) over the last 2 decades (1995 - 2014) (419); a discussion of the chem. diversity, biosynthesis, and biol. activity of the various compds. in cannabis, and how these compds. can be used to chem. classify cannabis cultivars (420); analytical testing for the cannabis industry (consumer safety vs. regulatory requirements) - an overview of current protocols for testing for the active phytochem. constituents (i.e., cannabinoids and terpenes), but also for potential contaminants including heavy metals, residual solvents, pesticides, mycotoxins, and microbiol. contaminants (421); use of flash chromatography for rapid extraction of cannabinoids from marijuana edibles (422); analysis of cannabis grown in eastern Oregon for THC, THC-A, CBD, and CBN (edibles, concentrates, and waxes were also tested) (423); comparison of fiber and seed productivity of 14 com. hemp cultivars were tested in 4 contrasting environments (Latvia, the Czech Republic, France, and Italy) (424); the influences of cultivation setting on the lipid distributions, concentrations, and carbon isotope ratios in cannabis (these lipids can currently be used to trace cultivation methods of cannabis and may become a more powerful marker in the future, once the mechanism(s) behind the patterns is uncovered) (425); detection of  $\Delta^9$ -THC and  $\Delta^8$ -THC (and also CBD and CBN) by HPLC/UV

(426); cleanup of marijuana edibles using automated flash column chromatography (427);

**Marijuana (Genetic and/or Proteomic Analyses):** **2012** investigations into transgenic marijuana (428); **2013** extraction of high quality DNA from seized Moroccan hashish (429); analysis of THCA Synthase gene expression by real-time quantitative PCR (430); chemotype and genotype of cannabinoids in hemp (431); by DNA analysis (432); polymorphism of DNA and accumulation of cannabinoids by cultivated and wild hemp (433); characterization of seeds by DNA analysis (434); **2014** a simple and efficient method for high quality genomic DNA isolation from cannabis containing high amount of polyphenols (435); diversity analysis in cannabis based on large-scale development of expressed sequence tag-derived simple sequence repeat markers (436); application of DNA barcoding in cannabis identification (437); a PCR marker linked to a THCA synthase polymorphism is a reliable tool to discriminate potentially THC-rich plants of cannabis (438); nomenclature proposal and SNPSTR haplotypes for 7 new cannabis STR loci (439); characterization of 15 STR cannabis loci - nomenclature proposal and SNPSTR haplotypes (440); **2015** the phytoremediation potential of hemp - identification and characterization of heavy metals responsive genes (441); genetic structure of 5 dioecious industrial hemp varieties (442); genetic identification of cannabis using chloroplast trnL-F gene (443); genetic resources of cannabis in the gene bank at INF&MP in Poznan (which holds about 150 accessions from various regions of the world) (444); cold acclimation induces distinctive changes in the chromatin state and transcript levels of COR genes in 9 cannabis varieties with contrasting cold acclimation capacities (445); sequence heterogeneity of cannabidiolic- and tetrahydrocannabinolic acid-synthase in cannabis and its relationship with chemical phenotype (446); the genetic structure of marijuana and hemp (447); gene duplication and divergence affecting drug content in cannabis (448); characterisation of cannabinoid composition in a diverse cannabis germplasm collection (449); **2016** proteomic characterization of hempseed (450); the inheritance of chemical phenotype in cannabis (regulation of the propyl-/pentyl cannabinoid ratio, and completion of a genetic model) (451); monitoring metabolite profiles of cannabis trichomes during flowering period using <sup>1</sup>H NMR-based metabolomics and real-time PCR (452); use of embryos extracted from individual cannabis seeds for genetic studies and forensic applications (a unique profile for each individual was obtained, and a clear differentiation between hemp and marijuana varieties was observed) (453); identification and characterization of the hemp WRKY transcription factors in response to abiotic stresses (454);

**Marijuana - Miscellaneous Topics:** **2014** the effects of photoperiod on phenological development and yields of industrial hemp (455); detection of pesticides in seized illegal cannabis plants by UPLC/MS-MS in pos. ESI mode using MRM and GC/MS using scan mode (456); **2015** germination characteristics of hemp seeds under single NaCl treatments of varying concentrations (457); method development towards quantifying marijuana consumption using sewage based drug epidemiology (458); medical marijuana's public health lessons - implications

for retail marijuana in Colorado (459); determination of herbicides paraquat, glyphosate, and aminomethylphosphonic acid in marijuana samples by CE (460); an overview of the occupational hazards for employees working in the state-permitted marijuana industries (461); issues with retail promotion of marijuana edibles (462); method development towards quantifying marijuana consumption using sewage based drug epidemiology (463); a series of editorials (published in Nature) concerning various aspects of state-permitted marijuana (464); an overview of health and safety issues for state-permitted marijuana businesses (465); a review on the ingredients in and safety of "hemp seed food" (466); **2016** the appropriateness of applying ISO/IEC 17025 standards to cannabis testing laboratories (467); quantification of THC-COOH in wastewater from a residential treatment plant as a tracer of cannabis use, using LC-MS/MS (468); oral cannabidiol does not alter the subjective, reinforcing, or cardiovascular effects of smoked cannabis (469); an overview of the changing regulations and rules of the state-permitted cannabis industry (470); the effects of ethephon (a plant growth regulator) on changes in the amt. of many terpenoid compds. in cannabis, including THC, CBD, chlorophyll, carotenoids,  $\alpha$ -tocopherol, and pyruvate (471); an overview of the American Herbal Product Assocn.'s (AHPA) industry guidelines on manufg., producing, dispensing, and lab. operation stds. as they apply to state-permitted cannabis (including the American Herbal Pharmacopeia's (AHP) cannabis monograph) (472); an overview on preserving personal cultivation rights while regulating commercial cultivation as agriculture (focusing on the excessive energy, water, and other resources needed for cannabis cultivation) (473); evaluation of three multiresidue methods for the determination of 61 pesticides on marijuana by LC-MS/MS (474); an overview of the establishment of the cannabis subdivision of the American Chemical Society (475); use of "cannavaping" as a means for administering "medical marijuana" (476); antifungal activity of the volatiles of high potency cannabis against *Cryptococcus neoformans* (477); quantification of THC-COOH in wastewater to assess cannabis consumption in Washington state (478);

**[Marijuana ("Synthetic Marijuana") - See "Synthetic Cannabinoids and Cannabimimetics" (Subsection 1.D)]**

**Mimosa**: **2013** characterization and purity of DMT isolated from *Mimosa tenuiflora* inner barks (479);

**Mushrooms (including Psilocybe mushrooms)**: **2013**: simultaneous determination of mushroom toxins by LC-TOF-MS (480); **2014** analysis of mushrooms by Fluorescent Random Amplified Microsatellites (F-RAMS) (15 samples of *Amanita rubescens* and 22 samples of other hallucinogenic and nonhallucinogenic mushrooms of the genera *Amanita* and *Psilocybe* were profiled) (481); **2015** identification of psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin in *Pholiotina cyanopus* by LC/MS (482); genetic identification of hallucinogenic and other poisonous mushrooms (483); **2016** DNA-based taxonomic identification of

basidiospores in hallucinogenic mushrooms in "grow-kits" (including LC-UV quali-/quantitative determination of psilocybin and psilocin) (484);

**Opium / Opium Poppy / Poppy Seeds (see also Papaver below, and Opiates in Subsection**

**1.C): 2013** the effects of potassium, boron, and strontium on poppy cultivation (such enhancements may impact impurity profiling studies based on elemental analysis) (485); **2014** simultaneous detn. of morphine, codeine, thebaine, oripavine, papaverine, and noscapine in poppy straw by 2 HILIC methods (486); a review of cold pressed poppy seed oils (487); unambiguous characterization of analytical markers in 4 opium samples using an ion mobility trace detector-mass spectrometer (488); physicochemical properties of opium marc (a waste product from commercial opium processing) (489); management of opium marc as a hazardous waste (490); results from an effort to detect opium fields from a Hyperion image covering a study area in Southwest Afghanistan (491); **2015** comparative analysis of volatile flavor compounds of poppy seed oil extracted by two different methods via GC/MS (492); analysis of alkaloids in poppy straw by HPLC (493); **2016** analysis of opium poppy by 2D-HPLC (494); analysis of poppy seeds (intended for use as food) that had been adulterated with poppy straw (i.e., containing morphine and codeine) by IRMS (495);

**Papaver (other species):** **2016** measurement of some benzyloquinoline alkaloids in *Papaver bracteatum* (496); developmental accumulation of thebaine and some gene transcripts in different organs of *Papaver bracteatum* (497);

**Papaver (Genetic and/or Proteomic Analyses):** **2011** characterization of SSR markers in opium poppies (498); **2014** a review of benzyloquinoline alkaloid biosynthesis in opium poppy (499); development of genomic simple sequence repeat markers in opium poppy by next-generation sequencing (500); comparative analysis of *Papaver somniferum* genotypes having contrasting latex and alkaloid profiles (501); transcriptome profiling of alkaloid biosynthesis in elicitor induced opium poppy (502); recessive loci Pps-1 and OM differentially regulate PISTILLATA-1 and APETALA3-1 expression for sepal and petal development in *Papaver somniferum* (503); variation in fatty acid composition of three Turkish opium poppy lines (504); **2015** regulation of the alkaloid biosynthesis by miRNA in opium poppy (505); comparative study for stability and adaptability through different models in developed high thebaine lines of opium poppy (506); **2016** molecular genetic diversity and association mapping of morphine content and agronomic traits in Turkish opium poppy germplasm (507);

**Peyote (and other mescaline-containing cacti):** **2013** analysis of "peyote tea" by GC/MS and GC/MS/MS in PCI mode (508); **2014** phytochemical study of *Echinopsis peruviana* (509);

**Plant Materials (Multiple Plants in Single Studies):** **2013** identification of plant materials

used as supporting matrices for pharmaceuticals, nutritional supplements, and illicit drugs, by DAD, evaporative light scattering detection, and MS (510); a review of chromatographic herbal fingerprints (the "herbs" and the chromatographic method(s) were not identified in the abstract) (511); isotopic analyses to discriminate between organic and "conventional" plants (512); the effects of 11 elements (Co, Mo, Zn, W, Cr, Cu, B, Fe, V, Mn, Ni plus Ca for second species) on the formation and accumulation of indoles and isoquinolines in seedlings of *Catharanthus roseus* L. and *Papaver somniferum* L. (513); analysis of the plant materials used as support matrices, by DNA analysis, GC/MS, and LC/MS (514); an overview and review of the application of 2D-IR for determining the composition, origin, and authenticity of herbal medications (515); **2014** evaluation of mycotoxins, mycobiota, and toxigenic fungi in opium poppy, licorice root, Indian rennet, and others (516); the study of elemental profile of some important medicinal plants by Flame AA (the study included *Papaver somniferum*) (517); comparison of plant DNA extraction kits for plants identification in forensic botany (the plant species were not identified in the abstract) (518); determination of metabolites in finely powdered plant material by Direct Laser Desorption Ionization MS (519); chemotaxonomical classification of the Solanaceae *Atropa belladonna*, *Datura stramonium*, *Hyoscyamus niger*, *Solanum dulcamara*, and *Duboisia* by FTIR/ATR in combination with cluster anal. (520); use of hyperspectral data for detection of cannabis and poppy sites, including those mixed with masking vegetation (521); **2015** transcriptome profiling of *Catha edulis* and *Ephedra sinica* identifies genes potentially involved in amphetamine-type alkaloid biosynthesis (522); phytoaccumulation of heavy metals in natural vegetation, including cannabis (523); application of chemometrics for identification of psychoactive plants (*Salvia divinorum*, *Mitragyna speciosa*, *Psychotria viridis*, and *Calea zacatechichi*) using GC/MS, AAS, and ICP/MS (524); the chemical properties of cold-pressed vegetable oils from seeds of hemp (*Cannabis sativa* L.), blue poppy (*Papaver somniferum* L.), and several other plants (525); biosynthesis of amphetamine-like alkaloids in *Catha edulis* and *Ephedra* spp. (526); profile of toxic metals in 12 different plant materials, including marijuana, by AA (527); use of EILC/MS with supersonic molecular beams for analysis, including cannabis (528); **2016** determination of Mn, Ni, Rb, and Sr in powdered stimulant plants (ginseng, guarana, and others) using high-resolution continuum source AA followed by chemometric classification (529); phytochemical profiling of plants using GC/MS (including cannabis) (530); use of high-throughput DART-HR-TOFMS to screen plant-based drugs of abuse for psychotropic alkaloids and adulterants (plants not identified in the abstract) (531); analysis of *Datura* spp. seeds, kratom powder, kava powder, *Salvia divinorum* leaves, Kanna crushed leaf material, *Mimosa hostilis*, *Banasteriopsis caapi*, and Morning Glory seeds by DART-HRMS (532);

***Psychotria viridis* (and related species):** **2015** examination of *Psychotria viridis* (DMT was identified by TLC and HPLC) (533); **2016** structural characterization of dimeric indole alkaloids (brachybotryne, its N-oxide deriv., along with bufotenine) from *Psychotria brachybotrya* by NMR spectroscopy and theoretical calculations (534);

***Salvia divinorum***: **2013** differentiation of *Salvia divinorum* from marijuana and tobacco by DNA analysis (535); **2014** quantitative determination of salvinorin A in *Salvia divinorum* (analytical methodology not identified in the abstract) (536); analysis of "legal high" products containing *Salvia divinorum* for Salvinorins A, B, C, and D (analytical methodology not identified in the abstract) (537); **2015** determination of salvinorin A in commercial products available in Mexico, using HPLC (538); **2016** an overview of the chem. and pharmacol. of *Salvia divinorum* and salvinorin A (539).

-----

### **1.C - Common Groups or Classes of Compounds or Substances (except Synthetic Cannabinoids and Cannabimimetics)**

**(2-Aminopropyl)indoles**: **2013** 2-, 3-, 4-, 5-, 6- and 7-(2-aminopropyl)indole - analyses by GC/MS and LC/MS (540);

**Amphetamine-Type Stimulants (ATSs) and Related Phenethylamines (PEAs)**: **2011** impurity profiling of various ATSs by physical characterization, qualitative and quantitative analyses, and identification of adulterants, byproducts, and precursors, using GC, GC/MS, and cluster analyses (541); **2012** analysis of 2-, 3-, and 4-methylmethamphetamine and 2-, 3-, and 4-methylamphetamine, by GC/MS and GC/IRD (542); analysis of methamphetamine, amphetamine, and ecstasy by insideneedle adsorption trap based on molecularly imprinted polymer followed by GC/FID (543); **2013** analysis of 4-bromo-2,5-beta-trimethoxyphenethylamine (BOB), 4-methyl-2,5-beta-trimethoxyphenethylamine (BOD), 3,4-methylenedioxy-beta-methoxyphenethylamine (BOH), and 4-methyl-2,5-dimethoxy-betahydroxyphenethylamine (BOHD), by LC-MS/MS (toxicological focus) (544); differentiation of stimulant amphetamines, hallucinogenic amphetamines, and nonamphetamines (none specified in the abstract) by GC/FTIR and cluster analysis (545); determination of ephedrine, methamphetamine, and amphetamine by SERS (546); analysis of amphetamine and methamphetamine by GC-MS after propylchloroformate derivatization (547); determination of diethylpropion, fenproporex, and sibutramine in counterfeit tablets, by FTIR/ATR (548); determination of amphetamines and precursors by a portable instrument combining miniaturized GC and IR Absorption Spectroscopy (549); determination of (unspecified) amphetamines by GC/FTIR (550); synthesis and characterization of 2-, 3-, and 4-methylamphetamine by GC/MS, HR-ESI-MS, NMR, and IR (551); a chemometric system for the automated detection of 159 ATSs, using GC/FTIR (552); a review of the 2C series of PEAs (553); analysis of methamphetamine, MDMA, and other ATSs by GC/MS after derivatization with iso-Bu chloroformate and SPME (toxicological focus) (554); detection of volatile compounds that could indicate an ATS by SPME-GC/MS (P2P was detected in every stimulant sample, and 1-phenyl-1,2-propanedione was detected in some stimulant

samples) (555); determination of (unspecified) amphetamines by GC/FTIR (556); a review of impurity profiling and syntheses of methamphetamine, MDMA, amphetamine, DMA, and PMA (557); identification of phenethylamine, ephedrine, and MDMA by Raman, SERS, and DFT (558); analysis of six (unspecified) isomers of mono-methoxyethylamphetamines and mono-methoxydimethylamphetamines (MeO-DMAs) by GC-EI-MS/MS (559); **2014** detection of amphetamines by cluster analysis (560); determination of N-ethyl- $\alpha$ -ethyl-phenethylamine (ETH), N,N-diethylphenethylamine, and phenethylamine in dietary supplements by LC-MS/MS (561); synthesis and SARs of N-benzyl phenethylamines as 5-HT<sub>2A/2C</sub> agonists (562); potential interferences in the GC/MS analyses of methiopropamine, 4-fluoroamphetamine, 4-fluoromethamphetamine, and 4-methylamphetamine (563); synthesis of [<sup>13</sup>C<sub>6</sub>]-labeled amphetamine, methamphetamine, MDA, MDMA, MDEA, PMA, PMMA, 3,5-dimethoxyphenethylamine, 4-bromo-2,5-dimethoxyphenethylamine, and 2,5-dimethoxy-4-iodophenethylamine (564); enantioselective hydrogenation of  $\alpha,\beta$ -disubstituted nitroalkenes to synthesize chiral amphetamines (565); synthesis of phenethylamine via anti-Markovnikov hydroamination of alkenes catalyzed by a two-component organic photoredox system (566); simultaneous enantiomeric separation of methamphetamine, ephedrine, pseudoephedrine, and the chloro-intermediates formed during the Emde method, after derivatization with trifluoroacetic anhydride (567); detection of amine-based stimulants by a novel fluorescent sensor (568); chiral separation of cathinone and amphetamine derivatives by HPLC/UV using sulfated  $\beta$ -cyclodextrin as a chiral mobile phase additive (569); **2015** comparisons of chiral analyses of 10 cathinone and amphetamine-derivatives by CEC, SFC, and 3 different LC methods (570); simultaneous voltammetric detection of MDMA and PMA (571); analysis of ATs by DSC (572); enantioselective synthesis of ephedrine, amphetamine, and their analogues via two stereocentered Co(III)-catalyzed hydrolytic kinetic resolution of racemic syn-benzyloxy epoxide (573); analysis of amphetamine, methamphetamine, norephedrine, norpseudoephedrine, ephedrine, pseudoephedrine, dimethylamphetamine, and methylephedrine by chiral CE/MS (574); determination of MDMA, methamphetamine, MDA, and MDEA by portable CE with contactless conductivity detection (575); fast separation of 11 cathinones and 4 phenylethylamines by SFC-positive-ESI-triple-quad-MS (576); "novel" sympathomimetics in supplements actually recapitulate the work of synthetic chemists at pharmaceutical firms during the 1930s and 1940s (577); characterization of N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine, N-(ortho-methoxybenzyl)-4-ethylamphetamine, N-(ortho-methoxybenzyl)-4-methylmethamphetamine, and N-(ortho-methoxybenzyl)-5-(2-aminopropyl)benzofuran by MS, IR, and NMR (578); **2016** electrochemiluminescent detection of methamphetamine and amphetamine (579);

**Barbiturates:** **2013** analysis of barbital, phenobarbital, pentobarbital, amobarbital, secobarbital, butalbital, pentothal, and butabarbital by IR and Raman (580); **2014** by colorimetric sensing (581); computing the acidities of barbituric and thiobarbituric acid (582); a theoretical study on the isomerization and tautomerism of 16 isomers of barbituric acid, using MP2 and B3LYP

(583); **2016** an overview of the polymorphism and tautomerism of barbituric acid (584); a review of the chem. of barbituric acids employed in the design and synthesis of different types of compds (585);

**Benzodiazepines:** **2013** cross reactivity of 3-hydroxyflunitrazepam, 7-aminonitrazepam, brotizolam, delorazepam, pinazepam, and  $\alpha$ -hydroxy-midazolam with a commercial immuno-assay test (includes LC-MS/MS analyses) (586); analysis of 11 different benzodiazepines and metabolites by SERS (benzodiazepines not identified in the abstract) (587); an FTIR/ATR spectral library of benzodiazepines (588); analysis of nitrazepam, clonazepam, lorazepam, chlordiazepoxide, alprazolam, clozapine, and diazepam by HPTLC with densitometric measurement and UV scanning (toxicological focus) (589); **2014** quantum chemical study of some benzodiazepines by density functional theory (590); determination of clonazepam and its related substances in pharmaceutical formulations by HPLC (591); determination of bromazepam, clonazepam, and diazepam in the Guanda River, Brazil (analytical methodology not identified in the abstract) (592); detection of diazepam, flunitrazepam, and temazepam in spiked drinks by GC/MS (593); a review of the analysis of benzodiazepines by LC with electro-chem. detn. (since 2006, with earlier reports given in summary) (594); analysis of diazepam, alprazolam, clorazepate, temazepam, and bromazepam by confocal Raman microscopy (595); differentiation of benzodiazepines by Raman (596); low temperature separation of the inter-converting enantiomers of diazepam, flunitrazepam, prazepam, and tetrazepam by dynamic HPLC on chiral stationary phases (597); detection of benzodiazepines in drinks by electrophoretic fingerprinting (598); **2015** use of supported liquid extraction for the analysis of benzodiazepines by SERS (599); characterization of clonazolam, deschloroetizolam, flubromazolam, and meclonazepam by NMR, GC-EI-MS, LC-MS/MS, LC-QTOF-MS, and IR (600); determination of diazepam, clonazepam, and alprazolam in dietary supplements by UHPLC-HR-Quad-MS (601); predictive modelling of the toxicity of benzodiazepines using descriptor-based QSTR, group-based QSTR, and 3D-toxicophore mapping (602); a study of the mechanism of mass spectral fragmentation of benzodiazepines (603); analysis of chlordiazepoxide, midazolam, nitrazepam, estazolam, oxazepam, lorazepam and alprazolam by HPLC with UV or DAD detection (604); **2016** analysis of benzodiazepines by chip-based electrochromatography coupled to ESI-MS detection (605); determination of chlordiazepoxide; lorazepam; diazepam; oxazepam; medazepam in an alc. "grappa" drink by packed sorbent (MEPS)-UHPLC-UV (606);

**Benzofurans:** **2015** pharmacological profile of 5-APB, 5-APDB, 6-APB, 6-APDB, 4-APB, 7-APB, 5-EAPB, 5-MAPDB, and the benzodifuran 2C-B-FLY (607);

**Bromo-, Chloro-, and Fluoro- Amphetamines and Methamphetamines:** **2013** analysis of 2-, 3-, and 4-chloro- and 2-, 3-, and 4-fluoro- amphetamines by CE-LIF, following derivatization

with fluorescein isothiocyanate (includes comparisons against CZE-UV, sweeping-MEKC-UV, and LC-Q-TOF-MS) (608); synthesis and characterization of fluoroamphetamines and fluoro-methamphetamines by GC/MS and LC-MS/MS, before and after derivatization with various reagents (compounds not specified in the abstract) (609); **2015** discrimination of 2-, 3-, and 4-fluoroamphetamine by Raman (610); differentiation of ring-substituted bromoamphetamine analogs by GC/MS (611); identification of the regioisomers of the chloroamphetamines and chloromethamphetamines by GC-MS/MS (612);

**Cathinones:** **2012** mass spectral fragmentation of 25 cathinones (not identified in the abstract) by GC-HR-TOF-MS using a soft ionization source (613); analysis of 4-MMC, 4-, 3-, or 2-fluoromethcathinone, 4-methoxymethcathinone, N-ethylcathinone, and N,N-dimethylcathinone by GC/MS (includes a stability study) (614); **2013** characterization of 31 synthetic cathinones (not identified in the abstract) by GC/MS, IR, and NMR (615); analysis of mephedrone, methylone, and MDPV by ambient ionization MS using arrays of low-temperature plasma probes, and also following injection of trifluoroacetic anhydride directly into the plasma stream for online derivatization (616); analysis of BMDP, butylone, MDPBP, MDPV, methylone, and pentylone by HPLC-HR-QTOF-MS (617); analysis of 38 cathinones (not specified in the abstract) by hybrid Q-TOF-MS and LC/MS/MS (618); an overview and review (619); analysis of (unspecified) "bath salt" cathinones by DART-MS (620); an overview and review of synthetic cathinones (621); analysis of 16 cathinones using "presumptive testing" (not specified in the abstract), TLC, and GC/MS (622); an overview of "bath salts" (including mephedrone, MDPV, and possibly others) (623); characterization of metaphedrone and pentedrone by single-crystal X-ray diffraction (624); analysis of 4-methylmethcathinone, three positional isomers of fluoromethcathinones, 4-methoxymethcathinone, N-ethylcathinone, N,N-dimethylcathinone, buphedrone, and pentedrone by GC/MS (625); a review of mephedrone, MDPV (and possibly others) (626); **2014** enantiomeric analysis of 10 new cathinones by CEC on a chiral stationary phase (627); identification of trace levels of synthetic cathinones using Raman (cathinones not identified in the abstract) (628); analysis of 13 synthetic cathinones and associated psychoactive substances by ESI-high performance-IMS (629); identification of MDPV, 3,4-methylenedioxy- $\alpha$ -pyrrolidinobutiophenone (MDPBP), 4-fluoromethcathinone (4-FMC), butylone, mephedrone, naphyrone, 4-methylethcathinone (4-MEC), ethcathinone,  $\alpha$ -pyrrolidinopentiophenone ( $\alpha$ -PVP), and 3-methyl- $\alpha$ -pyrrolidinopropiophenone (3-MPPP) by GC/FID and GC/MS (630); screening and comparative analysis of synthetic cathinones by portable microchip electrophoresis (631); chiral separation of 12 cathinones by cyclodextrin-assisted CE with UV and MS detection (632); use of DART-MS in-source collision induced dissociation and high mass accuracy for determination of new psychoactive cathinones (633); screening for 16 cathinones by "presumptive testing", TLC, and GC/MS (634); electrochemical detection of ( $\pm$ )-methcathinone, ( $\pm$ )-mephedrone, and ( $\pm$ )-4'-methyl-N-ethylcathinone (635); electroanalytical sensing of mephedrone and methylethcathinone (636); synthesis and characterization of 9 new derivs. of

cathinone (obtained by modifying the carbonyl group to create cyclic ketals and thioketals, oximes, and hydrazones of cathinone and of cathinone phthalimide; analytical methodologies not identified in the abstract) (637); QSAR modelling of 4-methylbuphedrone and 4-methoxy-N,N-dimethylcathinone, with comparison to methylone (638); characterization of 4-fluoromethcathinone, ethcathinone, buphedrone, methedrone, penthedrone, 3,4-dimethylmethcathinone, 4-methylethcathinone, and others by FTIR, GC/MS, <sup>1</sup>HNMR, and wavelength dispersive XRF (639); **2015** analytical and synthetic studies on substituted cathinones (no details provided in the abstract) (640); analysis of methcathinone, 3,4-methylenedioxy-methcathinone, 3,4-methylenedioxy-pyrovalerone, and 4'-methyl- $\alpha$ -pyrrolidinopropiophenone by LC/MS (641); isotopic profiling of cathinones for comparative analyses (642); identification and characterization of  $\alpha$ -PVT,  $\alpha$ -PBT, and their bromothienyl analogs (643); a review of the R- and S- isomers of cathinones, focusing on MDPV (644); an overview and review of the neurotoxicity of the cathinones (645); identification and characterization of 4-fluoro-PV9 and  $\alpha$ -PHP by HPLC, HPLC/DAD, ESI-Ion-Trap-MS in MS2 and MS3 modes, GC/MS, thermogravimetric anal., DSC, FTIR, UV/Vis, and NMR (646); compatibility of highly sulfated cyclodextrin with ESI at low nanoliter/minute flow rates and its application to CE-ESI/MS analysis of cathinone derivatives (647); the electrochemical detection of mephedrone (4-MMC) and 4'-methyl-N-ethylcathinone (4-MEC) (648); a study of the decomposition of the HCl salts of 8 cathinone derivatives in air (649); crystal structures of two forms of MDPV HCl and one form of ethylone HCl (650); preparation and characterization of the tertiary cathinones N,N-dimethylcathinone, N,N-diethylcathinone, and 2-(1-pyrrolidinyl)-propiofenone by NMR and MS (the enantiomers were also prepared and identified by HPLC and CD) (651); analysis of ( $\pm$ )-4'-methylmethcathinone and ( $\pm$ )-4'-methyl-N-ethylmethcathinone by HPLC/UV and amperometric detection ("NRG-2" is a focus) (652); **2016** differentiation of cyclic tertiary amine cathinone derivatives (the cyclic amines azetidine, pyrrolidine, piperidine, and azepane were incorporated into a series of cathinones related to MDPV) by product ion-EI-MS and MS/MS (653); thermal degradation of 4-ethylmethcathinone, 4-methylethcathinone, buphedrone, butylone, ethcathinone, ethylone, flephedrone, 3,4-methylenedioxy- $\alpha$ -pyrrolidinobutiophenone, 3,4-methylenedioxy-pyrovalerone, mephedrone, methcathinone, methedrone, methylone, 4-methyl- $\alpha$ -pyrrolidinobutiophenone, naphyrone, penthedrone, pentylone and pyrovalerone under GC/MS conditions (654); identification of methylone and penthedrone by NMR, IR, UV/Vis, MS/MS, and HR-TOF-MS (655); identification and characterization of iso-4-BMC,  $\beta$ -TH-naphyrone, mexedrone, and 4-MDMC by LCQTOF-MS, GC/MS, and NMR (656); chiral separation of new cathinones on chiral ion-exchange type stationary phases (657);

**"Ecstasy Tablets" (that is, Tablets or Powders specified in their Titles or Abstracts as Ecstasy - these may in fact contain MDMA, a mixture of MDMA with one or more other Drugs, or only one or more non-MDMA drugs):** **2013** elemental analysis of Ecstasy tablets by graphite furnace atomic absorption, for comparative analysis (abstract indicates Cu, Mg, Ba, Ni,

Cr, and Pb) (658); **2014** determination of metals (Zn, Al, Ca, Mg, K, Na, Ba, Fe, B, Cu, and Pt) in Ecstasy tablets using ICP-OES and XRF (659); **2015** a discussion of "luminescent" Ecstasy tablets (a marketing ploy) (660); detection of MDMA, methamphetamine, and 20 other substances in Ecstasy tablets, including caffeine, 2C-B, piperazines, amphetamines, and phencyclidine, by GC/MS (661); **2016** comparison of the purity and adulteration of the crystalline (powder) samples versus tablets in the Spanish Ecstasy market 2000-2014, by TLC, GC/MS, and UV (662);

**Ephedrines:** **2012** interconversion of ephedrine and pseudoephedrine during heptafluorobutyric anhydride derivatization (663); **2013** comparison of RP-UHPLC and HILIC for quantitation, with medium-resolution accurate MS (664); **2014** identification of ephedrine by use of charge-transfer complexes (with analysis of the complexes by elemental anal., IR, Raman, <sup>1</sup>H NMR, and UV-Vis (665);

**Ergot Alkaloids:** **2014** a review of the biosynthetic pathways of ergot alkaloids (666); detection of ergometrine, ergosine, ergotamine, ergocornine, ergocryptine, ergocristine) in rye and triticale grains (analytical methodologies not identified in the abstract) (667); determination of ergotamine tartrate in tablets using LC with fluorimetric and UV detection (668); an overview of the biosynthesis of the ergot alkaloids (669); identification of ergot alkaloid in two *Argyrea nervosa* "legal high" products by HPLC-HRMS/MS (670); a review of the detection of ergot alkaloid derivatives by TLC (671); aptamer-based extraction of ergot alkaloids from ergot contaminated rye feed (672); **2015** determination of ergot alkaloids in grain products by LC-ion trap-MS (673); an evaluation of fast dissolving tablets of ergotamine tartrate (674); determination of ergovaline in tall fescue seed and straw using a QuEChERS extraction method by HPLC with fluorescence detection (675); **2016** an overview and review (676); quantitative and qualitative transcriptome analysis of four industrial strains of *Claviceps purpurea* with respect to ergot alkaloid production (677); determination of ergot alkaloids in Morning Glory cultivars by LC-Q-TOF-MS (678); screening for total ergot alkaloids in rye flour by planar SPE-fluorescence detection and MS (679);

**Fentanyl Derivatives:** **2014** analysis of the inclusion complexes between cyclodextrins and fentanyls by NMR and computational studies (680); an efficient, optimized synthesis of fentanyl and related analogs (681); **2015** improved and optimized syntheses of fentanyl and related analogs (682);

**2-, 3-, and 4-Fluorophenmetrazines:** **2016** synthesis, characterization, and differentiation of the fluorophenmetrazine isomers (683);

**"FLY" Compounds:** **2014** synthesis of labeled 2C-B-FLY and Bromo-DragonFLY for use as

internal standards (684);

**Methiopropamine (and its 3-thienyl isomer):** 2013 synthesis and analysis/differentiation by GC (685);

**NBOMe Compounds:** 2013 characterization of 25D-NBOMe [2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine], 25E-NBOMe [2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine], and 25G-NBOMe [2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-(2-methoxybenzyl)ethanamine] (686); 2014 an overview and review (687); 2015 a review (688); detection of NBOMEs (and other NPSs) on blotter papers by direct ATR-FTIR (689); analysis of 25I-NBOMe, 25BNBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-methoxyphenyl)methyl]ethanamine derivatives on blotter paper by DART-Accu-TOF-MS and HPLC-triple quadrupole-MS (690); an overview (691);

**Opiates:** 2012 determination of morphine and codeine by HPLC-quadrupole mass selective detection (may be a toxicological study) (692); 2013 analysis of morphine and codeine by TLC and densitometry (693); 2014 some insights into hydrate formation and stability of morphinanes by powder X-ray diffraction, IR, DSC, and isothermal calorimetry (694); isomerization of codeine and morphine into hydrocodone and hydromorphone using a water-sol. rhodium complex formed from com. available [Rh(COD)(CH<sub>3</sub>CN)<sub>2</sub>]BF<sub>4</sub> and 1,3,5-triaza-7-phosphaadamantane (695); a review of the TLC of morphine analogs (compounds not identified in the abstract) (696); 2015 potential use of oriental poppy hairy roots for producing thebaine, morphine, and codeine (697); a review covering the synthesis of buprenorphine, naltrexone, naloxone, and nalbuphine from naturally occurring opiates such as thebaine and oripavine (698); the stereochemistry and spectral assignment of thebaine derivatives based on a 1D NOESY NMR study (699); degradation of morphine and codeine by gamma radiation in methanol (700); radiation induced destruction of thebaine, papaverine, and noscapine in methanol (701); a review of AH-7921 (702); separation of morphine, hydromorphone, and norcodeine using ESI and paper spray coupled to high-field asymmetric waveform IMS (703);

**Opiates (Bio-Engineered):** 2014 use of a microbial biomanufacturing platform for natural and semisynthetic opioids, using *Saccharomyces cerevisiae* (704); 2015 heroin from bio-engineered yeast (705); heroin from bio-engineered yeast (706); failure of an attempted large-scale effort to produce thebaine using home-brew type conditions (707); synthesis of morphinan alkaloids from norlaudanoline using *Saccharomyces cerevisiae* (708); a feasibility study for production of thebaine and hydrocodone from sugar by bio-engineered yeast (709); a review, detailing the current status of microbial benzylisoquinoline alkaloid synthesis and derivatization (710); a call to regulate the synthesis of morphine by bio-engineered yeasts (711); 2016 metabolic engineering for the production of plant isoquinoline alkaloids (712); complete biosynthesis of opioids

(thebaine) by yeast (713); a review of the production of thebaine and hydrocodone from D-glucose by fermentation (714); total biosynthesis of opiates (thebaine) by stepwise fermentation using engineered E. coli (715);

**1-(1-Phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy)**

**analogues:** 2014 characterization by GC-ion trap-EI-, CI-, and HR-MS, LC-ESI-triple-quadrupole linear ion trap-MS/MS, IR, DAD, and <sup>1</sup>H and <sup>13</sup>C NMR (716);

**Phenothiazines:** 2013 separation and identification of prochlorperazine, promethazine, chlorpromazine, and trifluoroperazine (717);

**Phosphodiesterase-5 Inhibitors - Cialis (tadalafil), Levitra (vardenafil), Viagra (sildenafil),**

**and similar drugs:** 2013 a multivariate-based wavenumber selection method for classifying Cialis and Viagra into authentic or counterfeit classes by ATR/FTIR (718); analysis for residual solvents in counterfeit tablets and capsules of Cialis and Viagra (analytical method not indicated in the abstract) (719); simultaneous qualitative and quantitative analysis of counterfeit Cialis by Raman (720); analysis of 38 compounds (sildenafil, tadalafil, vardenafil and their analogs) in illicit erectile dysfunction products by LC-ESI-MS/MS (721); differentiation between counterfeit and authentic Cialis and Viagra by ATR/FTIR with PCA (722); analysis and profiling by UPLC/MS (723); characterization of sildenafil citrate tablets from different sources by NIR chemical imaging and chemometric tools (724); 2014 profiling authentic and counterfeit Viagra and Cialis using XRF, direct infusion ESIMS, UPLC-MS, and ATR-FTIR (725); simultaneous determination of sildenafil, tadalafil, vardenafil and acetildenafil in health-care foodstuffs by UHPLC/MS (726); qualitative and quantitative analysis of sildenafil in traditional medicines and dietary supplements by HPLC/UV and IR (727); 2015 isolation and structural characterization of chloropropanoylpretadalafil in a dietary supplement by HPLC-UV, GC/FT-IR/MS, and HRMS (728); detection of sildenafil citrate in herbal formulations by UV/Vis (729); differentiating genuine and counterfeit Viagra tablets by dynamic thermal analysis (730); 2016 use of transmission-mode desorption electrospray MSMS to screen for synthetic phosphodiesterase-5 inhibitors in samples of adulterated herbal dietary supplements (731); analysis of dietary supplements containing phosphodiesterase type-5 (PDE-5) inhibitors by LC/MS and HPLC/UV (732);

**Piperazines:** 2012 differentiation of methylenedioxybenzylpiperazines and ethoxybenzylpiperazines by GC/IRD and GC/MS (733); 2013 characterization of six ring regioisomeric dimethoxybenzoylpiperazines (DMBzPs) by GC/MS and GC/IRD (734); analysis of the six-ring regioisomeric dimethoxybenzyl-N-methylpiperazines (DMBMPs) by GC/MS (735); a presumptive color spot test method for the detection of benzylpiperazine and piperazine analogues (736); determination of chlorophenylpiperazine isomers by CE (737); analysis of phenyl and benzyl piperazines by HPLC with chemiluminescence detection (738); 2014 six ring

regionisomeric dimethoxybenzoyl-N-methylpiperazines (DMBzMPs) by GC/MS and IR (739); analysis of regioisomeric bromodimethoxy benzyl piperazines related to 4-bromo-2,5-dimethoxybenzylpiperazine by GC/MS and FTIR (740); differentiation of the 1-(methylenedioxyphenyl)-2-piperazinopropanes and 1-(methoxyphenyl)-2-piperazinopropanones by GC/IRD and GC/MS (741); **2015** analysis of six ring regioisomeric dimethoxyphenylpiperazines (DOMePPs) by GC/MS and IR (742); analysis of 23 benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) containing tablets by HPLC and IRMS (743); an overview of 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) (744);

**Steroids:** **2013** determination of tetrahydrogestrinone and related anabolic androgenic steroids by MEKC (745); a study of authentic and counterfeit products (primarily stanozolol, testosterone, and nandrolone) seized in Brazil from 2006 to 2011 (746); analysis of methandienone and methyltestosterone in tablets by color testing and GC/MS (747); a review of the bioanalytical challenges in detecting unknown anabolic androgenic steroids (in doping control analysis) (748); screening for steroids in traditional medicine and nutraceutical products using electrospun cellulose acetate nanofibers as thin layer chromatographic media (749); **2015** analysis of anabolic steroids by GC-EI/MS, GC-EI/MS/MS, LC-ESI/MS/MS, LCAg+CIS/MS/MS, and GC-ESI/MS/MS (for doping control) (750); determination of anabolic-androgenic steroid adulterants in counterfeit drugs by UHPLC-MS/MS (751); identification and quantification of anabolic steroid esters by DART-HRMS (752); an overview and review of the anabolic androgenic steroids in supplements (753); determination of anabolic agents in dietary supplements by LC-HRMS (754); a summary of the designer steroids that are most commonly sold in dietary supplements (as of April 2014) (755); **2016** improved detection of steroids and evidence for their regiospecific decompositions using anion attachment MS (756); analysis of steroids in dietary supplements by non-targeted mass spectrometry (757); analysis of anabolic steroids by GC-CI-TQuad-MS (758);

**Tryptamines (see also Mushrooms):** **2013** characterization of AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole) by <sup>1</sup>H- and <sup>13</sup>C-NMR, GCEI/CI-ion trap-MS, U/HPLC-DAD, and HPLC/MS (759); simultaneous determination of tryptamine analogues in designer drugs using GC/MS and LC-MS/MS (only 5-methoxy-N,N-diethyltryptamine and 5-methoxy-N-methyl-N-isopropyltryptamine were identified in the abstract, among many more) (760); **2015** a review of the use, analysis, and toxicity of tryptamines (only DMT is specifically noted in the abstract) (761); **2016** synthesis of psilocin, bufotenin, serotonin, and various homologues and branched tryptamine derivatives (762); characterization of N,N-diallyltryptamine (DALT), and 2-phenyl-, 4-acetoxy-, 4-hydroxy-, 4,5-ethylenedioxy-, 5-methyl-, 5-methoxy-, 5-methoxy-2-methyl-, 5-ethoxy-, 5-fluoro-, 5-fluoro-2-methyl-, 5-chloro-, 5-bromo-, 5,6-methylenedioxy-, 6-fluoro-, 7-Me, and 7-ethyl DALTs, by NMR, GC/MS, EI/MS, low and high mass accuracy MS/MS, PDA, and GC solid-state IR (763).

-----

**1.D - Synthetic Cannabinoids and Cannabimimetics [Notes: Compounds are listed either by their acronym or full name as was specified in their respective abstract - no effort was made to transcribe acronyms to full chemical names or vice versa. Articles that include both synthetic cannabinoids and/or cannabimimetics with other drugs are detailed separately.]**

**Individual Synthetic Cannabinoids and Cannabimimetics:** **2013** identification of (1-(cyclohexylmethyl)-1H-indol-3-yl)(4-methoxynaphthalen-1-yl)methanone by LC/MS and NMR (764); purification and characterization of 3-methyl-6-[3-(trifluoromethyl)-phenyl]-1,2,4-triazolo[4,3-b]pyridazine (CL 218872) by MS, IR, and NMR (765); characterization of JWH-213 by LC-PDA-MS, GC/MS, high-res MS, and NMR (766); analysis of N-[3-(2-methoxyethyl)-4,5-dimethyl-2(3H)-thiazolylidene]-2,2,3,3-tetramethylcyclopropanecarboxamide (A-836339) by LC/MS, GC/MS, highres MS, NMR, and X-ray crystallography (767); identification of [1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone (A-834,735) by LC-ESI-QTOFMS, GC/MS, 1D- and 2D-NMR, and FTIR (768); **2014** an outbreak of exposure to a novel synthetic cannabinoid (abstract not available) (769); analysis of methyl 2-[[1-(5-fluoropentyl)-3-methyl-1h-indol-3-ylcarbonyl]amino]butyrate (770); structural elucidation of a new open chain isomer of the cannabimimetic cyclopropoylindole A-796,260 by NMR and MS (771); determination of HU-210 by HPLC (772); identification of JWH-018 by LC-MS/MS (773); **2015** isolation and identification of AB-FUBINACA (774); structural elucidation of N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide (a homolog of AZ-037) by NMR and MS (775); characterization of naphth-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (CBL-2201) by 1H, 13C, and 15N NMR, FTIR, and GC/MS (776); new monoclonal antibodies specific for 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) (777); identification of N,N-bis(1-pentyl-indol-3-yl-carboxy)naphthylamine (BiPICANA) by LC/MS, HRMS, NMR, and X-ray crystallography (778); analysis of AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] by GC/MS, LC/MS, LC/HRMS, and NMR (779); **2016** determination of the absolute configuration of MDMB-CHMICA by vibrational and electronic CD spectroscopy, Xray crystallog., and HPLC (780); separation and structural characterization of JWH-018-cyclohexyl methyl derivative (NE-CHMIMO) by flash chromatography, GC/MS, IR, and NMR (781); analysis of 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole by GC/MS, GC/HRMS, UHPLC/HRMS2, FTIR, and 1H and 13C NMR (782);

**Multiple Synthetic Cannabinoids and Cannabimimetics:**

[Note: Each year in this subsection is separated by a line space.]

**2012** separation and structural characterization of JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3-yl]-(4-methylnaphthalen-1-yl)methanone using GC/MS, NMR, and flash chromatography (783); analysis of cannabinoids by IR, GC/MS, LC/MS, and <sup>1</sup>H NMR (784); analysis of CP-47,497-C8 JWH-250, and RCS-4 by TLC, GC/MS, light optical microscopy, and "phytochemical reactions" (785);

**2013** analysis of JWH-018, JWH-019, JWH-073, and JWH-250 by GC/MS (786); analysis of 5F-UR-144 and UR-144 by GC/MS, LC-TOF-MS, and 1D- and 2D-NMR (787); an overview of synthetic cannabinoids in South Korea from 2009 to June 2013 (788); analysis of AM-2201, JWH-203, JWH-210 and RCS-4 by LC, high-res MS, LCQTOF-MS, and NMR (789); correlated results from the analyses of synthetic cannabinoids in Turkey from 2010 to 2012 (790); analysis of JWH-019, JWH-081, JWH-203, and JWH-250 by UHPLC-QTOF-MS (791); analysis of 28 (unspecified) "synthetic cannabinoids" by LC/ESI-MS/MS (toxicological focus) (792); isolation of cis- and trans- CP-47,497-C8 (and others not specified in the abstract) - extraction from plant materials by flash chromatography (793); analysis of azepane isomers of AM-1220 and AM-2233, AM-2233, and URB-597 by LC/MS, GC/MS, "accurate MS," and NMR (794); isolation and analysis of 1-butyl-3-(2-methoxybenzoyl)indole and the 2-methoxy isomer of RCS-4 by column chromatography and prep-HPLC, followed by GC/MS, ESI-TOFMS, and 1D- and 2D-NMR (795); a review of the analysis of synthetic cannabinoids on botanical materials (796); analysis of (unspecified) "cannabimimetics" bearing 2,2,3,3-tetramethylcyclopropane-carbonyl moieties by GC/MS, LC/MS, and NMR (797); characterization of some synthetic cannabinoids, derivatives of indole-3-carboxylic acid, by GC-HRMS, UHPLC-HRMS, NMR, and FTIR (798); detection of AB-001, AM-2232, APINACA, N,5-dimethyl-N-(1-oxo-1-(p-tolyl)butan-2-yl)-2-(N'-(p-tolyl)ureido)benzamide, (4-ethylnaphthyl)-AM-2201 (EAM-2201), 5-fluoropentyl-3-pyridinoylindole, 5FUR-144 (synonym: XLR11), 4-hydroxydiethyltryptamine (4-OH-DET), JWH-213, JWH-307, JWH-030, 4-methylbuphedrone, (4-methylnaphthyl)-AM-2201 (MAM-2201), (4-methylnaphthyl)-JWH-022 [synonym: N-(5-fluoropentyl)-JWH-122], N-(4-pentenyl)-JWH-122, UR-144, and URB-754 on plant materials (methods not specified in the abstract) (799); analysis of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) by LC/MS, GC/MS, high-res MS, and NMR (800); a pharmacological study of the structural features of synthetic cannabinoids and their in vivo cannabimimetic activity (801); simultaneous determination of JWH-018 and JWH-073 by UFLC (Ultra-Fast LC) (802); analysis of cannabicyclohexanol, JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, JWH-250, and RCS-4 by GC/MS, LC-QTOF-MS, and HPLC (803);

**2014** an overview of the emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products (804); chromatographic and mass spectral studies on 6 1-pentyl-acylindoles (regioisomeric synthetic cannabinoids) (805); analysis and

differentiation of substituted 1-alkyl-3-acylindoles (isomeric synthetic cannabinoids) by GC-MS, IR, and some exact mass GC-TOF-MS (806); differentiation of 1-alkyl-3-acylindoles and 1-acyl-3-alkylindoles (isomeric synthetic cannabinoids) by GC MS, and IR (807); a review (808); differences in the GC-EI-MS spectra of JWH-250, JWH-302, and JWH-201 (809); presumptive color-testing of synthetic cannabimimetics by Duquenois-Levine, van Urk, and 2,4-DNPH (810); analysis of AM-2201, JWH-122, JWH-203, JWH-210, and RCS-4 by DART-MS (811); identification and quantification of synthetic cannabinoids by GC/MS and GC/ECD (812); synthesis and biological activities of synthetic cannabinoids (813); structural elucidation, analytical characterization, and identification of [1-(5-fluoropentyl)-1H-indazol-3-yl-(naphthalen-1-yl)methanone, naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone, and 1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl(naphthalen-1-yl)methanone by GC/MS, GC/HR-MS, UHPLC-HR-MS, NMR, and FT-IR (814); identification and analysis of indol-3-carboxylates series and indazole-3-carboxylates (novel cannabinoids) by GC/MS, GC-HRMS, UHPLC-HRMS, NMR, and FTIR (815); analysis of the 6 benzoyl-substituted 1-pentylindoles (isomeric synthetic cannabinoids) by GC/MS and FTIR (816); simultaneous determination of 10 synthetic cannabinoids by HPLC (817);

**2015** a retrospective survey of synthetic cannabimimetics in Bulgaria 2010-2013 (818); synthesis and SARs of RCS-4 and its regioisomers and C4 homologue (819); identification of 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB), MAM-1220, and CHM-081 by GC/MS, LC/MS, and NMR (820); synthesis and spectroscopic analysis of analogues of 1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone and 1H-indol-3-yl(adamantan-1-yl)methanone by NMR, MS, FTIR, and GC-FTIR (821); quantitation of 32 synthetic cannabinoids (dibenzopyrans, cyclohexylphenols, naphthoylindoles, benzoylindoles, phenylacetylindoles, tetramethylcyclopropylindoles) on plant materials by a validated HPLC/UV method (822); QSARs of 43 cannabimimetic aminoalkylindole derivatives and their metabolites (823); qualitative and quantitative analysis of 2 fluorine containing cannabinoids (XLR-11 and AM-2201) by <sup>19</sup>F-NMR, with comparison against GC/MS (824); the variability of active ingredients in Spice within Alaska as an indicator mechanism for manufacture and distribution (825); rapid screening and quantification of synthetic cannabinoids in herbal products with COSY and TOCSY NMR (826); separation of cannabinoids on 3 different mixed-mode columns (827); an overview and review of synthetic cannabinoids (828); differentiation of the positional isomers of JWH-081 by GC-EI-MS and GC-MS/MS (829); identification and quantification of 5-fluoro-AB-PINACA, AB-CHMINACA, AB-FUBINACA, 5-fluoro-PB-22, 5-fluoro-AMB, MDMB-CHMICA, EAM-2201, and STS-135 by GC/MS (830); identification of synthetic cannabinoids by UHPLC-TOFMS and GC/MS (among 32 solutes, only JWH-018 and CP47,497 are identified in the abstract) (831); synthesis and characterization of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer (832); analysis of ADB-BINACA, AB-FUBICA,

ADB-FUBICA, and AB-BICA by LC-HRMS, GC/MS, and NMR (833); identification and analytical characteristics of 5 new synthetic cannabinoids with an indazole-3-carboxamide structure bearing an N-1-methoxycarbonylalkyl group by GC/MS, GC/HRMS, UHPLC-HR-MS/MS, and <sup>1</sup>H and <sup>13</sup>C NMR (834); a review of synthetic cannabinoids (835); analysis of 1-n-pentyl-3-(1-naphthoyl)indole (JWH-018), three deuterium-labeled analogues, and the inverse isomer 1-naphthoyl-3-n-pentylindole by MS (836); analysis of JWH-018 and its 5 regioisomers by GC/MS (837); separation and detection of cannabicyclohexanol (CCH: cis-isomer), trans-CCH, 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47497), 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)-cyclohexyl]-phenol (CP-55940), 3-(1,1'-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU-210), 2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol (CBD), (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone (JWH-018), (1-butyl-1H-indol-3-yl)-1-naphthalenyl-methanone (JWH-073) and 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone (JWH-250) by SFC/MS (838); an overview of illnesses and deaths from abuse of synthetic cannabinoids (839); syntheses and analytical characterizations of 15 N-alkyl-aryl-cyclohexylamines by GC and HPLC coupled to multiple forms of mass spectrometry, as well as NMR, UV/DAD, and IR (840); characterization of 2 thiazolylindoles and a benzimidazole (potential cannabinoids) by MS, IR, and NMR (841); a review of bioisosteric fluorine in the clandestine design of synthetic cannabinoids (842); identification and quantitation of 5-fluoro-ADBPINACA and MAB-CHMINACA by HRMS, GC/MS, and LC-MS/MS (843); a study on the fragmentation pathways of JWH-018 and JWH-073 (844); determination and identification of synthetic cannabinoids and their metabolites in different matrices by chromatographic, spectroscopic, and spectrometric methods (845);

**2016** differentiation of the 6 regioisomeric dimethoxybenzoyl-1-pentylindoles by EIMS and FT-IR (846); a study of the fragmentation of 21 synthetic cannabinoids with an iso-Pr group or a tert-Bu group by EI-Quad-MS and positive ESI-TOF-MS (847); analysis of 22 synthetic cannabinoids, and separately of JWH018 and 9 of its positional isomers, by ultra high performance SFC (848); variation in commercial "smoking mixtures" containing third-generation synthetic cannabinoids (849); identification of 6 synthetic cannabinoids by DART-LTQ ORBITRAP (850); identification of APINACA 2H-indazole analogue, AMPPPCA, and 5F-AMPPPCA by LC-QTOF-MS, GC-TOF-MS, and NMR (851); differentiation of JWH-122 and JWH-210 by GC-EI-MS/MS (852); analysis of 5F-AMB and PX-3 by <sup>1</sup>H and <sup>13</sup>C NMR, HR-MS/MS, and Raman (853); an overview and review of recent international trends in Spice use (854); analysis of the 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA (possible manufacturing impurities with cannabimimetic activities) by <sup>1</sup>H and <sup>13</sup>C NMR, GC/MS, and UV/Vis (855); rapid identification of 10 synthetic cannabinoids by DART-MS and NMR (856); use of a QSAR model to determine the affinity of synthetic cannabinoids to the CB1 receptor

(857); identification and characterization of ADB-BICA, NNL-1, NNL-2, and PPA(N)-2201 by LC-QTOF-MS, GC/MS, FTIR, and NMR (858); determination of 8 synthetic cannabinoids by heat assisted sample introduction and dielectric barrier discharge ionization MS (859);

**Synthetic Cannabinoids and Cannabimimetics with Other Drugs (except when a minor part of a larger study):**

**2012** identification of atropine, scopolamine, lysergamide mitragynine, 4-methoxymethcathinone, 3-fluoromethcathinone, JWH-073, JWH-081, JWH-0250, and JWH-0251 in "herbal products" purchased via the Internet in 2009 and 2010 by LC/PDA/MS and GC/MS (860); analysis of CP-47,497, CP-47,497-C8, JWH-018, JWH-073, JWH-200, MDPV, mephedrone, and methylone by UHPLC/TOFMS (861); **2013** a review, including a comparison of the natural and synthetic cannabinoid materials (862); identification of ADB-FUBINACA, ADBICA, AM-2201 4-methoxynaphthyl analog, APICA N-(5-fluoropentyl) analog, APINACA N-(5-fluoropentyl) analog, JWH-122 N-(5-chloropentyl) analog, QUPIC, QUCHIC, and UR-144; N-(5-chloropentyl) analog (alpha-pyrrolidinovalerothiophenone (alpha-PVT) and 3,4-dichloro-N-([1-(dimethylamino)cyclohexyl]methyl)benzamide (AH-7921) also identified) (863); an overview of Psilocybe mushrooms, 5-MeO-DIPT, tryptamine, MDMA and related compounds, synthetic cannabinoids, and cannabimimetics (864); **2014** analysis of piperazine derivatives (BZP, MPMP, TFMPP), cathinone derivatives (N-ethylcathinone, buthylone, ethylone, methylone, buphedrone, flephedrone), pyrovalerone derivatives (MDPV, naphyrone), and synthetic cannabinoids (AM-694, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-250), by GC-EI-MS (865); determination of AM-2201, JWH-018, JWH-022 JWH-073, JWH-122, JWH-203, JWH-210, JWH-250, HU-210, RCS-4, THC, and various metabolites by UHPLCMS/ MS (866); analysis of cocaine, methylone, 4'-methylethcathinone, 3,4-MDPV, JWH-210, JWH-250, and JWH-203 by ion mobility-TOF-MS (867); analysis of a mixture of diphenidine and 5-fluoro-AB-PINACA (868); **2015** an overview of cannabis vs. synthetic cannabinoids (869); an overview of synthetic cathinones and cannabinoids (870); a review of a major researcher's 50 years of research on cannabinoids, with future-looking comments (871); analysis of synthetic cathinones and cannabimimetic agents by MS, LC/MS, LC-MS/MS, NMR, IR, and DART-MS (872).

-----  
**1.E - Polydrug A: Mixed or Unrelated Individually Named Compounds or Substances**

[Note: Each year in this subsection is separated by a line space.]

**2012** analysis of cocaine, heroin, and MDMA by spectral fluorescence (873); use of a modified multiwall carbon nanotubes paste electrode for simultaneous voltammetric determination of morphine and diclofenac in biological and pharmaceutical samples (874); an extended overview

and review of "date-rape" drugs (GHB, MDMA, flunitrazepam, and ketamine) (875);

**2013** detection of flunitrazepam, ketamine, and MDMA by IMS (toxicological focus) (876); analysis of methoxetamine, 3-methoxyeticyclidine, and 3-methoxyphencyclidine by GC- and CI-MS, NMR, and HPLC-DAD-ESI-MS/MS (toxicological focus) (877); identification of 1,4-benzobenzodiazepines (clonazepam, flurazepam, alprazolam, midazolam, bromazepam, chlordiazepoxide, lorazepam, and diazepam) and antidepressants (bupropion, sertraline, paroxetine, and fluoxetine) as adulterants in phytotherapeutic dieting formulations by voltammetry (878); differentiation of anorexics (amfepramone, fenproporex, sibutramine), benzodiazepinic anxiolytics (clonazepam, flurazepam, alprazolam, midazolam, medazepam, chlordiazepoxide, diazepam), antidepressants (bupropione, fluoxetine, sertraline, paroxetine), diuretics (hydrochlorothiazide, furosemide, chlortalidone, amiloride, spironolactone), and hypoglycemics (glimepiride, chlorpropamide, glibenclamide) by a solid state electrochemical method (879); analysis of tramadol and morphine by spectrofluorimetry and spectrophotometry (880); determination of morphine, nalbuphine, and "naltrexone drugs" in bulk and pharmaceutical formulations by a kinetic spectrophotometric method (881); determination of tramadol, morphine, nalbuphine and naltrexone analgesic drugs using potassium permanganate and spectrophotometry (882); determination of 13 sedative-hypnotics in health foods (including phenobarbital, estazolam, and diazepam) by HPLC-MS/MS (883); detection of lidocaine, diazepam, and ketamine as adulteration in foodstuffs and beverages by HPLC (884); analysis of methaqualone, saccharin, paracetamol, and phenacetin in illicit drugs by HPLC (885); an overview of the analyses of BZP, mephedrone, JWH-018, TFMPP, sage poet, kratom, fly agaric, kava-kava, and others (886); determination of 4 cathinones (mephedrone, butylone, 4-Me-PPP, and 4-MEC) and 5 tryptamines (5-EtO-DPT, 5-EtO-DALT, 5-EtO-MIPT, 5-EtO-ALCHT, and 5-EtO-2-MALET) by ESI-AP-Ion Mobility-TOF-MS (887); identification of kratom, 2C-C-NBOMe, 25I-NBOMe, RH-34 and UR-144, 2-(2,3-dimethoxyphenyl)-N-(3,4,5-trimethoxybenzyl)ethanamine (DMA-NBTOMe), acetylated 25I-NBOMe, acetylated DMA-NBTOMe by GC/MS and NMR (888); analysis of barbital, clozapine, chlordiazepoxide, midazolam maleate, phenobarbital, perphenazine, promethazine HCl, chlormezanone, nitrazepam, amobarbital, oxazepam, secobarbital sodium, estazolam, lorazepam, clonazepam, alprazolam, diazepam, and triazolam by UHPLC with PDA detection (889); analysis of alprazolam, estazolam, clonazepam, diazepam, phenobarbital, midazolam maleate, triazolam, nitrazepam, barbital, secobarbital, chlordiazepoxide, lorazepam, amobarbital, and oxazepam by UHPLC with PDA detection (890); analysis of mephedrone, 5,6-methylenedioxy-2-aminoindane (MDAI), and MDMA by SERS on copper coins coated with deposited silver (891); detection of 6 chemical constituents illegally added into health foods for dieting by UPLC-MS/MS (only sibutramine HCl and phenolphthalein were identified in the abstract) (892); identification of undeclared synthetic drugs (ranitidine, orphenadrine citrate, piroxicam, and dexamethasone) in medicines illegally sold as phytotherapies by diffusion-ordered NMR spectroscopy and

HPLC-UV-SPE-NMR (893); the longterm stability of 4-MEC, MDAI, methoxetamine, 5-MeO-DALT, 6-APB, MPA, 5-IAI, MDAT, 2-AI, AMT, 25C-NBOMe, AH-7921, 5-MAPB in blood and plasma, as determined by HPLC/DAD, LC-MS/MS, and UHPLC-Q-TOF-MS (894); determination of dextromethorphan and levomethorphan in heroin by enantioselective HPLC and electronic CD (895); identification of sibutramine HCl, fenfluramine HCl, phenolphthalein, strychnine, ephedrine HCl, and hydrochlorothiazide in health foods with weight reducing properties by TLC and HPLC-MS/MS (896); a survey of 449 "legal highs" seized in Poland between mid-2008 and mid-2011 (including MPDV, caffeine, butylone, TFMPP, lidocaine, 4-MEC, mephedrone, pFPP, BZP, and MDPBP, and others) (897);

**2014** analysis of 4-fluoroamphetamine, methiopropamine, ethcathinone, 4-methylethcathinone, N-ethylbuphedrone, ethylphenidate, 5-MeO-DALT, dimethocaine, 5-(2-aminopropyl)benzofuran, and nitracaine by a Selective Reagent Ionisation-TOFMS (898); trends in Irish street-level heroin and cocaine 2010-2012 (899); terahertz detection of ketamine and ATSs (900); an overview of the presence of mephedrone, 4-methylethcathinone, BZP, MDPV, TFMPP, methoxetamine, 4-fluoromethcathinone, 4-methylamphetamine, PMA, methylone, PMMA, naphyrone, alpha-methyltryptamine, butylone, MDAI, desoxypipradrol, D2PM, MPA, synthetic cannabinoids, 2-AI, 5-IAI, 5-MeODALT, MDPBP, 5/6-APB, pentedrone, and pentylone in post-mortem and criminal casework (toxicological focus) (901); analysis of 2-aminopropylbenzofuran with 4 potential positional isomers, methiopropamine, and 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one by GC/MS and NMR (902); analysis of alprazolam and fluoxetine by UV/Vis (903); a review on detecting residues of chlorpromazine and diazepam in foods (904); identification of ephedrine, caffeine, furosemide, fenfluramine, phenolphthalein, sibutramine, N-desmethyl sibutramine, and N-didesmethyl sibutramine in weight controlling health food by UHPLC/DAD (905); analysis of bromazepam, flunitrazepam, fluoxetine hydrochloride, clozapine, and risperidone by TLC (906); analysis of cocaine, LSD, levamisole, papaverine, and others by MALDI-HRMS, HPLC/DAD, and Quad-MS (907); analysis of cocaine, heroin, methamphetamine, oxycodone, and amphetamine on currency by LC/MS (908); syntheses, characterization, and in vitro metabolism of nitracaine, methoxypiperamide and meph tetramine (909); analysis of MDMA and mCPP by CE (910); determination of the stability in solution of 4-MEC, MDAI, methoxetamine, 5-MeO-DALT, 6-APB, MPA, 5-IAI, MDAT, 2-AI, AMT, 25C-NBOMe, AH-7921, and 5-MAPB by HPLC-DAD, LC-MS/MS, and UHPLC-Q-TOF-MS (911); analysis of amphetamine, methamphetamine, MDMA, N,N-dimethylamphetamine, PMA, PMMA, BZP, TFMPP, mCPP, and MeOP by DESI-MS (912); analysis of 3-methylmethcathinone, methylone, butylone, 4-methylethcathinone, flephedrone, methylenedioxypropylvalerone, pentedrone, methoxetamine, APINACA, AKB48, benzydamine, meta-chlorophenylpiperazine, 5-MeO-DALT, 5-MeOMIPT, 6-APB, 4-APB, diphenidine, and others, by single quadrupole GC/MS, positive ESI-LC/HRMS, and NMR (913); determination of lidocaine, ketamine, and diazepam in foodstuffs using micellar LC (914);

analysis of amphetamine, methamphetamine, caffeine, paracetamol, and theophylline by HPLC (915); identification of the piperazine derivative MT-45 (I-C6), the synthetic peptide Noopept (GVS-111), the synthetic cannabinoid A-834735, 4-methoxy- $\alpha$ -PVP, and 4-methylbuphedrine (analytical methodologies not provided in the abstract) (916); analysis of FUB-PB-22, 5-fluoro-NNEI indazole analog (5-fluoro-MN-18), AM-2201 indazole analog (THJ-2201), XLR-12, 5-fluoro-AB-PINACA, 5-chloro-AB-PINACA, AB-CHMINACA, and 5-fluoro-AMB; DL-4662,  $\alpha$ -PHP, 4-methoxy- $\alpha$ -POP, 4-methoxy- $\alpha$ -PHPP, and 4-fluoro- $\alpha$ -PHPP; 2-(2-ethylaminopropyl)-benzofuran (2-EAPB), nitracaine, diclofensine, diphenidine, 1-benzylpiperidine, and acetyl-fentanyl (analytical methodologies not identified in the abstract) (917); analysis of mixtures of methamphetamine, MDMA, and ketamine by GC/MS and GC/FID (918); **2015** analysis of dextromethorphan, 2-aminoindane, and lidocaine using handheld NIR, Raman, and FTIR/ATR instruments (919); examination of "third hand smoke" from cocaine and methamphetamine as a source of recoverable trace evidence (920); detection of cocaine and ketamine by paper microfluidic devices (921); qualitative, quantitative, and temporal study of cutting agents for cocaine and heroin confiscated in western Switzerland from 2006 to 2014 (analytical methodologies not identified in the abstract) (922); detection of cocaine, phytocannabinoids, nicotine, caffeine, and others in the air by collection on filters with analysis by GC/MSD (923); detection of nicotine, caffeine, cocaine, cannabinol, cannabidiol, and THC on particulates in indoor air (analytical methodology not identified in the abstract) (924); trends from 2002 to 2013 in the diversion and abuse of oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol (925); validation of a GC/FID for the quantitation of cocaine and heroin (926); analysis of various NPSs, including "Synthacaine" (purported to be a mixt. of methiopropamine (MPA) and dimethocaine, but instead containing MPA and benzocaine), two positional isomers of (2-amino-propyl)-benzofuran (5-APB and 6-APB), 2-amino-1-(4-bromo-2,5-dimethoxyphenethyl)ethanone (bk-2C-B), and 2-(ethylamino)-1-(4-methylphenyl)-pentan-1-one (MEAP) (analytical methodologies not identified in the abstract) (927); analysis of two component mixts. of morphine-papaverine and acridine-papaverine by TLC-IMS (928); identification of brodifacoum, black tar heroin and its impurities (morphine, codeine, noscapine, papaverine, and monoacetyl-morphine), crack cocaine, and 1-methylaminoanthraquinone by an atmospheric solid analysis probe interfaced to a linear ion trap-MS (929); analysis of 25H-NBOMe, 25D-NBOMe, 25E-NBOMe, 25I-NBMD, RH34, escaline, 5-DBFPV, 3,4-MDPHP, 3,4-dimethyl-NEB, 3,4-dimethyl- $\alpha$ -ethylaminopentiophenone, 3,4-dimethyl- $\alpha$ -PVP, 4F- $\alpha$ -ethylaminopentiophenone, bk-IVP, bk-IBP, MMXE, 25INBOMe, ADB-CHIMINACA, 5F-ADB, and butane-1,4-diol by GC/MS, HRMS, and NMR (930); determination of amphetamine, cocaine, methadone, diazepam, methylphenidate, oxazepam, tramadol, morphine, buprenorphine, and 6-monoacetyl-morphine by SERS (931); determination of 22 drugs of abuse and transformation products in airborne particulate matter by pressurized liquid extraction followed by LC-MS/MS (cannabinol, cocaine, and methamphetamine were the most abundant compds; the other 18 compds were not identified in the abstract) (932); detection of THC, methamphetamine, and amphetamine at low

ppb level in air using a field asymmetric IMS microchip sensor (933); use of paper microfluidic devices for presumptive identification of cocaine, opiates, ketamine, various phenethylamines, and others (934); detection of phytocannabinoids, cocaine, lidocaine, and nicotine by ESI-FT-ICR-MS (with comparison against the fast blue B colorimetric test (935); use of fluorescent d10 metal complexes for the presumptive identification of cocaine, PCP, diphenhydramine, and benzylpiperazine (936); determination of benzodiazepines and zolpidem in water samples (using polypropylene tubes as single-use and low-cost sorptive extraction materials) (937); determination of phentermine, phendimetrazine, phenmetrazine, fenfluramine, benfluorex, mephentermine, fencanfamine, sibutramine, sildenafil, vardenafil, and tadalafil in food supplements by LC-HR-MS (938); analysis of venlafaxine, escitalopram, fluoxetine, candesartan, risperidone, trihexyphenidyl, thioridazine, aripiprazole, and trifluoperazine by UHPLC (939); a review of the published voltammetric and potentiometric methods developed for determination of dextromethorphan and diphenhydramine (940); analysis of FDU-NNEI, AB-CHMINACA, MN-18, N-OHEDMA, dimethoxy- $\alpha$ -PHP (analytical methodologies not identified in the abstract) (941); analysis of methamphetamine, morphine, and codeine by a probe ESI-MS with a discontinuous atmospheric pressure interface (942); determination of barbital, phenobarbital, chlormezanone, amobarbital, zopiclone, melatonin, chlorphenamine maleate, clozapine, zaleplone, zolpidem tartrate, oxazepam, nitrazepam, triazolam, clonazepam, midazolam maleate, diazepam, and olanzapine in traditional Chinese medicines and health foods by HPLC (943); determination of carbamazepine, doxepin, diazepam, lorazepam, amitriptyline, temazepam, oxazepam, and alprazolam in an urban water system (analytical method not identified in the abstract) (944);

**2016** use of screen-printed electrodes for quantification of cocaine and THC (945); the persistence of illicit drug smoke residues from cocaine and methamphetamine and their recovery from common household surfaces (946); chemical profiling of cocaine and heroin as a tool to decipher the structure and organisation of illicit drug markets (947); a review of the cutting of cocaine and heroin (948); analysis of mephedrone and MDAI by microcrystalline testing and Raman microspectroscopy (949); use of a fluorescence probe for ketamine and methamphetamine detection without pretreatment (950); IMS response of cocaine, heroin, methamphetamine, MDMA, and THC against environmental background levels (951); the vaporization enthalpy and vapor pressure of fenpropidin and phencyclidine (PCP) at  $T/K = 298.15$  by correlation GC (952); simultaneous determination of morphine and naltrexone by HPLC (953); analysis of 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APB-NBOMe by LC-QTOF-MS, GC/MS, and NMR (954); sorption of ionized pharmaceutical and illicit drugs to a mixed-mode coated micro-sampler, including amphetamine, amitriptyline, promazine, chlorpromazine, triflupromazine, difenzoquat, 8 basic pharmaceutical and illicit drugs (MDMA, atenolol, alprenolol, metoprolol, morphine, nicotine, tramadol, verapamil, 3 neutral benzodiazepines (diazepam, temazepam, and oxazepam), and diclofenac (955); analysis of a mixt. of cocaine, MDA, and MDMA by single analyzer precursor scanning using an ion trap (956); analysis of the

phenethylamine derivative 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(3,4-methylenedioxyphenyl)-methyl]ethanamine (25I-NB34MD) and the piperazine derivative 1-(3,4-difluoromethylenedioxybenzyl)piperazine (DF-MDBP) by LC/MS, GC/MS, HRMS, and NMR (957).

----- Next Section Moved Up to Reduce Deadspace -----

## 2. Instrument Focus

Forensic Chemists must maintain familiarity with updates in current instrumental techniques and become versant in new, improved methods of analysis. Improved/existing and new technologies are reviewed and applied to both routine and specialized analyses of drugs. In cases where improved performance is observed, case reports are generated for the forensic community.

### **2.A - Polydrug B: Mixed or Unrelated Groups of Compounds or Substances Named**

**Groups of Compounds:** 2013 analysis of 277 "selected" synthetic cannabinoids and cathinones, amphetamines, natural cannabinoids, opioids, cocaine and other "important drugs of abuse" by UHPLC-HR-TOFMS (toxicological focus) (958); analysis of cathinones, phenethylamines, tryptamines, and piperazines by LCQQQ-MS/MS in the MRM mode (toxicological focus) (959); **2014** analysis of various phenethylamines, cathinones, synthetic cannabinoids, and tryptamines by IMS (compounds not identified in the abstract) (960); an overview and literature review of synthetic cannabinoids and synthetic cathinones (961); a review of the analysis of (unspecified) "psychostimulants" by TLC (962); qualitative analysis of 34 synthetic cannabinoids and synthetic cathinones by GC-triple quadrupole-MS/MS (963); screening and identification of cathinones, synthetic cannabinoids/cannabimimetics, and phenethylamines by UHPLC with DAD and MS detection (964); a review of the analysis of of (unspecified) "anesthetics" by TLC (965); identification of 61 different psychoactive substances (predominantly substituted phenethylamines, cathinones, tryptamines and synthetic cannabinoids) by LC-chemiluminescence-nitrogen detection (966); analysis of morphine and a series of adrenergic phenolic amines (not identified in the abstract) by chemiluminescence detection on 3D-printed and CNC milled flow-cells (967); crossreactivity of 24 phenylethylamines (including 8 cathinone derivatives), 3 piperazines, and 3 tryptamines in commercial enzyme-linked immunosorbent assays (968); chiral analysis of seven benzo-furys, four cathinones, two diphenidines, ethylphenidate, methiopropamine, and thiothionone by CE (969); an overview of the appearance and evolution of cannabimimetics and cathinones (970); **2015** characterization of 25INB2OMe, 25I-NB3OMe, 25I-NB4OMe, 25I-NB2B, 25I-NB3B, 25I-NB4B, their 5-methoxytryptamine counterparts, and 6 meta-substituted N-benzyl derivs. of 5-methoxytryptamine (CF<sub>3</sub>, F, CH<sub>3</sub>, Cl, I, SCH<sub>3</sub>), by GC/ion trap-MS in both EI and CI modes, LC/DAD, IR, ESI-QTOF-MS/MS, and Triple-Quad-MS/MS (971); analysis of 11 phenethylamines and cathinones by 1H-NMR, COSY, TOCSY, and DOSY

(972); an overview of synthetic cannabinoids and designer cathinones (973); regioisomeric and enantiomeric analyses of 24 designer cathinones and phenethylamines using UHPLC and CE with added cyclodextrins (compounds not identified in the abstract) (974); a review of the detection methods (including covering colorimetric detection, immunochem. assays, GC/MS analyses, and LC/MS) for synthetic cannabinoids and cathinones (975); cross-reactivity of 2,5-dimethoxyamphetamines, "2C" cmpds (2,5-dimethoxyphenethylamines),  $\beta$ -keto amphetamines, substituted amphetamines, piperazines,  $\alpha$ -pyrrolidinopropiophenones, tryptamines and PCP analogs on five commercial immunoassay screening kits (976); **2016** separations of barbiturates, sulfonamides, nucleic bases, and nucleosides on polymethacrylate zwitterionic monolithic micro-columns in 2D-LC (977);

**Abused Substances Illegally Added to Licit Pharmaceuticals, Herbal Medications, Health Supplements, and Foodstuffs (Notes: A) Specific, named compounds are compiled in their individual categories above; B) There are many dozens/hundreds of highly repetitive articles pertaining to adulteration of Chinese foods, food seasonings, health care supplements, sexual enhancement aids, Chinese Traditional Medicines, etc.; only a select six of these are included below):** **2012** analysis of for anorexigenic, benzodiazepinic, and antidepressant drugs in phytopharmaceuticals by GC/MS (978); **2013** detection of undeclared synthetic drugs in traditional herbal medicines, using LC-MS/MS, GC-MS/MS, and similar techniques (979); standardless <sup>1</sup>H-NMR determination of a "wide range of" pharmacologically active substances in dietary supplements and medicines (only mesterolone is specifically mentioned in the abstract) (980); **2014** detection of 35 illegally added steroid compounds in foods and dietary supplements by LC-MS/MS (981); detection of 29 weight loss compounds in foods and dietary supplements by LC-MS/MS (982); a review of the determination of pharmacologic adulterants in herbal-based pharmaceuticals by CE (983); rapid identification of 22 drugs illegally added into sleep-improving health foods by UHPLC-TOF-MS (984); **2015** simultaneous analysis of 28 narcotic adulterants (not identified in the abstract) used in dietary supplements by LC-MS/MS (985); analysis of 24 sedative-hypnotic drugs (not identified in the abstract) illegally added into health foods, by UPLC-ESI-QTOF/ MS (986); screening of 24 sedative hypnotics illegally added to "improving sleep" health foods by HPLC-ion trap-MS (987); determination of 36 chemicals added into traditional Chinese medicines and health care products by UPLC-MS/MS (988); substitute reference substance and secondary mass spectral libraries for rapid screening of sedative hypnotic drugs illegally added to Chinese drugs and health products by HPLC-DAD and HPLC-MS/MS (989); an overview and review of alkaloids in foods (990); determination of caffeine and adrenergic stimulants in food supplements by HPLC/DAD (991); identification of chemical substances illegally adulterated in traditional Chinese medicines and health foods by physico-chem. anal., TLC, HPLC, LC/MS, GC/MS, CE, ion mobility chromatog., IR, NIR, Raman, and LC-MS/MS (992); **2016** a comprehensive strategy to detect the fraudulent adulteration of herbs by FTIR and chemometrics, as well as LC-HRMS

(993); direct determination of 42 chemical drugs illegally added in herbal medicines and dietary supplement by HPLC-Quadrupole-electrostatic field Orbitrap-HRMS (994); an overview of regulation of dietary supplements in the U.S. and issues of adulteration with phenethylamines (995); detection of low molecular weight adulterants in beverages by DART-MS (996); an overview and review of the adulteration of herbal sexual enhancers and dieting aids (997);

### **Abused Drugs and Pharmaceuticals in Surface Waters and Municipal Wastewater Streams:**

[Note: Each year in this subsection is separated by a line space.]

**2012** analysis of sewage in the Brazilian Federal District as a means for estimating cocaine consumption (analytical method not specified in the abstract) (998);

**2013** a study of the uncertainty associated with the estimation of community illicit drug consumption via analysis of sewage (999); analysis for mephedrone, methylone, MDPV, BZP, TFMPP, methcathinone, and MDMA in sewage in Adelaide, Australia, by SPE-LC-MS/MS (1000); a review of drugs of abuse in waters and wastewaters: occurrence, analysis, and forensic applications (1001); detection of of pharmaceuticals and "food additives" in sewage by SPE-LC-MS/MS (1002); by online-SPE-LC/MS (1003); analysis for 25 different drugs in wastewater by solid phase extraction and GC/MS (1004); detection of of illicit drugs in wetlands water by LC/MS (1005); analysis of wastewater in Finland for abused drugs and opioids, using SPE and LC-MS/MS (1006);

**2014** identification and quantification of trace concns. of pharmaceuticals (caffeine, prazosin, enalapril, carbamazepine, nifedipine, levonorgestrel, simvastatin, hydrochlorothiazide, gliclazide, diclofenac-Na, and mefenamic acid) in surface waters, by LC-TOF/MS (1007); removal efficiencies of cocaine, amphetamine, methamphetamine, THC-COOH, benzoylecgonine, MDMA, ketamine, heroin, and other drugs at a wastewater treatment plant (analytical methodology not identified in the abstract) (1008); determination of stimulants, hallucinogens and their metabolites, opioids, morphine derivs., benzodiazepines, antidepressants, and others in wastewaters in England (analytical methodologies not identified in the abstract) (1009); population normalization using ammonium in wastewater-based epidemiology, and its application to illicit drug monitoring (benzoyl ecgonine, THC-COOH, cocaine, and 4-hydroxy-3-methoxymethamphetamine are named in the abstract) (1010); use of a cavitand-grafted silicon microcantilever as a universal probe for illicit and designer drugs in water (1011); determination of amphetamines, MDMA, cocaine, opioids, cannabis, and ketamine, and their major metabolites, in urban wastewaters by UHPLC-MS/MS (1012); determination of 1525 micro-pollutants and transformation products in wastewater by LC-QTOF-MS with an accurate-mass

database (1013); survey of the occurrence of pharmaceuticals in Spanish drinking waters (1014); highly sensitive determination of 68 psychoactive pharmaceuticals, illicit drugs, and related human metabolites in wastewater by LC-MS/MS (1015); screening of illicit and licit drugs in waters in Colombia by LC-QTOF-MS (1016); determination of 21 acidic pharmaceuticals and personal care products in the Turia River Basin, Spain by LC/MS-MS/ESI-NI (1017); a selection of papers from the first international multidisciplinary conference on detecting illicit drugs in wastewater (1018); evaluation of illicit and licit drug consumption based on wastewater analysis in Fort de France urban area (Martinique, Caribbean) (1019); determination of nalbuphine, naltrexone, morphine, and tramadol by a bromatometric assay (1020); a review of the analysis of chiral pharmaceuticals in the environment (wastewater) by chiral chromatography coupled with mass spectrometry (1021); a sampling method for detecting analgesics, psycholeptics, anti-depressants, and illicit drugs in aquatic environments in the Czech Republic (1022); quantification of (unspecified) target drugs in different wastewater samples by a validated SPE/LC-MS/MS method (1023); the ecotoxicity and contribution to the environmental hazard of pharmaceuticals in hospital wastewater (1024); use of columns containing sand and undisturbed fine-grained sediments to simulate injection of wastewater contg. caffeine, methamphetamine, and acetaminophen into a septic system, leaky sewer, or landfill (1025); a review of the determination of pharmaceuticals and illicit drugs in waters by LC-HRMS (1026); communal assessment of drugs of abuse and identification of their transformation products by analysis of sewage/wastewater by online SPE-LC-HRMS (1027); estimation of illicit and pharmaceutical drug consumption estimated via wastewater analysis (1028); a review of the occurrence, effects, and methods for detection of antibiotics and illicit drugs in the environment (1029); determination of cocaine, benzoylecgonine, ecgonine methylester, methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 6-monoacetylmorphine, amphetamine, methamphetamine, ecstasy, mephedrone, methylenedioxypropylamphetamine, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol, ketamine, and norketamine in sewage (analytical method not identified in the abstract) (1030); an overview of international management trend of pharmaceuticals and personal care products in water environments (1031); the transformation products of illicit drugs in the aquatic environment (1032); estimation of amphetamine and methamphetamine use through sewage-based analysis (1033); determination of pharmaceuticals and personal care products in a mesoscale subtropical watershed and their application as sewage markers (1034); comparison of illicit drug use in three selected towns in Slovakia by wastewater analysis (1035); identification of contaminants in water by UHPLC-QTOF-MS (1036); analysis for ethyl sulfate in raw wastewater for estimation of alcohol consumption and its correlation with drugs of abuse in the city of Barcelona, Spain (1037); an overview of organic contaminants in surface water and groundwater in Italy (1038); determination of amphetamines in wastewater by LC-MS/MS (1039); a discussion of the need to develop ethical guidelines for researchers using sewage epidemiol. to monitor drug use in the general population and in specific precincts, including prisons, schools, and workplaces (1040); determination of benzodiazepines, related pharmaceuticals, and metabolites in water by SPE and

LC-MS/MS (1041); using biomarkers in wastewater to monitor community drug use (focus on NPSs) (1042); determination of over 400 priority and emerging pollutants in water and wastewater by SPE and LCTOF-MS (1043); removal efficiencies of amphetamine-type stimulants, cocaine and benzoylecgonine, opioids, codeine, MDA, fentanyl, dihydrocodeine, and heroin at each point of wastewater treatment (analytical methodology not identified in the abstract) (1044); determination of cocaine, benzoylecgonine, propranolol, diclofenac, amitriptyline, carbamazepine, carbamazepine-epoxide, citalopram, metoprolol, carisoprolol, and sertraline in urban streams in Brazil (analytical methodology not identified in the abstract) (1045); systematic screening for common wastewater marking pharmaceuticals in urban aquatic environments (1046);

**2015** occurrence and in-stream attenuation of wastewater-derived pharmaceuticals in Iberian rivers, Spain (1047); determination of 4 benzodiazepines (bromazepam, carbamazepine, diazepam, and nordiazepam) and 4 barbiturates (barbital, pentobarbital, phenobarbital, and secobarbital) in river water and wastewater using SPE followed by LC-(ESI)MS/MS (1048); screening for pharmaceuticals and illicit drugs in wastewater and surface waters of Spain and Italy by UHPLC-QTOF-MS and LC-LTQ-Orbitrap-MS (1049); determination of heroin and methadone in wastewater in Lausanne, Switzerland (analytical methodology not identified in the abstract) (1050); fast determination of 40 drugs in water (10 effluent wastewater and 10 surface water samples) using large volume direct injection LC-MS/MS (1051); determination of 10 synthetic cannabinoids, cathinones, piperazines and pyrrolidophenones in wastewater by LC-MS/MS (1052); determination of ketamine and mephedrone in wastewater in 17 cities in Italy, by SPE-LC-MS/MS (1053); methamphetamine and ketamine (analytical methodology not identified in the abstract) (1054); an overview and review of determination of contaminants in water by UHPLC/MS (1055); detection of cocaine and benzoylecgonine (and other drugs) in samples collected from three sewage treatment plants in Cyprus by off-line solid phase extn. followed by LC-MS/MS (1056); screening for more than 1,000 licit and illicit drugs and their metabolites in wastewater and surface waters from the Bogota, Colombia area by SPE followed by UHPLC-QTOF-MS (1057); detection of amphetamines, opioids, cocaine [sic], cannabinoids, lysergics, and their corresponding metabolites by SPE-LC-HR-MS (1058); advances towards a universal screening for organic pollutants in waters, by GC-QTOF-MS and LC-QTOF-MS (1059 and 1060); detection of illicit drugs in raw sewage influents by HRMS (1061); chemometric application of pharmaco-signatures in different aquatic systems (1062); determination of methoxetamine, butylone, ethylone, methylone, methiopropamine, PMMA, and PMA in sewage by LC-ESI-MS/MS (1063); the systematic and day-to-day effects of chemical-derived population estimates on wastewater-based drug epidemiology (1064); use of a Fenton-like reaction to remove illicit drugs and pharmaceuticals from wastewater (emphasis on methamphetamine and tramadol) (1065); determination of amphetamine and methamphetamine at 10 wastewater treatment plants by LC-HR-MS/MS (1066); detection of methamphetamine,

amphetamine, and codeine in wastewater (analytical methodology not identified in the abstract) (1067); analysis of pharmacologically active compounds in the environment by chiral LC-MS/MS (1068); detection of 4'-methyl- $\alpha$ -pyrrolidinohexanophenone (MPHP), 2-[4-(ethylsulfanyl)-2,5-dimethoxyphenyl]ethanamine (2C-T-2; Rosy), 4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine (4-MAR), and 1-(4-methoxyphenyl)-2-propanamine (PMA) in raw sewage by HR-MS (location not identified in the abstract) (1069); linking drugs of abuse in wastewater to contamination of surface and drinking water (17 drugs of abuse, including cocaine, several amphetamines, opioid drugs, and 2 metabolites, benzoylecgonine, and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (a metabolite of methadone) were investigated; analytical methodology not identified in the abstract) (1070); determination of alcohol and cocaine co-consumption in 2 European cities as assessed by wastewater analysis using LC-MS/MS (1071); wastewater-based epidemiology of stimulant drugs based on analysis of sewage samples from 42 European cities collected daily for one week in March, 2013 (1072); determination of 25 synthetic psychoactive compds., including amphetamine, sympathomimetic substituted amphetamines, synthetic cathinones, and ketamine, in raw wastewater, secondary effluent, and river water by SPE followed by LC-MS/MS (1073); comparison of wastewater analysis and population surveys for use of methamphetamine, MDMA, and cocaine (1074); determination of cocaine and benzoylecgonine in the Esmeraldas watershed in Ecuador (analytical methodology not identified in the abstract) (1075); comparison of population surveys with wastewater analysis for monitoring illicit drug consumption in Italy from 2010-2014 (1076);

**2016** identification of "a wide range of suspected and unknown compds. in environmental samples" by LC-HRMS (1077); determination of the occurrence and spatial distribution of 158 pharmaceuticals, drugs of abuse, and related metabolites in offshore seawater by SPME and LC-MS/MS (1078); determination of pharmaceuticals in coastal systems using SPE and UPLC-MS/MS (1079); use of wastewater-based epidemiology to estimate consumption of methamphetamine, benzoylecgonine, MDMA, methadone, oxycodone, and hydrocodone (analytical methodology not identified in the abstract) (1080); analysis of illicit drugs in wastewater to assess the market share held by criminal groups (1081); determination of amphetamine, methamphetamine, MDMA, and cocaine in 7 locations in Belgium over 2011-2015 (analytical methodology not identified in the abstract) (1082); validation and uncertainties evaluation of an isotope dilution-SPELC-MS/MS for the quantification of drug residues in surface waters (including diazepam and MDMA) (1083); determination of cocaine and benzoylecgonine in environmental samples by newly developed sorbent materials (1084); detection of opioid analgesics, amphetamines, cocaine, heroin, stimulants, anesthetics, sedatives, anxiolytics, designer drugs, phosphodiesterase-5 inhibitors, and amphetamine and methamphetamine drug precursors in wastewaters by LC-MS/MS (1085); quantitative analysis of morphine, oxymorphone, hydromorphone, oxycodone, hydrocodone, and THC-COOH in river and wastewater by UHPLCMSMS with an API/ESI source (1086); source discrimination of drug

residues in wastewater by chiral LC-MS-MS (a case study) (1087); determination of drugs of abuse and alcohol consumption through sewage-based epidemiology among different groups of population on the Greek Island of Lesbos (1088); screening for drugs of abuse in the wastewater in a small college town in Southern Arkansas by GC/MS, GC/FID, and HPLC/MS (1089); screening for NPSs in urban wastewater using HRMS (1090); evaluation of sampling plans for cocaine, methamphetamine, MDMA, and methadone in wastewater (1091); wastewater based epidemiology in Finland (samples analyzed by UHPLC-MS/MS) (1092); estimation of drug abuse in 9 Polish cities by wastewater analysis by HPLC-MS/MS (1093); determination of heroin, cocaine, amphetamine, MDMA, methamphetamine, cannabis, codeine, and methadone in 6 Croatian cities (analytical methodology not identified in the abstract) (1094); correlated results from an Australia-wide wastewater monitoring of cocaine/benzoylecgonine, methamphetamine, and MDMA (analysis by LC-MS/MS) (1095); determination of cocaine, MDMA, and methamphetamine residues in wastewater by LC/MS (1096); common illicit drugs (primarily methamphetamine and ketamine and their metabolites in surface waters) (analytical methodology not identified in the abstract) (1097); removal of psychoactive pharmaceuticals and illicit drugs from wastewaters by zerovalent iron and iron(VI) (1098); determination of cocaine, benzoylecgonine, ephedrine, MDMA, methadone and its metabolite EDDP in Spanish river basins by online SPE-LC-ESI-MS/MS (1099); a review on the stability of illicit drugs in sewers and wastewater samples (1100); analyses for 48 emerging pollutants, including 25 drugs of abuse and metabolites, 17 cytostatic drugs, and 6 iodinated contrast media, in tap water in Madrid, Spain by SPE and LCMS/MS (1101); effects of time delay between sample collection and extraction of wastewater samples for amphetamine and opioid analysis (1102); quant. analysis of 33 compds in a Brazillian coastal zone., including cocaine and bezoylecgonine, by LC-MS/MS (1103); detection and quantification of various opioid compounds (primarily heroin and morphine) in urban wastewater in Cookeville, Tennessee by LC-MS/MS (1104); determination of cocaine, methamphetamine, MDMA, amphetamine, codeine, morphine, heroin, fentanyl, oxycodone, methadone, BZP, TFMPP, methcathinone, methylone, mephedrone, MDPV, alpha-PVP, PMA, 25C-NBOMe, 25B-NBOMe, 25I-NBOMe, and cannabis in Adelaide, Australia for up to 4 years between Dec. 2011 and Dec. 2015 (analytical methodology not identified in the abstract) (1105); determination of metabolites of methamphetamine, cocaine, THC, and heroin by LC/MS (1106); determination of amphetamine-like compds., ketamine, cocaine, and opioids in North China (analytical methodology not identified in the abstract) (1107); detection of cocaine in wastewater with DNA-directed immobilization aptamer sensors (1108);

**"Novel Psychoactive Substances" (NPSs): 2013** a review of 1320 cases containing one or more of 26 synthetic cannabinoids, 12 designer stimulants, and 5 hallucinogenic-like drugs (1109); an overview of the New Zealand approach to regulated NPSs (1110); **2014** a study of the prevalence and correlates of NPS use amongst a group of regular Ecstasy users in Australia (1111); a review (1112); a review (1113); a report from the European Drug Emergencies

Network on their efforts to improve the knowledge of acute drug toxicity of recreational drugs and NPS (1114); an overview of the effects and risks associated with NPSs (toxicological focus) (1115); an overview of legislation against NPSs in Ireland (1116); identification of NPSs by FTIR, Raman, and GC-IR (1117); an overview of the emerging trends in the abuse of NPSs (1118); an overview (1119); detection and presumptive identification of NPSs by a portable NIR spectrometer (1120); the impact of new retail restrictions and product licensing on the regulated legal market for NPS products in New Zealand (1121); an overview of the high variability of active ingredients concentration, mislabelled preparations, and presence of multiple psychoactive substances in NPS products (1122); **2015** wide-range screening of NPSs by FIA-HRMS (1123); detection and characterization of NPSs by IMS (1124); a review (1125); a brief overview of recent trends (1126); rapid screening of 35 NPSs by IMS and DART-QTOF-MS (1127); a study on the prediction of bioactivity of NPSs (1128); detection of NPSs by SERS (1129); an overview of recent developments in the analysis of NPSs (1130); an overview of NPSs and their impact on forensic science (1131); an overview and review, covering years 2013-2015 (1132); **2016** a proposal for a new categorization of NPSs based on neurobiol. mechanisms of action (1133); an overview of how NPSs are studied, produced, marketed, and controlled (1134); screening for 221 NPSs by infrared and Raman (1135); a review on the screening for NPSs by LC coupled with low-and high-resoln. MS (covering PubMed-listed studies from Jan. 2014 to Jan. 2016) (1136); detection of NPSs in street samples by NIR and chemometrics (1137); an update on New Zealand's legal market for NPSs (1138); an overview of the pharmacology of stimulant and hallucinogen NPSs (1139); a brief overview of the NPS situation in Japan (1140); a brief overview of the analytical challenges posed by NPSs (1141);

**"Hallucinogens", "Hypnotics" (and similar generic terms):** **2013** editorial remarks against the global prohibition of psychoactive drugs (1142); **2014** a review of the non-medical use of dissociative drugs (1143); a review of the determination of of anxiolytics and sedatives by TLC (1144); **2015** sedative-hypnotic and anxiolytic effects of "lotus leaf alkaloid extract" (the exact species of lotus - there are many - was not identified in the abstract) (1145);

**"Illicit Drugs" (including "Controlled Substances," "Drugs of Abuse," "Illicit Drugs," "Narcotics," "Seized Drugs," and similar generic terms):** **2012** "drugs of abuse" by Raman (1146); use of spatially offset Raman to detect "illicit drugs" through opaque plastic containers, colored glass bottles, paper envelopes, and clothes (1147); a review on THz time-domain spectroscopy (including THz spectra for "drugs of abuse") (1148); detection of "drugs of abuse" using SERS (1149); application of handheld FTIR and Raman spectrometers for detection of "drugs of abuse" (1150); a review of the analysis of "seized drugs" by UHPLC and UHPLC-MS (1151); a short review of recent advances in analysis of "drugs" (and other substrates) by MS (1152); **2013** an evaluation of the results of impurity profiling of "illicit drugs" from different analytical methods and/or from different laboratories (1153); detection of trace amounts of "illicit

drugs" on surfaces by direct analyte-probed nanoextraction coupled to nanospray ionization-mass spectrometry (1154); detection of "drugs" concealed inside diffusely scattering packaging, including plastic, paper, and cloth, by spatially offset Raman (1155); analysis of "illicit drugs" by ambient pressure thermal desorption ionization MS (1156); rapid screening for 73 "toxic and harmful substances" in foods by UHPLC/MS, with sample cleanup using the QuEChERS system (1157); an overview and review of the analysis of "illegal drug products" (1158); the effects of solvents on the analysis of "drugs" by ESI-MS (1159); a review of the analysis of "law-evading and illegal drugs" using liq.-liq. extn. and GC/MS (1160); a review of CE and CEC methods used for analysis of "drugs" in biological matrices (1161); use of a supramolecular sensor array with two fluorescent receptors to detect "addictive OTC drugs" (1162); analysis of "seized drugs" by LC-ESI/MS/MS and AP-MALDI-MS/MS, with comparisons of the two techniques (1163); detection of "illicit substances" and pharmaceutical counterfeits by nuclear quadrupole and magnetic resonance (1164); annual review of "banned substances" (sports doping focus) (1165); an overview of advanced analytical instrumentation and methods for "drugs of abuse" (toxicological focus) (1166); **2014** screening of textiles for "contraband drugs" using portable Raman spectroscopy and chemometrics (1167); an evaluation of the effectiveness of MS, IR, and portable Raman to analyze commonly encountered drug mixts., as well as "legal highs" (1168); screening of "drugs of abuse" using a commercial paper spray system (1169); detection of "abused drugs" by HPLC (1170); an overview of recent trends in the analysis of "emerging drugs of abuse" (1171); analysis of designer drugs ("bath salts") by Raman and SERS (1172); a review of new designer "drugs of abuse" (1173); a quantitative structure-toxicity relationship of the aquatic toxicity for various "narcotic pollutants" using the norm indexes (1174); **2015** a comprehensive review of the pyrolysis of "drugs of abuse" (1175); analysis of "drugs of abuse" (naturally occurring psychotropic drugs and new designer drugs) by DART-MS (1176); use of diazonium ions for the presumptive testing of "narcotics" containing an activated aromatic ring (1177); screening for "illicit drugs" by direct-heating HSSPME with GC/MS (1178); identification of "abused drugs" by GC/FTIR (1179); an overview and review of "drugs of abuse" and their detection methodologies (1180); determination of "illicit drugs" and their metabolites on banknotes by methanol extn. followed by LC-MS/MS (1181); a review of alkylsilyl derivatization techniques in the analysis of "illicit drugs" by GC (GHB, amphetamines, opiates, and cannabinoids were mentioned in the abstract) (1182); indirect chiral separation of "new recreational drugs" by GC/MS using trifluoroacetyl-l-prolyl chloride (1183); **2016** results of the Trans European Drug Information (TEDI) project (results for cocaine, ecstasy, and amphetamine, plus comments on NPSs detected between 2008 and 2013) (1184); rapid identification of "seized controlled substances" and related compounds by MS/MS without chromatography (1185); screening of "drugs of abuse" using DART-MS (1186); "forensic drug" analysis by chemical derivatization followed by GC/MS and LC/MS (1187); a survey of the qual. distribution of "drugs of abuse" (mostly NPSs) confiscated in Italy between 2013 and 2015 (1188);

**Pharmaceuticals/Counterfeits (with a focus on differentiation of legitimate versus counterfeit products, or for monitoring quality control for legitimate pharmaceuticals; see also a significant number of citations concerning counterfeits under Phosphodiesterase-5 Inhibitors, above):** **2012** a review of the detection of counterfeit medications by Raman (1189); **2013** a review of a paper-based test for screening for counterfeits (1190); a general overview of the chromatographic techniques used to characterize counterfeit and illegal pharmaceuticals (1191); an overview of chromatographic and spectroscopic counterfeit detection methods (1192); examination of tablet surfaces by Multimodal DESI-MS imaging to detect counterfeits (1193); detection of counterfeit medications with portable Raman (1194); analysis of pharmaceuticals by Raman (1195); a review on the detection of counterfeit medications, focusing on HPLC and MS, but also discussing color testing, TLC, GC, Raman, NIR, FTIR, and NMR, using antimalarial drugs and sildenafil as illustrative examples (1196); **2014** detection of counterfeit medications with Raman and NIR (1197); confirmational identification of pharmaceuticals via DART-TOF-MS (1198); an overview of pharmaceutical process validation of solid dosage form (1199); **2015** systematic chemical and packaging analysis of counterfeit medications to derive useful intelligence (1200); **2016** an analytical strategy for rapid identification of counterfeit medications (1201); a review of the identification of counterfeit medicines by chemometrics (1202); a comprehensive review on prevalence, detection, and prevention of counterfeit drugs (1203).

-----

## **2.B - Instrument Focus**

**General Overviews and Reviews (and articles covering multiple techniques):** **2014** an overview of forensic drug analyses, including an analytical road-map (1204); an overview of drug testing, covering chem. testing, chromatog., spectroscopy, CE, immunoassay, and IMS (1205); **2015** a review of miniaturized separation techniques for forensic drugs analysis (including CE, CEC, and nano-LC) (1206);

**Color Testing:** **2014** the effect of benzene ring substituents on the mechanism of Duquenois Levine test for (phyto-)cannabinoid detection (1207); detection of pharmaceuticals using paper analytical devices (embedded with various color-testing reagents) (1208); **2015** use of presumptive color tests for NPSs (abstract not available) (1209); the modernization of physical appearance and solution color tests using quantitative tristimulus colorimetry (1210);

**Computerized Tomography (CT):** **2015** dual-energy CT behavior of heroin, cocaine, and typical adulterants (1211); use of CT (and X-ray, ultrasound, and MRI) to detect body packing (1212);

**Electrophoresis (and Related Techniques):** **2013** determination of active ingredients and preservatives in pharmaceuticals by CZE (1213); a review of recent advances in electrodriven enantioseparations (listed applications include "pharmaceutical" and "forensic") (1214); **2014** separation of acidic drugs by CEC using both chlorinated and nonchlorinated polysaccharide-based selectors (1215); a comprehensive overview and review (1216); a review of the application of CE techniques in toxicological analysis (1217); a review of recent method developments and applications of CE/DAD to pharmaceuticals (1218); **2015** a review of electromigrative sepn. techniques in forensic toxicol. (1219);

**Gas Chromatography:** **2013** forensic applications of GC (1220); **2016** a review of the forensic potential of comprehensive 2D-GC (1221); cleanup of complex matrices (containing drugs) by QuEChERS followed by GC analysis (1222);

**Hyperspectral Imaging:** **2013** development of a handheld widefield hyperspectral imaging (HSI) sensor for standoff detection of explosive, chemical, and narcotic residues (stated applications include "locating production facilities of illegal drugs") (1223);

**Infrared Spectroscopy:** **2013** use of IR spectral imaging for drug quality control (1224); **2014** analysis of varied substrates by FTIR spectroscopic imaging (1225); use of a handheld near IR spectrometer for the classification of 140 different substances, including cocaine, heroin, oxycodone, diazepam, synthetic cathinones, and synthetic cannabinoids (1226);

**Ion Chromatography:** **2012** ion chromatographic analysis of pharmaceuticals to determine authenticity and adulteration (listed applications include "forensic analysis") (1227); **2014** a review of ion chromatography-mass spectrometry (1228);

**Ion Mobility Spectroscopy:** **2014** use of DESI-AP-IMS for drug detection (1229);

**"Lab-on-a-Chip" (Microfluidics):** **2011** the use of microfluidic platforms for solid form screening of pharmaceuticals by Raman (1230); **2013** an overview of "forensic drug analysis" by microfluidic devices (1231); **2014** enhancement of chemiluminescent detection in microfluidic systems, for anal. of a wide range of compds., including illicit drugs and pharmaceuticals (1232);

**Liquid Chromatography:** **2012** an overview of good laboratory practices for HPLC (1233); an overview of some of the most recent applications of hyphenated LC techniques for forensic analyses (1234); **2013** quantitative structure-retention relationships models for prediction of HPLC retention time of small molecules (1235); **2014** use of immobilized polysaccharide-based stationary phases for enantioseparation in normal versus reversed phase HPLC (1236); a review of the use of chiral supercritical fluid chromatography for analysis of pharmaceuticals and drugs

of abuse (1237); a review of HILIC, discussing the development, basic sepn. mechanisms, stationary and mobile phases, and summarizing its applications in several research fields (1238); **2015** a chemometric approach to improve the accuracy and precision of quantitation in 2D-LC with dual detectors and multivariate curve resolution (1239); simultaneous determination of hydrophobicity and dissociation constant for 161 drugs by gradient RP-HPLC/MS (1240); HPLC method development using structure-based database search, physico-chemical prediction, and chromatographic simulation (1241); **2016** automated screening of reversed-phase stationary phases for small-molecule separations using LC/MS (emphasis on LC) (1242); simulation of elution profiles under gradient elution conditions, with mismatched injection and mobile phase solvents (includes simulated sepn. of selected amphetamines) (1243);

**Mass Spectrometry:** **2012** the mass spectra of designer drugs (reference text) (1244); **2013** use of Desorption Electro-Flow Focusing Ionization of explosives and narcotics for ambient pressure mass spectrometry (the "narcotics" included cocaine; no others were listed in the abstract) (1245); a review of DART-MS (1246); a review of ultrasensitive MS of organic molecules (listed applications include "forensics") (1247); a review of ambient MS, including DESI, DART, and extractive ESI (listed applications include "forensic identification") (1248); an evaluation of standardized software for processing GC/MS data from different instruments (1249); the application of ultra-fast triple quadrupole LC-MS/MS for forensic analysis of "abused drugs" (1250); a review of DESI-MS (listed applications include "illicit drugs") (1251); evaluation and testing of an alternative search algorithm for compound identification using the Wiley Registry of Tandem Mass Spectral Data, MSforID (1252); mass spectrometry using Matrix Assisted Ionization in vacuum (1253); **2014** recent advances in forensic drug analysis by DART-MS (1254); **2015** a review of surfaceassisted laser desorption ionization (SALDI) MS for forensic analysis (1255); a review of forensic mass spectrometry (1256); a wide use target screening system for GC/MS (1257); a new quant. contained-electrospray process for ESI-MS (1258); the use of the partial least squares method to model the positive ESI response produced by small pharmaceutical molecules (1259); a review of the characterization of synthetic and natural product pharmaceuticals by functional group analysis using ESI-ion trap-MS (1260); the use of online chemistry databases to facilitate structure identification (1261); a review of identification criteria and complicating factors for drug confirmation by mass spectrometry (1262); **2016** a review of the applications of ambient mass spectrometry to forensic chemistry (1263); a review of DART-MS (1264); determination of trace palladium in chemical bulk drug by ICP-MS (1265); a review of DART-MS (1266);

**Microextraction Techniques:** **2013** a review of liquid phase micro-extraction (LPME) techniques used in analysis of Chinese traditional medicines (1267); a review (listed applications include forensic and pharmaceutical) (1268); **2015** a review of SPME techniques (1269); **2016** a review of coupling SPME with ambient MS (1270); a review of microextraction in forensic

toxicology (1271); an overview of microextraction techniques for illicit drug testing (1272);

**Microscopy and Microscopic Instrumental Techniques:** **2013** comparison between microcrystalline tests performed on microscope slides versus flat capillary tubes (1273); **2014** a review of developments in applications of FTIR microspectroscopy, covering 2005 to 2013 (1274); **2015** use of an FTIR/ATR microscope for detecting analytes in high-interfering matrixes and in products with unknown ingredients (illicit tablets, counterfeit tablets, and unknown powders) (1275);

**Nuclear Magnetic Resonance Spectroscopy:** **2013** tracking authentic pharmaceuticals by  $^2\text{H}$ - and  $^{13}\text{C}$ -NMR (1276); **2015** cocaine, MDMA, and "metilona" (possibly methylone?) by "No-D NMR" (i.e., without the use of deuterated solvents) (1277); an overview of a "crime-scene NMR laboratory" (1278); **2016** improving the performance of high-precision qNMR measurements by a double integration procedure (1279); a review of the use of quant.  $^1\text{H}$  NMR spectroscopy in drug discovery and development (including a review of the pertinent literature between 1963 and 2015) (1280);

**Raman:** **2013** Use of THz-Raman accessing molecular structure with Raman spectroscopy for enhanced chemical identification, analysis, and monitoring (especially for discrimination of polymorphs) (1281); **2014** deep Raman detection with 2D correlation analysis for elucidation of a subsurface component under thick powder or packed contents in a bottle (1282); **2016** a review of the applications of SERS in forensic science (1283);

**Spectrophotometry:** **2014** methods for evaluating the visual limits of color perception (a proposal to create common rules for constructing color test scales for visual colorimetric assays) (1284); the molecular electron ionization cross - section and  $\lambda_{\text{max}}$  in the studies of activities of alkaloids (1285); **2015** defining optimal conditions of colors in 3D space in dependence on gamma values, illumination, and background color (1286); **2016** a review of derivative UV-Vis spectrophotometry (1287);

**Stable Isotopes:** **2011** forensic applications (reference text) (1288); **2012** a review of the forensic applications of IRMS (1289); **2013** a review of inter-laboratory comparability of stable isotope data (1290); an extensive review of the isotopic anatomies of molecules and minerals (1291); the use of carbon stable isotope ratios in drugs characterization (by IRMS) (1292); global isoscapes for  $\delta^{18}\text{O}$  and  $\delta^2\text{H}$  in precipitation (1293); **2014** spatial, seasonal, and source variability in the stable oxygen and hydrogen isotopic composition of tap waters throughout the U.S. (1294); **2015** precipitation isotope ( $\delta^{18}\text{O}$ ) zones revealed in time series modeling across Canada and northern U.S. (1295); simple spreadsheet templates for the determination of the measurement uncertainty of stable isotope ratio delta values (1296); a review of IRMS for source

determination (1297);

**Supercritical Fluid Chromatography:** 2016 an evaluation of innovative stationary phase ligand chemistries and analytical conditions for the analysis of basic drugs by SFC (1298);

**Thin Layer Chromatography (and similar Planar Chromatographic Methods):** 2013 an overview, including "forensic applications" (1299);

**"Vibrational Spectroscopy" (Raman, mid-, near- and far-IR, and THz Spectroscopy):** 2012 a review of the use of IR spectroscopy, terahertz spectroscopy and Raman spectroscopy in forensic sciences (1300); a review of sampling techniques for Raman, mid-, near- and far-IR, and THz spectroscopy (1301);

**X-Ray Techniques:** 2013 the use of energy dispersive X-ray diffraction (ED-XRD) spectra of drugs (and explosives) to detect "body packing" (1302);

**Other:** 2012 trace determination of metals (copper, zinc, nickel, cobalt, iron, arsenic, antimony, bismuth, vanadium, molybdenum, selenium, and lead) in drugs and pharmaceuticals as N-phenyl[1,2 methane fullerene C<sub>60</sub>]C<sub>61</sub> complexes (1303); 2013 the use of gamma detectors in explosives and narcotics detection systems (1304); a review of microfluidic paper-based analytical devices and micro total analysis systems (1305); the utility of cyclodextrins in analytical chemistry (1306); 2014 a review of the use of acidic potassium permanganate as a chemiluminescence reagent (1307); the use of a chiral diffraction grating to measure the enantiomeric excess of a chiral compound (1308); the application of UV laserinduced solid-state fluorescence spectroscopy for characterization of solid dosage forms (1309); 2015 a review of miniaturized separation techniques (1310); a review of the pyrolysis of drugs of abuse (1311); an overview of emerging hyphenated SEMEDX (scanning electron microscopy with energy dispersive X-ray spectroscopy) and Raman spectroscopy systems (1312); a review of capacitively coupled contactless conductivity detection (1313); 2016 a review of enhanced performance separations, covering papers published in *Analytical Chemistry* from late 2014 through May 2016 (1314).

### 3. Miscellaneous Topics

**Abuse Deterrent Formulations (see also numerous, specific examples under oxycodone and opiates):** **2013** an overview of prescription drug abuse and the need for abuse deterrent formulations (1315); **2014** development and impact of prescription opioid abuse deterrent formulation technologies (1316); the use of prescription opioids with abuse-deterrent technology to address opioid abuse (1317); a review of extended release hydrocodone (1318); the U.S. FDA draft guidance for developing abuse-deterrent opioid analgesics (1319); an overview of anti-drug-abuse measures, including abuse-deterrent formulations (1320); an overview of methods used to reduce abuse potential of commonly abused pharmaceuticals (1321); **2015** an overview of the advance in the R&D of abuse-deterrent opioid analgesics (1322); an overview of abuse-deterrent formulations in countering opioid misuse and abuse (1323); an overview and review of abuse-deterrent formulations (1324); **2016** a comparison of the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs (1325); a review and assessment of the potential impact of abuse-deterrent formulations of prescription opioid analgesics (1326); an overview of prodrug technology and its application for developing abuse-deterrent opioids (1327); a review (1328); an assessment of extended release abuse deterrent formulations (1329);

**Anions and Cations:** **2016** a review of the simultaneous separation of cations and anions by CE (1330);

**Bacteria:** **2014** recovery and identification of bacterial DNA from heroin and methamphetamine (1331); **2016** a discussion of a recent increase in drug abusers in Scotland who have presented with *Staphylococcus aureus* bacteremia with life-threatening complications due to their injection of NPSs (1332); the use of microbe analyses for forensic and criminal investigations (1333);

**Canines:** **2014** the efficacy of drug detection by fully-trained police dogs varies by breed, training level, type of drug and search environment (1334); treatment and prevention of acute poisoning of drug dogs caused by exposure to methamphetamine, ketamine, and MDMA (1335); **2015** a review of the advances in the use of odor as forensic evidence through optimizing and standardizing instruments and canines (1336);

**Clandestine Laboratories - Appraisals and Safety:** **2014** an update on the hazards and health effects assocd. with clandestine drug laboratories (1337); an evaluation of the acute and chronic environmental effects of clandestine methamphetamine waste (1338); adsorption and desorption characteristics of methamphetamine, MDMA, and pseudoephedrine in soils (1339); an overview and discussion of home preparations of abused substances (1340); **2015** vehicle-mounted portable mass spectrometry for covert detection of clandestine methamphetamine laboratories

(1341); **2016** decontamination of personal protective equipment and related materials contaminated with toxic chemicals (1342);

**Degradation of Drugs and Pharmaceuticals:** **2014** a review of forced degradation and stability indicating studies of drugs (1343); determination of pharmaceutical impurities and degradation products by NMR (1344); **2015** analysis of degradation products from drugs by a rapid resolution LC-collision energy correlated-MS (1345); **2016** a stability-indicating UPLC-MS/MS assay for 1960's era pharmaceuticals in dosage forms (1346);

**Education:** **2013** use of forensic science to teach method development in undergraduate analytical laboratories (1347); the use of paper-based diagnostics with high school students to model forensic investigation and colorimetric analysis (1348); **2014** the use of forensic science and simulated crimes in a one-week long "Criminal Camp" to teach the theory and practice of basic concepts in chem., physics, medicine, and biol. (1349); using education to combat "chemophobia" (1350); a course for non-science majors at a college that looks at the chem. behind the crime itself, and the chem. behind the anal. of evidence from the crime (1351); a discussion for the need for forensic science programs to develop job-related skills in their students (1352); an overview of forensic science (1353); initiation and evolution of a forensic chemistry program (1354); the use of forensic chem.-themed activities to introduce fundamental concepts, such as the scientific method, to middle and high school students (1355); an overview of the chemistry behind forensic science (1356); use of presumptive and confirmatory tests using analogs of illicit drugs as an undergraduate instrumental methods exercise (using multiple color tests, GC-MS, and ATR-FTIR) (1357); utilizing the "CSI Effect" in chemistry instruction (1358); a discussion for the need, development, and implementation of an effective continuing forensic science education program (1359); a discussion of the need for robust and rigorous scientific research in academia based on need-based input from forensic practitioners who see the day-to-day issues in their laboratories (1360); an overview of the Forensic Science Education Programs Accreditation Commission's (FEPAC) accreditation program, the FEPAC stds., and the process involved in seeking FEPAC accreditation (1361); careers in forensic chemistry (1362); using The Poisoner's Handbook in conjunction with teaching a first-term general / organic / biochemistry course (1363); **2015** a universal internet-based prevention program for ecstasy and NPSs (for teenaged students) (1364); a discussion of the efforts to develop integrated forensic platforms that allow for the forensic investigation of human biol. traces, identification of illicit drugs, and the study of digital evidence (1365); a case study review of a problem based learning approach used to educate and train young forensic scientists through the use of six sigma investigative tools (using hydrolysis of cocaine to benzoylecgonine at various pHs as the teaching example) (1366); **2016** a performance task case study (misconduct) for teaching data analysis and critical thinking (1367); using a "Drug of the Week" approach to educate chemistry students about prescription drugs and their abuse (1368); use of a variety of small scenes using doll house

furniture to educate criminal justice majors (1369);

**Immunoassays:** **2014** a review of the practical aspects of immunoassays and their application in clin. chem. for anal. of medicines and drugs of abuse (1370); the use cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays (1371);

**Impurities and Impurity Profiling:** **2012** a review of detection techniques for trace pharmaceutical impurities (1372); **2013** an overview (1373); a review of impurities in pharmaceuticals (1374); comparison of CCC and prep-HPLC for separating minor impurities in drugs (1375); **2014** analysis of impurities in drugs by LC-MS (1376); an overview of impurity profiling of pharmaceuticals (1377); a compendium of techniques for the analysis of pharmaceutical impurities, including TLC, HPTLC, HPLC, UPLC, GC., flash chromatog., SFC, CE, MECC, UV/Vis, IR, NMR, MS, LC/MS, LC-MS/MS, LC/NMR, HPLC/DAD-MS, HPLC/DAD/NMR-MS, UHPLC-MS, UHPLC-MS/MS, and chemometrics (1378); analysis and impurity identification in pharmaceuticals (1379); an overview of the impurity profiling methods for pharmaceuticals per current U.S. Pharmacopoeia guidelines (1380); **2015** method development for impurity profiling using SFC and comparing 6 different stationary phases (1381); an overview and review of recent advances in pharmaceutical impurity profiling (1382); a review of impurity profiling of drugs since 2010 (1383); development of an achiral SFC method with UV and MS detection for impurity profiling of drugs (1384 and 1385); an overview and review of impurity profiling of pharmaceuticals (1386); a review of impurity profiling, covering TLC, HPLC, HPTLC, LC-MS-MS, LC-NMR, LCNMR-MS, GC-MS, and LC-MS (1387); a review of impurity profiling of drugs (1388); **2016** an analysis of ionic interactions when characterizing 9 different stationary phases for drug impurity profiling with SFC (1389);

**Inhalants:** **2015** an overview of the abuse of nitrous oxide (1390);

**Labelling and Packaging:** **2012** examination of counterfeit labels on pharmaceuticals by IR and Raman (1391); **2013** a study on the effects of common drug packaging materials on nondestructive detection of contents by Raman spectrometry (1392); **2014** quantitative analysis of torn and cut duct tape physical end matching (1393); detection of counterfeit blister packaging by FTIR and chemometric methods (1394); a review of the identification of stamp impressions, including by microscopy, computer-assisted artificial identification, and anal. methods (UV-Vis, fluorometry, IR spectroscopy, Raman spectroscopy, TLC, LC, GC, and MS) (1395); **2015** evaluation of drug packaging by DSC (1396); determination of ethylene dichloride in drug packaging material made of polyethylene dichloride by headspace GC/ECD (1397);

**Legal Issues:** **2014** a regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the U.S. (1398); an effort to develop objective scientific methods to quantify and define

the important "substantially similar" structural parameter used in several laws (1399); **2015** a proposal for objective scientifically-derived measures of molecular structural similarity (1400);

**Precursors:** **2013** impurity profiling of sassafras oils by GC×GC-TOF-MS (1401); **2014** a brief overview of the precursors for drugs of abuse (1402); determination of safrole in ethanol extract of nutmeg (*Myristica fragrans* Houtt) using RP-HPLC (1403);

**Quality Assurance:** **2013** use of a software tool ("Drugs WorkBook") for the quantification of illicit drugs (1404);

**Sampling Plans:** **2013** a study of particle size of amphetamine, heroin, cocaine, and herbal cannabis and its influence on mass reduction (1405); a general sampling plan for the quant. instrumental anal. of heroin, cocaine, amphetamine, cannabis resin, MDMA tablets, and herbal cannabis (1406); a new sampling plan which focuses on sample heterogeneity (from ENFSI) (1407);

**Sensors (Biological and Instrumental):** **2013** a review of biological organisms as volatile compound detectors (stated applications include illicit drugs) (1408); **2014** assessing the potential of metal oxide semiconducting gas sensors for illicit drug detection markers (1409); use of a parasitic wasp as a biosensor for cocaine (1410); a review of biosensors in forensic analysis (1411); **2015** detection of illicit drugs by trained honeybees (1412);

**Soil:** **2012** forensic examination (reference text) (1413); **2014** by elemental analysis (1414); use of visible microspectrophotometry and FTIR/ATR for examination of soils for trace evidence (1415); **2016** protocols for soil examinations (1416);

**Surveys of Drug Use:** **2014** a comparative evaluation of whether computer survey technology improve reports on alcohol and illicit drug use in the general population (1417); an overview of 4 different systems utilized in Australia for monitoring drug use (1418); the use of internet snapshot surveys to enhance understanding of the availability of 2 NPSs (4-methylaminorex and 4,4'-dimethylaminorex) (1419); a survey of pharmacological cognitive enhancement among university students in the UK and Ireland who were abusing "smart drugs" (modafinil, methylphenidate, or Adderall) (1420); **2015** a measure of the "interest" in MDPV, methylone, 4-MEC, 4-HO-MET, MXE, 6-APB, AH-7921, and 3-MMC before and after its scheduling in Sweden (1421); an update on the Pistoia Alliance Controlled Substance Compliance Service Project (1422); a discussion and evaluation of the contents, the destinations, and the sources of 960 postal items seized by Swiss customs at the Swiss border between 2013 and 2014 (1423);

**Other:** **2013** collection of trace chemicals from diverse surfaces by use of strippable coatings

(1424); the practical relevance of pattern uniqueness in forensic science (1425); **2014** a review of resolution by fractional crystallization of diastereomeric salts (1426); determination of water in active pharmaceutical ingredients using ionic liquid HS-GC and two different detection protocols (not identified in the abstract) (1427); reducing the complexity of an agent-based local heroin market model (1428); the examination of trace physical evidence and artificial materials (1429); use of an online database of chemical compounds for the purpose of structure identification (1430); **2015** a discussion of the comparison processes and evaluation systems that form a forensic intelligence framework, advocating scientific decision criteria and a structured but flexible and dynamic architecture (1431); an overview of ingestion of illicit drugs by "parachuting" (1432); the use of DNA sequencing analyses of the fungal diversity found in dust samples for geo-sourcing (1433); an assessment of the toxicity of the refill liquids for electronic cigarettes (based on the presence of microorganisms, diethylene glycol, ethylene glycol, hydrocarbons, ethanol, aldehydes, tobacco-specific nitrosamines, and solvents) (1434).

### **References:**

1. Sarfaraz S, Readdy ChVR, Shareef KMA. Method development, validation and determination of alprazolam in its pharmaceutical dosage by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone. *Journal of Chemical and Pharmaceutical Research* 2014;6(9):411-418.
2. Nunes CN, Pauluk LE, dos Anjos VE, Lopes MC, Quinaia SP. New approach to the determination of contaminants of emerging concern in natural water: Study of alprazolam employing adsorptive cathodic stripping voltammetry. *Analytical and Bioanalytical Chemistry* 2015: Ahead of Print.
3. Frison G, Odoardi S, Frasson S, Sciarrone R, Ortar G, Romolo FS, Strano Rossi S. Characterization of the designer drug bk-2C-B (2-amino-1-(bromodimethoxyphenyl)ethan-1-one) by gas chromatography/mass spectrometry without and with derivatization with 2,2,2-trichloroethyl chloroformate, liquid chromatography/high-resolution mass spectrometry, and nuclear magnetic resonance. *Rapid Communications in Mass Spectrometry* 2015;29(13):1196-1204.
4. Power JD, Kavanagh P, O'Brien J, Barry M, Twamley B, Talbot B, Dowling G, Brandt SD. Test purchase, identification and synthesis of 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one (bk-2C-B). *Drug Testing and Analysis* 2015;7(6):512-518.
5. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. 5-(2-Amino-propyl)indole: A new player in the drama of 'legal highs' alerts the community. *Drug and*

Alcohol Review 2015;34(1):51-57.

6. Power JD, Barry MG, Scott KR, Kavanagh PV. An unusual presentation of a customs importation seizure containing amphetamine, possibly synthesized by the APAAN - P2P Leuckart route. *Forensic Science International* 2013: Ahead of Print.
7. Power JD, O'Brien J, Talbot B, Barry M, Kavanagh P. The identification of an impurity product, 4,6-dimethyl-3,5-diphenylpyridin-2-one in an amphetamine importation seizure, a potential route specific by-product for amphetamine synthesized by the APAAN to P2P, Leuckart route. *Forensic Science International* 2014;241:e13-e19.
8. Mullerova L, Dubsky P, Ordogova M, Gas B. Determination of relative enantiomer migration order using a racemic sample. *Journal of Chromatography A* 2015;1424:139-143.
9. Power JD, Kavanagh P, McLaughlin G, Dowling G, Barry M, O'Brien J, Talbot B, Twamley B, Brandt SD. Forensic analysis of P2P derived amphetamine synthesis impurities: Identification and characterization of indene by-products. *Drug Testing and Analysis* 2016: Ahead of Print.
10. Bartzatt R, Ehlers S, Handler N. Barbitol assay by reversed phase high performance liquid chromatography. *Analytical Chemistry: An Indian Journal* 2013;13(6):242-247.
11. Pramanik C, Bapat K, Chaudhari A, Kulkarni MG, Kolla R, Sompalli S, Tripathy NK, Gurjar MK. An efficient, scalable process for Benzphetamine hydrochloride. *Organic Process Research & Development* 2014;18(4):495-500.
12. Monteiro MS, Bastos MdL, Guedes de Pinho P, Carvalho M. Update on 1-benzyl-piperazine (BZP) party pills. *Archives of Toxicology* 2013;87(6):929-947.
13. Beckett NM, Grice DI, Carter JF, Cresswell SL. Precursor discrimination of designer drug benzylpiperazine using  $\delta^{13}\text{C}$  and  $\delta^{15}\text{N}$  stable isotopes. *Science & Justice* 2015;55(1):57-62.
14. Burrai L, Nieddu M, Palomba M, Pirisi MA. Identification and quantitation of 4-bromo-2,5-dimethoxyamphetamine in seized blotters. *Legal Medicine* 2015;17(1):56-59.
15. Duffau BE, Camargo C, Cassels BK, Kogan M, Fuentes E. Analysis of a new potent hallucinogen, 25-B-NBOMe, in blotters by high-performance thin-layer chromatography.

Journal of Planar Chromatography - Modern TLC 2015;28(5):395-397.

16. Papoutsis I, Nikolaou P, Stefanidou M, Spiliopoulou C, Athanaselis S. 25B-NBOMe and its precursor 2C-B: Modern trends and hidden dangers. *Forensic Toxicology* 2015;33(1):1-11.
17. Zuba D, Adamowicz P, Byrska B. Detection of buphedrone in biological and nonbiological material - Two case reports. *Forensic Science International* 2013;227(1-3):15-20.
18. Wiegand TJ, Le Lait M-C, Bartelson BB, Dart RC, Green JL. Analysis of the abuse and diversion of the buprenorphine transdermal delivery system. *Journal of Pain* 2016;17(6):745-752.
19. Cinosi E, Corazza O, Santacroce R, Lupi M, Acciavatti T, Martinotti G, di Giannantonio M. New drugs on the internet: The case of Camfetamine. *BioMed Research International* 2014:419026/1-419026/9.
20. Pandhare AT, Gaikwad VB, Toche RB, Patil VB, Doundkar BB. Detection of chloral hydrate adulteration in traditional alcoholic beverage toddy by head space gas chromatography. *World Journal of Pharmaceutical Research* 2015;4(2):814-818.
21. Zuba D, Sekula K, Buczek A. 25C-NBOMe - New potent hallucinogenic substance identified on the drug market. *Forensic Science International* 2013;227(1-3):7-14.
22. Bersani FS, Corazza O, Albano G, Valeriani G, Santacroce R, Posocco FBM, Cinosi E, Simonato P, Martinotti G, Bersani G, Schifano F. 25C-NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. *BioMed Research International* 2014:734749/1-734749/7.
23. Taschwer M, Weiss JA, Kunert O, Schmid MG. Analysis and characterization of the novel psychoactive drug 4-chloromethcathinone (clephedrone). *Forensic Science International* 2014;244:e56-e59.
24. Hall AB, Coy SL, Nazarov EG, Vouros P. Rapid separation and characterization of cocaine and cocaine cutting agents by Differential Mobility Spectrometry - Mass Spectrometry. *Journal of Forensic Sciences* 2012;57(3):750-756.
25. Zou R, Lou X, Ou H, Zhang Y, Wang W, Yuan M, Guan M, Luo Z, Liu Y. Highly

- specific triple-fragment aptamer for optical detection of cocaine. *RSC Advances* 2012;2(11):4636-4638.
26. Asturias-Arribas L, Alonso-Lomillo MA, Dominguez-Renedo O, Arcos-Martinez MJ. Electrochemical determination of cocaine using screen-printed Cytochrome P450 2B4 based biosensors. *Talanta* 2013;105:131-134.
  27. Dujourdy L, Charvoz C, Dalmaso M, Dufour AB. Ala recherche du juste dosage: Statistique appliquee a l'analyse de la cocaine. *Annales Pharmaceutiques Francaises* 2013;71(3):193-200.
  28. Heller M, Vitali L, Siqueira MA, Sako AVF, Piovezan M, Micke GA. Capillary electrophoresis with UV detection to determine cocaine on circulated banknotes. *ISRN Analytical Chemistry* 2013:489705/1-489705.
  29. Mallette JR, Casale JF, Jones LM. The separation of cocaine and phenyltetrahydroimidazothiazole mixtures. *Microgram Journal* 2013;10(2):12-16.
  30. Pagano B, Lauri I, De Tito S, Persico G, Chini MG, Malmendal A, Novellino E, Randazzo A. Use of NMR in profiling of cocaine seizures. *Forensic Science International* 2013;231(1-3):120-124.
  31. Rodrigues NVS, Cardoso EM, Andrade MVO, Donnici CL, Sena MM. Analysis of seized cocaine samples by using chemometric methods and FTIR spectroscopy. *Journal of the Brazilian Chemical Society* 2013;24(3):507-517.
  32. Rodrigues NM, Guedes M, Augusti R, Marinho PA. Cocaine contamination in Belo Horizonte - MG paper currency. *Revista Virtual de Quimica* 2013;5(2):125-136.
  33. Rubio C, Strano-Rossi S, Taberner MJ, Anzillotti L, Chiarotti M, Bermejo AM. Hygrine and cuscohygrine as possible markers to distinguish coca chewing from cocaine abuse in workplace drug testing. *Forensic Science International* 2013;227(1-3):60-63.
  34. Shi Y, Dai H, Sun Y, Hu J, Ni P, Li Z. Fluorescent sensing of cocaine based on a structure switching aptamer, gold nanoparticles and graphene oxide. *Analyst* 2013;138(23):7152-7156.
  35. Zacca JJ, Groberio TS, Maldaner AO, Vieira ML, Braga JWB. Correlation of cocaine hydrochloride samples seized in Brazil based on determination of residual solvents: An

- innovative chemometric method for determination of linkage thresholds. *Analytical Chemistry* 2013;85(4):2457-2464.
36. Zhang S-b, Liu Q, Hu X, Liu X-w, Shen G-y, Lu J-l. Label-free and universal fluorescent biosensing system based on isothermal circular strand-displacement polymerization. *Huaxue Chuanganqi* 2013;33(3):22-28.
  37. Armenta S, Guardia Mdl, Alcalá M, Blanco M, Perez-Alfonso C, Galipienso N. Ion mobility spectrometry evaluation of cocaine occupational exposure in forensic laboratories. *Talanta* 2014;130:251-258.
  38. Asturias-Arribas L, Alonso-Lomillo MA, Dominguez-Renedo O, Arcos-Martinez MJ. Sensitive and selective cocaine electrochemical detection using disposable sensors. *Analytica Chimica Acta* 2014;834:30-36.
  39. Bertucci C, Tedesco D, Fabini E, Di Pietra AM, Rossi F, Garagnani M, Del Borrello E, Andrisano V. Determination of levamisole and tetramisole in seized cocaine samples by enantioselective high-performance liquid chromatography and circular dichroism detection. *Journal of Chromatography A* 2014;1363:150-154.
  40. Bisceglia KJ, Lippa KA. Stability of cocaine and its metabolites in municipal wastewater - The case for using metabolite consolidation to monitor cocaine utilization. *Environmental Science and Pollution Research* 2014;21(6):4453-4460.
  41. Botelho ED, Cunha RB, Campos AFC, Maldaner AO. Chemical profiling of cocaine seized by Brazilian Federal Police in 2009-2012: Major components. *Journal of the Brazilian Chemical Society* 2014;25(4):611-618.
  42. Floriani G, Gasparetto JC, Pontarolo R, Goncalves AG. Development and validation of an HPLC-DAD method for simultaneous determination of cocaine, benzoic acid, benzoylecgonine and the main adulterants found in products based on cocaine. *Forensic Science International* 2014;235:32-39.
  43. Fukushima AR, Carvalho VM, Carvalho DG, Diaz E, Bustillos JO, Spinosa Hde S, Chasin AA. Purity and adulterant analysis of crack seizures in Brazil. *Forensic Science International* 2014;243:95-98.
  44. Groberio TS, Zacca JJ, Talhavini M, Braga JWB. Quantification of cocaine hydrochloride in seized drug samples by infrared spectroscopy and PLSR. *Journal of the*

Brazilian Chemical Society 2014;25(9):1696-1703.

45. Hoyt MR, Sosa-Saenz S, Hoyt CB, Fernand V. Microfluidic paper drug sensors: Lowcost, hand-held devices for forensic investigation. Abstracts, 70th Southwest Regional Meeting of the American Chemical Society, Fort Worth, TX, United States, November 19-22, 2014: SWRM-323.
46. Mallette JR, Casale JF. Rapid determination of the isomeric truxillines in illicit cocaine via capillary gas chromatography/flame ionization detection and their use and implication in the determination of cocaine origin and trafficking routes. *Journal of Chromatography A* 2014;1364:234-240.
47. Montesano C, Sergi M, Perez G, Curini R, Compagnone D, Mascini M. Bio-inspired solid phase extraction sorbent material for cocaine: A cross reactivity study. *Talanta* 2014;130:382-387.
48. Mozes O, Guranda L, Portnoy O, Apter S, Konen E, Amitai MM. Radiographic features of intracorporeally smuggled liquid cocaine. *Forensic Science, Medicine, and Pathology* 2014;10(4):535-542.
49. Pereira AG, D'Avila FB, Lukasewicz-Ferreira PC, Holler MG, Limberger RP, Froehlich PE. Determination of cocaine, its metabolites and pyrolytic products by LC-MS using a chemometric approach. *Analytical Methods* 2014;6(2):456-462.
50. Perez-Alfonso C, Galipienso N, Garrigues S, de la Guardia M. A green method for the determination of cocaine in illicit samples. *Forensic Science International* 2014;237:70-77.
51. Smith JE, Griffin DK, Leny JK, Hagen JA, Chavez JL, Kelley-Loughnane N. Colorimetric detection with aptamer-gold nanoparticle conjugates coupled to an android based color analysis application for use in the field. *Talanta* 2014;121:247-255.
52. Stojanovska N, Tahtouh M, Kelly T, Beavis A, Fu S. Qualitative analysis of seized cocaine samples using desorption electrospray ionization - mass spectrometry (DESI-MS). *Drug Testing and Analysis* 2014: Ahead of Print.
53. Wilson A, Aitken C, Sleeman R, Carter J. The evaluation of evidence relating to traces of cocaine on banknotes. *Forensic Science International* 2014;236:67-76.

54. Wren SP, Nguyen TH, Gascoine P, Lacey R, Sun T, Grattan KTV. Preparation of novel optical fibre-based cocaine sensors using a molecular imprinted polymer approach. *Sensors and Actuators, B: Chemical* 2014;193:35-41.
55. Yang Y-c, Liu H-l, Zhao Y, Du L-m, Pang T-t, Fu Y-l. Study on interaction of psulfonated calix[4]arene with cocaine hydrochloride by spectrofluorometry. *Fenxi Ceshi Xuebao* 2014;33(7):825-829.
56. Almeida VGK, Cassella RJ, Pacheco WF. Determination of cocaine in Real banknotes circulating at the State of Rio de Janeiro, Brazil. *Forensic Science International* 2015;251:50-55.
57. Anzanello MJ, Kahmann A, Marcelo MCA, Mariotti KC, Ferrao MF, Ortiz RS. Multicriteria wavenumber selection in cocaine classification. *Journal of Pharmaceutical and Biomedical Analysis* 2015;115:562-569.
58. de Araujo WR, Maldaner AO, Costa JL, Paixao TRLC. Development of an electro-analytical method for the quantification of aminopyrine in seized cocaine samples. *Microchemical Journal* 2015;121:213-218.
59. Broseus J, Huhtala S, Esseiva P. First systematic chemical profiling of cocaine police seizures in Finland in the framework of an intelligence-led approach. *Forensic Science International* 2015;251:87-94.
60. Cerreta MM, Furton KG. An assessment of detection canine alerts using flowers that release methyl benzoate, the cocaine odorant, and an evaluation of their behavior in terms of the VOCs produced. *Forensic Science International* 2015;251:107-114.
61. Colley VL, Casale JF. Differentiation of South American crack and domestic (US) crack cocaine via headspace-gas chromatography/mass spectrometry. *Drug Testing and Analysis* 2015;7(3):241-246.
62. Docimo T, Davis AJ, Luck K, Fellenberg C, Reichelt M, Phillips M, Gershenzon J, D'Auria JC. Influence of medium and elicitors on the production of cocaine, amino acids and phytohormones by *Erythroxylum coca* calli. *Plant Cell, Tissue and Organ Culture* 2015;120(3):1061-1075.
63. Du Q, Chen C-P, Du L-M. Spectrofluorimetric study on the inclusion behavior of psulfonated calix [4, 6, 8] arene with cocaine hydrochloride. *Analytical Chemistry: An*

Indian Journal 2015;15(8):281-289.

64. Dziadosz M, Klintschar M, Teske J. Consumption of levamisole in cocaine preparations. *Journal of Forensic Sciences* 2015;60(2):538.
65. Groberio TS, Zacca JJ, Botelho ED, Talhavini M, Braga JWB. Discrimination and quantification of cocaine and adulterants in seized drug samples by infrared spectroscopy and PLSR. *Forensic Science International* 2015;257:297-306.
66. Huff DE, Crawford SL, Bellott BJ. Determination of cocaine concentration in creek water via solid-phase extraction. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: ANYL-145.
67. Lapachinske SF, Okai GG, dos Santos A, de Bairros AV, Yonamine M. Analysis of cocaine and its adulterants in drugs for international trafficking seized by the Brazilian Federal Police. *Forensic Science International* 2015;247:48-53.
68. Lausmann T, Grzesiak I, Krest A, Stirnat K, Meier-Giebing S, Ruschewitz U, Klein A. Copper thiocyanato complexes and cocaine - A case of 'black cocaine.' *Drug Testing and Analysis* 2015;7(1):56-64.
69. Maldaner AO, Botelho ED, Zacca JJ, Camargo MA, Braga JW, Groberio TS. Brazilian Federal District cocaine chemical profiling - Mass balance approach and new adulterant routinely quantified (aminopyrine). *Journal of the Brazilian Chemical Society* 2015;26(6):1227-1231.
70. Mallette JR, Casale JF. Headspace-gas chromatographic-mass spectrometric analysis of South American commercial solvents and their use in the illicit conversion of cocaine base to cocaine hydrochloride. *Journal of Forensic Sciences* 2015;60(1):45-53.
71. Marcelo MCA, Mariotti KC, Ferrao MF, Ortiz RS. Profiling cocaine by ATR-FTIR. *Forensic Science International* 2015;246:65-71.
72. Mokhtarzadeh A, Ezzati Nazhad Dolatabadi J, Abnous K, de la Guardia M, Ramezani M. Nanomaterial-based cocaine aptasensors. *Biosensors & Bioelectronics* 2015;68:95-106.
73. Monfreda M, Varani F, Cattaruzza F, Ciambrone S, Proposito A. Fast profiling of cocaine seizures by FTIR spectroscopy and GC-MS analysis of minor alkaloids and residual solvents. *Science & Justice* 2015;55(6):456-466.

74. Neves MAD, Blaszykowski C, Bokhari S, Thompson M. Ultra-high frequency piezoelectric aptasensor for the label-free detection of cocaine. *Biosensors & Bioelectronics* 2015;72:383-392.
75. Penido CAFO, Pacheco MTT, Zangaro RA, Silveira Jr, L. Identification of different forms of cocaine and substances used in adulteration using near-infrared Raman spectroscopy and infrared absorption spectroscopy. *Journal of Forensic Sciences* 2015;60(1):171-178.
76. Pereira AG, D'Avila FB, Ferreira PCL, Holle MGr, Limberguer RP, Froehlich PE. Method development and validation for determination of cocaine, its main metabolites and pyrolytic products by HPLC-UV-CAD. *Chromatographia* 2015: Ahead of Print.
77. Ribeiro MFM, Wilmo da Cruz Jr. J, Dockal ER, McCord BR, Firmino de Oliveira M. Voltammetric determination of cocaine using carbon screen printed electrodes chemically modified with uranyl Schiff base films. *Electroanalysis* 2015: Ahead of Print.
78. Wren SP, Piletsky SA, Karim K, Gascoine P, Lacey R, Tong S, Grattan KTV. Computational design and fabrication of optical fibre fluorescent chemical probes for the detection of cocaine. *Journal of Lightwave Technology* 2015;33(12):2572-2579.
79. Brueggemann M, Karu E, Hoffmann T. Critical assessment of ionization patterns and applications of ambient desorption/ionization mass spectrometry using FAPA-MS. *Journal of Mass Spectrometry* 2016;51(2):141-149.
80. De Carvalho TC, Tosato F, Souza LM, Santos H, Merlo BB, Ortiz RS, Rodrigues RRT, Filgueiras PR, Franca HS, Augusti R, Romao W, Vaz BG. Thin layer chromatography coupled to paper spray ionization mass spectrometry for cocaine and its adulterants analysis. *Forensic Science International* 2016;262:56-65.
81. de Jong M, Slegers N, Kim J, Van Durme F, Samyn N, Wang J, De Wael K. Electrochemical fingerprint of street samples for fast on-site screening of cocaine in seized drug powders. *Chemical Science* 2016: Ahead of Print.
82. Mallette JR, Casale JF, Jordan J, Morello DR, Beyer PM. Geographically sourcing cocaine's origin - Delineation of the nineteen major coca growing regions in South America. *Scientific Reports* 2016;6:23520.
83. Marcelo MCA, Fiorentin TR, Mariotti KC, Ortiz RS, Limberger RP, Ferrao MF.

- Determination of cocaine and its main adulterants in seized drugs from Rio Grande do Sul, Brazil, by a Doehlert optimized LC-DAD method. *Analytical Methods* 2016;8(26):5212-5217.
84. Morris F, Peterson E, Manhart M, Heemstra J, Harris J. Single-molecule kinetics study of a small-molecule-dependent split aptamer assembly. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: ANYL-71.
  85. Nakayama H, Kenjjou N, Shigetoh N, Ito Y. Fluorescence immunoassay for cocaine detection. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy* 2016;35(2):83-85.
  86. Neves MAD, Blaszykowski C, Thompson M. Utilizing a key aptamer structure-switching mechanism for the ultrahigh frequency detection of cocaine. *Analytical Chemistry* 2016:Ahead of Print.
  87. Nielsen LS, Villesen P, Lindholst C. Stability of cocaine impurity profiles during 12 months of storage. *Forensic Science International* 2016;264:56-62.
  88. Russo D, Spasiano D, Vaccaro M, Cochran KH, Richardson SD, Andreozzi R, Li Puma G, Reis NM, Marotta R. Investigation on the removal of the major cocaine metabolite (benzoylecgonine) in water matrices by UV254 / H<sub>2</sub>O<sub>2</sub> process by using a flow microcapillary film array photoreactor as an efficient experimental tool. *Water Research* 2016;89:375-383.
  89. Silva TG, de Araujo WR, Munoz RAA, Richter EM, Santana MHP, Coltro WKT, Paixao TRLC. Simple and sensitive paper-based device coupling electrochemical sample pretreatment and colorimetric detection. *Analytical Chemistry* 2016:Ahead of Print.
  90. Vazquez D, Garcinuno B, Tejedor J, Pardo R, Deban L. Polarographic determination of the stability constant of the ternary complex formed between cocaine and cobalt thiocyanate. *Toxicological & Environmental Chemistry* 2016:Ahead of Print.
  91. Zhang S, Hu X, Geng H, Huang M, Qiu Y, Shen C, Wang S, Shen G, Yang M. A highly sensitive and signal-on electrochemical aptasensor based on restriction endonuclease induced background elimination. *Journal of the Electrochemical Society* 2016;163(8):B411-B416.

92. Zhang S, Wang L, Liu M, Qiu Y, Wang M, Liu X, Shen G, Yu R. A novel, label-free fluorescent aptasensor for cocaine detection based on a G-quadruplex and ruthenium polypyridyl complex molecular light switch. *Analytical Methods* 2016;8(18):3740-3746.
93. Sabia R, De Martino M, Cavazzini A, Villani C. Dynamic behavior of clobazam on highperformance liquid chromatography chiral stationary phases. *Chirality* 2015: Ahead of Print.
94. Sylaja B, Gunasekaran S, Srinivasan S. Spectroscopic and quantum chemical studies of molecular geometry, frontier molecular orbital, NLO, NBO analysis of 7-chloro-1-methyl-5-phenyl-1,5-dihydrobenzo[1,4]diazepine-2,4-dione. *Optik* 2016: Ahead of Print.
95. Huang L, Yang X, Qi C, Niu X, Zhao C, Zhao X, Shangguan D, Yang Y. A label-free electrochemical biosensor based on a DNA aptamer against codeine. *Analytica Chimica Acta* 2013;787:203-210.
96. Lodha A, Pandya A, Sutariya PG, Menon SK. A smart and rapid colorimetric method for the detection of codeine sulphate, using unmodified gold nanoprobe. *RSC Advances* 2014;4(92):50443-50448.
97. Shen B, Jiang H, Li Y. Determination of related substances of codeine phosphate sustained release capsules by HPLC. *Heilongjiang Yiyao* 2014;27(4):755-758.
98. Jedinger N, Schrank S, Fischer JM, Breinhaelter K, Khinast J, Roblegg E. Development of an abuse- and alcohol-resistant formulation based on hot-melt extrusion and film coating. *AAPS PharmSciTech* 2015: Ahead of Print.
99. Kuo C-S, Lin C-F, Hong P-KA. Photocatalytic mineralization of codeine by UV-A/TiO<sub>2</sub> - Kinetics, intermediates, and pathways. *Journal of Hazardous Materials* 2016;301:137-144.
100. Frison G, Zamengo L, Zancanaro F, Tisato F, Traldi P. Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography / mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multi-stage mass spectrometry, and nuclear magnetic resonance. *Rapid Communications in Mass Spectrometry* 2016;30(1):151-160.
101. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. A "Krokodil" emerges from the murky waters of addiction. Abuse trends of an old drug. *Life Sciences*

2014;102(2):81-87.

102. Alves EA, Grund J-PC, Afonso CM, Netto ADP, Carvalho F, Dinis-Oliveira RJ. The harmful chemistry behind krokodil (desomorphine) synthesis and mechanisms of toxicity. *Forensic Science International* 2015;249:207-213.
103. Neves JF, Alves EA, Soares JX, Cravo SM, Silva AM, Pereira Netto AD, Carvalho F, Dinis-Oliveira RJ, Afonso CM. Data analysis of "krokodil" samples obtained by street-like synthesis. *Data in Brief* 2015;6:83-88.
104. Bibi S, Bremner DH, Macdougall-Heasman M, Reid R, Simpson K, Tough A, Waddell S, Stewart IJ, Matthews KH. A preliminary investigation to group disparate batches of licit and illicit diazepam tablets using differential scanning calorimetry. *Analytical Methods* 2015: Ahead of Print.
105. Matos APS, Costa JS, Boniatti J, Seiceira RC, Pitaluga Jr A; Oliveira DL, Vicoso AL, Holandino C. Compatibility study between diazepam and tablet excipients - Infrared spectroscopy and thermal analysis in accelerated stability conditions. *Journal of Thermal Analysis and Calorimetry* 2016: Ahead of Print.
106. Elliott SP, Brandt SD, Smith C. The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. *Drug Testing and Analysis* 2016: Ahead of Print.
107. Bijlsma L, Miserez B, Ibanez M, Vicent C, Guillamon E, Ramsey J, Hernandez F. Identification and characterization of a novel cathinone derivative 1-(2,3-dihydro-1H-inden-5-yl)-2-phenyl-2-(pyrrolidin-1-yl)-ethanone seized by Customs in Jersey. *Forensic Toxicology* 2015: Ahead of Print.
108. Narkedimilli J, Ravindrakumar Y, Mohanty S, Srinivasarao T, Jayashree A. Analytical characterization of two new related impurities of diltiazem by high resolution mass spectrometry and NMR techniques. *Oriental Journal of Chemistry* 2015;31(3):1801-1809.
109. Weiss JA, Taschwer M, Kunert O, Schmid MG. Analysis of a new drug of abuse: Cathinone derivative 1-(3,4-dimethoxyphenyl)-2-(ethylamino)pentan-1-one. *Journal of Separation Science* 2015;38(5):825-828.
110. Coppola M, Mondola R. 4,4'-DMAR: Chemistry, pharmacology and toxicology of a

new synthetic stimulant of abuse. *Basic & Clinical Pharmacology & Toxicology* 2015;Ahead of Print.

111. Glanville J, Dargan PI, Wood DM. 4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR, 4,4'-dimethylaminorex): Availability, prevalence of use, desired effects and acute toxicity. *Human Psychopharmacology* 2015;30(3):193-198.
112. Monakhova YB, Ilse M, Hengen J, El-Atma O, Kuballa T, Kohl-Himmelseher M, Lachenmeier DW. Rapid assessment of the illegal presence of 1,3-dimethylamylamine (DMAA) in sports nutrition and dietary supplements using <sup>1</sup>H NMR spectroscopy. *Drug Testing and Analysis* 2014;6(9):944-948.
113. Avula B, Smillie TJ, Wang Y-H, Zweigenbaum J, El Sohly MA, Khan IA. Fast identification of 1,3-dimethylamylamine using direct analysis in real time-QToF-MS. *Journal of AOAC International* 2015;98(3):757-759.
114. Cohen PA, Travis JC, Venhuis BJ. A synthetic stimulant never tested in humans, 1,3-dimethylbutylamine (DMBA), is identified in multiple dietary supplements. *Drug Testing and Analysis* 2015;7(1):83-87.
115. Oner N, Tamer O, Avci D, Atalay Y. Conformational, spectroscopic and nonlinear optical properties of biologically active N,N-dimethyltryptamine molecule: A theoretical study. *Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy* 2014;133:542-549.
116. Winstock AR, Kaar S, Borschmann R. Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. *Journal of Psychopharmacology* 2014;28(1):49-54.
117. Hanumanturayudu K, Sreeramulu J, Maheswara RM. Determination of stability indicating assay method for eszopiclone in pharmaceutical drug substances a comparative study by UPLC and HPLC. *International Journal of Bioassays* 2013;2(3):554-558.
118. Lee J, Choe S, Choi H, Heo S, Kim E, Kim H, Bang E, Chung H. Identification of N-ethyl-alpha-ethylphenethylamine in crystalline powder seized for suspected drug trafficking: A research chemical or a new designer drug? *Forensic Toxicology* 2013;31(1):54-58.

119. Hamby D, Burnett A, Jablonsky M, Twamley B, Kavanagh PV, Gardner EA. Identification of 2-(ethylamino)-1-(4-methylphenyl)-1-pentanone (4-MEAP), a new "Legal High" sold by an internet vendor as 4-methyl pentedrone. *Journal of Forensic Sciences* 2015;60(3):721-726.
120. Maheux CR, Alarcon IQ, Copeland CR, Cameron TS, Linden A, Grossert JS. Identification of polymorphism in ethylone hydrochloride: Synthesis and characterization. *Drug Testing and Analysis* 2015:Ahead of Print.
121. Kai Y-m, Li L, Zhao T-x, Dong Z, Zhang L-j, Liang D-h, Li H-b. An improved synthesis of etizolam. *Xinan Keji Daxue Xuebao* 2014;29(1):10-12.
122. Katselou M, Papoutsis I, Nikolaou P, Qammaz S, Spiliopoulou C, Athanaselis S. Fenethylamine (Captagon) abuse - Local problems from an old drug become universal. *Basic & Clinical Pharmacology & Toxicology* 2016:Ahead of Print.
123. Lurie IS, Berrier AL, Casale JF, Iio R, Bozenko JS. Profiling of illicit fentanyl using UHPLC-MS/MS. *Forensic Science International* 2012;220(1-3):191-196.
124. Schauer CKMW, Shand JAD, Reynolds TM. The fentanyl patch boil-up - A novel method of opioid abuse. *Basic & Clinical Pharmacology & Toxicology* 2015:Ahead of Print.
125. Vu A, DeHope A, Williams AM. Investigation of the organic and inorganic chemical attribution signatures of fentanyl. *Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ANYL-182.*
126. Mayer BP, DeHope AJ, Mew DA, Spackman PE, Williams AM. Chemical attribution of fentanyl using multivariate statistical analysis of orthogonal mass spectral data. *Analytical Chemistry* 2016:Ahead of Print.
127. Alotaibi MR, Husbands SM, Blagbrough IS. <sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N HMBC, and <sup>19</sup>F NMR spectroscopic characterisation of seized flephedrone, cut with benzocaine. *Journal of Pharmaceutical and Biomedical Analysis* 2015;107:535-538.
128. Moosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auwärter V. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. *Journal of Mass Spectrometry* 2013;48(11):1150-1159.

129. Smith JP, Metters JP, Kampouris DK, Lledo-Fernandez C, Sutcliffe OB, Banks CE. Forensic electrochemistry: The electroanalytical sensing of Rohypnol (flunitrazepam) using screen-printed graphite electrodes without recourse for electrode or sample pre-treatment. *Analyst* 2013;138(20):6185-6191.
130. Lledo-Fernandez C, Pollard P, Romerosa A. The date rape drug - Flunitrazepam - electroanalytical sensing using electrogenerated chemiluminescence. *International Journal of Electrochemical Science* 2014;9(1):227-237.
131. Honeychurch KC, Davidson GM, Brown E, Hart JP. Novel reductive-reductive mode electrochemical detection of Rohypnol following liquid chromatography and its determination in coffee. *Analytica Chimica Acta* 2015;853:222-227.
132. Ali EMA, Edwards HGM. The detection of flunitrazepam in beverages using portable Raman spectroscopy. *Drug Testing and Analysis* 2016: Ahead of Print.
133. Guillon J, Pinaud N, Marchivie M, Ronga L, Benazzouz A, Moreau S. Crystal structure of a fluoro analogue of 3,4-(methylenedioxy)amphetamine. *X-Ray Structure Analysis Online* 2015;31(4):1-2.
134. Gaspar H, Bronze S, Ciriaco S, Queiros CR, Matias A, Rodrigues J, Oliveira C, Cordeiro C, Santos S. 4F-PBP (4'-fluoro- $\alpha$ -pyrrolidinobutyrophenone), a new substance of abuse: Structural characterization and purity NMR profiling. *Forensic Science International* 2015;252:168-176.
135. Qian Z, Xu P, Liu K, Gao L. Discussion of crystal water in heroin hydrochloride standard substance. *Huaxue Fenxi Jiliang* 2012;21(1):93-94.
136. Lurie IS, Driscoll SE, Cathapermal SS, Panicker S. Determination of heroin and basic impurities for drug profiling by ultra-high-pressure liquid chromatography. *Forensic Science International* 2013;231(1-3):300-305.
137. Terry JM, Smith ZM, Learey JJ, Shalliker RA, Barnett NW, Francis PS. Chemiluminescence detection of heroin in illicit drug samples. *Talanta* 2013;116:619-625.
138. Balayssac S, Retailleau E, Bertrand G, Escot M-P, Martino R, Malet-Martino M, Gilard V. Characterization of heroin samples by 1H NMR and 2D DOSY 1H NMR. *Forensic Science International* 2014;234:29-38.

139. Hays PA, Schoenberger T. Uncertainty measurement for automated macro program processed quantitative proton NMR spectra. *Analytical and Bioanalytical Chemistry* 2014; 406(28):7397-7400.
140. Hou Y-f, Bai J. Research progress on detection methods of heroin. *Huaxue Gongchengshi* 2014;28(5):58-59.
141. Liu C, Hua Z, Bai Y, Liu Y. Profiling and classification of illicit heroin by ICP-MS analysis of inorganic elements. *Forensic Science International* 2014;239:37-43.
142. Alabkal NA, Metwally EK, Elnagdi MH, Aldosery FI, Abbas NS. Quantitative analysis of components of heroin seized in Kuwait by gas chromatography/mass spectrometry. *American Chemical Science Journal* 2015;8(2):1-8.
143. Casale JF, Casale ES, Toske SG, Hays PA, Panicker S. Characterization and origin of the 'B' and 'C' compounds in the acid/neutral forensic signatures of heroin - Products from the acylation of porphyrroxine and subsequent hydrolysis. *Drug Testing and Analysis* 2015: Ahead of Print.
144. Liu C, Hua Z, Bai Y. Classification of illicit heroin by UPLC-Q-TOF analysis of acidic and neutral manufacturing impurities. *Forensic Science International* 2015: Ahead of Print.
145. Szocs L, Orgovan G, Toth G, Kraszni M, Gergo L, Hosztafi S, Noszal B. Site- and species-specific hydrolysis rates of heroin. *European Journal of Pharmaceutical Sciences* 2016;89:105-114.
146. Esposito S, Deventer K, Van Eenoo P. Identification of the growth hormone-releasing hormone analogue [Pro1, Val14]-hGHRH with an incomplete C-term amidation in a confiscated product. *Drug Testing and Analysis* 2014;6(11-12):1155-1159.
147. Gaudio MC, Valvo L, Borioni A. Identification and quantification of the doping agent GHRP-2 in seized unlabelled vials by NMR and MS: A case-report. *Drug Testing and Analysis* 2014;6(3):295-300.
148. Jin Y-x, Shi L-h, Wu L-q, Liu W-l, Wang J. Quantification of human growth hormone by isotope dilution-high performance liquid chromatography-mass spectrometry. *Fenxi Huaxue* 2015;43(7):1016-1020.

149. Murphy B, Snajdr I, Machara A, Endoma-Arias MAA, Stamatatos TC, Cox DP, Hudlicky T. Conversion of thebaine to oripavine and other useful intermediates for the semi-synthesis of opiate-derived agents: Synthesis of hydromorphone. *Advanced Synthesis & Catalysis* 2014;356(11-12):2679-2687.
150. Stoddard KI, Huggett DB. Wastewater effluent hydrocodone concentrations as an indicator of drug disposal program success. *Bulletin of Environmental Contamination and Toxicology* 2015: Ahead of Print.
151. Mazurek J, Hoffmann M, Fernandez Casares A, Cox DP, Minardi MD, Sasine J. Two orthorhombic polymorphs of hydromorphone. *Acta Crystallographica, Section E: Crystallographic Communications* 2016;72(5):730-733.
152. Pazos D, Giannasi P, Rossy Q, Esseiva P. Combining internet monitoring processes, packaging and isotopic analyses to determine the market structure: Example of gamma-butyrolactone. *Forensic Science International* 2013: Ahead of Print.
153. Rosi L, Frediani P, Bartolucci G. Determination of gamma-hydroxybutyric acid and its precursors (gamma-butyrolactone and 1,4-butanediol) in dietary supplements through the synthesis of their isotopologues and analysis by GC-MS method. *Journal of Pharmaceutical and Biomedical Analysis* 2013;74:31-38.
154. Zhai D, Agrawalla BK, Eng PSF, Lee S-C, Xu W, Chang Y-T. Development of a fluorescent sensor for an illicit date rape drug - GBL. *Chemical Communications* 2013;49(55):6170-6172.
155. van Amsterdam J, Brunt T, Pennings E, van den Brink W. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. *Regulatory Toxicology and Pharmacology* 2014;70(2):507-513.
156. Zhai D, Tan YQE, Xu W, Chang Y-T. Development of a fluorescent sensor for illicit date rape drug GHB. *Chemical Communications* 2014;50(22):2904-2906.
157. Guandalini L, Soldani G, Rosi L, Calamai L, Bartolucci G. A methodological approach to the selection of liquid reagents for chemical ionization ion trap-gas chromatography mass spectrometry: A case study of GBL and 1,4-BD. *International Journal of Mass Spectrometry* 2015;388:34-39.
158. Jimenez-Perez R, Sevilla JM, Pineda T, Blazquez M, Gonzalez-Rodriguez J.

Comparative study of gamma-hydroxybutyric acid (GHB) and other derivative compounds by spectroelectrochemistry Raman (SERS) on platinum surface. *Electrochimica Acta* 2016;193:154-159.

159. Nazarouk M, Dai Z. Detecting 1,4-butanediol in drinks. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-44.
160. Mazoyer C, Carlier J, Boucher A, Peoc'h M, Lemeur C, Gaillard Y. Fatal case of a 27-year-old male after taking Iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in Iboga roots and postmortem biological material. *Journal of Forensic Sciences* 2013;58(6):1666-1672.
161. Sekula K, Zuba D. Structural elucidation and identification of a new derivative of phenethylamine using quadrupole time-of-flight mass spectrometry. *Rapid Communications in Mass Spectrometry* 2013;27(18):2081-2090.
162. Tonai K, Yukimoto T, Osaki N, Teshigawara N. Study of screening reagent for ketamine identification. *Kanzei Chuo Bunsekishoho* 2012;52:67-76.
163. Hoonka S, Dubey NP, Esteve-Romero J, Durgbanshi A, Bose D. Rapid screening of ketamine in confiscated orange juice by thin layer chromatography. *Journal of the Indian Chemical Society* 2013;90(4):513-517.
164. Zhou Z-g. Study on application and control of O-chlorophenyl cyclopentyl ketone. *Hubei Minzu Xueyuan Xuebao, Ziran Kexueban* 2013;31(4):419-421.
165. Bianchi F, Bisceglie F, Dugheri S, Arcangeli G, Cupelli V, del Borrello E, Sidisky L, Careri M. Ionic liquid-based solid phase microextraction necklaces for the environmental monitoring of ketamine. *Journal of Chromatography A* 2014;1331:1-9.
166. Chaudhary S, Kumar P, Chaudhary M, Kothiyal P. Validated method development for estimation of ketamine HCl as API and in pharmaceutical dosage forms by UV-spectroscopy. *Research Journal of Pharmaceutical, Biological and Chemical Sciences* 2014;5(4):686-692.
167. Lledo-Fernandez C, Pollard P, Kruanetr S. Electroanalytical sensing of ketamine using electrogenerated chemiluminescence. *Journal of the Electrochemical Society* 2014;161(1):H36-H40.

168. Potter DE, Choudhury M. Ketamine: Repurposing and redefining a multifaceted drug. *Drug Discovery Today* 2014;19(12):1848-1854.
169. Matsumoto T, Yukimoto T, Osaki N, Teshigawara N. Synthesis and analysis of lisdexamfetamine dimesylate. *Kanzei Chuo Bunsekishoho* 2012;52:61-65.
170. Merli D, Zamboni D, Protti S, Pesavento M, Profumo A. Electrochemistry and analytical determination of lysergic acid diethylamide (LSD) via adsorptive stripping voltammetry. *Talanta* 2014;130:456-461.
171. Mabbott S, Correa E, Cowcher DP, Allwood JW, Goodacre R. Optimization of parameters for the quantitative surface-enhanced Raman scattering detection of mephedrone using a fractional factorial design and a portable Raman spectrometer. *Analytical Chemistry* 2013;85(2):923-931.
172. Delori A, Maclure P, Bhardwaj RM, Johnston A, Florence AJ, Sutcliffe OB, Oswald IDH. Drug solid solutions - A method for tuning phase transformations. *CrystEngComm* 2014;16(26):5827-5831. [Note: CrystEngComm is the full name of this journal.]
173. Fergus S, Kellett K, Gerhard U. The khat and meow meow tale: Teaching the relevance of chemistry through novel recreational drugs. *Journal of Chemical Education* 2014: Ahead of Print.
174. Miserez B, Ayrton O, Ramsey J. Analysis of purity and cutting agents in street mephedrone samples from South Wales. *Forensic Toxicology* 2014;32(2):305-310.
175. Sathaphut N, Sutcliffe OB, Oswald IDH. Putting the squeeze on mephedrone hydrogen sulfate. *Zeitschrift fuer Kristallographie - Crystalline Materials* 2014;229(2):101-111.
176. Babu NS, Tadesse S. Computational studies on molecular structure and interpretation of vibrational spectra, thermodynamical and HOMO-LUMO analysis of mephedrone using density functional theory and ab initio methods. *European Journal of Biomedical and Pharmaceutical Sciences* 2015;2(2):18-33.
177. Parastekar V, Barhate V. Spectrophotometric determination of mephedrone in a bulk form. *International Journal of Current Pharmaceutical Research* 2015;7(3):51-55.
178. Power JD, Kavanagh P, McLaughlin G, O'Brien J, Talbot B, Barry M, Twamley B,

- Dowling G, Brandt SD. Identification and characterization of an imidazolium by-product formed during the synthesis of 4-methylmethcathinone (mephedrone). *Drug Testing and Analysis* 2015: Ahead of Print.
179. Kellett K, Broome JH, Zloh M, Kirton SB, Fergus S, Gerhard U, Stair JL, Wallace KJ. Small molecule recognition of mephedrone using an anthracene molecular clip. *Chemical Communications* 2016;52(47):7474-7477.
180. Esposito FM, Crumpton S, Mitchell J, Flegel RR. Evaluation of the 20% d-methamphetamine requirement for determining illicit use of methamphetamine in urine. *Journal of Analytical Toxicology* 2012;36(6):399-404.
181. Pal R, Megharaj M, Naidu R, Klass G, Cox M, Kirkbride KP. Degradation in soil of precursors and by-products associated with the illicit manufacture of methylamphetamine: Implications for clandestine drug laboratory investigation. *Forensic Science International* 2012;220(1-3):245-250.
182. Salouros H, Collins M, Cawley A, Longworth M. Methylamphetamine synthesis: Does an alteration in synthesis conditions affect the  $\delta^{13}\text{C}$ ,  $\delta^{15}\text{N}$  and  $\delta^2\text{H}$  stable isotope ratio values of the product? *Drug Testing and Analysis* 2012; 4(5): 330-336.
183. Choe S, Heo S, Choi H, Kim E, Chung H, Lee J. Analysis of pharmaceutical impurities in the methamphetamine crystals seized for drug trafficking in Korea. *Forensic Science International* 2013;227(1-3):48-51.
184. Hughes J, Ayoko G, Collett S, Golding G. Rapid quantification of methamphetamine: using attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and chemometrics. *PLoS One* 2013;8(7):e69609.
185. Iwata YT, Mikuma T, Kuwayama K, Tsujikawa K, Miyaguchi H, Kanamori T, Inoue H. Applicability of chemically modified capillaries in chiral capillary electrophoresis for methamphetamine profiling. *Forensic Science International* 2013;226(1-3):235-239.
186. Lloyd A, Russell M, Blanes L, Doble P, Roux C. Lab-on-a-Chip screening of methamphetamine and pseudoephedrine in samples from clandestine laboratories. *Forensic Science International* 2013;228(1-3):8-14.
187. McKenzie EJ, Miskelly GM, Butler PAG. Dynamic solid phase microextraction analysis for airborne methamphetamine: Quantitation using isotopically substituted

- methamphetamine. *Analytical Methods* 2013;5(17):4391-4396.
188. McKenzie EJ, Miskelly GM, Butler PAG. Detection of methamphetamine in indoor air using dynamic solid phase microextraction: A supplementary method to surface wipe sampling. *Analytical Methods* 2013;5(20):5418-5424.
  189. NicDaeid N, Jayaram S, Kerr WJ. Elemental profiling using ICPMS of methylamphetamine hydrochloride prepared from proprietary medication using the Moscow and hypophosphorous synthesis. *Science & Justice* 2013;53(3):278-285.
  190. NicDaeid N, Jayamana S, Kerr WJ, Meier-Augenstein W, Kemp HF. Influence of precursor solvent extraction on stable isotope signatures of methylamphetamine prepared from over-the-counter medicines using the Moscow and hypophosphorous routes. *Analytical and Bioanalytical Chemistry* 2013;405(9):2931-2941.
  191. Salouros H, Sutton GJ, Howes J, Hibbert DB, Collins M. Measurement of stable isotope ratios in methylamphetamine: A link to its precursor source. *Analytical Chemistry* 2013;85(19):9400-9408.
  192. Su Y, Wu X-j, Quan J-j, Yu Y-p. Study on first principle of methylamphetamine in aqueous solution. *Huaxue Gongchengshi* 2013;27(10):54-57.
  193. Triplett JS, Hatfield JA, Kaeff TL, Ramsey CR, Robinson SD, Standifer AF. Raman spectroscopy as a simple, rapid, nondestructive screening test for methamphetamine in clandestine laboratory liquids. *Journal of Forensic Sciences* 2013;58(6):1607-1614.
  194. Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. Chemical profiling of seized methamphetamine putatively synthesized from phenylacetic acid derivatives. *Forensic Science International* 2013;227(1-3):42-44.
  195. Xin Y, Oderji HY, Hai R, Ding H. Molecular dynamics simulation on terahertz spectra of methamphetamine hydrochloride. *Advanced Materials Research* 2013;760-762(Optoelectronics Engineering and Information Technologies in Industry):35-39.
  196. Andrighetto LM, Stevenson PG, Pearson JR, Henderson LC, Conlan XA. DryLab optimised two-dimensional high performance liquid chromatography for differentiation of ephedrine and pseudoephedrine based methamphetamine samples. *Forensic Science International* 2014;244:302-305.

197. Boles TH, Wells MJM. Pilot survey of methamphetamine in sewers using a Polar Organic Chemical Integrative Sampler. *Science of the Total Environment* 2014;472:9-12.
198. Choodum A, Parabun K, Klawach N, Daeid NN, Kanatharana P, Wongniramaikul W. Real time quantitative colourimetric test for methamphetamine detection using digital and mobile phone technology. *Forensic Science International* 2014;235:8-13.
199. Iwata YT, Kuwayama K, Tsujikawa K, Kanamori T, Inoue H. Profiling of methamphetamine. *Bunseki Kagaku* 2014;63(3):221-231.
200. Toske SG, Morello DR, Berger JM, Vazquez ER. The use of  $\delta^{13}\text{C}$  isotope ratio mass spectrometry for methamphetamine profiling: Comparison of ephedrine and pseudoephedrine-based samples to P2P-based samples. *Forensic Science International* 2014;234:1-6.
201. Wang J, Wang H. Synthesis of 10-ethylacridine-2-sulfonyl chloride and application in detection of methamphetamine. *Huaxue Shiji* 2014;36(4):357-360.
202. Kim TH, Ho HW, Brown CL, Cresswell SL, Li Q. Amine-rich carbon nanodots as a fluorescence probe for methamphetamine precursors. *Analytical Methods* 2015: Ahead of Print.
203. Kuo C-S, Lin C-F, Hong P-KA. Photocatalytic degradation of methamphetamine by UV/TiO<sub>2</sub> - Kinetics, intermediates, and products. *Water Research* 2015;74:1-9.
204. Morelato M, Beavis A, Tahtouh M, Ribaux O, Kirkbride KP, Roux C. The use of methylamphetamine chemical profiling in an intelligence-led perspective and the observation of inhomogeneity within seizures. *Forensic Science International* 2015;246:55-64.
205. Rouhani S, Haghgoo S. A novel fluorescence nanosensor based on 1,8-naphthalimidethiophene doped silica nanoparticles, and its application to the determination of methamphetamine. *Sensors and Actuators, B: Chemical* 2015;209:957-965.
206. Toske SG, McConnell JB, Brown JL, Tuten JM, Miller EE, Phillips MZ, Vazquez ER, Lurie IS, Hays PA, Guest EM. Isolation and characterization of a newly identified impurity in methamphetamine synthesized via reductive amination of 1-phenyl-2-propanone (P2P) made from phenylacetic acid/lead (II) acetate. *Drug Testing and*

Analysis 2015: Ahead of Print.

207. Wang T, Yu Z, Shi Y, Xiang P. Enantiomer profiling of methamphetamine in white crystal and tablet forms (Ma Old) using LC-MS-MS. *Journal of Analytical Toxicology* 2015;39(7):551-556.
208. Choe S, Lee J, Choi H, Park Y, Lee H, Jo J, Park Y, Kim E, Pyo J, Lee HJ, Kim S. Estimation of the synthetic routes of seized methamphetamines using GC-MS and multivariate analysis. *Forensic Science International* 2016;259:85-94.
209. Newberry L, Boles T. Demethylation of methamphetamine by ultraviolet tertiary treatment at wastewater treatment plants. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: ENVR-462.
210. Xu Z, Jiang J, Wang X, Han K, Ameen A, Khan I, Chang T-W, Liu GL. Large-area, uniform and low-cost dual-mode plasmonic naked-eye colorimetry and SERS sensor with handheld Raman spectrometer. *Nanoscale* 2016: Ahead of Print.
211. Idris M, John C, Ghosh P, Shukla SK, Baggi TRR. Simultaneous determination of methaqualone, saccharin, paracetamol, and phenacetin in illicit drug samples by HPLC. *Journal of Analytical Science and Technology* 2013;4(1-8):4/1-4/6.
212. Chang Y, Xu P, Gao L. Detection of methcathinone by HPLC. *Huaxue Fenxi Jiliang* 2012;21(1):67-69.
213. Chang Y, Zhang C, Gao L. Qualitative and quantitative analysis of methcathinone by LC/MS/MS method. *Huaxue Fenxi Jiliang* 2013;22(3):51-53.
214. Zhang H, Zhao L. Quantitative analysis of methcathinone by gas chromatography/mass spectrometry. *Shanxi Yike Daxue Xuebao* 2013;44(12):939-941.
215. Cumba LR, Kolliopoulos AV, Smith JP, Thompson PD, Evans PR, Sutcliffe OB, do Carmo DR, Banks CE. Forensic electrochemistry: Indirect electrochemical sensing of the components of the new psychoactive substance "Synthacaine". *Analyst* 2015;140(16):5536-5545.
216. Lanza M, Acton WJ, Sulzer P, Breiev K, Juerschik S, Jordan A, Hartungen E, Hanel G, Maerk L, Maerk TD, Mayhew CA. Selective reagent ionisation-time of flight-mass spectrometry: A rapid technology for the novel analysis of blends of new psychoactive

- substances. *Journal of Mass Spectrometry* 2015;50(2):427-431.
217. Westwell AD, Hutchings A, Caldicott DGE. The identification and chemical characterization of a new arylcyclohexylamine, methoxetamine, using a novel emergency department toxicosurveillance tool. *Drug Testing and Analysis* 2013;5(3):203-207.
218. Zawilska JB. Methoxetamine - A novel recreational drug with potent hallucinogenic properties. *Toxicology Letters* 2014;230(3):402-407.
219. Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV. First reported fatalities associated with the 'research chemical' 2-methoxydiphenidine. *Journal of Analytical Toxicology* 2015;39(4):287-293.
220. Cosbey S, Kirk S, McNaul M, Peters L, Prentice B, Quinn A, Elliott SP, Brandt SD, Archer RP. Multiple fatalities involving a new designer drug: para-Methyl-4-methyl-aminorex. *Journal of Analytical Toxicology* 2014;38(6):383-384.
221. Fornal E, Stachniuk A, Wojtyla A. LC-Q/TOF Mass spectrometry data driven identification and spectroscopic characterisation of a new 3,4-methylenedioxy-N-benzyl cathinone (BMDP). *Journal of Pharmaceutical and Biomedical Analysis* 2013;72:139-144.
222. Lourenco TC, Bosio GC, Cassiano NM, Cass QB, Moreau RLM. Chiral separation of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers using batch chromatography with peak shaving recycling and its effects on oxidative stress status in rat liver. *Journal of Pharmaceutical and Biomedical Analysis* 2013;73:13-17.
223. Morelato M, Beavis A, Tahtouh M, Ribaux O, Kirkbride P, Roux C. The use of organic and inorganic impurities found in MDMA police seizures in a drug intelligence perspective. *Science & Justice* 2013: Ahead of Print.
224. Schäffer M, Dieckmann S, Pütz M, Kohles T, Pyell U, Zimmermann R. Impact of reaction parameters on the chemical profile of 3,4-methylenedioxymethamphetamine synthesized via reductive amination: Target analysis based on GC-qMS compared to nontargeted analysis based on GC×GC-TOF-MS. *Forensic Science International* 2013;233(1-3):201-211.
225. McManaman KM, Smith RW. Effect of extraction procedure and gas chromatography temperature program on discrimination of MDMA exhibits. *Journal of Forensic Sciences*

2014;59(2):327-336.

226. Tadini MC, Balbino MA, Eleoterio IC, Siqueira de Oliveira L, Dias LG, Jean-Francois Demets G, Firmino de Oliveira M. Developing electrodes chemically modified with cucurbit[6]uril to detect 3,4-methylenedioxymethamphetamine (MDMA) by voltammetry. *Electrochimica Acta* 2014;121:188-193.
227. Bermudez C, Cabezas C, Mata S, Berdakin M, Tejedor JM, Alonso JL. Analysis of illicit drugs by direct ablation of solid samples. *European Journal of Mass Spectrometry* 2015;21(6):775-781.
228. Connor LE, Delori A, Hutchison IB, Nic Daeid N, Sutcliffe OB, Oswald IDH. The Ecstasy and the agony - Compression studies of 3,4-methylenedioxymethamphetamine (MDMA). *Acta Crystallographica, Section B: Structural Science, Crystal Engineering and Materials* 2015;71(1): 3-9.
229. Heather E, Shimmon R, McDonagh AM. Organic impurity profiling of 3,4-methylenedioxymethamphetamine (MDMA) synthesised from catechol. *Forensic Science International* 2015;248:140-147.
230. Theakstone AG, Smith ZM, Terry JM, Barnett NW, Francis PS. Chemiluminescence detection of MDMA in street drug samples using tris(2,2'-bipyridine)ruthenium(III). *Drug Testing and Analysis* 2015: Ahead of Print.
231. McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Mahony O, Brandt SD, Patrick J, Archer RP, Partilla JS, Baumann MH. Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR). *Drug Testing and Analysis* 2015;7(7):555-564.
232. Csak R, Demetrovics Z, Racz J. Transition to injecting 3,4-methylenedioxypyrovalerone (MDPV) among needle exchange program participants in Hungary. *Journal of Psychopharmacology* 2013;27(6):559-563.
233. Chen X-g, Wang X-l, Da H, Guo Y-m, Qi H-j, Liu L, Xiao Y-q. Progress of research of  $\alpha$ -pyrrolidinophenone designer drug methylenedioxypyrovalerone. *Shandong Huagong* 2014;43(4):60-61,65.
234. Da H, Chen X-g, Guo Y-m, Qi H-j, Liu L, Xiao Y-q. Analysis of designer drug

- methylenedioxypropylone by gas liquid-mass spectrometry and liquid chromatography - mass spectrometry. *Fujian Fenxi Ceshi* 2014;23(6):1-4.
235. Zhou Z. Methylenedioxypropylone - A new designer drug. *Zhongguo Yaowu Yilaixing Zazhi* 2014;23(2):86-88.
236. Gil D, Adamowicz P, Skulska A, Tokarczyk B, Stanaszek R. Analysis of 4-MEC in biological and non-biological material - Three case reports. *Forensic Science International* 2013; 228(1-3): e11-e15.
237. Lopez-Avila V, Zorio M. Identification of methylhexanamine by GC high-resolution tofms and soft ionization. *Forensic Science International* 2013;231(1-3):113-119.
238. Cohen PA, Bloszies C, Yee C, Gerona R. An amphetamine isomer whose efficacy and safety in humans has never been studied,  $\beta$ -methylphenylethylamine (BMPEA), is found in multiple dietary supplements. *Drug Testing and Analysis* 2015: Ahead of Print.
239. Blachut D, Szawkalo J, Czarnocki Z. Identification of common impurities present in the synthetic routes leading to 4-methylthioamphetamine (4-MTA). Part II: Reductive amination and nitropropene route. *Forensic Science International* 2012;217(1-3):60-70.
240. Blachut D, Wojtasiewicz K, Krawczyk K, Maurin J, Szawkalo J, Czarnocki Z. Identification and synthesis of by-products found in 4-methylthioamphetamine (4-MTA) produced by the Leuckart method. *Forensic Science International* 2012;216(1-3):108-120.
241. Bayurka SV. Development of identification and quantitative determination methods of mianserin suitable for the chemical and toxicological analysis. *Visnik Farmatsii* 2012;(2):52-56.
242. Espinosa-Bosch M, Ruiz-Sanchez A, Sanchez-Rojas F, Bosch-Ojeda C. Analytical methodologies for the determination of midazolam in pharmaceuticals. *Chromatographia* 2015;78(9-10):609-619.
243. Pesek JJ, Matyska MT, Kim AM. Evaluation of stationary phases based on silica hydride for the analysis of drugs of abuse. *Journal of Separation Science* 2013;36(17):2760-2766.
244. Yang Y-l, Li X-k, Li Y-s, Liu M, Feng L-j, Tang H-b. Determination of morphine in

- compound liquorice tablets by HPLC with online solid-phase extraction. *Yaowu Fenxi Zazhi* 2013;33(11):1920-1923.
245. Cordova-Mateo E, Poater J, Teixeira-Dias B, Bertran O, Estrany F, del Valle LJ, Sola M, Aleman C. Electroactive polymers for the detection of morphine. *Journal of Polymer Research* 2014;21(10):1-13.
246. Hao H, Zhou H, Zeng L, Liu J, Liu Y. Highly sensitive detection of morphine based on molecular imprinting polymers using surface plasmon resonance. *Journal of Chemical and Pharmaceutical Research* 2014;6(6):1699-1708.
247. Keyvanfard M, Amri F. Kinetic spectrophotometric determination of morphine in pharmaceutical samples. *Oriental Journal of Chemistry* 2014;30(4):1841-1846.
248. Moellendal H, Balcells D, Eisenstein O, Syversen L, Rachel Suissa M. Conformational complexity of morphine and morphinum in the gas phase and in water. A DFT and MP2 study. *RSC Advances* 2014;4(47):24729-24735.
249. Wang YQ, Zhang JL, Schuchardt F, Wang Y. Degradation of morphine in opium poppy processing waste composting. *Bioresource Technology* 2014;168:235-239.
250. Acevska J, Stefkov G, Cvetkovikj I, Petkovska R, Kulevanova S, Cho JH, Dimitrovska A. Fingerprinting of morphine using chromatographic purity profiling and multivariate data analysis. *Journal of Pharmaceutical and Biomedical Analysis* 2015;109:18-27.
251. Hu L, Dai Q, Liu F, Liu S-q. Study on the stability of morphine sulfate orally disintegrating tablets. *Zhongguo Yaofang* 2015;26(4):515-518.
252. Jash SK, Gorai D. Sugar derivatives of morphine: A new window for the development of potent anesthetic drugs. *Natural Products and Bioprospecting* 2015;5(3):111-127.
253. Borges RS, Vale JKL, Pereira GAN, Veiga AAS, Junior JB, da Silva ABF. An antioxidant mechanism of morphine and related derivatives. *Medicinal Chemistry Research* 2016: Ahead of Print.
254. Miolo G, Tucci M, Mazzoli A, Ferrara SD, Favretto D. Photostability of 6-MAM and morphine exposed to controlled UV irradiation in water and methanol solution: HRMS for the characterization of transformation products and comparison with the dry state. *Journal of Pharmaceutical and Biomedical Analysis* 2016;126:48-59.

255. Petrusovski G, Acevska J, Stefkov G, Poceva Panovska A, Micovski I, Petkovska R, Dimitrovska A, Ugarkovic S. Characterization and origin differentiation of morphine derivatives by DSC/TG and FTIR analysis using pattern recognition techniques. *Journal of Thermal Analysis and Calorimetry* 2016: Ahead of Print.
256. Vergara AV, Pernites RB, Tiu BDB, de Leon ACC, Mangadlao JD, Binag CA, Advincula RC. Capacitive detection of morphine via cathodically electropolymerized, molecularly imprinted poly(p-aminostyrene) films. *Macromolecular Chemistry and Physics* 2016: Ahead of Print.
257. Yang Y-L, Ye X-X, Li Y-S, Tan Z-F, Jiang J-Z. Determination of morphine in pharmaceutical products by on-line solid-phase extraction and high-performance liquid chromatography. *Analytical Letters* 2016: Ahead of Print.
258. Hosztafi S. Recent advances in the chemistry of oripavine and its derivatives. *Advances in Bioscience and Biotechnology* 2014;5(8):704-717.
259. Jin X, Du Z. Determination of related substances in oxycodone & acetaminophen tablets by HPLC. *Zhongguo Yaoye* 2013;22(21):31-32.
260. Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated Oxycontin tablets: Assessing comparative preferences and tampering potential. *Journal of Psychopharmacology* 2013;27(9):808-816.
261. Dong G-m. Research progress on the powerful narcotic analgesic of compound oxycodone. *Zhongguo Yaolixue Yu Dulixue Zazhi* 2014;28(5):758-764.
262. Havens JR, Leukefeld CG, DeVeugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. *Drug and Alcohol Dependence* 2014;139:9-17.
263. Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (Oxycontin) with an abuse-deterrent formulation. *Pharmacoepidemiology and Drug Safety* 2014;23(12):1238-1246.
264. Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance B. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. *Drug and Alcohol*

Dependence 2015: Ahead of Print.

265. Peacock A, Degenhardt L, Hordern A, Larance B, Cama E, White N, Kihlas I, Bruno R. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. *International Journal of Drug Policy* 2015;26(12):1265-1272.
266. Eisenhauer TD, Matchett M, Heasley R, Morton T, Devarakonda K, Giuliani M, Young JL, Barrett T. Evaluation of the tamper-resistant properties of biphasic immediate-release / extended-release oxycodone/acetaminophen tablets. *Drug Development and Industrial Pharmacy* 2016;42(1):157-165.
267. Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanpera I. Phenazepam abuse in Finland: Findings from apprehended drivers, post-mortem cases and police confiscations. *Forensic Science International* 2012;220(1-3):111-117.
268. Macher AM, Penders TM. False-positive phencyclidine immunoassay results caused by 3,4-methylenedioxypyrovalerone (MDPV). *Drug Testing and Analysis* 2013;5(2):130-132.
269. Huang X-y, Yu H-c, Tan X-c, Lei F-h, Huang X-h. Preparation and properties of an electrochemical sensor based on molecular imprinted polymer for phenobarbital detection. *Fenxi Shiyanshi* 2014;33(5):550-554.
270. Yu H-c, Huang X-y, Tan X-c, Lei F-h, Mao H-j. Preparation and application of phenobarbital electrochemical sensor based on molecular imprinted technique and electropolymerization membrane. *Fenxi Ceshi Xuebao* 2014;33(7):752-757.
271. Zencirci N, Griesser UJ, Gelbrich T, Kahlenberg V, Jetti RKR, Apperley DC, Harris RK. New solvates of an old drug compound (Phenobarbital): Structure and stability. *Journal of Physical Chemistry B* 2014;118(12):3267-3280.
272. Wang J. Simultaneous determination of two components in aspirin and phenobarbital powders by HPLC. *Zhongguo Yaoshi* 2015;18(2):343-345.
273. Roy S, Goud NR, Matzger AJ. Polymorphism in phenobarbital: Discovery of a new polymorph and crystal structure of elusive form V. *Chemical Communications* 2016: Ahead of Print.
274. Akhtar N, Javed MM, Zahoor S, Babar ME, Ikram-ul-Haq. Rapid isolation/selection of

- best yeast culture and its metabolic control for the biotransformation of benzaldehyde to 1-hydroxy-1-phenyl-2-propanone. *Pakistan Journal of Zoology* 2014;46(3):783-787.
275. Maroney KAN, Culshaw PN, Wermuth UD, Cresswell SL. Investigation of the 1-phenyl-acetylcarbinol process to substituted benzaldehydes of interest. *Forensic Science International* 2014;235:52-61.
276. Kandar S, Suresh AK, Noronha SB. (R)-PAC Biosynthesis in [BMIM][PF6]/aqueous biphasic system using *Saccharomyces cerevisiae* BY4741 cells. *Applied Biochemistry and Biotechnology* 2015;175(4):1771-1788.
277. Doughty D, Painter B, Pigou PE, Johnston MR. The synthesis and investigation of impurities found in clandestine laboratories: Baeyer-Villiger Route Part I; Synthesis of P2P from benzaldehyde and methyl ethyl ketone. *Forensic Science International* 2016;263:55-66.
278. Schjerning O, Rosenzweig M, Pottegaard A, Damkier P, Nielsen J. Abuse potential of Pregabalin - A systematic review. *CNS Drugs* 2016;30(1):9-25.
279. Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshoefer L, Auwaerter V. characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. *Forensic Toxicology* 2013;31(2):263-271.
280. Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Inoue H. Thermal degradation of alpha-pyrrolidinopentiophenone during injection in gas chromatography / mass spectrometry. *Forensic Science International* 2013;231(1-3):296-299.
281. Wood MR, Bernal I, Lalancette RA. The dangerous new synthetic drug  $\alpha$ -PVP as the hydrated chloride salt  $\alpha$ -pyrrolidinopentiophenone hydrochloride 0.786-hydrate. *Acta Crystallographica, Section C: Structural Chemistry* 2016;72(1):48-51.
282. Sáiz J, Mai TD, López ML, Bartolomé C, Hauser PC, García-Ruiz C. Rapid determination of scopolamine in evidence of recreational and predatory use. *Science & Justice* 2013;53(4):409-414.
283. Phattanawasin P, Sotaphun U, Sukwattanasinit T, Akkarawarantorn J, Kitchaiya S. Quantitative determination of sibutramine in adulterated herbal slimming formulations by TLC-image analysis method. *Forensic Science International* 2012;219(1-3):96-100.

284. Csupor D, Boros K, Danko B, Veres K, Szendrei K, Hohmann J. Rapid identification of sibutramine in dietary supplements using a stepwise approach. *Pharmazie* 2013;68(1):15-18.
285. Cavalcante da Silva N, Honorato RS, Pimentel MF, Garrigues S, Cervera ML, de la Guardia M. Near infrared spectroscopy detection and quantification of herbal medicines adulterated with sibutramine. *Journal of Forensic Sciences* 2015;60(5):1199-1205.
286. Brooker L, Cawley A, Drury J, Edey C, Hasick N, Goebel C. Stable carbon isotope ratio profiling of illicit testosterone preparations - Domestic and international seizures. *Drug Testing and Analysis* 2014;6(10):996-1001.
287. Lei YT, Lu Y, Zhang TC, Qi Y, Lu YF. Rapid screening of testosterone in the aquatic environment using direct analysis in real-time (DART) mass spectrometry. *Environmental Earth Sciences* 2016;75(12):1-7.
288. Toomey V, Lanzarotta A, Lorenz L. Identification of a purported dietary supplement ingredient using a multi-pronged analysis approach. Abstracts, 47th Central Regional Meeting of the American Chemical Society, Covington, KY, United States, May 18-21, 2016: CERM-3.
289. Winstock AR, Borschmann R, Bell J. The non-medical use of tramadol in the UK: Findings from a large community sample. *International Journal of Clinical Practice* 2014;68(9):1147-1151.
290. Prabavathi N, Nilufer A, Krishnakumar V. FT-IR, FT-Raman and DFT quantum chemical study on the molecular conformation, vibrational and electronic transitions of 1-(m-(trifluoromethyl)phenyl)piperazine. *Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy* 2014;121:483-493.
291. Mahapatra AK, Sameeraja NH, Murthy PN. Development of modified-release tablets of zolpidem tartrate by biphasic quick/slow delivery system. *AAPS PharmSciTech* 2014: Ahead of Print.
292. Abdelrahman MM, Naguib IA, El Ghobashy MR, Ali NA. Quantitative determination of zopiclone and its impurity by four different spectrophotometric methods. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 2015;137:617-624.
293. Naguib IA, Abdelrahman MM, El Ghobashy MR, Ali NA. HPTLC method for

- quantitative determination of zopiclone and its impurity. *Journal of Chromatographic Science* 2015;53(8):1395-1399.
294. Mironidou-Tzouveleki M, Savvidis M, Apostolidou K, Mitsopoulos S, Tzouveleki I, Kalousis K. Hallucinogenic plant and fungal species naturally growing in Mediterranean countries. *Epitheorese Klinikes Farmakologias kai Farmakokinetikes, International Edition* 2013;27(3):131-144.
295. Appendino G, Minassi A, Tagliatela-Scafati O. Recreational drug discovery: Natural products as lead structures for the synthesis of smart drugs. *Natural Product Reports* 2014;31(7):880-904.
296. Chen X. Profiling and characterization of bioactive substances of herbal medicine and their metabolites using mass spectrometry. *Handbook of Metabolic Pathways of Xenobiotics* 2014;2:723-786.
297. Ujvary I. Psychoactive natural products: Overview of recent developments. *Annali dell'Istituto Superiore di Sanita* 2014;50(1):12-27.
298. Queiroz MMF, Marti G, Queiroz EF, Marcourt L, Castro-Gamboa I, Bolzani VS, Wolfender JL. LC-MS/MS quantitative determination of Tetrapteryx mucronata alkaloids, a plant occasionally used in Ayahuasca preparation. *Phytochemical Analysis* 2015: Ahead of Print.
299. Lesiak AD, Musah RA. Application of ambient ionization high resolution mass spectrometry to determination of the botanical provenance of the constituents of psychoactive drug mixtures. *Forensic Science International* 2016;266:271-280.
300. Bhalerao SA, Verma DR, Gavankar RV, Teli NC, Rane YY, Didwana VS, Trikannad A. Phytochemistry, pharmacological profile and therapeutic uses of Piper betle Linn. - An overview. *Research & Reviews: Journal of Pharmacognosy and Phytochemistry* 2013;1(2):10-19.
301. Nagaki J, Noguchi H, Saegusa T. Study on the identification of coca leaves using DNA analysis. *Kanzei Chuo Bunsekishoho* 2012;52:77-83.
302. Casale JF, Mallette JR, Jones LM. Chemosystematic identification of fifteen new cocaine-bearing Erythroxylum cultigens grown in Colombia for illicit cocaine production. *Forensic Science International* 2014;237:30-39.

303. Docimo T, Schmidt GW, Luck K, Delaney SK, D'Auria JC. Selection and validation of reference genes for quantitative gene expression studies in *Erythroxylum coca*. *F1000 Research* 2014;2:37/1-37/11.
304. Schaeffer M, Groeger T, Puetz M, Zimmermann R. Assessment of the presence of damiana in herbal blends of forensic interest based on comprehensive two-dimensional gas chromatography. *Forensic Toxicology* 2013;31(2):251-262.
305. Fang S-t, Liu X, Kong N-n, Liu S-j, Xia C-h. A new essential oil component from *Datura stramonium*. *Zhongcaoyao* 2013;44(15):2035-2038.
306. Fu H, Shan W-g, Li X-l, Li F, Wang Z-j, Hou X-r, Lin R-c, Guan X-y, Liu Q-m. Recent research developments on potent Chinese medicine *Flos daturae* and supplementary reports on test methods. *Yaowu Fenxi Zazhi* 2013;33(10):1822-1834.
307. Fukuda T. Poisoning by the use of *Datura* plants. *Japanese Journal of Clinical Toxicology* 2014;27(1):10-13.
308. Altameme HJ, Hameed IH, Kareem MA. Analysis of alkaloid phytochemical compounds in the ethanolic extract of *Datura stramonium* and evaluation of antimicrobial activity. *African Journal of Biotechnology* 2015;14(19):1668-1674.
309. Wu Y-n, Xu L, Chen J, Wang B, Zhao R. DNA molecular identification of *Datura* medicinal plants using ITS2 barcode sequence. *Zhongyaocai* 2015;38(9):1852-1857.
310. Zhang X-q, Zhang H, Shi X-l. Distribution of hyoscyamine and scopolamine in *Datura stramonium* produced in Guizhou. *Zhongyaocai* 2015;38(1):49-52.
311. Zhou J-L, Liu W, Guo Z-X, Chen B-L. Fingerprint analysis of *Daturae flos* using rapid resolution liquid chromatography-electrospray ionization mass spectrometry combined with stoichiometry. *Journal of Liquid Chromatography & Related Technologies* 2015;38(1):137-142.
312. Jin L, Zhang X-f, Cui Z-j, Zhu T-t, Wang Z-h, Ma Y, Lin L, Gao T-p. Determination of ephedrine and pseudoephedrine in *Herba ephedrae* from different habitats and species by HPLC method. *Zhongshouyi Yiyao Zazhi* 2013;32(1):43-46.
313. Lu Y, Liu J, Gong X, Su X, Qiu F. Research progress on ephedra's pharmacological effects and its content determination. *Zhongguo Yiyao Daobao* 2013;10(24):38-40.

314. Wang X. Optimum conditions of extracting ephedrine from *Ephedra sinica* by response surface methodology based on the HPLC determination. *Zhongguo Niangzao* 2013;32(11):72-75.
315. Yi Z, Dong Y, Qin S, Wang L, Wang Y, Fan Q. Correlation between the main alkaloid contents and the powder fractions of pulverized *Ephedra sinica*. *Analytical Methods* 2014;6(18):7559-7562.
316. Ibragic S, Sofic E. Chemical composition of various *Ephedra* species. *Bosnian Journal of Basic Medical Sciences* 2015;15(3):21-27.
317. Matsumoto M, Hirayama M, Ohtomi N, Ohno T, Nomura Y, Iida O, Sugimura K, Kawahara N, Tsuchida T, Mikage M. Influence of genetic factors on the ephedrine alkaloid composition ratio of *Ephedra* plants. *Journal of Natural Medicines* 2015;69(1):63-67.
318. Zhang N, Wang C-l, Hou B-l, Sun Y-n, Liu Z-l, Liu J-l. Identification and determination of biogenic amines in *Ephedrae herba* by RP-HPLC with precolumn derivatization. *Yaowu Fenxi Zazhi* 2015;35(3):389-395.
319. Paulke A, Kremer C, Wunder C, Wurglics M, Schubert-Zsilavec M, Toennes SW. Studies on the alkaloid composition of the Hawaiian Baby Woodrose *Argyrea nervosa*, a common legal high. *Forensic Science International* 2015;249:281-293.
320. Gambaro V, Arnoldi S, Colombo ML, Dell'Acqua L, Guerrini K, Roda G. Determination of the active principles of *Catha edulis*: Quali-quantitative analysis of cathinone, cathine, and phenylpropanolamine. *Forensic Science International* 2012;217(1-3):87-92.
321. Atlabachew M, Chandravanshi BS, Redi-Abshiro M, Torto N, Chigome S, Pule BO. Evaluation of the effect of various drying techniques on the composition of the psychoactive phenylpropylamino alkaloids of khat (*Catha edulis* Forsk) chewing leaves. *Bulletin of the Chemical Society of Ethiopia* 2013;27(3):347-358.
322. Dell'Acqua L, Roda G, Arnoldi S, Rusconi C, Turati L, Gambaro V. Improved GC method for the determination of the active principles of *Catha edulis*. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 2013;929:142-148.
323. Roda G, Liberti V, Arnoldi S, Argo A, Rusconi C, Suardi S, Gambaro V. Capillary

- electrophoretic and extraction conditions for the analysis of *Catha edulis* active principles. *Forensic Science International* 2013;228(1-3):154-159.
324. Algabr M, Abu Dunia A-M, Aissaoui H, Hammoud L, Mekkiou R, Benayache S, Benayache F. Flavonoids glycosides from leaves of *Catha edulis* (Celastraceae). *Pharma Chemica* 2015;7(11):193-196.
  325. Atlabachew M, Combrinck S, McCrindle RI. Cation-exchange solid-phase and liquidliquid extraction for the determination of khat alkaloids by reversed phase HPLC-DAD. *Bulletin of the Chemical Society of Ethiopia* 2015;29(3):331-339.
  326. Atlabachew M, Combrinck S, Sandasi M, Chen W, Viljoen A. Rapid differentiation of khat (*Catha edulis* Vahl. Endl.) using single point and imaging vibrational spectroscopy. *Vibrational Spectroscopy* 2015: Ahead of Print.
  327. Atlabachew M, Torto N, Chandravanshi BS, Redi-Abshiro M, Chigome S, Mothibedi K, Combrinck S. A (-)-norephedrine-based molecularly imprinted polymer for the solid-phase extraction of psychoactive phenylpropylamino alkaloids from khat (*Catha edulis* Vahl. Endl.) chewing leaves. *Biomedical Chromatography* 2015: Ahead of Print.
  328. Getasetegn M. Chemical composition of *Catha edulis* (khat): A review. *Phytochemistry Reviews* 2015: Ahead of Print.
  329. Nichols T, Khondkar P, Gibbons S. The psychostimulant drug khat (*Catha edulis*): A mini-review. *Phytochemistry Letters* 2015: Ahead of Print.
  330. Kowalczyk AP, Lozak A, Zjawiony JK. Comprehensive methodology for identification of Kratom in police laboratories. *Forensic Science International* 2013;233(1-3):238-243.
  331. Parthasarathy S, Ramanathan S, Murugaiyah V, Hamdan MR, Said MI, Lai C-S, Mansor SM. A simple HPLC-DAD method for the detection and quantification of psychotropic mitragynine in *Mitragyna speciosa* (Ketum) and its products for the application in forensic investigation. *Forensic Science International* 2013;226(1-3):183-187.
  332. Lesiak AD, Cody RB, Dane AJ, Musah RA. Rapid detection by direct analysis in real time-mass spectrometry (DART-MS) of psychoactive plant drugs of abuse: The case of *Mitragyna speciosa* aka "Kratom". *Forensic Science International* 2014;242:210-218.
  333. Limsuwanchote S, Wungsintaweekul J, Keawpradub N, Putalun W, Morimoto S, Tanaka

- H. Development of indirect competitive ELISA for quantification of mitragynine in Kratom (*Mitragyna speciosa* (Roxb.) Korth.). *Forensic Science International* 2014;244:70-77.
334. Scott TM, Yeakel JK, Logan BK. Identification of mitragynine and O-desmethyltramadol in Kratom and legal high products sold online. *Drug Testing and Analysis* 2014;6(9):959-963.
335. Wang M, Carrell EJ, Ali Z, Avula B, Avonto C, Parcher JF, Khan IA. Comparison of three chromatographic techniques for the detection of mitragynine and other indole and oxindole alkaloids in *Mitragyna speciosa* (Kratom) plants. *Journal of Separation Science* 2014;37(12):1411-1418.
336. Avula B, Sagi S, Wang Y-H, Wang M, Ali Z, Smillie TJ, Zweigenbaum J, Khan IA. Identification and characterization of indole and oxindole alkaloids from leaves of *Mitragyna speciosa* Korth using liquid chromatography-accurate QToF mass spectrometry. *Journal of AOAC International* 2015;98(1):13-21.
337. Aziz Z. Kratom: The epidemiology, use and abuse, addiction potential, and legal status. *Kratom and Other Mitragynines* 2015:309-319.
338. Gogineni V, Leon F, Avery BA, McCurdy C, Cutler SJ. Phytochemistry of *Mitragyna speciosa*. *Kratom and Other Mitragynines* 2015:77-94.
339. Kikura-Hanajiri R. The detection of mitragynine and its analogs. *Kratom and Other Mitragynines* 2015:153-165.
340. Kitajima M, Takayama H. Chemistry of mitragyna alkaloids. *Kratom and Other Mitragynines* 2015:101-116.
341. Raffa RB. Chemistry of mitragynines: A brief introduction. *Kratom and Other Mitragynines* 2015:95-100.
342. Raffa RB, Beckett JR, Brahmhatt VN, Ebinger TM, Fabian CA, Nixon JR, Orlando ST, Rana CA, Tejani AH, Tomazic RJ. Short overview of mitragynines. *Kratom and Other Mitragynines* 2015:9-21.
343. Ramanathan S, Parthasarathy S, Murugaiyah V, Magosso E, Tan SC, Mansor SM. Understanding the physicochemical properties of mitragynine, a principal alkaloid of

- Mitragyna speciosa, for preclinical evaluation. *Molecules* 2015;20(3):4915-4927.
344. Guddat S, Goergens C, Steinhart V, Schaenzer W, Thevis M. Mitragynine (Kratom) - Monitoring in sports drug testing. *Drug Testing and Analysis* 2016:Ahead of Print.
345. Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of mitragynine (Kratom): A survey of the literature. *Brain Research Bulletin* 2016:Ahead of Print.
346. Tran L, Ng K. Extraction of an active component (mitragynine) from Kratom leaves. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-788.
347. Muccio Z, Wockel C, An Y, Jackson GP. Comparison of bulk and compound-specific delta13C isotope ratio analyses for the discrimination between cannabis samples. *Journal of Forensic Sciences* 2012;57(3):757-764.
348. Potter DJ, Duncombe P. The effect of electrical lighting power and irradiance on indoor grown cannabis potency and yield. *Journal of Forensic Sciences* 2012;57(3):618-622.
349. Zhai W-f, Zhang C-s, Gao L-s. Study on determination of delta-9-tetrahydrocannabinol in cannabis by high performance liquid chromatography. *Fenxi Ceshi Xuebao* 2012;31(11):1379-1384.
350. Abot A, Bonnafous C, Touchard F, Thibault F, Chocinski-Arnault L, Lemoine R, Dedaldechamp F. Effects of cultural conditions on the hemp (*Cannabis sativa*) phloem fibres: Biological development and mechanical properties. *Journal of Composite Materials* 2013;47(8):1067-1077.
351. Ameer S, Haddou B, Derriche Z, Canselier JP, Gourdon C. Cloud point extraction of delta-9-tetrahydrocannabinol from cannabis resin. *Analytical and Bioanalytical Chemistry* 2013;405(10):3117-3123.
352. Cadola L, Broseus J, Esseiva P. Chemical profiling of different hashish seizures by gas chromatography-mass spectrometry and statistical methodology: A case report. *Forensic Science International* 2013:Ahead of Print.
353. Kaniewski R, Banach J, Jakimcio-Turowski J. Renewable resources and plant biotechnology: Hemp essential oil - Production, characterization, application. *Organic*

- Chemistry, Biochemistry, Biotechnology and Renewable Resources 2013;1:71-79.
354. Omar J, Olivares M, Alzaga M, Etxebarria N. Optimisation and characterisation of marihuana extracts obtained by supercritical fluid extraction and focused ultrasound extraction and retention time locking GC-MS. *Journal of Separation Science* 2013;36(8):1397-1404.
  355. Orellana FA, Galvez CG, Roldan MT, Garcia-Ruiz C. Applications of laser-ablation inductively-coupled-plasma mass spectrometry in chemical analysis of forensic evidence. *TrAC, Trends in Analytical Chemistry* 2013;42:1-34.
  356. Sevigny EL. Is today's marijuana more potent simply because it's fresher? *Drug Testing and Analysis* 2013;5(1):62-67.
  357. Wan G, Li X, Qin J, Li G, Huang J, Luo P. Supercritical CO<sub>2</sub> extraction of Bama Cannabis sativa seed oil and its fatty acid composition analysis. *Zhongguo Youzhi* 2013;38(9):11-13.
  358. Wang X. Flavonoids extraction from Fructus cannabis with ultrasonic [sic]. *Shipin Gongye* 2013;34(10):93-95.
  359. Wang Q-l, Zhang A-z. UHPLC-MS/MS determination of characteristic cannabinol in hemp food. *Lihua Jianyan, Huaxue Fence* 2013;49(6):720-724.
  360. Zamengo L, Frison G, Bettin C, Sciarrone R. Variability of cannabis potency in the Venice Area (Italy): A survey over the period 2010-2012. *Drug Testing and Analysis* 2013: Ahead of Print.
  361. Aizpurua-Olaizola O, Omar J, Navarro P, Olivares M, Etxebarria N, Usobiaga A. Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry. *Analytical and Bioanalytical Chemistry* 2014;406(29):7549-7560.
  362. Aladic K, Jokic S, Moslavac T, Tomas S, Vidovic S, Vladic J, Subaric D. Cold pressing and supercritical CO<sub>2</sub> extraction of hemp (Cannabis sativa) seed oil. *Chemical and Biochemical Engineering Quarterly* 2014;28(4):481-490.
  363. Ambach L, Penitschka F, Broillet A, Konig S, Weinmann W, Bernhard W. Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using

- HPLC-DAD. *Forensic Science International* 2014;243:107-111.
364. Amjadi M, Sodouri T. A surface plasmon resonance-based method for detection and determination of cannabinoids using silver nanoparticles. *Journal of Applied Spectroscopy* 2014;81(2):232-237.
365. Angelini LG, Tavarini S, Cestone B, Beni C. Variation in mineral composition in three different plant organs of five fibre hemp (*Cannabis sativa* L.) cultivars. *Agrochimica* 2014;58(1):1-18.
366. Balbino MA, Eleoterio IC, de Oliveira LS, de Menezes MMT, Fernando de Andrade J, Ipolito AJ, de Oliveira MF. A comparative study between two different conventional working electrodes for detection of  $\Delta^9$ -tetrahydrocannabinol using square-wave voltammetry: A new sensitive method for forensic analysis. *Journal of the Brazilian Chemical Society* 2014;25(3):589-596.
367. Bozza S, Broseus J, Esseiva P, Taroni F. Bayesian classification criterion for forensic multivariate data. *Forensic Science International* 2014;244:295-301.
368. Cantrell S, McGill J. Duquenois-Levine test revisited: Studies toward reviewable data. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-798.
369. Choudhary N, Siddiqui MB, Bi S, Khatoon S. Variation in preliminary phytochemicals screening of *Cannabis sativa* L. leaf, stem and root. *International Journal of Pharmacognosy* 2014;1(8):516-519.
370. Da Porto C, Decorti D, Natolino A. Separation of aroma compounds from industrial hemp inflorescences (*Cannabis sativa* L.) by supercritical CO<sub>2</sub> extraction and on-line fractionation. *Industrial Crops and Products* 2014;58:99-103.
371. Eiras MM, de Oliveira DN, Ferreira MS, Benassi M, Cazenave SOS, Catharino RR. Fast fingerprinting of cannabinoid markers by laser desorption ionization using silica plate extraction. *Analytical Methods* 2014;6(5):1350-1352.
372. Jacobs AD, Steiner RR. Detection of the Duquenois-Levine chromophore in a marijuana sample. *Forensic Science International* 2014;239:1-5.
373. Kostic MD, Jokovic NM, Stamenkovic OS, Rajkovic KM, Milic PS, Veljkovic VB. The

- kinetics and thermodynamics of hempseed oil extraction by n-hexane. *Industrial Crops and Products* 2014;52:679-686.
374. Lesma G, Consonni R, Gambaro V, Remuzzi C, Roda G, Silvani A, Vece V, Visconti GL. Cannabinoid-free *Cannabis sativa* L. grown in the Po valley: Evaluation of fatty acid profile, antioxidant capacity and metabolic content. *Natural Product Research* 2014;28(21):1801-1807.
375. Marchini M, Charvoz C, Dujourdy L, Baldovini N, Filippi J-J. Multidimensional analysis of cannabis volatile constituents: Identification of 5,5-dimethyl-1-vinyl-bicyclo[2.1.1]hexane as a volatile marker of hashish, the resin of *Cannabis sativa* L. *Journal of Chromatography A* 2014;1370:200-215.
376. Montserrat-de la Paz S, Marin-Aguilar F, Garcia-Gimenez, MD, Fernandez-Arche MA. Hemp (*Cannabis sativa* L.) seed oil: Analytical and phytochemical characterization of the unsaponifiable fraction. *Journal of Agricultural and Food Chemistry* 2014;62(5):1105-1110.
377. Omar J, Olivares M, Amigo JM, Etxebarria N. Resolution of co-eluting compounds of *Cannabis sativa* in comprehensive two-dimensional gas chromatography/mass spectrometry detection with multivariate curve resolution-alternating least squares. *Talanta* 2014;121:273-280.
378. Radosavljevic-Stevanovic N, Markovic J, Agatonovic-Kustrin S, Razic S. Metals and organic compounds in the biosynthesis of cannabinoids: A chemometric approach to the analysis of *Cannabis sativa* samples. *Natural Product Research* 2014;28(8):511-516.
379. Schafroth MA, Zuccarello G, Krautwald S, Sarlah D, Carreira EM. Stereodivergent total synthesis of  $\Delta^9$ -tetrahydrocannabinols. *Angewandte Chemie, International Edition* 2014;53(50):13898-13901.
380. Winston ME, Hampton-Marcell J, Zarraindia I, Owens SM, Moreau CS, Gilbert JA, Hartsel JA, Kennedy SJ, Gibbons SM. Understanding cultivar-specificity and soil determinants of the cannabis microbiome. *PLoS One* 2014;9(6):e99641/1-e99641/11.
381. Zamengo L, Frison G, Bettin C, Sciarrone R. Cannabis potency in the Venice area (Italy): Update 2013. *Drug Testing and Analysis* 2014: Ahead of Print.
382. Zhao X, Li H-l, Chen S-j. Extraction of flavonoids from fruit of *Cannabis sativa* under

- ultrasonic wave and its scavenging activity of DPPH radical. *Zhongguo Shipin Tianji* 2014;(6):112-118.
383. Ahmed SA, Ross SA, Slade D, Radwan MM, Khan IA, El Sohly MA. Minor oxygenated cannabinoids from high potency *Cannabis sativa* L. *Phytochemistry* 2015: Ahead of Print.
384. Aladic K, Jarni K, Barbir T, Vidovic S, Vladic J, Bilic M, Jokic S. Supercritical CO<sub>2</sub> extraction of hemp (*Cannabis sativa* L.) seed oil. *Industrial Crops and Products* 2015;76:472-478.
385. Baldwin SD. Ab initio quantum mechanical calculations on  $\Delta^9$  THC and important neurotransmitters: Implications for potential receptor interactions. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: COMP-391.
386. Da Porto C, Decorti D, Natolino A. Potential oil yield, fatty acid composition, and oxidation stability of the hempseed oil from four *Cannabis sativa* L. cultivars. *Journal of Dietary Supplements* 2015;12(1):1-10.
387. Donnelly J, Hernandez FE. Conformational study of  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) linear and nonlinear circular dichroism. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: BIOT-478.
388. Eikel D, Prosser SJ, Henion JD. Using compact mass spectrometry for detection and quantification of cannabis-related compounds. *LC-GC Europe* 2015;(Suppl.):20-27.
389. El-Deftar MM, Robertson J, Foster S, Lennard C. Evaluation of elemental profiling methods, including laser-induced breakdown spectroscopy (LIBS), for the differentiation of cannabis plant material grown in different nutrient solutions. *Forensic Science International* 2015;251:95-106.
390. Geng J, Shu Y, Tao S, Xue W. Quality analysis of *Cannabis sativa* seed oils extracted by different methods. *Zhongguo Youzhi* 2015;40(5):45-49.
391. Giese MW, Lewis MA, Giese L, Smith KM. Method for the analysis of cannabinoids and terpenes in cannabis. *Journal of AOAC International* 2015;98(6):1503-1522.
392. Glaeser F, Broehmer MC, Hurrle T, Nieger M, Braese S. The Diels-Alder approach to

- $\Delta^9$ -tetrahydrocannabinol derivatives. *European Journal of Organic Chemistry* 2015;2015(7):1516-1524. [Note: The publication year and volume are both "2015".]
393. Hoffmann WD, Jackson GP. Isobaric drug analyses using direct analysis in real time (DART) and hydrogen/deuterium exchange. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ANYL-249.
394. Jencic B, Jeromel L, Ogrinc Potocnik N, Vogel-Mikus K, Kovacec E, Regvar M, Siketic Z, Vavpetic P, Rupnik Z, Bucar K, Kelemen M, Kovac J, Pelicon P. Molecular imaging of cannabis leaf tissue with MeV-SIMS method. *Nuclear Instruments & Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms* 2015: Ahead of Print.
395. Klein RFX. Analysis of marijuana by liquid chromatographic techniques - A literature survey, 1990 - 2015. *Microgram Journal* 2015;12(1-4):1-17.
396. LaFrate A. State mandated testing of retail marijuana in Colorado. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHAS-4.
397. Lake R, Rigdon A, Freeman R, Carroll F, Kahler T. Increasing sample throughput of cannabis analyses on any LC system. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHAS-12.
398. Pandohee J, Holland BJ, Li B, Tsuzuki T, Stevenson PG, Barnett NW, Pearson JR, Jones OAH, Conlan XA. Screening of cannabinoids in industrial-grade hemp using two-dimensional liquid chromatography coupled with acidic potassium permanganate chemiluminescence detection. *Journal of Separation Science* 2015: Ahead of Print.
399. Peschel W, Politi M. <sup>1</sup>H NMR and HPLC/DAD for *Cannabis sativa* L. chemotype distinction, extract profiling and specification. *Talanta* 2015;140:150-165.
400. Petrovic M, Debeljak Z, Kezic N, Dzidara P. Relationship between cannabinoids content and composition of fatty acids in hempseed oils. *Food Chemistry* 2015;170:218-225.
401. Rice S, Koziel JA. Characterizing the smell of marijuana by odor impact of volatile compounds: An application of simultaneous chemical and sensory analysis. *PLoS One* 2015;10(12):e0144160/1-e0144160/17.

402. Rigdon A, Cochran J, Hilliard C, Schroeder W, Schroeder C, Flood T. GC methods for cannabis safety and potency testing. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHAS-7.
403. Rigdon A, Lake R, Freeman R, Carroll F, Kahler T. Recent improvements in chromatography: Advancing chromatographic data quality to make a safer cannabis product. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHAS-6.
404. Taschwer M, Schmid MG. Determination of the relative percentage distribution of THCA and  $\Delta^9$ -THC in herbal cannabis seized in Austria - Impact of different storage temperatures on stability. *Forensic Science International* 2015: Ahead of Print.
405. Tian Y, Zhang F, Jia K, Wen M, Yuan Ch. Quantification of cannabinoid content in cannabis. *Journal of Applied Spectroscopy* 2015;82(4):628-633.
406. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. *JAMA, The Journal of the American Medical Association* 2015;313(24):2491-2493.
407. Wang Z, Zhang J, Zhang Y. Simultaneous determination of the cannabidiol, cannabidiol and  $\Delta^9$ -tetrahydrocannabinol in athletic nutrition by gas chromatography-mass spectrometry. *Zhongguo Yundong Yixue Zazhi* 2015;34(4):98-403.
408. Wianowska D, Dawidowicz AL, Kowalczyk M. Transformations of tetrahydrocannabinol, tetrahydrocannabinolic acid and cannabidiol during their extraction from *Cannabis sativa* L. *Journal of Analytical Chemistry* 2015;70(8):920-925.
409. Wilcox MJ, Marcu J, Kababick JP, Jacyno M, Pryor EM. Improving quality control methods for cannabis using flash chromatography. Abstracts, Joint 41st Great Lakes and 46th Central Regional Meeting of the American Chemical Society, Grand Rapids, MI, United States, May 27-30, 2015: JGLCRM-71.
410. Zerihun A, Chandravanshi BS, Debebe A, Mehari B. Levels of selected metals in leaves of *Cannabis sativa* L. cultivated in Ethiopia. *SpringerPlus* 2015;4(1):1-10.
411. Zhang L-m, Tian A-y, Hao L-m, Zhang G-j, Wang Z-z, Ba J-m, Lu J-k, Hao X-m. Optimized methodology for simultaneous extraction of total flavonoids, total phenolic compounds and antioxidant capacity from hemp leaves. *Shipin Keji* 2015;40(2):

269-276.

412. Aizpurua-Olaizola O, Soydaner U, Ozturk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A. Evolution of the cannabinoid and terpene content during the growth of *Cannabis sativa* plants from different chemotypes. *Journal of Natural Products* 2016;79(2):324-331.
413. Angelini LG, Tavarini S, Di Candilo M. Performance of new and traditional fiber hemp (*Cannabis sativa* L.) cultivars for novel applications: Stem, bark, and core yield and chemical composition. *Journal of Natural Fibers* 2016;13(2):238-252.
414. Brown A, Sweet J, Yu C. Heated headspace solid phase microextraction of marijuana for chemical testing. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-156.
415. Brown A, Sweet J, Yu C. Rapid quantitative chemical analysis of cannabinoids in seized cannabis using heated headspace solid-phase microextraction and gas chromatography / mass spectrometry. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: SCHB-19.
416. Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. *Journal of Pharmaceutical and Biomedical Analysis* 2016;128:201-209.
417. Despres H, Marcu J. Report from a Colorado private laboratory on regional cannabis potency from using UPLC analysis. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: SCHB-18.
418. Elsohly MA. Potency trends in confiscated cannabis and analytical methods. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-49.
419. El Sohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the United States. *Biological Psychiatry* 2016: Ahead of Print.
420. Fishedick J. Cannabis: Taxonomy and secondary metabolism. Abstracts of Papers,

- 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-52.
421. Hudalla C. Analytical testing for the cannabis industry: Consumer safety vs. regulatory requirements. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: SCHB-20.
422. Marcu J, Kababick JP, Wilcox MJ, Jacyno M. Improving quality control methods for cannabis using flash chromatography. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-51.
423. Riggle J, Nilsson Z, Spikerman D. Extraction and quantitation of cannabinoids in locally grown medicinal cannabis flowers and other extraction products. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-520.
424. Tang K, Struik PC, Yin X, Thouminot C, Bjelkova M, Stramkale V, Amaducci S. Comparing hemp (*Cannabis sativa* L.) cultivars for dual-purpose production under contrasting environments. *Industrial Crops and Products* 2016;87:33-44.
425. Tipple BJ, Hambach B, Barnette JE, Chesson LA, Ehleringer JR. The influences of cultivation setting on inflorescence lipid distributions, concentrations, and carbon isotope ratios of *Cannabis* sp. *Forensic Science International* 2016;262:233-241.
426. Tseng K, Ono T, Hirose T, Kimata K. Detecting delta-9-tetrahydrocannabinol ( $\Delta$ 9-THC) and delta-8-tetrahydrocannabinol ( $\Delta$ 8-THC) by UV-HPLC. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-163.
427. Wilcox M, Marcu J, Kababick J, Jacyno M. Rapid front end cleanup of cannabis-infused edibles using automated flash column chromatography. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-142.
428. Cascini F. Investigations into the hypothesis of transgenic cannabis. *Journal of Forensic Sciences* 2012;57(3):718-721.
429. Abdelaziz El Alaoui M, Melloul M, Amine SA, Stambouli H, El Bouri A, Soulaymani A, El Fahime E. Extraction of high quality DNA from seized Moroccan cannabis resin

- (hashish). PLoS One 2013;8(10):e74714.
430. Cascini F, Passerotti S, Boschi I. Analysis of THCA synthase gene expression in cannabis: A preliminary study by real-time quantitative PCR. *Forensic Science International* 2013;231(1-3):208-212.
431. Chen X, Guo M, Zhang Q, Xu Y, Guo H, Yang M, Yang Q. Chemotype and genotype of cannabinoids in hemp landrace from southern Yunnan. *Xibei Zhiwu Xuebao* 2013;33(9):1817-1822.
432. Johnson CE, Premasuthan A, Trask JS, Kanthaswamy S. Species identification of cannabis sativa using real-time quantitative PCR (qPCR). *Journal of Forensic Sciences* 2013;58(2):486-490.
433. Sarsenbaev KN, Kozhamzharova LS, Yessimsiitova Z, Seitbayev KZH. Polymorphism of DNA and accumulation of cannabinoids by the cultivated and wild hemp in Chu Valley. *World Applied Sciences Journal* 2013;26(6):744-749.
434. Shirley N, Allgeier L, LaNier T, Coyle HM. Analysis of the NMI01 marker for a population database of cannabis seeds. *Journal of Forensic Sciences* 2013;58(S1):S176-S182.
435. Dahiya D. A simple and efficient method for high quality genomic DNA isolation from Cannabis sativa containing high amount of polyphenols. *International Journal of Advanced Biotechnology and Research* 2014;5(2):208-213.
436. Gao C, Xin P, Cheng C, Tang Q, Chen P, Wang C, Zang G, Zhao L. Diversity analysis in Cannabis sativa based on large-scale development of expressed sequence tag-derived simple sequence repeat markers. *PLoS One* 2014;9(10):e110638/1-e110638/7.
437. Song B-k, Yang X-y, Ni P-y, Pei L, Zhang Y, Xu X-y. Application of DNA barcoding in cannabis identification. *Guangxi Zhiwu* 2014;34(4):552-556.
438. Staginnus C, Zoerntlein S, de Meijer E. A PCR marker linked to a THCA synthase polymorphism is a reliable tool to discriminate potentially THC-rich plants of Cannabis sativa L. *Journal of Forensic Sciences* 2014;59(4):919-926.
439. Valverde L, Lischka C, Erlemann S, de Meijer E, de Pancorbo MM, Pfeiffer H, Koehnemann S. Nomenclature proposal and SNPSTR haplotypes for 7 new Cannabis

- sativa L. STR loci. *Forensic Science International: Genetics* 2014;13:185-186.
440. Valverde L, Lischka C, Scheiper S, Nedele J, Challis R, de Pancorbo MM, Pfeiffer H, Kohnemann S. Characterization of 15 STR cannabis loci: Nomenclature proposal and SNPSTR haplotypes. *Forensic Science International: Genetics* 2014;9:61-65.
441. Ahmad R, Tehsin Z, Malik ST, Asad SA, Shahzad M, Bilal M, Shah MM, Khan SA. Phytoremediation potential of hemp (*Cannabis sativa* L.): Identification and characterization of heavy metals responsive genes. *Soil, Air, Water* 2015: Ahead of Print.
442. Chen X, Guo R, Wan R, Xu Y, Zhang Q, Guo M, Guo H, Yang M. Genetic structure of five dioecious industrial hemp varieties in Yunnan. *Fenzi Zhiwu Yuzhong* 2015;13(9):2069-2075.
443. Dias VHG, Ribeiro ASD, Mello ICT, Silva R, Sabino BD, Garrido RG, Seldin L, Moura-Neto RS. Genetic identification of *Cannabis sativa* using chloroplast trnL-F gene. *Forensic Science International: Genetics* 2015;14:201-20.
444. Mankowska G, Silska G. Genetic resources of *Cannabis sativa* L. in the collection of the gene bank at INF&MP in Poznan. *Journal of Natural Fibers* 2015;12(4):332-340.
445. Mayer BF, Ali-Benali MA, Demone J, Bertrand A, Charron J-B. Cold acclimation induces distinctive changes in the chromatin state and transcript levels of COR genes in *Cannabis sativa* varieties with contrasting cold acclimation capacities. *Physiologia Plantarum* 2015;155(3):281-295.
446. Onofri C, de Meijer EPM, Mandolino G. Sequence heterogeneity of cannabidiolic- and tetrahydrocannabinolic acid-synthase in *Cannabis sativa* L. and its relationship with chemical phenotype. *Phytochemistry* 2015: Ahead of Print.
447. Sawler J, Stout JM, Gardner KM, Hudson D, Vidmar J, Butler L, Page JE, Myles S. The genetic structure of marijuana and hemp. *PLoS One* 2015;10(8):e0133292/1-e0133292/9.
448. Weiblen GD, Wenger JP, Craft KJ, ElSohly MA, Mehmedic Z, Treiber EL, Marks MD. Gene duplication and divergence affecting drug content in *Cannabis sativa*. *New Phytologist* 2015;208(4):1241-1250.
449. Welling MT, Liu L, Shapter T, Raymond CA, King GJ. Characterisation of cannabinoid

- composition in a diverse *Cannabis sativa* L. germplasm collection. *Euphytica* 2015: Ahead of Print.
450. Aiello G, Fasoli E, Boschini G, Lammi C, Zanoni C, Citterio A, Arnoldi A. Proteomic characterization of hempseed (*Cannabis sativa* L.). *Journal of Proteomics* 2016: Ahead of Print.
  451. de Meijer EPM, Hammond KM. The inheritance of chemical phenotype in *Cannabis sativa* L. (V): Regulation of the propyl-/pentyl cannabinoid ratio, completion of a genetic model. *Euphytica* 2016: Ahead of Print.
  452. Happyana N, Kayser O. Monitoring metabolite profiles of *Cannabis sativa* L. trichomes during flowering period using <sup>1</sup>H NMR-based metabolomics and real-time PCR. *Planta Medica* 2016: Ahead of Print.
  453. Soler S, Borrás D, Vilanova S, Sifres A, Andujar I, Figas MR, Llosa ER, Prohens J. Use of embryos extracted from individual *Cannabis sativa* seeds for genetic studies and forensic applications. *Journal of Forensic Sciences* 2016;61(2):494-500.
  454. Xin P-F, Gao C-S, Cheng C-H, Tang Q, Dong Z-X, Zhao L-N, Zang G-G. Identification and characterization of the hemp WRKY transcription factors in response to abiotic stresses. *Biologia Plantarum* 2016: Ahead of Print.
  455. Hall J, Bhattarai SP, Midmore DJ. The effects of photoperiod on phenological development and yields of industrial hemp. *Journal of Natural Fibers* 2014;11(1):87-106.
  456. Schneider S, Bebing R, Dauberschmidt C. Detection of pesticides in seized illegal cannabis plants. *Analytical Methods* 2014;6(2):515-520.
  457. Cheng X, Dou Y-m, Tang P, Zhang Q. Germination characteristics of hemp seeds under single NaCl treatment. *Jiangxi Nongye Xuebao* 2015;27(6):30-32.
  458. Fryhle H, Pellman MC, Burgard DA. Method development towards quantifying marijuana consumption using sewage based drug epidemiology: Preliminary results for treatment plant. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHED-308.
  459. Ghosh TS, Van Dyke M, Maffey A, Whitley E, Erpelding D, Wolk L. Medical

- marijuana's public health lessons - Implications for retail marijuana in Colorado. *New England Journal of Medicine* 2015;372(11):991-993.
460. Lanaro R, Costa JL, Cazenave SOS, Zanolli-Filho LA, Tavares MFM, Chasin AAM. Determination of herbicides paraquat, glyphosate, and aminomethylphosphonic acid in marijuana samples by capillary electrophoresis. *Journal of Forensic Sciences* 2015;60(S1):S241-S247.
461. Lieberman J. Taking care of Mary Jane's workers. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHAS-1.
462. MacCoun RJ, Mello MM. Half-baked - The retail promotion of marijuana edibles. *New England Journal of Medicine* 2015;372(11):989-991.
463. Pellman MC, Fryhle H, Burgard DA. Method development towards quantifying marijuana consumption using sewage based drug epidemiology: Preliminary results for treatment plant. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHED-305.
464. Various authors. *Nature* 2015;525(7570):S1-S18.
465. Villano C. Marijuana health and safety for licensed and regulated businesses. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHAS-3.
466. Wei Y-y, Li L. Advance on functional ingredients and safety of hemp seed food. [Editor's Comment: Title translation is likely inaccurate.] *Shipin Gongye* 2015;36(7):256-260.
467. Audino S. Consumer safety and an accredited laboratory. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-70.
468. Carpenter R, Westerman D, Burgard D. Quantifying THC-COOH as a tracer of cannabis use in wastewater from a residential treatment plant using LC-MS/MS. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-904.

469. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. *Neuropsychopharmacology* 2016: Ahead of Print.
470. Ludwig C. Navigating the ever changing regulations and rules of the cannabis industry. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-68.
471. Mansouri H, Salari F, Asrar Z, Nasibi F. Effects of ethephon on terpenoids in *Cannabis sativa* L. in vegetative stage. *Journal of Essential Oil-Bearing Plants* 2016;19(1):94-102.
472. Marcu J, Sherer S, Nevedal K. Results from auditing medical cannabis operations in the United States. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-71.
473. Nevedal K, Marcu J. Responsible cultivation policy: Preserving personal cultivation rights while regulating commercial cultivation as agriculture. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-50.
474. Perez-Parada A, Alonso B, Rodriguez C, Besil N, Cesio V, Diana L, Burgueno A, Bazzurro P, Bojorge A, Gerez N, Heinzen H. Evaluation of three multiresidue methods for the determination of pesticides in marijuana (*Cannabis sativa* L.) with liquid chromatography-tandem mass spectrometry. *Chromatographia* 2016: Ahead of Print.
475. Pryor E, Marcu J, Wilcox M. Building a subdivision at the ACS: Sowing the seeds of change. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-48.
476. Varlet V, Concha-Lozano N, Berthet A, Plateel G, Favrat B, De Cesare M, Lauer E, Augsburger M, Thomas A, Giroud C. Drug vaping applied to cannabis: Is "cannavaping" a therapeutic alternative to marijuana? *Scientific Reports* 2016;6:25599.
477. Wanas AS, Radwan MM, Mehmedic Z, Jacob M, Khan IA, Elsohly MA. Antifungal activity of the volatiles of high potency *Cannabis sativa* L. against *Cryptococcus neoformans*. *Records of Natural Products* 2016;10(2):214-220.
478. Westerman D, Carpenter R, Burgard D. Quantification of THC-COOH in wastewater: A

- tool to assess cannabis consumption in WA State. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-914.
479. Gaujac A, Martinez ST, Gomes AA, de Andrade SJ, da Cunha Pinto A, David JM, Navickiene S, de Andrade JB. Application of analytical methods for the structural characterization and purity assessment of N,N-dimethyltryptamine, a potent psychedelic agent isolated from *Mimosa tenuiflora* inner barks. *Microchemical Journal* 2013;109:78-83.
480. Yoshioka N, Akamatsu S, Mitsuhashi T, Todo C, Asano M, Ueno Y. A simple method for the simultaneous determination of mushroom toxins by liquid chromatography - time-of-flight mass spectrometry. *Forensic Toxicology* 2013: Ahead of Print.
481. Kallifatidis B, Borovicka J, Stranska J, Drabek J, Mills DK. Fluorescent random amplified microsatellites (F-RAMS) analysis of mushrooms as a forensic investigative tool. *Forensic Science International: Genetics* 2014;9:25-32.
482. Halama M, Poliwoda A, Jasicka-Misiak I, Wieczorek PP, Rutkowski R. *Pholiotina cyanopus*, a rare fungus producing psychoactive tryptamines. *Open Life Sciences* 2015;10(1):40-51.
483. Kowalczyk M, Sekula A, Mleczko P, Olszowy Z, Kujawa A, Zubek S, Kupiec T. Practical aspects of genetic identification of hallucinogenic and other poisonous mushrooms for clinical and forensic purposes. *Croatian Medical Journal* 2015;56(1):32-40.
484. Gambaro V, Roda G, Visconti GL, Arnoldi S, Casagni E, Dell'Acqua L, Fare F, Paladino E, Rusconi C, Arioli S, Mora D. DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin. *Journal of Pharmaceutical and Biomedical Analysis* 2016: Ahead of Print.
485. Kadar I. Effect of potassium, boron and strontium on poppy (*Papaver somniferum* L.) *Agrokemija es Talajtan* 2013;62(2):359-372.
486. Acevska J, Stefkov G, Nakov N, Petkovska R, Ugrinova L, Kulevanova S, Dimitrovska A. Chemometric approach for the development, optimization and validation of HILIC methods used for the determination of alkaloids from poppy straw. *Macedonian Journal of Chemistry and Chemical Engineering* 2014;33(1):73-83.

487. Emira DD, Guneser O, Yilmaz E. Cold pressed poppy seed oils: Sensory properties, aromatic profiles and consumer preferences. *Grasas y Aceites (Sevilla, Spain)* 2014;65(3):e029/1-e029/13.
488. Liuni P, Romanov V, Binette M-J, Zaknoun H, Tam M, Pilon P, Hendrikse J, Wilson DJ. Unambiguous characterization of analytical markers in complex, seized opiate samples using an enhanced ion mobility trace detector-mass spectrometer. *Analytical Chemistry* 2014;86(21):10772-10779.
489. Soniya S. Assessment of physicochemical properties of solid waste - Opium marc. *International Research Journal of Environmental Sciences* 2014;3(7):79-80.
490. Soniya S. Management of hazardous waste - Opium marc. *International Research Journal of Environmental Sciences* 2014;3(8):64-66.
491. Wang J-J, Zhang Y, Bussink C. Unsupervised multiple endmember spectral mixture analysis-based detection of opium poppy fields from an EO-1 Hyperion image in Helmand, Afghanistan. *Science of the Total Environment* 2014;476-477:1-6.
492. Guo J, Kong D, Hu L. Comparative analysis of volatile flavor compounds of poppy seed oil extracted by two different methods via gas chromatography / mass spectrometry. *Journal of PharmaSciTech* 2015;4(2):36-38.
493. Larygova A, Endlova L, Vrbovsky V, Navratilova Z. Analysis of alkaloids in poppy straw by high performance liquid chromatography. *Chemicke Listy* 2015;109(3):229-234.
494. Burns NK, Andrighetto LM, Conlan XA, Purcell SD, Barnett NW, Denning J, Francis PS, Stevenson PG. Blind column selection protocol for two-dimensional high performance liquid chromatography. *Talanta* 2016;154:85-91.
495. Syromyatnikov SV, Sarychev II, Kedys DN, Fainberg VS. A study on the isotope composition of carbon <sup>13</sup>C in poppy seeds and narcotic poppy straw present in the same package aimed at the revelation of the possible artificial superinducements of a narcotic substance. *Journal of Analytical Chemistry* 2016: Ahead of Print.
496. Rezaei M, Naghavi MR, Hosseinzadeh AH, Abbasi A. Measurement of some benzyloquinoline alkaloids in different organs of Persian poppy during ontogenetical stages. *Chemistry & Biodiversity* 2016;13(5):539-543.

497. Rezaei M, Naghavi MR, Hoseinzade AH, Abbasi A. Developmental accumulation of thebaine and some gene transcripts in different organs of *Papaver bracteatum*. *Industrial Crops and Products* 2016;80:262-268.
498. Lee EJ, Jin GN, Lee KL, Han MS, Lee YH, Yang MS. Exploiting expressed sequence tag databases for the development and characterization of gene-derived simple sequence repeat markers in the opium poppy (*Papaver somniferum* L.) for forensic applications. *Journal of Forensic Sciences* 2011;56(5):1131-1135.
499. Beaudoin GAW, Facchini PJ. Benzylisoquinoline alkaloid biosynthesis in opium poppy. *Planta* 2014;240(1):19-32.
500. Celik I, Gultekin V, Allmer J, Doganlar S, Frary A. Development of genomic simple sequence repeat markers in opium poppy by next-generation sequencing. *Molecular Breeding* 2014;34(2):323-334.
501. Chaturvedi N, Singh M, Shukla AK, Shasany AK, Shanker K, Lal RK, Khanuja SPS. Comparative analysis of *Papaver somniferum* genotypes having contrasting latex and alkaloid profiles. *Protoplasma* 2014;251(4):857-867.
502. Gurkok T, Turktas M, Parmaksiz I, Unver T. Transcriptome profiling of alkaloid biosynthesis in elicitor induced opium poppy. *Plant Molecular Biology Reporter* 2014: Ahead of Print.
503. Singh SK, Shukla AK, Dhawan OP, Shasany AK. Recessive loci Pps-1 and OM differentially regulate PISTILLATA-1 and APETALA3-1 expression for sepal and petal development in *Papaver somniferum*. *PLoS One* 2014;9(6):e101272/1-e101272/9.
504. Valizadeh N, Rahimi A, Arslan N. Variation in fatty acid composition of three Turkish slit flower opium poppy (*Papaver somniferum* L.) lines. *International Journal of Biosciences* 2014;4(2):268-274.
505. Boke H, Ozhuner E, Turktas M, Parmaksiz I, Ozcan S, Unver T. Regulation of the alkaloid biosynthesis by miRNA in opium poppy. *Plant Biotechnology Journal* 2015;13(3):409-420.
506. Shukla S, Mishra BK, Mishra R, Siddiqui A, Pandey R, Rastogi A. Comparative study for stability and adaptability through different models in developed high thebaine lines of opium poppy (*Papaver somniferum* L.). *Industrial Crops and Products* 2015;74:875-886.

507. Celik I, Camci H, Kose A, Kosar FC, Doganlar S, Frary A. Molecular genetic diversity and association mapping of morphine content and agronomic traits in Turkish opium poppy (*Papaver somniferum*) germplasm. *Molecular Breeding* 2016;36(4):1-13.
508. Gambelunghe C, Marsili R, Aroni K, Bacci M, Rossi R. GC-MS and GC-MS/MS in PCI mode determination of mescaline in peyote tea and in biological matrices. *Journal of Forensic Sciences* 2013;58(1):270-278.
509. Baldera-Aguayo PA, Pinedo VMR. Phytochemical study of *Echinopsis peruviana*. *Revista de la Sociedad Quimica del Peru* 2014;80(3):202-210.
510. Deconinck E, De Leersnijder C, Custers D, Courselle P, De Beer JO. A strategy for the identification of plants in illegal pharmaceutical preparations and food supplements using chromatographic fingerprints. *Analytical and Bioanalytical Chemistry* 2013;405(7):2341-2352.
511. Goodarzi M, Russell PJ, Vander Heyden Y. Similarity analyses of chromatographic herbal fingerprints: A review. *Analytica Chimica Acta* 2013: Ahead of Print.
512. Laursen KH, Mihailova A, Kelly SD, Epov VN, Berail S, Schjoerring JK, Donard OFX, Larsen EH, Pedentchouk N, Marca-Bell AD, Halekoh U, Olesen JE, Husted S. Is it really organic? - Multi-isotopic analysis as a tool to discriminate between organic and conventional plants. *Food Chemistry* 2013;141(3):2812-2820.
513. Lovkova MY, Buzuk GN. Elements - Regulators of formation and accumulation of indoles and isoquinolines in medicinal plants. *Mikroelementy v Meditsine (Moscow, Russian Federation)* 2013;14(1):12-19.
514. Ogata J, Uchiyama N, Kikura-Hanajiri R, Goda Y. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. *Forensic Science International* 2013;227(1-3):33-41.
515. Zhou Q, Chen J, Sun S. What can two-dimensional correlation infrared spectroscopy (2D-IR) tell us about the composition, origin and authenticity of herbal medicines? *Biomedical Spectroscopy and Imaging* 2013;2(2):101-113.
516. Ahmad B, Ashiq S, Hussain A, Bashir S, Hussain M. Evaluation of mycotoxins, mycobiota, and toxigenic fungi in selected medicinal plants of Khyber Pakhtunkhwa, Pakistan. *Fungal Biology* 2014;118(9-10):776-784.

517. Iqbal T, Khan MGR, Zaman T, Ullah F, Ahmad W, Iqbal A, Ullah N, Inayat A, Younas M, Khurshid S, Ur Rehman H. The study of elemental profile of some important medicinal plants collected from Distract Karak, Khyber Pakhtunkhwa, Pakistan. *International Journal of Chemical and Pharmaceutical Sciences (Erode, India)* 2014;5(2):69-74.
518. Kikkawa HS, Sugita R, Seto Y. Comparison of plant DNA extraction kits for plants identification in forensic botany. *Bunseki Kagaku* 2014;63(3):269-273.
519. Musharraf SG, Ali A, Choudhary MI, Atta-ur-Rahman. Probing of metabolites in finely powdered plant material by Direct Laser Desorption Ionization Mass Spectrometry. *Journal of the American Society for Mass Spectrometry* 2014;25(4):530-537.
520. Naumann A, Kurtze L, Kraehmer A, Hagels H, Schulz H. Discrimination of Solanaceae taxa and quantification of scopolamine and hyoscyamine by ATR-FTIR spectroscopy. *Planta Medica* 2014;80(15):1315-1320.
521. Sedelnikov VP, Lukashevich EL, Karpukhina OA. Experience of use of hyperspectral data for detection the vegetation containing narcotic substances. *Issledovanie Zemli iz Kosmosa* 2014;(1):49-65.
522. Groves RA, Hagel JM, Zhang Y, Kilpatrick K, Levy A, Marsolais F, Lewinsohn E, Sensen CW, Facchini PJ. Transcriptome profiling of khat (*Catha edulis*) and *Ephedra sinica* reveals gene candidates potentially involved in amphetamine-type alkaloid biosynthesis. *PLoS One* 2015;10(3):e0119701/1-e0119701/21.
523. Irshad M, Ruqia B, Hussain Z. Phytoaccumulation of heavy metals in natural vegetation at the municipal wastewater site in Abbottabad, Pakistan. *International Journal of Phytoremediation* 2015;17(12):1269-1273.
524. Kowalczyk AP, Lozak A, Kiljan M, Trak KM, Zjawiony JK. Application of chemometrics for identification of psychoactive plants. *Acta Poloniae Pharmaceutica* 2015;72(3):517-525.
525. Krajewska M, Andrejko D, Slaska-Grzywna B. Chemical properties of cold-pressed vegetable oils. *Przemysl Chemiczny* 2015;94(10):1714-1716.
526. Lewinsohn E, Hagel J, Krizevski R, Bar E, Groves RA, Levy A, Kilpatrick K, Zhang Y, Dudai N, Sensen CW, Ben Shabat S, Yaron S, Frederic M, Facchini PJ. Biosynthesis of

amphetamine-like alkaloids in *Catha edulis* and *Ephedra* spp., two distantly related taxa. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: AGFD-25.

527. Saeed R, Ur Rehman H, Masood Z, Shams S, Iqbal T, Gul Riaz Khan M, Ullah H, Akbar A, Ullah A, Akhwan S, Ali S. Profile of toxic metals in intoxicated items collected from different areas of Khyber Pakhtunkhwa, Pakistan. *American-Eurasian Journal of Toxicological Sciences* 2015;7(2):68-71.
528. Seemann B, Alon T, Tsizin S, Fialkov AB, Amirav A. Electron ionization LC-MS with supersonic molecular beams - The new concept, benefits and applications. *Journal of Mass Spectrometry* 2015;50(11):1252-1263.
529. de Gois JS, Almeida TS, de Andrade RM, Toaldo IM, Bordignon-Luiz MT, Borges DLG. Direct solid analysis for the determination of Mn, Ni, Rb and Sr in powdered stimulant plants using high-resolution continuum source atomic absorption spectrometry followed by chemometric classification based on elemental composition, polyphenol content and antioxidant activity. *Microchemical Journal* 2016;124:283-289.
530. Kumar V, Sharma A, Thukral AK, Bhardwaj R. Phytochemical profiling in the leaves of some medicinal plants using GC-MS. *International Journal of Pharmacy (Hyderabad, India)* 2016;6(1):124-128.
531. Lesiak AD, Cody RB, Ubukata M, Musah RA. Direct analysis in real time high resolution mass spectrometry as a tool for rapid characterization of mind-altering plant materials and revelation of supplement adulteration - The case of kanna. *Forensic Science International* 2016;260:66-73.
532. Musah RA, Lesiak A, Giffen JE. Towards development of a mass spectrometric database for the rapid identification of plant drugs of abuse by ambient ionization mass spectrometry. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-438.
533. Kowalczyk AP, Lozak A, Bachlinski R, Duszynska A, Sakowska J, Zjawiony JK. Identification challenges in examination of commercial plant material of *Psychotria viridis*. *Acta Poloniae Pharmaceutica* 2015;72(4):747-755.
534. Ribeiro MAdS, Gomes CMB, Formagio ASN, Pereira ZV, Melo UZ, Basso EA, da Costa WF, Baldoqui DC, Sarragiotto MH. Structural characterization of dimeric indole

- alkaloids from *Psychotria brachybotrya* by NMR spectroscopy and theoretical calculations. *Tetrahedron Letters* 2016;57(12):1331-1334.
535. Murphy TM, Bola G. DNA identification of *Salvia divinorum* samples. *Forensic Science International Genetics* 2013;7(1):189-193.
536. Lin P-X, Li J-H, Chen S-H, Chang H-C, McKetin R. Quantitative determination of salvinorin A, a natural hallucinogen with abuse liability, in internet-available *Salvia divinorum* and endemic species of salvia in Taiwan. *Journal of Food and Drug Analysis* 2014;22(3):370-378.
537. Xavier Moreira F, Carvalho F, de Lourdes Bastos M, Guedes de Pinho P. Analytical investigation of legal high products containing *Salvia divinorum* traded in smartshops and internet. *Forensic Science International* 2014;242:255-260.
538. Hernández-Bello R, García-Rodríguez RV, García-Sosa K, Peña-Rodríguez LM, Vázquez-Hernández M, Ramos-Morales FR, Corcoran O, Sánchez-Medina A. Salvinorin A content in legal high products of *Salvia divinorum* sold in Mexico. *Forensic Science International* 2015;249:197-201.
539. Prisinzano T. *Salvia divinorum*: A unique CNS active plant. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: AGFD-54.
540. Scott KR, Power JD, McDermott SD, O'Brien JE, Talbot BN, Barry MG, Kavanagh PV. Identification of (2-aminopropyl)indole positional isomers in forensic samples. *Drug Testing and Analysis* 2013: Ahead of Print.
541. Nguyen DT, Hoang MH, Bui TH. Preliminary study on tracing back to the origin of the stupeficient drug ATS found in Vietnam. *Tap Chi Duoc Hoc* 2011;51(11):42-47.
542. Davis S, Blakey K, Rands-Trevor K. GC-MS and GC-IRD analysis of 2-, 3- and 4-methylmethamphetamine and 2-, 3- and 4-methylamphetamine. *Forensic Science International* 2012;220(1-3):67-73.
543. Djozan D, Farajzadeh MA, Sorouraddin SM, Baheri T. Determination of methamphetamine, amphetamine and ecstasy by inside-needle adsorption trap based on molecularly imprinted polymer followed by GC-FID determination. *Microchimica Acta* 2012;179(3-4):209-217.

544. Boatto G, Pirisi MA, Burrai L, Baralla E, Demontis MP, Varoni MV, Nieddu MA. An LC-MS-MS method for quantitation of four new phenethylamines (BOX series) in plasma: In vivo application. *Forensic Toxicology* 2013: Ahead of Print.
545. Ciochina S, Praisler M. Cluster analysis applied for the discrimination of illicit amphetamines. *Analele Universitatii "Dunarea de Jos" din Galati, Fascicola II: Matematica, Fizica, Mecanica Teoretica* 2013;36(1):60-67.
546. Hara Y, Hasebe T, Katada T. Identification of illicit drugs using surface-enhanced-Raman-scattering spectroscopy. *Kanzei Chuo Bunsekishoho* 2013;53:61-65.
547. Hino C, Arai K, Watase J. Quantitative analysis of a trace amount of amphetamine and methamphetamine contained in a tablet by GC-MS using propylchloroformate derivatization method. *Kanzei Chuo Bunsekishoho* 2013;53:85-88.
548. Mariotti KdC, Ortiz RS, Souza DZ, Mileski TC, Froehlich PE, Limberger RP. Trends in counterfeit amphetamine-type stimulants after its prohibition in Brazil. *Forensic Science International* 2013;229(1-3):23-26.
549. Menrli S, Liberatore N, Luciani D, Viola R, Cardinali GC, Elmi I, Poggi A, Zampolli S, Biavardi E, Dalcanale E, Bonadio F, Delemont O, Esseiva P, Romolo FS. Rapid screening and identification of illicit drugs by IR absorption spectroscopy and gas chromatography. *Proceedings of SPIE* 2013;8631(Quantum Sensing and Nanophotonic Devices X):86312F/1-86312F/10.
550. Mirela P, Stefanut C. Selective amplifier used for the efficient detection of amphetamines. *Analele Universitatii Maritime din Constanta* 2013;19:231-235.
551. Power JD, Clarke K, McDermott SD, McGlynn P, Barry M, White C, O'Brien J, Kavanagh P. The identification of 4-methylamphetamine and its synthesis by-products in forensic samples. *Forensic Science International* 2013;228(1-3):115-131.
552. Praisler M, Ciochina S. Detection of illegal amphetamines based on principal component analysis and discriminant analysis. *Analele Universitatii "Dunarea de Jos" din Galati, Fascicola II: Matematica, Fizica, Mecanica Teoretica* 2013;36(1):68-75.
553. Qian Z-h, Xu P, Liu K-l. Introduction of 2C-series phenethylamines. *Zhongguo Yaowu Lanyong Fangzhi Zazhi* 2013;19(2):102-104.

554. Racamonde I, Rodil R, Quintana JB, Cela R. In-sample derivatization-solid-phase microextraction of amphetamines and ecstasy related stimulants from water and urine. *Analytica Chimica Acta* 2013;770:75-84.
555. Sato H, Hara Y, Hasebe T, Shinohara J, Takahashi S, Katada T, Aoyama S. Identification of volatile elements from stimulants. *Kanzei Chuo Bunsekishoho* 2013;53:67-73.
556. Stefanut C, Mirela P. Optimized detection of amphetamines based on principal component analysis. *Analele Universitatii Maritime din Constanta* 2013;19:223-230.
557. Stojanovska N, Fu S, Tahtouh M, Kelly T, Beavis A, Kirkbride KP. A review of impurity profiling and synthetic route of manufacture of methylamphetamine, 3,4-methylenedioxymethylamphetamine, amphetamine, dimethylamphetamine and p-methoxyamphetamine. *Forensic Science International* 2013;224(1-3):8-26.
558. Taplin F, O'Donnell D, Kubic T, Leona M, Lombardi J. Application of Raman spectroscopy, surface-enhanced Raman scattering (SERS), and density functional theory for the identification of phenethylamines. *Applied Spectroscopy* 2013;67(10):1150-1159.
559. Zaitso K, Miyagawa H, Sakamoto Y, Matsuta S, Tsuboi K, Nishioka H, Katagi M, Sato T, Tatsuno M, Tsuchihashi H, Suzuki K, Ishii A. Mass spectrometric differentiation of the isomers of mono-methoxyethylamphetamines and mono-methoxydimethylamphetamines by GC-EI-MS-MS. *Forensic Toxicology* 2013;31(2):292-300.
560. Ciochina S, Praisler M. Evaluation of the efficiency of amphetamines detection by cluster analysis. *Scientific Bulletin - University "Politehnica" of Bucharest, Series B: Chemistry and Materials Science* 2014;76(2):157-166.
561. El Sohly MA, Gul W. LC-MS-MS analysis of dietary supplements for N-ethyl- $\alpha$ -ethylphenethylamine (ETH), N,N-diethylphenethylamine and phenethylamine. *Journal of Analytical Toxicology* 2014;38(2):63-72.
562. Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Brauner-Osborne H, Kristensen JL. Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT<sub>2A/2C</sub> Agonists. *ACS Chemical Neuroscience* 2014;5(3):243-249.
563. Holler JM, Vorce SP, Knittel JL, Malik-Wolf B, Levine B, Bosy TZ. Evaluation of designer amphetamine interference in GC-MS amine confirmation procedures. *Journal of Analytical Toxicology* 2014;38(5):295-303.

564. Karlsen M, Liu HL, Berg T, Johansen JE, Hoff BH. Synthesis of [<sup>13</sup>C<sub>6</sub>]-labeled phenethylamine derivatives for drug quantification in biological samples. *Journal of Labelled Compounds and Radiopharmaceuticals* 2014;57(5):378-387.
565. Li S, Huang K, Zhang X. Enantioselective hydrogenation of  $\alpha,\beta$ -disubstituted nitroalkenes. *Chemical Communications* 2014;50(64):8878-8881.
566. Nguyen TM, Manohar N, Nicewicz DA. anti-Markovnikov hydroamination of alkenes catalyzed by a two-component organic photoredox system: Direct access to phenethylamine derivatives. *Angewandte Chemie, International Edition* 2014;53(24):6198-6201.
567. Plotka JM, Simeonov V, Morrison C, Biziuk M, Namiesnik J. Capillary gas chromatography using a  $\beta$ -cyclodextrin for enantiomeric separation of methylamphetamine, its precursors and chloro intermediates after optimization of the derivatization reaction. *Journal of Chromatography A* 2014;1347:146-156.
568. Ren C, Lee JS, Glass TE. A novel fluorescent sensor for hydrophobic amines in aqueous solution. *Supramolecular Chemistry* 2014;26(7-8):607-611.
569. Taschwer M, Seidl Y, Mohr S, Schmid MG. Chiral separation of cathinone and amphetamine derivatives by HPLC/UV using sulfated  $\beta$ -cyclodextrin as chiral mobile phase additive. *Chirality* 2014;26(8):411-418.
570. Albals D, Heyden YV, Schmid MG, Chankvetadze B, Mangelings D. Chiral separations of cathinone and amphetamine-derivatives: Comparative study between capillary electrochromatography, supercritical fluid chromatography and three liquid chromatographic modes. *Journal of Pharmaceutical and Biomedical Analysis* 2015: Ahead of Print.
571. Banks CE, Cumba L, Sutcliffe O, Zuway KY, Smith J, do Carmo DR. Forensic electrochemistry: Simultaneous voltammetric detection of MDMA and its fatal counterpart "Dr Death" (PMA). *Analytical Methods* 2015: Ahead of Print.
572. Boumrah Y, Bouanani S, Khimeche K, Dahmani A. Analysis of synthetic drugs by differential scanning calorimetry - Case of amphetamine-type stimulants (ATS). *Journal of Thermal Analysis and Calorimetry* 2015;120(1):583-590.
573. Lalwani KG, Sudalai A. A short enantioselective synthesis of ephedrine, amphetamine and their analogues via two stereocentered Co(III)-catalyzed hydrolytic kinetic resolution of racemic syn-benzyloxy epoxide. *Tetrahedron Letters* 2015;56(46):6488-6490.

574. Mikuma T, Iwata YT, Miyaguchi H, Kuwayama K, Tsujikawa K, Kanamori T, Inoue H. The use of a sulfonated capillary on chiral capillary electrophoresis/mass spectrometry of amphetamine-type stimulants for methamphetamine impurity profiling. *Forensic Science International* 2015;249:59-65.
575. Nguyen TA, Pham TN, Ta TT, Nguyen XT, Nguyen TL, Le TH, Koenka IJ, Sáiz J, Hauser PC, Mai TD. Screening determination of four amphetamine-type drugs in streetgrade illegal tablets and urine samples by portable capillary electrophoresis with contactless conductivity detection. *Science & Justice* 2015;55(6):481-486.
576. Pauk V, Zihlova V, Borovcova L, Havlicek V, Schug K, Lemr K. Fast separation of selected cathinones and phenylethylamines by supercritical fluid chromatography. *Journal of Chromatography A* 2015;1423:169-176.
577. Rasmussen N, Keizers PHJ. History full circle: 'Novel' sympathomimetics in supplements. *Drug Testing and Analysis* 2015:Ahead of Print.
578. Westphal F, Girreser U, Waldmueller D. Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs. *Drug Testing and Analysis* 2015:Ahead of Print.
579. McGeehan J, Dennany L. Electrochemiluminescent detection of methamphetamine and amphetamine. *Forensic Science International* 2016;264:1-6.
580. Lin L, Lv J, Ji Y, Feng J, Liu Y, Wang Z, Zhang W. Characterization of barbiturates by infrared and Raman microscopy. *Analytical Letters* 2013:Ahead of Print.
581. Young MC, Liew E, Hooley RJ. Colorimetric barbiturate sensing with hybrid spin crossover assemblies. *Chemical Communications* 2014;50(39):5043-5045.
582. Landrum JE, Magers DH. Computing acidities of barbituric and thiobarbituric acid. Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014: CHED-640.
583. Valadbeigi Y, Farrokhpour H, Tabrizchi M. Theoretical study on the isomerization and tautomerism in barbituric acid. *Structural Chemistry* 2014;25(6):1805-1810.
584. Marshall M, Hudson B, Lopez V. Barbituric acid: A polymorph and tautomer chameleon. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego,

CA, United States, March 13-17, 2016: CHED-1506.

585. Mohammadi Ziarani G, Aleali F, Lashgari N. Recent applications of barbituric acid in multicomponent reactions. *RSC Advances* 2016;6(56):50895-50922.
586. Bertol E, Vaiano F, Furlanetto S, Mari F. Cross-reactivities and structure-reactivity relationships of six benzodiazepines to EMIT immunoassay. *Journal of Pharmaceutical and Biomedical Analysis* 2013;84:168-172.
587. Doctor EL, McCord B. Comparison of aggregating agents for the surface-enhanced Raman analysis of benzodiazepines. *Analyst* 2013;138(20):5926-5932.
588. Singh RR, Kumar A, Kaur R. FTIR analysis of some pills of forensic interest. *Research Journal of Pharmaceutical, Biological and Chemical Sciences* 2013;4(4):708-712.
589. Vani N, Mohan BM, Nagendrappa G. A new high-performance thin-layer chromatographic method for determination of diazepam in spiked blood samples. *Journal of Planar Chromatography-Modern TLC* 2013;26(4):343-348.
590. El Assyry A, Benali B, Boucetta A, Lakhrissi B. Quantum chemical study by density functional theory (DFT) of some benzodiazepine derivatives. *Journal of Materials and Environmental Science* 2014;5(6):1860-1867.
591. Eldin AB, Shalaby A, Abdallah MS, Shaldam MA, Abdallah MA. Applying green analytical chemistry (GAC) for development of stability indicating HPLC method for determining clonazepam and its related substances in pharmaceutical formulations and calculating uncertainty. *Arabian Journal of Chemistry* 2014: Ahead of Print.
592. Ferreira AP. Environmental investigation of psychiatric pharmaceuticals: Guandu River, Rio De Janeiro State, Southeast Brazil. *Journal of Chemical Health Risks* 2014;4(3):25-32.
593. Gautam L, Sharratt SD, Cole MD. Drug facilitated sexual assault: Detection and stability of benzodiazepines in spiked drinks using gas chromatography-mass spectrometry. *PLoS One* 2014;9(2):e89031.
594. Honeychurch KC, Hart JP. Electrochemical detection of benzodiazepines, following liquid chromatography, for applications in pharmaceutical, biomedical and forensic investigations. *Insciences Journal* 2014;4(1):1-18.

595. Lv J, Zhang W, Feng J, Liu Y. Characterization and discrimination of diazepam, alprazolam, clorazepate, temazepam and bromazepam with confocal Raman microscopy. *Journal of Advanced Microscopy Research* 2014;9(1):29-33.
596. Montalvo G, Lopez-Melero L, Ortega-Ojeda F, Pena MA, Garcia-Ruiz C. Raman spectral signatures for the differentiation of benzodiazepine drugs. *Analytical Methods* 2014;6(24):9536-9546.
597. Sabia R, Ciogli A, Pierini M, Gasparrini F, Villani C. Dynamic high performance liquid chromatography on chiral stationary phases. Low temperature separation of the interconverting enantiomers of diazepam, flunitrazepam, prazepam and tetrazepam. *Journal of Chromatography A* 2014;1363:144-149.
598. Saiz J, Ortega-Ojeda F, Lopez-Melero L, Montalvo G, Garcia-Ruiz C. Electrophoretic fingerprinting of benzodiazepine tablets in spike drinks. *Electrophoresis* 2014;35(21-22):3250-3257.
599. Doctor EL, McCord B. The application of supported liquid extraction in the analysis of benzodiazepines using surface enhanced Raman spectroscopy. *Talanta* 2015;144:938-943.
600. Huppertz LM, Bisel P, Westphal F, Franz F, Auwaerter V, Moosmann B. Characterization of the four designer benzodiazepines clonazepam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. *Forensic Toxicology* 2015: Ahead of Print.
601. Jiang S, Tan H, Guo C, Gong L, Shi F. Development of an ultra-high-performance liquid chromatography coupled to high-resolution quadrupole-Orbitrap mass spectrometry method for the rapid detection and confirmation of illegal adulterated sedative-hypnotics in dietary supplements. *Food Additives & Contaminants, Part A: Chemistry, Analysis, Control, Exposure & Risk Assessment* 2015: Ahead of Print.
602. Kar S, Roy K. Predictive toxicity modelling of benzodiazepine drugs using multiple in silico approaches: Descriptor-based QSTR, group-based QSTR and 3D-toxicophore mapping. *Molecular Simulation* 2015;41(4):345-355.
603. Treu A, Rittner M, Kemken D, Schiebel H-M, Spittler P, Dülcks T. Loss of atomic nitrogen from even-electron ions? A study on benzodiazepines. *Journal of Mass Spectrometry* 2015;50(8):978-986.

604. Yang Q, Wang H, Gao Y, Li J, Jiao J, Quan Q, Chen J. Application of substitution method of reference substance in the rapid determination of sedative drugs by HPLC. *Zhongguo Xiandai Yingyong Yaoxue* 2015;32(11):1376-1381.
605. Dietze C, Hackl C, Gerhardt R, Seim S, Belder D. Chip-based electrochromatography coupled to ESI-MS detection. *Electrophoresis* 2016:Ahead of Print.
606. Magrini L, Cappiello A, Famiglini G, Palma P. Microextraction by packed sorbent (MEPS)-UHPLC-UV: A simple and efficient method for the determination of five benzodiazepines in an alcoholic beverage. *Journal of Pharmaceutical and Biomedical Analysis* 2016;125:48-53.
607. Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. *British Journal of Pharmacology* 2015;172(13):3412-3425.
608. Chen K-F, Lee H, Liu J-T, Lee H-A, Lin C-H. A microwave-assisted fluorescent labeling method for the separation and detection of amphetamine-like designer drugs by capillary electrophoresis. *Forensic Science International* 2013;228(1-3):95-99.
609. Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H. Differentiation of regioisomeric fluoroamphetamine analogs by gas chromatography - mass spectrometry and liquid chromatography - tandem mass spectrometry. *Forensic Toxicology* 2013;31(2):241-250.
610. Chen Y-F, Liu J-T, Pan D-S. Discrimination of fluoroamphetamine regioisomers by Raman spectroscopy. *Journal of the Chinese Chemical Society* 2015:Ahead of Print.
611. Inoue H, Negishi S, Nakazono Y, Iwata YT, Tsujikawa K, Ohtsuru O, Miyamoto K, Yamashita T, Kasuya F. Differentiation of ring-substituted bromoamphetamine analogs by gas chromatography - tandem mass spectrometry. *Forensic Toxicology* 2015:Ahead of Print.
612. Negishi S, Nakazono Y, Iwata YT, Kanamori T, Tsujikawa K, Kuwayama K, Yamamuro T, Miyamoto K, Yamashita T, Kasuya F, Inoue H. Differentiation of regioisomeric chloroamphetamine analogs using gas chromatography-chemical ionization-tandem mass spectrometry. *Forensic Toxicology* 2015:Ahead of Print.
613. Lopez-Avila V, Gao W, Urdahl R. Mass spectral fragmentation of cathinones by high-resolution TOFMS using a soft ionization source. *Journal of Pharmaceutical and*

Scientific Innovation 2012;1(6):44-53.

614. Tsujikawa K, Mikuma T, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. Degradation pathways of 4-methylmethcathinone in alkaline solution and stability of methcathinone analogs in various pH solutions. *Forensic Science International* 2012;220(1-3):103-110.
615. Chonan Y, Ogawa R, Nagasawa Y, Matsumoto T, Kosone K, Saegusa T. Study of method for identifying synthetic cathinones. *Kanzei Chuo Bunsekishoho* 2013;53:75-84.
616. Dalgleish JK, Wleklinski M, Shelley JT, Mulligan CC, Ouyang Z, Cooks RG. Arrays of low-temperature plasma probes for ambient ionization mass spectrometry. *Rapid Communications in Mass Spectrometry* 2013;27(1):135-142;S135/1-S135/9.
617. Fornal E. Identification of substituted cathinones: 3,4-Methylenedioxy derivatives by high performance liquid chromatography-quadrupole time of flight mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis* 2013;81-82:13-19.
618. Fornal E. Formation of odd-electron product ions in collision-induced fragmentation of electrospray-generated protonated cathinone derivatives: Aryl alpha-primary amino ketones. *Rapid Communications in Mass Spectrometry* 2013;27(16):1858-1866.
619. Gautam L, Shanmuganathan A, Cole MD. Forensic analysis of cathinones. *Forensic Science Review* 2013;25(1-2):47-64.
620. Lesiak AD, Musah RA, Cody RB, Domin MA, Dane AJ, Shepard JRE. Direct analysis in real time mass spectrometry (DART-MS) of "bath salt" cathinone drug mixtures. *Analyst* 2013;138(12):3424-3432.
621. Napierala C, Mancebo M, Peronny S. Synthetic cathinones: Are they tomorrow's amphetamines? *Actualite Chimique* 2013;378-379:100-105.
622. Nic Daeid N, Savage KA, Ramsay D, Holland C, Sutcliffe OB. Development of gas chromatography-mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 16 "legal high" cathinone derivatives. *Science & Justice* 2013: Ahead of Print.
623. Qian Z-h, Xu P, Liu K-l. New drug of designer cathinones "bath salts". *Zhongguo Yaowu Lanyong Fangzhi Zazhi* 2013;19(1):42-44.

624. Trzybinski D, Niedzialkowski P, Ossowski T, Trynda A, Sikorski A. Single-crystal X-ray diffraction analysis of designer drugs: Hydrochlorides of metaphedrone and pentedrone. *Forensic Science International* 2013;Ahead of Print.
625. Tsujikawa K, Mikuma T, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. Identification and differentiation of methcathinone analogs by gas chromatography-mass spectrometry. *Drug Testing and Analysis* 2013;5(8):670-677.
626. Zawilska JB, Wojcieszak J. Designer cathinones - An emerging class of novel recreational drugs. *Forensic Science International* 2013;231(1-3):42-53.
627. Aturki Z, Schmid MG, Chankvetadze B, Fanali S. Enantiomeric separation of new cathinone derivatives designer drugs by capillary electrochromatography using a chiral stationary phase, based on amylose tris(5-chloro-2-methylphenylcarbamate). *Electrophoresis* 2014;35(21-22):3242-3249.
628. Chance CD, Callender AF, Gray SL. Identifying trace-levels of synthetic cathinones using Raman spectroscopy. Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014: ANYL-193.
629. Joshi M, Cetroni B, Camacho A, Krueger C, Midey AJ. Analysis of synthetic cathinones and associated psychoactive substances by ion mobility spectrometry. *Forensic Science International* 2014;244:196-206.
630. Leffler AM, Smith PB, de Armas A, Dorman FI. The analytical investigation of synthetic street drugs containing cathinone analogs. *Forensic Science International* 2014;234:50-56.
631. Lloyd A, Russell M, Blanes L, Somerville R, Doble P, Roux C. The application of portable microchip electrophoresis for the screening and comparative analysis of synthetic cathinone seizures. *Forensic Science International* 2014;242:16-23.
632. Merola G, Fu H, Tagliaro F, Macchia T, McCord BR. Chiral separation of 12 cathinone analogs by cyclodextrin-assisted capillary electrophoresis with UV and mass spectrometry detection. *Electrophoresis* 2014;35(21-22):3231-3241.
633. Musah RA, Cody RB, Domin MA, Lesiak AD, Dane AJ, Shepard JRE. DART-MS in-source collision induced dissociation and high mass accuracy for new psychoactive substance determinations. *Forensic Science International* 2014;244:42-49.

634. Nic Daeid N, Savage KA, Ramsay D, Holland C, Sutcliffe OB. Development of gas chromatography-mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 16 'legal high' cathinone derivatives. *Science & Justice* 2014;54(1):22-31.
635. Smith JP, Metters JP, Irving C, Sutcliffe OB, Banks CE. Forensic electrochemistry: The electroanalytical sensing of synthetic cathinone-derivatives and their accompanying adulterants in "legal high" products. *Analyst* 2014;139(2):389-400.
636. Smith JP, Metters JP, Khreit OIG, Sutcliffe OB, Banks CE. Forensic electrochemistry applied to the sensing of new psychoactive substances: Electroanalytical sensing of synthetic cathinones and analytical validation in the quantification of seized street samples. *Analytical Chemistry* 2014;86(19):9985-9992.
637. Smolianitski E, Wolf E, Almog J. Proactive forensic science: A novel class of cathinone precursors. *Forensic Science International* 2014;242:219-227.
638. Yun J. Quantitative-structure activity relationship (QSAR) model for abuse-liability evaluation of designer drugs. *Yakhak Hoechi* 2014;58(1):53-57.
639. Zancajo VMR, Brito J, Carrasco MP, Bronze MR, Moreira R, Lopes A. Analytical profiles of "legal highs" containing cathinones available in the area of Lisbon, Portugal. *Forensic Science International* 2014;244:102-110.
640. Abiedalla Y, Abdel-Hay K, DeRuiter J, Clark CR. Analytical and synthetic studies on substituted cathinones: Bath salt-type aminoketone designer drugs. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ANYL-126.
641. Chen X. Simultaneous determination of four designer drugs and their major metabolites by liquid chromatography-mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 2015;992:1-7.
642. Collins M, Doddridge A, Salouros H. Cathinones: Isotopic profiling as an aid to linking seizures. *Drug Testing and Analysis* 2015: Ahead of Print.
643. Doi T, Asada A, Takeda A, Tagami T, Katagi M, Matsuta S, Kamata H, Kawaguchi M, Satsuki Y, Sawabe Y, Obana H. Identification and characterization of  $\alpha$ -PVT,  $\alpha$ -PBT, and their bromothienyl analogs found in illicit drug products. *Forensic Toxicology* 2015: Ahead of Print.

644. Glennon RA. Phenylalkylaminone: Scaffolding for drugs of abuse, with a focus on synthetic cathinones. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: MEDI-250.
645. Karch SB. Cathinone neurotoxicity ("The "3Ms"). *Current Neuropharmacology* 2015;13(1):21-25.
646. Majchrzak M, Rojkiewicz M, Celinski R, Kus P, Sajewicz M. Identification and characterization of new designer drug 4-fluoro-PV9 and  $\alpha$ -PHP in the seized materials. *Forensic Toxicology* 2015: Ahead of Print.
647. Moini M, Rollman CM. Compatibility of highly sulfated cyclodextrin with electrospray ionization at low nanoliter/minute flow rates and its application to capillary electrophoresis / electrospray ionization mass spectrometric analysis of cathinone derivatives and their optical isomers. *Rapid Communications in Mass Spectrometry* 2015;29(3):304-310.
648. Tan F, Smith JP, Sutcliffe OB, Banks CE. Regal electrochemistry: Sensing of the synthetic cathinone class of new psychoactive substances (NPSs). *Analytical Methods* 2015: Ahead of Print.
649. Tsujikawa K, Yamamuro T, Kuwayama K, Kanamori T, Iwata YT, Inoue H. Instability of the hydrochloride salts of cathinone derivatives in air. *Forensic Science International* 2015;248:48-54.
650. Wood MR, Lalancette RA, Bernal I. Crystallographic investigations of select cathinones: Emerging illicit street drugs known as 'bath salts'. *Acta Crystallographica, Section C: Structural Chemistry* 2015;71(1):32-38.
651. Zhou M-J, Bouazzaoui S, Jones LE, Goodrich P, Bell SEJ, Sheldrake GN, Horton PN, Coles SJ, Fletcher NC. Isolation and structural determination of non-racemic tertiary cathinone derivatives. *Organic & Biomolecular Chemistry* 2015: Ahead of Print.
652. Zuway KY, Smith JP, Foster CW, Kapur N, Banks CE, Sutcliffe OB. Detection and quantification of new psychoactive substances (NPSs) within the evolved "legal high" product, NRG-2, using high performance liquid chromatography-amperometric detection (HPLC-AD). *Analyst* 2015;140(18):6283-6294.
653. Abiedalla Y, Abdel-Hay K, DeRuiter J, Randall Clark C. Differentiation of cyclic tertiary

- amine cathinone derivatives by product ion electron ionization mass spectrometry. *Rapid Communications in Mass Spectrometry* 2016;30(6):763-772.
654. Kerrigan S, Savage M, Cavazos C, Bella P. Thermal degradation of synthetic cathinones: Implications for forensic toxicology. *Journal of Analytical Toxicology* 2016;40(1):1-11.
655. Poklis JL, Wolf CE, El Jordi OI, Liu K, Zhang S, Poklis A. Analysis of the first- and second-generation raving dragon novelty bath salts containing methylone and pentedrone. *Journal of Forensic Sciences* 2015;60(S1):S234-S240.
656. Qian Z, Jia W, Li T, Liu C, Hua Z. Identification and analytical characterization of four synthetic cathinone derivatives iso-4-BMC,  $\beta$ -TH-naphyrone, mexedrone, and 4-MDMC. *Drug Testing and Analysis* 2016: Ahead of Print.
657. Wolrab D, Fruhauf P, Moulisova A, Kuchar M, Gerner C, Lindner W, Kohout M. Chiral separation of new designer drugs (cathinones) on chiral ion-exchange type stationary phases. *Journal of Pharmaceutical and Biomedical Analysis* 2016;120:306-315.
658. French HE, Went MJ, Gibson SJ. Graphite furnace atomic absorption elemental analysis of ecstasy tablets. *Forensic Science International* 2013;231(1-3):88-91.
659. Bora T, Aydin H, Atac Y, Sen N, Aksoy C. Determination of metals contamination in illicit ecstasy drug samples using ICP-OES and XRF. *Atomic Spectroscopy* 2014;35(4):139-146.
660. Cox M, Cook M. Luminescent ecstasy tablets. Authentication tool or cunning marketing tactic? *Forensic Science International* 2015;249:e1-e6.
661. Togni LR, Lanaro R, Resende RR, Costa JL. The variability of ecstasy tablets composition in Brazil. *Journal of Forensic Sciences* 2015;60(1):147-151.
662. Vidal Gine C, Ventura Vilamala M, Fornis Espinosa I, Gil Lladanosa C, Calzada Alvarez N, Fito Fruitos A, Rodriguez Rodriguez J, Domingo Salvany A, de la Torre Fornell R. Crystals and tablets in the Spanish ecstasy market 2000-2014: Are they the same or different in terms of purity and adulteration? *Forensic Science International* 2016;263:164-168.
663. Wong CH, Ho EN, Kwok WH, Leung DK, Leung GN, Tang FP, Wong AS, Wong JK, Yu NH, Wan TS. Interconversion of ephedrine and pseudoephedrine during chemical

- derivatization. *Drug Testing and Analysis* 2012;4(12):1028-1033.
664. Gray N, Heaton J, Musenga A, Cowan DA, Plumb RS, Smith NW. Comparison of reversed-phase and hydrophilic interaction liquid chromatography for the quantification of ephedrine using medium-resolution accurate mass spectrometry. *Journal of Chromatography A* 2013;1289:37-46.
665. Refat MS, Ibrahim OB, Saad HA, Adam AMA. Usefulness of charge-transfer complexation for the assessment of sympathomimetic drugs: Spectroscopic properties of drug ephedrine hydrochloride complexed with some  $\pi$ -acceptors. *Journal of Molecular Structure* 2014;1064:58-69.
666. Gerhards N, Neubauer L, Tudzynski P, Li S-M. Biosynthetic pathways of ergot alkaloids. *Toxins* 2014;6(12):3281-3295.
667. Herzog E, Baehr R-P, Fischer C, Schoene F. Ergot alkaloids in Thuringian cereals with different levels of ergot infection. *VDLUFA-Schriftenreihe* 2014(Volume Date 2013);69:540-544.
668. Ibrahim F, Wahba MEK. Liquid chromatographic determination of ergotamine tartrate in its combined tablets using fluorimetric and UV detection: Application to content uniformity testing. *Separation Science and Technology* 2014;49(14):2228-2240.
669. Jakubczyk D, Cheng JZ, O'Connor SE. Biosynthesis of the ergot alkaloids. *Natural Product Reports* 2014;31(10):1328-1338.
670. Paulke A, Kremer C, Wunder C, Wurglics M, Schubert-Zsilavec M, Toennes SW. Identification of legal highs - Ergot alkaloid patterns in two *Argyrea nervosa* products. *Forensic Science International* 2014;242:62-71.
671. Petruczynik A. TLC of ergot alkaloid derivatives. *Chromatographic Science Series* 2014;106(Thin Layer Chromatography in Drug Analysis):351-354.
672. Rouah-Martin E, Maho W, Mehta J, De Saeger S, Covaci A, Van Dorst B, Blust R, Robbens J. Aptamer-based extraction of ergot alkaloids from ergot contaminated rye feed. *Advances in Bioscience and Biotechnology* 2014;5(8):692-698.
673. Bryla M, Szymczyk K, Jedrzejczak R, Roszko M. Application of liquid chromatography / ion trap mass spectrometry technique to determine ergot alkaloids in grain products.

- Food Technology and Biotechnology 2015;53(1):18-28.
674. Nagendrakumar D, Keshavshetti GG, Mogale P, Bhalke N. Design and evaluation of fast dissolving tablets of ergotamine tartrate. *International Journal of Current Pharmaceutical Research* 2015;7(2):101-104.
675. Walker K, Durringer J, Craig AM. Determination of the ergot alkaloid ergovaline in tall fescue seed and straw using a QuEChERS extraction method with high-performance liquid chromatography-fluorescence detection. *Journal of Agricultural and Food Chemistry* 2015;63(16):4236-4242.
676. Jakubczyk D, O'Connor S. Ergot alkaloids. *RSC Drug Discovery Series* 2016;50(Privileged Scaffolds in Medicinal Chemistry):379-397.
677. Majeska Cudejkova M, Vojta P, Valik J, Galuszka P. Quantitative and qualitative transcriptome analysis of four industrial strains of *Claviceps purpurea* with respect to ergot alkaloid production. *New Biotechnology* 2016: Ahead of Print.
678. Nowak J, Wozniakiewicz M, Klepacki P, Sowa A, Koscielniak P. Identification and determination of ergot alkaloids in Morning Glory cultivars. *Analytical and Bioanalytical Chemistry* 2016;408(12):3093-3102.
679. Oellig C, Melde T. Screening for total ergot alkaloids in rye flour by planar solid phase extraction-fluorescence detection and mass spectrometry. *Journal of Chromatography A* 2016;1441:126-133.
680. Mayer BP, Valdez CA, Lau EY. Nuclear magnetic resonance and computational study of inclusion complexes between cyclodextrins and fentanyl. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ANYL-198.
681. Valdez CA, Leif RN, Mayer BP. An efficient, optimized synthesis of fentanyl and related analogs. *PLoS One* 2014;9(9):e108250/1-e108250/8.
682. Hok S, Leif RN, Mayer BP, Valdez CA. Improved and optimized syntheses of fentanyl and related analogs. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ORGN-507.
683. McLaughlin G, Morris N, Kavanagh PV, Dowling G, Power JD, Twamley B, O'Brien J,

- Talbot B, Sitte HH, Brandt SD. Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers. *Drug Testing and Analysis* 2016: Ahead of Print.
684. Lima HM, Sreenivasan U, Yaser K, Cooper J. Design and synthesis of labeled 2C-BFLY and Bromo-DragonFLY for internal standards used in forensic analysis. Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014: ORGN-477.
685. Angelov D, O'Brien J, Kavanagh P. The syntheses of 1-(2-thienyl)-2-(methylamino)-propane (methiopropamine) and its 3-thienyl isomer for use as reference standards. *Drug Testing and Analysis* 2013;5(3):145-149.
686. Zuba D, Sekula K. Analytical characterization of three hallucinogenic N-(2-methoxy)-benzyl derivatives of the 2C-series of phenethylamine drugs. *Drug Testing and Analysis* 2013;5(8):634-645.
687. Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. *Journal of Psychopharmacology* 2014;28(8):780-788.
688. Kyriakou C, Marinelli E, Frati P, Santurro A, Afxentiou M, Zaami S, Busardo FP. NBOMe: New potent hallucinogens - Pharmacology, analytical methods, toxicities, fatalities: A review. *European Review for Medical and Pharmacological Sciences* 2015;19(17):3270-3281.
689. Neto JC. Rapid detection of NBOMe's and other NPS on blotter papers by direct ATR-FTIR spectrometry. *Forensic Science International* 2015;252:87-92.
690. Poklis JL, Raso SA, Alford KN, Poklis A, Peace MR. Analysis of 25I-NBOMe, 25BNBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-methoxyphenyl)methyl]ethanamine derivatives on blotter paper. *Journal of Analytical Toxicology* 2015;39(8):617-623.
691. Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. *Clinical Toxicology* 2015;53(2):85-92.
692. Barsegyan SS, Purvina EA, Salomatina EM, Sviridova TA, Fedorova TN. Determination of morphine and codeine in forensic chemical studies with the use of a single quadrupole

- mass-selective detector coupled to the HPLC system. *Sudebno-Meditsinskaya Ekspertiza* 2012;55(6):33-37.
693. Kormishin VA, Voronin AV, Vorornina TV, Shatalaev IF. Densitometric analysis of opiates forensic examination. *Sorbtsionnye i Khromatograficheskie Protsessy* 2013;13(1):32-36.
694. Braun DE, Gelbrich T, Kahlenberg V, Griesser UJ. Insights into hydrate formation and stability of morphinanes from a combination of experimental and computational approaches. *Molecular Pharmaceutics* 2014;11(9):3145-3163.
695. Gomez AB, Holmberg P, Baeckvall J-E, Martin-Matute B. Transition metal-catalyzed redox isomerization of codeine and morphine in water. *RSC Advances* 2014;4(74):39519-39522.
696. Jozwiak G. TLC of morphine analogs. *Chromatographic Science Series* 2014;106(Thin Layer Chromatography in Drug Analysis):323-332.
697. Hashemi SM, Naghavi MR. Production and gene expression of morphinan alkaloids in hairy root culture of *Papaver orientale* L. using abiotic elicitors. *Plant Cell, Tissue and Organ Culture* 2015: Ahead of Print.
698. Hudlicky T. Recent advances in process development for opiate-derived pharmaceutical agents. *Canadian Journal of Chemistry* 2015;93(5):492-501.
699. Jiang D, Xu J. Stereochemistry and spectral assignment of thebaine derivatives: A 1D NOESY NMR study. *Bopuxue Zazhi* 2015;32(1):95-104.
700. Kantoglu O, Ergun E. Degradation of morphine and codeine by gamma radiation in methanol solution. *Radiochimica Acta* 2015;103(2):137-147.
701. Kantoglu O, Ergun E. Radiation induced destruction of thebaine, papaverine and noscapine in methanol. *Radiation Physics and Chemistry* 2015: Ahead of Print.
702. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. AH-7921: The list of new psychoactive opioids is expanded. *Forensic Toxicology* 2015;33(2):195-201.
703. Manicke NE, Belford M. Separation of opiate isomers using electrospray ionization and paper spray coupled to high-field asymmetric waveform ion mobility spectrometry.

- Journal of the American Society for Mass Spectrometry 2015;26(5):701-705.
704. Thodey K, Galanie S, Smolke CD. A microbial biomanufacturing platform for natural and semisynthetic opioids. *Nature Chemical Biology* 2014;10(10):837-844.
705. Anon. Heroin can be synthesized in synthetic biology? *Gendai Kagaku* 2015;533:26-27.
706. Ehrenberg R. Engineered yeast paves way for home-brew heroin. *Nature* 2015;521(7552):267-268.
707. Endy D, Galanie S, Smolke CD. Complete absence of thebaine biosynthesis under home-brew fermentation conditions. *Synthetic Biology* 2015:24299/1-24299/11.
708. Fossati E, Narcross L, Ekins A, Falguyret JP, Martin VJ. Synthesis of morphinan alkaloids in *Saccharomyces cerevisiae*. *PLoS One* 2015;10(4):e0124459.
709. Galanie S, Thodey K, Trenchard IJ, Filsinger Interrante M, Smolke CD. Complete biosynthesis of opioids in yeast. *Science* 2015;349(6252):1095-1100.
710. Narcross L, Fossati E, Bourgeois L, Dueber JE, Martin VJJ. Microbial factories for the production of benzyloquinoline alkaloids. *Trends in Biotechnology* 2015: Ahead of Print.
711. Oye KA, Lawson JCH, Bubela T. Drugs: Regulate 'home-brew' opiates. *Nature* 2015;521(7552):281-283.
712. Diamond A, Desgagne-Penix I. Metabolic engineering for the production of plant isoquinoline alkaloids. *Plant Biotechnology Journal* 2016;14(6):1319-1328.
713. Galanie S, Thodey K, Trenchard I, Filsinger Interrante M, Smolke C. Complete biosynthesis of opioids in yeast. *Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: BIOT-201.*
714. Hoehne M, Kabisch J. Brewing painkillers: A yeast cell factory for the production of opioids from sugar. *Angewandte Chemie, International Edition* 2016;55(4):1248-1250.
715. Nakagawa A, Matsumura E, Koyanagi T, Katayama T, Kawano N, Yoshimatsu K, Yamamoto K, Kumagai H, Sato F, Minami H. Total biosynthesis of opiates by stepwise fermentation using engineered *Escherichia coli*. *Nature Communications* 2016;7:10390.

716. Wallach J, De Paoli G, Adejare A, Brandt SD. Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. *Drug Testing and Analysis* 2014;6(7-8):633-650.
717. Thangadurai S, Kannan MS, Dhanalakshmi A. Thin layer chromatographic separation and identification of certain phenothiazines. *Analytical Chemistry: An Indian Journal* 2013;13(9):332-336.
718. Anzanello MJ, Ortiz RS, Limberger RP, Mayorga P. A multivariate-based wavenumber selection method for classifying medicines into authentic or counterfeit classes. *Journal of Pharmaceutical and Biomedical Analysis* 2013;83:209-214.
719. Deconinck E, Canfyn M, Sacre P-Y, Courselle P, De Beer JO. Evaluation of the residual solvent content of counterfeit tablets and capsules. *Journal of Pharmaceutical and Biomedical Analysis* 2013;81-82:80-88.
720. Fraser SJ, Oughton J, Batten WA, Clark ASS, Schmierer DM, Gordon KC, Strachan CJ. Simultaneous qualitative and quantitative analysis of counterfeit and unregistered medicines using Raman spectroscopy. *Journal of Raman Spectroscopy* 2013: Ahead of Print.
721. Lee ES, Lee JH, Han KM, Kim JW, Hwang IS, Cho S, Han SY, Kim J. Simultaneous determination of 38 phosphodiesterase-5 inhibitors in illicit erectile dysfunction products by liquid chromatography-electrospray ionization-tandem mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis* 2013;83:171-178.
722. Ortiz RS, Mariotti KdC, Fank B, Limberger RP, Anzanello MJ, Mayorga P. Counterfeit Cialis and Viagra fingerprinting by ATR-FTIR spectroscopy with chemometry: Can the same pharmaceutical powder mixture be used to falsify two medicines? *Forensic Science International* 2013;226(1-3):282-289.
723. Ortiz RS, Mariotti KdC, Holzschuh MH, Romao W, Limberger RP, Mayorga P. Profiling counterfeit Cialis, Viagra and analogs by UPLC-MS. *Forensic Science International* 2013;229(1-3):13-20.
724. Sabin GP, Lozano VA, Rocha WFC, Romao W, Ortiz RS, Poppi RJ. Characterization of sildenafil citrate tablets of different sources by near infrared chemical imaging and chemometric tools. *Journal of Pharmaceutical and Biomedical Analysis* 2013;85:207-212.

725. Anzanello MJ, Ortiz RF, Limberger R, Mariotti K. A framework for selecting analytical techniques in profiling authentic and counterfeit Viagra and Cialis. *Forensic Science International* 2014;235:1-7.
726. Chen J-h, Hou C-y, Lu Y, Jiang J, Feng N. Simultaneous determination of 4 kinds of illicit drugs in health-care foodstuffs by ultra performance liquid chromatography-mass spectrometry. *Shipin Anquan Zhiliang Jiance Xuebao* 2014;5(7):2027-2032.
727. Podder AK, Chakrobarty JK, Faroque ABM. Qualitative and quantitative analysis of sildenafil in traditional medicines and dietary supplements. *Asian Journal of Pharmaceutical and Clinical Research* 2014;7(S2):25-30.
728. Kern SE, Lorenz LM, Lanzarotta A, Nickum EA, Litzau JJ. Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. *Journal of Pharmaceutical and Biomedical Analysis* 2016;128:360-366.
729. Pandey A, Parikh P. Detection of sildenafil citrate from aphrodisiac herbal formulations. *International Journal of Pharmaceutical Sciences and Research* 2015;6(9):4080-4085.
730. Wilczynski S. The use of dynamic thermal analysis to distinguish between genuine and counterfeit drugs. *International Journal of Pharmaceutics (Amsterdam, Netherlands)* 2015;490(1-2):16-21.
731. Frycak P, Hartmanova L, Lorencova I, Lemr K. Screening of synthetic phosphodiesterase-5 inhibitors in herbal dietary supplements using transmission-mode desorption electrospray and high-resolution mass spectrometry. *Journal of Mass Spectrometry* 2016;51(5):358-362.
732. Hanson B, Flurer R, Kern S, Nickum E, Toomey V, Voelker S. Analysis of dietary supplements containing phosphodiesterase type-5 (PDE-5) inhibitors. Abstracts, 47th Central Regional Meeting of the American Chemical Society, Covington, KY, United States, May 18-21, 2016: CERM-4.
733. Abdel-Hay KM, Awad T, DeRuiter J, Clark CR. Differentiation of methylenedioxybenzylpiperazines and ethoxybenzylpiperazines by GC-IRD and GC-MS. *Journal of Chromatographic Science* 2012;50(7):553-563.
734. Abdel-Hay KM, DeRuiter J, Randall Clark C. GC-MS and GC-IRD studies on the six ring regioisomeric dimethoxybenzoylpiperazines (DMBzPs). *Forensic Science*

International 2013;231(1-3):54-60.

735. Abdel-Hay KM, DeRuiter J, Clark CR. Gas chromatography/mass spectrometry analysis of the six-ring regioisomeric dimethoxybenzyl-N-methylpiperazines (DMBMPs). *Rapid Communications in Mass Spectrometry* 2013;27(22):2551-2558.
736. Philp M, Shimmom R, Stojanovska N, Tahtouh M, Fu S. Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials. *Analytical Methods* 2013;5(20):5402-5410.
737. Siroká J, Polesel DN, Costa JL, Lanaro R, Tavares MF, Polášek M. Separation and determination of chlorophenylpiperazine isomers in confiscated pills by capillary electrophoresis. *Journal of Pharmaceutical and Biomedical Analysis* 2013;84:140-147.
738. Waite RJ, Barbante GJ, Barnett NW, Zammit EM, Francis PS. Chemiluminescence detection of piperazine designer drugs and related compounds using tris(2,2'-bipyridine)-ruthenium(III). *Talanta* 2013;116:1067-1072.
739. Abdel-Hay KM, Terrell CM, DeRuiter J, Clark CR. GC-MS and IR studies on the six ring regionisomeric dimethoxybenzoyl-N-methylpiperazines (DMBzMPs). *Forensic Science International* 2014;237:53-61.
740. Abdel-Hay KM, DeRuiter J, Clark CR. Regioisomeric bromodimethoxy benzyl piperazines related to the designer substance 4-bromo-2,5-dimethoxybenzylpiperazine: GCMS and FTIR analysis. *Forensic Science International* 2014;240:126-136.
741. Abdel-Hay KM, DeRuiter J, Clark CR. Differentiation of the 1-(methylenedioxyphenyl)-2-piperazinopropanes and 1-(methoxyphenyl)-2-piperazinopropanones by GC-IRD and GC-MS. *Forensic Science International* 2014;235:40-51.
742. Abdel-Hay KM, De Ruiter J, Clark CR. GC-MS and IR studies on the six ring regioisomeric dimethoxyphenylpiperazines (DOMePPs). *Journal of Forensic Sciences* 2015;60(2):285-294.
743. Beckett NM, Cresswell SL, Grice DI, Carter JF. Isotopic profiling of seized benzylpiperazine and trifluoromethylphenylpiperazine tablets using  $\delta^{13}\text{C}$  and  $\delta^{15}\text{N}$  stable isotopes. *Science & Justice* 2015;55(1):51-56.
744. Siddiqi S, Verney C, Dargan P, Wood DM. Understanding the availability, prevalence of

- use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. *Clinical Toxicology* 2015;53(1):54-59.
745. Chen H-X, Huang M-H, Zhang X-X. Micellar electrokinetic chromatography analysis of tetrahydrogestrinone and related anabolic androgenic steroids. *Analytical Methods* 2013;5(19):5019-5023.
746. da Justa Neves DB, Marcheti RGA, Caldas ED. Incidence of anabolic steroid counterfeiting in Brazil. *Forensic Science International* 2013;228(1-3):e81-e83.
747. Favretto D, Castagna F, Maietti S, Boscolo-Berto R, Ferrara SD. When color fails: Illicit blue tablets containing anabolic androgen steroids. *Journal of Pharmaceutical and Biomedical Analysis* 2013;83:260-264.
748. Pozo OJ, De Brabanter N, Fabregat A, Segura J, Ventura R, Van Eenoo P, Deventer K. Current status and bioanalytical challenges in the detection of unknown anabolic androgenic steroids in doping control analysis. *Bioanalysis* 2013;5(21):2661-2677.
749. Rojanarata T, Plianwong S, Su-uta K, Opanasopit P, Ngawhirunpat T. Electrospun cellulose acetate nanofibers as thin layer chromatographic media for eco-friendly screening of steroids adulterated in traditional medicine and nutraceutical products. *Talanta* 2013;115:208-213.
750. Cha E, Kim S, Kim HJ, Lee KM, Kim KH, Kwon O-S, Lee J. Sensitivity of GC-EI/MS, GC-EI/MS/MS, LC-ESI/MS/MS, LC-Ag+CIS/MS/MS, and GC-ESI/MS/MS for analysis of anabolic steroids in doping control. *Drug Testing and Analysis* 2015: Ahead of Print.
751. Cho S-H, Park HJ, Lee JH, Do J-A, Heo S, Jo JH, Cho S. Determination of anabolic-androgenic steroid adulterants in counterfeit drugs by UHPLC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis* 2015;111:138-146.
752. Doue M, Dervilly-Pinel G, Pouponneau K, Monteau F, Le Bizec B. Direct analysis in real time - high resolution mass spectrometry (DART-HRMS): A high throughput strategy for identification and quantification of anabolic steroid esters. *Drug Testing and Analysis* 2015;7(7):603-608.
753. Joseph JF, Parr MK. Synthetic androgens as designer supplements. *Current Neuropharmacology* 2015;13(1):89-100.

754. Odoardi S, Castrignano E, Martello S, Chiarotti M, Strano-Rossi S. Determination of anabolic agents in dietary supplements by liquid chromatography-high-resolution mass spectrometry. *Food Additives & Contaminants, Part A: Chemistry, Analysis, Control, Exposure & Risk Assessment* 2015;32(5):635-647.
755. Rahnama CD, Crosnoe LE, Kim ED. Designer steroids - Over-the-counter supplements and their androgenic component: Review of an increasing problem. *Andrology* 2015;3(2):150-155.
756. Dumont Q, Barcenas M, Dossmann H, Bailloux I, Buisson C, Mechin N, Molina A, Lasne F, Rannulu NS, Cole RB. Improved steroids detection and evidence for their regiospecific decompositions using anion attachment mass spectrometry. *Analytical Chemistry* 2016;88(7):3585-3591.
757. Falconer T. Non-targeted mass spectrometric analysis of dietary supplements. Abstracts, 47th Central Regional Meeting of the American Chemical Society, Covington, KY, United States, May 18-21, 2016: CERM-6.
758. Polet M, Van Gansbeke W, Van Eenoo P, Deventer K. Gas chromatography/chemical ionization triple quadrupole mass spectrometry analysis of anabolic steroids: Ionization and collision-induced dissociation behavior. *Rapid Communications in Mass Spectrometry* 2016;30(4):511-522.
759. Elliott SP, Brandt SD, Freeman S, Archer RP. AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): An analytical challenge and implications for forensic analysis. *Drug Testing and Analysis* 2013;5(3):196-202.
760. Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H. Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry. *Forensic Toxicology* 2013: Ahead of Print.
761. Tittarelli R, Mannocchi G, Pantano F, Romolo FS. Recreational use, analysis and toxicity of tryptamines. *Current Neuropharmacology* 2015;13(1):26-46.
762. Bartolucci S, Mari M, Di Gregorio G, Piersanti G. Observations concerning the synthesis of tryptamine homologues and branched tryptamine derivatives via the borrowing hydrogen process: Synthesis of psilocin, bufotenin, and serotonin. *Tetrahedron* 2016;72(18):2233-2238.

763. Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Meyer MR, Maurer HH, Halberstadt AL. Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ringsubstituted derivatives. *Drug Testing and Analysis* 2016: Ahead of Print.
764. Edmunds R, Locos O, Brown D, Reynolds D. Identification of the synthetic cannabinoid (1-(cyclohexylmethyl)-1h-indol-3-yl)(4-methoxynaphthalen-1-yl)methanone on plant material. *Microgram Journal* 2013;10(1):3-7.
765. Erisman EP, Augustine LM. Purification and characterization of 3-methyl-6-[3-(trifluoromethyl)-phenyl]-1,2,4-triazolo[4,3-b]pyridazinol (CL 218872). *Microgram Journal* 2013;10(2):17-21.
766. Takahashi K, Uchiyama N, Fukiwake T, Hasegawa T, Saijou M, Motoki Y, Kikura-Hanajiri R, Goda Y. Identification and quantitation of JWH-213, a cannabimimetic indole, as a designer drug in a herbal product. *Forensic Toxicology* 2013;31(1):145-150.
767. Uemura N, Fukaya H, Kanai C, Yoshida M, Nakajima J-i, Takahashi M, Suzuki J, Moriyasu T, Nakae D. Identification of a synthetic cannabinoid A-836339 as a novel compound found in a product. *Forensic Toxicology* 2013: Ahead of Print.
768. Zuba D, Geppert B, Sekula K, Zaba C. [1-(Tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone: A new synthetic cannabinoid identified on the drug market. *Forensic Toxicology* 2013;31(2):281-291.
769. Monte AA, Bronstein AC, Cao DJ, Heard KJ, Hoppe JA, Hoyte CO, Iwanicki JL, Lavonas EJ. An outbreak of exposure to a novel synthetic cannabinoid. *New England Journal of Medicine* 2014;370(4):389-390.
770. Shevyrin, VA, Morzherin YY, Melkozerov VP, Nevero AS. New synthetic cannabinoid - methyl 2-{{[1-(5-fluoropentyl)-3-methyl-1h-indol-3-ylcarbonyl]amino}butyrate - as a designer drug. *Chemistry of Heterocyclic Compounds* 2014;50(4):583-586.
771. Westphal F, Girreser U, Knecht S. Structure elucidation of a new open chain isomer of the cannabimimetic cyclopropoylindole A-796,260. *Forensic Science International* 2014;234:139-148.
772. Zhai W-f, Zhang C-s, Gao L-s. Study on determination of HU-210 in novel "spice" drugs by HPLC. *Huaxue Gongchengshi* 2014;28(7):26-28.

773. Zhai W-f, Zhang C-s, Li P, Gao L-s. LC-MS/MS analysis of a sample of novel "spice" drugs. *Huaxue Gongchengshi* 2014;28(10):26-27,50.
774. Alsoud ARA, Al-Tannak N, Bojabarah H, Orabi KY. AB-FUBINACA, a synthetic cannabinoid in "Funky Green Stuff". *International Journal of Pharmacy and Pharmaceutical Sciences* 2015;7(10):111-115.
775. Girreser U, Roesner P, Vasilev A. Structure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted <sup>13</sup>C NMR shifts - A case study. *Drug Testing and Analysis* 2015: Ahead of Print.
776. Kondrasenko AA, Goncharov EV, Dugaev KP, Rubaylo AI. CBL-2201. Report on a new designer drug: Naphth-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate. *Forensic Science International* 2015;257:209-213.
777. Nakayama H, Kenjyou N. New monoclonal antibodies specific for 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy* 2015;34(1):55-58.
778. Nakajima J-i, Takahashi M, Uemura N, Seto T, Fukaya H, Suzuki J, Yoshida M, Kusano M, Nakayama H, Zaitso K, Ishii A, Moriyasu T, Nakae D. Identification of N,N-bis(1-pentylindol-3-yl-carboxy)naphthylamine (BiPICANA) found in an herbal blend product in the Tokyo metropolitan area and its cannabimimetic effects evaluated by in vitro [<sup>35</sup>S]GTPγS binding assays. *Forensic Toxicology* 2015;33(1):84-92.
779. Uchiyama N, Asakawa K, Kikura-Hanajiri R, Tsutsumi T, Hakamatsuka T. A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] identified in illegal products. *Forensic Toxicology* 2015: Ahead of Print.
780. Andernach L, Pusch S, Weber C, Schollmeyer D, Muenster-Mueller S, Puetz M, Opatz T. Absolute configuration of the synthetic cannabinoid MDMB-CHMICA with its chemical characteristics in illegal products. *Forensic Toxicology* 2016;34(2):344-352.
781. Angerer V, Biesel P, Moosmann B, Westphal F, Auwaerter V. Separation and structural characterization of the new synthetic cannabinoid JWH-018 cyclohexyl methyl derivative "NE-CHMIMO" using flash chromatography, GC-MS, IR and NMR spectroscopy. *Forensic Science International* 2016: Ahead of Print.

782. Shevyrin V, Melkozerov V, Eltsov O, Shafran Y, Morzherin Y. Synthetic cannabinoid 3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detection in illicit market of new psychoactive substances. *Forensic Science International* 2016;259:95-100.
783. Moosmann B, Kneisel S, Girreser U, Brecht V, Westphal F, Auwaerter V. Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS, NMR analysis and a flash chromatography system. *Forensic Science International* 2012;220(1-3):e17-e22.
784. Sato H, Chonan Y, Ishikawa J, Kosone K, Kumazawa T. Analysis of cannabinoid compounds. *Kanzei Chuo Bunsekishoho* 2012;52:85-90.
785. Shabalina AE, Kirichek AV, Kaletina NI, Vandishev VV. The investigation of components in smoking blends containing synthetic cannabinoids RCS-4, JWH-250, CP-47,497-C8. *Voprosy Biologicheskoi, Meditsinskoi i Farmatsevticheskoi Khimii* 2012;(9):67-72.
786. Choi H, Heo S, Choe S, Yang W, Park Y, Kim E, Chung H, Lee J. Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GCMS. *Analytical and Bioanalytical Chemistry* 2013;405(12):3937-3944.
787. Choi H, Heo S, Kim E, Hwang BY, Lee C, Lee J. Identification of (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone and its 5-pentyl fluorinated analog in herbal incense seized for drug trafficking. *Forensic Toxicology* 2013;31(1):86-92.
788. Chung H, Choi H, Heo S, Kim E, Lee J. Synthetic cannabinoids abused in South Korea: Drug identifications by the National Forensic Service from 2009 to June 2013. *Forensic Toxicology* 2013: Ahead of Print.
789. Denooz R, Vanheugen J-C, Frederich M, de Tullio P, Charlier C. Identification and structural elucidation of four cannabimimetic compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in seized products. *Journal of Analytical Toxicology* 2013;37(2):56-63.
790. Gurdal F, Asirdizer M, Aker RG, Korkut S, Gocer Y, Kucukbrahimoglu EE, Ince CH. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. *Journal of Forensic and Legal Medicine* 2013;20(6):667-672.

791. Ibanez M, Bijlsma L, Nuijs ALN, Sancho JV, Haro G, Covaci A, Hernandez F. Quadrupole-time-of-flight mass spectrometry screening for synthetic cannabinoids in herbal blends. *Journal of Mass Spectrometry* 2013;48(6):685-694.
792. Kneisel S, Speck M, Moosmann B, Corneillie TM, Butlin NG, Auwaerter V. LC/ESIMS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. *Analytical and Bioanalytical Chemistry* 2013;405(14):4691-4706.
793. Moosmann B, Kneisel S, Wohlfarth A, Brecht V, Auwärter V. A fast and inexpensive procedure for the isolation of synthetic cannabinoids from 'Spice' products using a flash chromatography system. *Analytical and Bioanalytical Chemistry* 2013;405(12):3929-3935.
794. Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Uemura N, Hamano T. Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3'-(aminocarbonyl)(1,1'-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area. *Forensic Toxicology* 2013;31(1):76-85.
795. Park Y, Lee C, Lee H, Pyo J, Jo J, Lee J, Choi H, Kim S, Hong RS, Park Y, Hwang BY, Choe S, Jung JH. Identification of a new synthetic cannabinoid in a herbal mixture: 1-Butyl-3-(2-methoxybenzoyl)indole. *Forensic Toxicology* 2013;31(2):187-196.
796. Presley BC, Jansen-Varnum SA, Logan BK. Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. *Forensic Science Review* 2013;25(1-2):27-46.
797. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y. Identification and analytical properties of new synthetic cannabimimetics bearing 2,2,3,3-tetramethyl-cyclopropanecarbonyl moiety. *Forensic Science International* 2013;226(1-3):62-73.
798. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y. Analytical characterization of some synthetic cannabinoids, derivatives of indole-3-carboxylic acid. *Forensic Science International* 2013;232(1-3):1-10.
799. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y. URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. *Forensic Science International* 2013;227(1-3):21-32.

800. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. *Forensic Toxicology* 2013;31(1):93-100.
801. Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids. *Life Sciences* 2013: Ahead of Print.
802. Xu P, Lin W-s, Li X-n, Liu L-l, Ling X-m, Lu W. UFLC simultaneous determination of two narcotics compositions in a novel spice. *Yaowu Fenxi Zazhi* 2013;33(9):1538-1541.
803. Zuba D, Byrska B. Analysis of the prevalence and coexistence of synthetic cannabinoids in "herbal high" products in Poland. *Forensic Toxicology* 2013;31(1):21-30.
804. Brents LK, Prather PL. The K2/Spice phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. *Drug Metabolism Reviews* 2014;46(1):72-85.
805. Clark CR, Abdel Hay K, DeRuiter J, Smith F, Belal T, Thaxton A. Chromatographic and mass spectral studies on alkyl-acylindoles: Regioisomeric synthetic cannabinoids. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-800.
806. Clark CR, Smith FT, Abdel-Hay KM, DeRuiter J. Forensic chemistry of substituted 1-alkyl-3-acylindoles: Isomeric synthetic cannabinoids. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ANYL-122.
807. DeRuiter J, Smith FT, Abdel-Hay K, Clark CR. Analytical differentiation of 1-alkyl-3-acylindoles and 1-acyl-3-alkylindoles: Isomeric synthetic cannabinoids. *Analytical Chemistry* 2014;86(8):3801-3808.
808. ElSohly MA, Gul W, Wanas AS, Radwan MM. Synthetic cannabinoids: Analysis and metabolites. *Life Sciences* 2014;97(1):78-90.
809. Harris DN, Hokanson S, Miller V, Jackson GP. Fragmentation differences in the EI spectra of three synthetic cannabinoid positional isomers: JWH-250, JWH-302, and

- JWH-201. *International Journal of Mass Spectrometry* 2014;368:23-29.
810. Isaacs RCA. A structure-reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse. *Forensic Science International* 2014;242:135-141.
811. Lesiak AD, Musah RA, Domin MA, Shepard JRE. DART-MS as a preliminary screening method for "Herbal Incense": Chemical analysis of synthetic cannabinoids. *Journal of Forensic Sciences* 2014;59(2):337-343.
812. Muller KJ, Huang L. Identification and quantification of synthetic cannabinoids using gas chromatography. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: CHED-237.
813. Schlatter J. Synthetic cannabinoids: Synthesis and biological activities. *Studies in Natural Products Chemistry* 2014;43:291-311.
814. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y. 3-Naphthoyl-indazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: Chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures. *Forensic Science International* 2014;242:72-80.
815. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Baranovsky A, Shafran Y. Synthetic cannabinoids as designer drugs: New representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data. *Forensic Science International* 2014;244:263-275.
816. Smith FT, DeRuiter J, Abdel-Hay K, Clark CR. GC-MS and FTIR evaluation of the six benzoyl-substituted-1-pentylindoles: Isomeric synthetic cannabinoids. *Talanta* 2014;129:171-182.
817. Zhai W-f, Zhang C-s, Gao L-s. Simultaneous determination of 10 synthetic cannabinoids in novel "spice" drugs by high performance liquid chromatography. *Fenxi Ceshi Xuebao* 2014;33(8):893-898.
818. Andreeva-Gateva PA, Nankova VH, Angelova VT, Gatev TN. Synthetic cannabimimetics in Bulgaria 2010-2013. *Drug and Alcohol Dependence* 2015: Ahead of Print.

819. Banister SD, Stuart J, Conroy T, Longworth M, Manohar M, Beinat C, Wilkinson SM, Kevin RC, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. *Forensic Toxicology* 2015: Ahead of Print.
820. Blakey K, Boyd S, Atkinson S, Wolf J, Slotjje PM, Goodchild K, McGowan J. Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense. *Forensic Science International* 2015: Ahead of Print.
821. Carlsson A, Lindberg S, Wu X, Dunne S, Josefsson M, Åstot C, Dahlen J. Prediction of designer drugs: Synthesis and spectroscopic analysis of synthetic cannabinoid analogues of 1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone and 1H-indol-3-yl(adamantan-1-yl)methanone. *Drug Testing and Analysis* 2015: Ahead of Print.
822. Ciolino LA. Quantitation of synthetic cannabinoids in plant materials using high performance liquid chromatography with UV detection (validated method). *Journal of Forensic Sciences* 2015;60(5):1171-1181.
823. D'Archivio AA, Maggi MA, Ruggieri F. Quantitative structure-retention relationships of cannabimimetic aminoalkylindole derivatives and their metabolites. *Journal of Pharmaceutical and Biomedical Analysis* 2015;109:136-141.
824. Davidson J, Predecki DP, Richardson JN. Qualitative and quantitative analysis of fluorine containing synthetic cannabinoids. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHED-317.
825. Emery D, Iceman CR, Hayes SM. Geographic variability of active ingredients in Spice within Alaska as an indicator mechanism for manufacture and distribution. Abstracts, 70th Northwest Regional Meeting of the American Chemical Society, Pocatello, ID, United States, June 21-24, 2015: NORM-48.
826. Fowler F, Voyer B, Marino M, Finzel J, Veltri M, Wachter NM, Huang L. Rapid screening and quantification of synthetic cannabinoids in herbal products with NMR spectroscopic methods. *Analytical Methods* 2015;7(18):7907-7916.
827. Hung C-H, Zukowski J, Jensen DS, Miles AJ, Sulak C, Dadson AE, Linford MR. Separation of cannabinoids on three different mixed-mode columns containing carbon/nanodiamond/amine-polymer superficially porous particles. *Journal of Separation*

Science 2015:Ahead of Print.

828. Kemp AM, Clark MS, Dobbs T, Galli R, Sherman J, Cox R. Top ten facts you need to know about synthetic cannabinoids: Not so nice Spice. *American Journal of Medicine* 2015:Ahead of Print.
829. Kusano M, Zaitso K, Nakayama H, Nakajima J, Hisatsune K, Moriyasu T, Matsuta S, Katagi M, Tsuchihashi H, Ishii A. Positional isomer differentiation of synthetic cannabinoid JWH-081 by GC-MS/MS. *Journal of Mass Spectrometry* 2015;50(3):586-591.
830. Langer N, Lindigkeit R, Schiebel H-M, Papke U, Ernst L, Beuerle T. Identification and quantification of synthetic cannabinoids in "spice-like" herbal mixtures: Update of the German situation for the spring of 2015. *Forensic Toxicology* 2015:Ahead of Print.
831. Marginean I, Rowe WF, Lurie IS. The role of ultra high performance liquid chromatography with time of flight detection for the identification of synthetic cannabinoids in seized drugs. *Forensic Science International* 2015;249:83-91.
832. McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Brandt SD. The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer. *Drug Testing and Analysis* 2015:Ahead of Print.
833. Qian Z, Hua Z, Liu C, Jia W. Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances. *Forensic Toxicology* 2015:Ahead of Print.
834. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT. Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group. *Analytical and Bioanalytical Chemistry* 2015:Ahead of Print.
835. Shevyrin VA, Morzherin YY. Cannabinoids: Structures, effects, and classification. *Russian Chemical Bulletin* 2015;64(6):1249-1266.
836. Thaxton A, Belal TS, Smith F, De Ruiter J, Abdel-Hay KM, Clark CR. Mass spectral studies on 1-n-pentyl-3-(1-naphthoyl)indole (JWH-018), three deuterium-labeled analogues and the inverse isomer 1-naphthoyl-3-n-pentylindole. *Rapid Communications*

- in Mass Spectrometry 2015;29(9):871-877.
837. Thaxton A, Belal TS, Smith F, DeRuiter J, Abdel-Hay KM, Clark CR. GC-MS studies on the six naphthoyl-substituted 1-n-pentyl-indoles: JWH-018 and five regioisomeric equivalents. *Forensic Science International* 2015;252:107-113.
838. Toyo'oka T, Kikura-Hanajiri R. A reliable method for the separation and detection of synthetic cannabinoids by supercritical fluid chromatography with mass spectrometry, and its application to plant products. *Chemical & Pharmaceutical Bulletin* 2015;63(10):762-769.
839. Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. *New England Journal of Medicine* 2015;373(2):103-107.
840. Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, Dempster NM, Brandt SD. Syntheses and analytical characterizations of N-alkyl-aryl cyclohexylamines. *Drug Testing and Analysis* 2015: Ahead of Print.
841. Westphal F, Soennichsen FD, Knecht S, Auwaerter V, Huppertz L. Two thiazolylindoles and a benzimidazole: Novel compounds on the designer drug market with potential cannabinoid receptor activity. *Forensic Science International* 2015;249:133-147.
842. Wilkinson SM, Banister SD, Kassiou M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. *Australian Journal of Chemistry* 2015;68(1):4-8.
843. Wurita A, Hasegawa K, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O. Identification and quantitation of 5-fluoro-ADB-PINACA and MABCHMINACA in dubious herbal products. *Forensic Toxicology* 2015: Ahead of Print.
844. Xing Y, Xu X, Liu X, Xu B, Ma Q, Lei H. Study on the mass fragmentation pathway of the synthetic cannabinoids JWH-018 and JWH-073. *International Journal of Mass Spectrometry* 2015: Ahead of Print.
845. Znaleziona J, Ginterová P, Petr J, Ondra P, Válka I, Ševčík J, Chrastina J, Maier V. Determination and identification of synthetic cannabinoids and their metabolites in different matrices by modern analytical techniques - A review. *Analytica Chimica Acta* 2015;874:11-25.

846. Abdel-Hay KM, De Ruiter J, Smith F, Alsegiani AS, Thaxton-Weissenfluh A, Clark CR. GC-MS differentiation of the six regioisomeric dimethoxybenzoyl-1-pentylindoles: Isomeric cannabinoid substances. *Journal of Pharmaceutical and Biomedical Analysis* 2016;125:360-368.
847. Akamatsu S, Yoshida M. Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray. *Journal of Mass Spectrometry* 2016;51(1):28-32.
848. Breitenbach S, Rowe WF, McCord B, Lurie IS. Assessment of ultra high performance supercritical fluid chromatography as a separation technique for the analysis of seized drugs: Applicability to synthetic cannabinoids. *Journal of Chromatography A* 2016;1440:201-211.
849. Frinculescu A, Lyall CL, Ramsey J, Miserez B. Variation in commercial smoking mixtures containing third-generation synthetic cannabinoids. *Drug Testing and Analysis* 2016: Ahead of Print.
850. Habala L, Valentova J, Pechova I, Fuknova M, Devinsky F. DART - LTQ ORBITRAP as an expedient tool for the identification of synthetic cannabinoids. *Legal Medicine* 2016;20:27-31.
851. Jia W, Meng X, Qian Z, Hua Z, Li T, Liu C. Identification of three cannabimimetic indazole and pyrazole derivatives, APINACA 2H-indazole analogue, AMPPPCA, and 5FAMPPPCA. *Drug Testing and Analysis* 2016: Ahead of Print.
852. Kusano M, Yamanaka M, Zaitso K, Nakayama H, Nakajima J-i, Moriyasu T, Tsuchihashi H, Ishii A. Regioisomeric differentiation of the alkyl-substituted synthetic cannabinoids JWH-122 and JWH-210 by GC-EI-MS/MS. *Forensic Toxicology* 2016: Ahead of Print.
853. Lobo Vicente J, Chassaigne H, Holland MV, Reniero F, Kolar K, Tirendi S, Vandecasteele I, Vinckier I, Guillou C. Systematic analytical characterization of new psychoactive substances: A case study. *Forensic Science International* 2016;265:107-115.
854. Loeffler G, Delaney E, Hann M. International trends in Spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. *Brain Research Bulletin* 2016: Ahead of Print.

855. Longworth M, Banister SD, Mack JBC, Glass M, Connor M, Kassiou M. The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. *Forensic Toxicology* 2016: Ahead of Print.
856. Marino MA, Voyer B, Cody RB, Dane AJ, Veltri M, Huang L. Rapid identification of synthetic cannabinoids in herbal incenses with DART-MS and NMR. *Journal of Forensic Sciences* 2016;61(S1):S82-S91.
857. Paulke A, Proschak E, Sommer K, Achenbach J, Wunder C, Toennes SW. Synthetic cannabinoids: In silico prediction of the cannabinoid receptor 1 affinity by a quantitative structure-activity relationship model. *Toxicology Letters* 2016;245,:1-6.
858. Qian Z, Jia W, Li T, Hua Z, Liu C. Identification and analytical characterization of four synthetic cannabinoids ADB-BICA, NNL-1, NNL-2, and PPA(N)-2201. *Drug Testing and Analysis* 2016: Ahead of Print.
859. Smoluch M, Babij M, Zuba D, Schroeder G, Gotszalk T, Silberring J. Heat assisted sample introduction and determination of cannabinoids by dielectric barrier discharge ionization mass spectrometry. *International Journal of Mass Spectrometry* 2015: Ahead of Print.
860. Hiramata Y, Kanatoshi A, Chonan T. Chemical analysis for psychotropic herbal products purchased via the internet in fiscal year 2009. *Hokkaidoritsu Eisei Kenkyushoho* 2012;62:15-20.
861. Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. *Journal of Analytical Toxicology* 2012;36(6):360-371.
862. Dujourdy L, Soto T. Natural cannabis or synthetic cannabinoids? *Actualite Chimique* 2013;378-379:106-111.
863. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative alpha-PVT and an opioid receptor agonist AH-7921 identified in illegal products. *Forensic Toxicology* 2013;31(2):223-240.

864. Wada K, Funada M, Tomiyama K, Aoo N. Present situation of abuse of illegal drugs including law-evading hallucinatory herbs. *Nippon Yakuzashikai Zasshi* 2013;65(1):13-17.
865. Maciów-Glab M, Rojek S, Kula K, Klys M. "New designer drugs" in aspects of forensic toxicology. *Archiwum Medycyny Sadowej i Kryminologii* 2014;64(1):20-33.
866. Simões SS, Silva I, Ajenjo AC, Dias MJ. Validation and application of an UPLCMS/MS method for the quantification of synthetic cannabinoids in urine samples and analysis of seized materials from the Portuguese market. *Forensic Science International* 2014;243:117-125.
867. Sysoev AA, Poteshin SS, Chernyshev DM, Karpov AV, Tuzkov YB, Kyzmin VV, Sysoev AA. Analysis of new synthetic drugs by ion mobility time-of-flight mass spectrometry. *European Journal of Mass Spectrometry* 2014;20(2):185-192.
868. Wurita A, Hasegawa K, Minakata K, Watanabe K, Suzuki O. A large amount of new designer drug diphenidine coexisting with a synthetic cannabinoid 5-fluoro-AB-PINACA found in a dubious herbal product. *Forensic Toxicology* 2014;32(2):331-337.
869. Bolognini D, Ross RA. Medical cannabis vs. synthetic cannabinoids: What does the future hold? *Clinical Pharmacology & Therapeutics* 2015;97(6):568-570.
870. DeArmas A. History and nomenclature of synthetic cathinones and cannabinoids. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-39.
871. Mechoulam R. Looking ahead after 50 years of research on cannabinoids. *Cannabinoids* 2014:1-15.
872. White M. Analysis of synthetic cathinones and cannabimimetic agents. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-43.
873. Mazina J, Aleksejev V, Ivkina T, Kaljurand M, Poryvkina L. Qualitative detection of illegal drugs (cocaine, heroin and MDMA) in seized street samples based on SFS Data and ANN: Validation of method. *Journal of Chemometrics* 2012;26(8-9):442-455.
874. Mokhtari A, Karimi-Maleh H, Ensafi AA, Beitollahi H. Application of modified

- multiwall carbon nanotubes paste electrode for simultaneous voltammetric determination of morphine and diclofenac in biological and pharmaceutical samples. *Sensors and Actuators, B: Chemical* 2012;169:96-105.
875. Parsons SM. Date-rape drugs with emphasis on GHB. *Forensic Chemistry Handbook* 2012:355-434.
876. Demoranville LT, Verkouteren JR. Measurement of drug facilitated sexual assault agents in simulated sweat by ion mobility spectrometry. *Talanta* 2013;106:375-380.
877. De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ. From the street to the laboratory: Analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. *Journal of Analytical Toxicology* 2013;37(5):277-283.
878. Domenech-Carbo A, Martini M, de Carvalho ML, Viana C, Domenech-Carbo MT, Silva M. Standard additions-dilution method for absolute quantification in voltammetry of microparticles. Application for determining psychoactive 1,4-benzodiazepine and antidepressants drugs as adulterants in phytotherapeutic formulations. *Journal of Pharmaceutical and Biomedical Analysis* 2013;80:159-163.
879. Domenech-Carbo A, Martini M, de Carvalho LM, Viana C, Domenech-Carbo MT, Silva M. Screening of pharmacologic adulterant classes in herbal formulations using voltammetry of microparticles. *Journal of Pharmaceutical and Biomedical Analysis* 2013;74:194-204.
880. El-Didamony AM, Ali II. Spectrofluorimetric and spectrophotometric analysis of two analgesic drugs in pharmaceutical formulations and biological fluids. *Journal of Forensic Sciences* 2013;58(5):1322-1329.
881. El-Didamony AM, Saad MZ, Saleem NO. Kinetic spectrophotometric method for the determination of morphine, nalbuphine and naltrexone drugs in bulk and pharmaceutical formulations. *Journal of the Chilean Chemical Society* 2013;58(3):1907-1913.
882. El-Didamony AM, Saad MZ, Saleem NO. Determination of tramadol, morphine, nalbuphine and naltrexone analgesic drugs using potassium permanganate by visible spectrophotometry. *Main Group Chemistry* 2014;13(2):175-186.
883. Guo W-x, Gu X-r, Dong J, Li P, Dong G-b. Determination of sedative-hypnotics in

- health food by HPLC-MS/MS. *Guangpu Shiyanshi* 2013;30(5):2294-2297.
884. Hoonka S, Durgbanshi A, Esteve-Romero J, Dubey NP, Bose D. Simultaneous determination of three stupeficients in foodstuff using high performance liquid chromatography. *Journal of Liquid Chromatography & Related Technologies* 2013: Ahead of Print.
885. Idris M, John C, Ghosh P, Shukla SK, Baggi TRR. Simultaneous determination of methaqualone, saccharin, paracetamol, and phenacetin in illicit drug samples by HPLC. *Journal of Analytical Science and Technology* 2013;4(1-8):4/1-4/6.
886. Jakubowska I, Choma J. Properties and detection of 'designer drugs'. *Biuletyn Wojskowej Akademii Technicznej* 2013;62(2):123-143.
887. Kanu AB, Brandt SD, Williams MD, Zhang N, Hill HH. Analysis of psychoactive cathinones and tryptamines by electrospray ionization atmospheric pressure ion mobility time-of-flight mass spectrometry. *Analytical Chemistry* 2013;85(18):8535-8542.
888. Ladroue V, Besacier F, Hologne M. A conditioning facility of new synthetic drugs discovered in France. *Annales de Toxicologie Analytique* 2013;25(4):175-184.
889. Lin F, Li J, Li T, Zhu X-h, Wang S. Rapid determination of 18 psychoactive drugs illegally added in health food by ultra-high performance liquid chromatography with photodiode array detector. *Shipin Keji* 2013;38(9):303-308.
890. Lin F, Li T, Li J, Zhu X-h, Yang M. Rapid determination of 14 psychoactive drugs in sleep-improving health-care foods by ultra-high performance liquid chromatography - photodiode array detection. *Shipin Kexue (Beijing, China)* 2013;34(22):218-223.
891. Mabbott S, Eckmann A, Casiraghi C, Goodacre R. 2p or not 2p: Tuppence-based SERS for the detection of illicit materials. *Analyst* 2013;138(1):118-122. [Author's Note: Despite the unusual title, this is a legitimate scientific article.]
892. Niu Z-r, Zhang Q-s, Cao J, Gu X-z. Research of rapid detection for six chemical constituents illegally added into health foods for diet by UPLC-MS-MS. *Zhongguo Shiyan Fangjixue Zazhi* 2014;20(18):91-94.
893. Silva LMA, Filho EGA, Thomasi SS, Silva BF, Ferreira AG, Venancio T. Use of diffusion-ordered NMR spectroscopy and HPLC-UV-SPE-NMR to identify undeclared

- synthetic drugs in medicines illegally sold as phytotherapies. *Magnetic Resonance in Chemistry* 2013;51(9):541-548.
894. Soh YNA, Elliott S. An investigation of the stability of emerging new psychoactive substances. *Drug Testing and Analysis* 2013: Ahead of Print.
895. Tedesco D, Di Pietra AM, Rossi F, Garagnani M, Del Borrello E, Bertucci C, Andrisano V. Determination of dextromethorphan and levomethorphan in seized heroin samples by enantioselective HPLC and electronic CD. *Journal of Pharmaceutical and Biomedical Analysis* 2013;81-82:76-79.
896. Wan L, Wang D, Ding Y, Zheng Y. Study on the rapid identification of adulterants in health food with weight reducing function. *Zhongguo Yaoshi (Beijing, China)* 2013;27(12):1285-1290.
897. Zuba D, Byrska B. Prevalence and co-existence of active components of "legal highs." *Drug Testing and Analysis* 2013;5(6):420-429.
898. Acton WJ, Lanza M, Agarwal B, Juerschik S, Sulzer P, Breiev K, Jordan A, Hartungen E, Hanel G, Maerk L, Mayhew CA, Maerk TD. Headspace analysis of new psychoactive substances using a selective reagent ionisation-time of flight-mass spectrometer. *International Journal of Mass Spectrometry* 2014;360:28-38.
899. Boyle M, Carroll L, Clarke K, Clarke P, Coyle HJ, English H, Goff M, Kane E, Killoran S, O'Connor K. What's the deal? Trends in Irish street-level heroin and cocaine 2010-2012. *Drug Testing and Analysis* 2014;6(9):953-958.
900. Cao S, Yu W, Wang T, Shen H, Han X, Xu W, Zhang X. Meta-micro-windmill structure with multiple absorption peaks for the detection of ketamine and amphetamine type stimulants in teraHertz domain. *Optical Materials Express* 2014;4(9):1876-1884.
901. Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. *Forensic Science International* 2014;243:55-60.
902. Gardner EA. Identifying emerging drugs of abuse. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-801.
903. Gorakh WJ, Ahuja D, Angshu B. Development and validation of analytical methods for

- alprazolam and fluoxetine in pharmaceutical dosage form. *American Journal of PharmTech Research* 2014;4(1):1-15.
904. Li X-l, Zhang N, Wang W-l. Research progress on detecting residues of chlorpromazine and diazepam in foods. *Anhui Nongye Kexue* 2014;42(2):565-567,580.
905. Lin F, Li T, Guo J-b, Liu H-j, Zhu X-h, Mou X. Rapid inspection of 8 illegally adulterated chemical drugs in weight controlling health food by ultra-high performance liquid chromatography-photodiode array detector. *Shipin Keji* 2014;39(7):318-324.
906. Lini RS, Tomoike C, Froemming EdO, Bando E, Nogueira de Melo GA, Mossini SAG, Nishiyama P. Drugs characterization by thin layer chromatography. *Revista Brasileira de Farmacia* 2014;95(1):486-498.
907. Ostermann, KM, Luf A, Lutsch NM, Dieplinger R, Mechtler TP, Metz TF, Schmid R, Kasper DC. MALDI Orbitrap mass spectrometry for fast and simplified analysis of novel street and designer drugs. *Clinica Chimica Acta* 2014;433:254-258.
908. Parker P, Beers B, Vergne MJ. Development of a high-throughput LCMS method for the analysis of drugs on currency. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-380.
909. Power JD, Scott KR, Gardner EA, Curran McAteer BM, O'Brien JE, Brehon M, Talbot B, Kavanagh PV. The syntheses, characterization and in vitro metabolism of nitracaine, methoxypiperamide and mephtetramine. *Drug Testing and Analysis* 2014;6(7-8):668-675.
910. Porto SKSS, Nogueira T, Blanes L, Doble P, Sabino BD, do Lago CL, Angnes L. Analysis of ecstasy tablets using capillary electrophoresis with capacitively coupled contactless conductivity detection. *Journal of Forensic Sciences* 2014;59(6):1622-1626.
911. Soh YN, Elliott S. An investigation of the stability of emerging new psychoactive substances. *Drug Testing and Analysis* 2014;6(7-8):696-704.
912. Stojanovska N, Kelly T, Tahtouh M, Beavis A, Fu S. Analysis of amphetamine-type substances and piperazine analogues using desorption electrospray ionisation mass spectrometry. *Rapid Communications in Mass Spectrometry* 2014;28(7):731-740.

913. Strano Rossi S, Odoardi S, Gregori A, Peluso G, Ripani L, Ortar G, Serpelloni G, Romolo FS. An analytical approach to the forensic identification of different classes of new psychoactive substances (NPSs) in seized materials. *Rapid Communications in Mass Spectrometry* 2014;28(17):1904-1916.
914. Subhra H, Prakash D-N, Abhilasha D, Josep E-R, Devasish B. Simultaneous determination of psychoactive compounds in foodstuffs using micellar liquid chromatography with direct injection. *Journal of AOAC International* 2014;97(2):409-414.
915. Sultan M. Simultaneous HPLC determination and validation of amphetamine, methamphetamine, caffeine, paracetamol and theophylline in illicit seized tablets. *International Journal of Pharmacy and Pharmaceutical Sciences* 2014;6(4):294-298.
916. Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy- $\alpha$ -PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. *Forensic Toxicology* 2014;32(1):9-18.
917. Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T. Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. *Forensic Toxicology* 2014;32(2):266-281.
918. Zhu B, Meng L, Zheng K. Inspection and analysis of mixed drugs recently seized in China. *Forensic Science International* 2014;242:e44-e47.
919. Assi S, Guirguis A, Halsey S, Fergus S, Stair JL. Analysis of 'legal high' substances and common adulterants using handheld spectroscopic techniques. *Analytical Methods* 2015;7(2):736-746.
920. Bitter JL, Staymates ME, Fletcher RA, Gillen JG. Examining third hand smoke from illicit drugs as a potential source of recoverable trace evidence. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ANYL-116.
921. Bottoms J, Wang L, McCord B. Developing paper microfluidic devices to detect drugs of abuse. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO,

United States, March 22-26, 2015: CHED-279.

922. Broseus J, Gentile N, Bonadio Pont F, Garcia Gongora JM, Gaste L, Esseiva P. Qualitative, quantitative and temporal study of cutting agents for cocaine and heroin over 9 years. *Forensic Science International* 2015;257:307-313.
923. Cecinato A, Balducci C, Perilli M, Krejci R, Johansson C, Green DC, Panteliadis P. Illicit drugs in the air of three Northern European cities. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ENVR-494.
924. Cecinato A, Balducci C, Perilli M, Romagnoli P. Illicit drugs in the indoor air. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ENVR-495.
925. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States. *New England Journal of Medicine* 2015;372(3):241-248.
926. Dujourdy L, Charvoz C, Dalmaso M, Dufour A-B. What a validation strategy means for the quantitation of cocaine and heroin? *Forensic Science International* 2015;251:32-39.
927. Gardner E. Identification of emerging drugs of abuse. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: CHAL-46.
928. Ilbeigi V, Tabrizchi M. Thin layer chromatography - ion mobility spectrometry (TLC-IMS). *Analytical Chemistry* 2015;87(1):464-469.
929. Jagerdeo E, Clark JA, Leibowitz JN, Reda LJ. Rapid analysis of forensic samples using an atmospheric solid analysis probe interfaced to a linear ion trap mass spectrometer. *Rapid Communications in Mass Spectrometry* 2015;29(2):205-212.
930. Kaizaki-Mitsumoto A, Noguchi N, Yamaguchi S, Odanaka Y, Matsubayashi S, Kumamoto H, Fukuhara K, Funada M, Wada K, Numazawa S. Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market. *Forensic Toxicology* 2015: Ahead of Print.

931. Massarini E, Wasterby P, Landstrom L, Lejon C, Beck O, Andersson PO. Methodologies for assessment of limit of detection and limit of identification using surface-enhanced Raman spectroscopy. *Sensors and Actuators, B: Chemical* 2015;207(Part A):437-446.
932. Mastroianni N, Postigo C, Lopez de Alda M, Viana M, Rodriguez A, Alastuey A, Querol X, Barcelo D. Comprehensive monitoring of the occurrence of 22 drugs of abuse and transformation products in airborne particulate matter in the city of Barcelona. *Science of the Total Environment* 2015;532:344-352.
933. Mohsen Y, Gharbi N, Lenouvel A, Guignard C. Detection of  $\Delta^9$ -tetrahydrocannabinol, methamphetamine and amphetamine in air at low ppb level using a field asymmetric ion mobility spectrometry microchip sensor. *Procedia Engineering* 2014;87:536-539.
934. Musile G, Wang L, Bottoms J, Tagliaro F, McCord B. The development of paper microfluidic devices for presumptive drug detection. *Analytical Methods* 2015: Ahead of Print.
935. Nascimento IR, Costa HB, Souza LM, Soprani LC, Merlo BB, Romao W. Chemical identification of cannabinoids in street marijuana samples using electrospray ionization FTICR mass spectrometry. *Analytical Methods* 2015;7(4):1415-1424.
936. Nash DJ, Blair RG. Fluorescent d10 metal complexes for the presumptive identification of substances of abuse and the implementation of a cell phone fluorimeter for field identification. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: INOR-915.
937. Racamonde I, Quintana JB, Rodil R, Cela R. Application of polypropylene tubes as single-use and low-cost sorptive extraction materials for the determination of benzodiazepines and zolpidem in water samples. *Microchemical Journal* 2015;119:58-65.
938. Strano-Rossi S, Odoardi S, Castrignano E, Serpelloni G, Chiarotti M. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) determination of stimulants, anorectic drugs and phosphodiesterase-5 inhibitors (PDE5I) in food supplements. *Journal of Pharmaceutical and Biomedical Analysis* 2015;106:144-152.
939. Thakkar R, Saravaia H, Shah A. Determination of antipsychotic drugs known for narcotic action by ultra performance liquid chromatography. *Analytical Chemistry Letters* 2015;5(1):1-11.

940. Thapliyal N, Patel H, Karpoormath R, Goyal RN, Patel R. A categorical review on electroanalytical determination of non-narcotic over-the-counter abused antitussive drugs. *Talanta* 2015;142:157-163.
941. Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T. A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids ABCHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N-OHEDMA, and a cathinone derivative dimethoxy- $\alpha$ -PHP, newly identified in illegal products. *Forensic Toxicology* 2015: Ahead of Print.
942. Usmanov DT, Saha S, Chuin CL, Ninomiya S, Mandal MK, Hiraoka K. Probe electrospray ionization mass spectrometry with discontinuous atmospheric pressure interface. *European Journal of Mass Spectrometry* 2015;21(3):327-334.
943. Wang T-j, Han D-q, Lu Y, Yin G, Yan Y, Li X-q, Wang J, Jiang K, Fu X-s, Zhang Q-y. HPLC determination of 17 additive chemical components in traditional Chinese medicines and health food. *Yaowu Fenxi Zazhi* 2015;35(7):1223-1230.
944. Wu M, Xiang J, Que C, Chen F, Xu G. Occurrence and fate of psychiatric pharmaceuticals in the urban water system of Shanghai, China. *Chemosphere* 2015;138:486-493.
945. Balbino MA, Oiye EN, Ribeiro MFM, Junior JWC, Eleoterio IC, Ipolito AJ, de Oliveira MF. Use of screen-printed electrodes for quantification of cocaine and  $\Delta$ 9-THC: Adaptions to portable systems for forensic purposes. *Journal of Solid State Electrochemistry* 2016: Ahead of Print.
946. Bitter JL. The persistence of illicit drug smoke residues and their recovery from common household surfaces. *Drug Testing and Analysis* 2016: Ahead of Print.
947. Broseus J, Baechler S, Gentile N, Esseiva P. Chemical profiling: A tool to decipher the structure and organisation of illicit drug markets. *Forensic Science International* 2016;266:18-28.
948. Broseus J, Gentile N, Esseiva P. The cutting of cocaine and heroin: A critical review. *Forensic Science International* 2016;262:73-83.
949. Elie L, Elie M, Cave G, Vetter M, Croxton R, Baron M. Microcrystalline testing used in combination with Raman micro-spectroscopy for absolute identification of novel psychoactive substances. *Journal of Raman Spectroscopy* 2016: Ahead of Print.

950. Fan T, Xu W, Yao J, Jiao Z, Fu Y, Zhu D, He Q, Cao H, Cheng J. Naked-eye visible solid illicit drug detection at picogram level via a multiple-anchored fluorescent probe. *ACS Sensors* 2016:Ahead of Print.
951. Forbes TP, Najarro M. Ion mobility spectrometry nuisance alarm threshold analysis for illicit narcotics based on environmental background and a ROC-curve approach. *Analyst* 2016:Ahead of Print.
952. Gobble C, Walker B, Chickos JS. The vaporization enthalpy and vapor pressure of fenpropidin and phencyclidine (PCP) at  $T/K = 298.15$  by correlation gas chromatography. *Journal of Chemical & Engineering Data* 2016;61(2):896-902.
953. Jafari-Nodoushan M, Barzin J, Mobedi H. A stability-indicating HPLC method for simultaneous determination of morphine and naltrexone. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 2016;1011:163-170.
954. Liu C, Jia W, Qian Z, Li T, Hua Z. Identification of five substituted phenethylamine derivatives 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APBNBOMe. *Drug Testing and Analysis* 2016:Ahead of Print.
955. Peltenburg H, Timmer N, Bosman IJ, Hermens JLM, Droge STJ. Sorption of structurally different ionized pharmaceutical and illicit drugs to a mixed-mode coated micro-sampler. *Journal of Chromatography A* 2016;1447:1-8.
956. Snyder DT, Pulliam CJ, Cooks RG. Single analyzer precursor scans using an ion trap. *Rapid Communications in Mass Spectrometry* 2016;30(7):800-804.
957. Uchiyama N, Kikura-Hanajiri R, Hakamatsuka T. A phenethylamine derivative 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(3,4-methylenedioxyphenyl)methyl]ethanamine (25INB34MD) and a piperazine derivative 1-(3,4-difluoromethylenedioxybenzyl)-piperazine (DFMDBP), newly detected in illicit products. *Forensic Toxicology* 2016;34(1):166-173.
958. Sundström M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanperä I. A high sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. *Analytical and Bioanalytical Chemistry* 2013:Ahead of Print.

959. Swortwood MJ, Boland DM, DeCaprio AP. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. *Analytical and Bioanalytical Chemistry* 2013;405(4):1383-1397.
960. Armenta S, Garrigues S, Guardia M, Brassier J, Alcalá M, Blanco M, Perez-Alfonso C, Galipienso N. Detection and characterization of emerging psychoactive substances by ion mobility spectrometry. *Drug Testing and Analysis* 2014: Ahead of Print.
961. Cottencin O, Rolland B, Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): Review of literature. *Current Pharmaceutical Design* 2014;20(25):4106-4111.
962. Drozd J. TLC of psychostimulants. *Chromatographic Science Series* 2014;106(Thin Layer Chromatography in Drug Analysis):399-436.
963. Gwak S, Arroyo-Mora LE, Almirall JR. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry. *Drug Testing and Analysis* 2015;7(2):121-130.
964. Li L, Lurie IS. Screening of seized emerging drugs by ultra-high performance liquid chromatography with photodiode array ultraviolet and mass spectrometric detection. *Forensic Science International* 2014;237:100-111.
965. Natic MM. Thin-layer chromatography of anesthetics. *Chromatographic Science Series* 2014;106(Thin Layer Chromatography in Drug Analysis):355-398.
966. Rasanen I, Kyber M, Szilvay I, Rintatalo J, Ojanpera I. Straightforward single-calibrant quantification of seized designer drugs by liquid chromatography-chemiluminescence nitrogen detection. *Forensic Science International* 2014;237:119-125.
967. Spilstead KB, Learey JJ, Doeven EH, Barbante GJ, Mohr S, Barnett NW, Terry JM, Hall RM, Francis PS. 3D-Printed and CNC milled flow-cells for chemiluminescence detection. *Talanta* 2014;126:110-115.
968. Swortwood MJ, Hearn WL, DeCaprio AP. Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays. *Drug Testing and Analysis* 2014;6(7-8):716-727.
969. Taschwer M, Hofer MG, Schmid MG. Enantioseparation of benzofurans and other novel

- psychoactive compounds by CE and sulfobutylether  $\beta$ -cyclodextrin as chiral selector added to the BGE. *Electrophoresis* 2014;35(19):2793-2799.
970. Temerdashev AZ, Grigor'ev IM, Rybal'chenko AM. Evolution of new narcotic substances and methods of their determination. *Journal of Analytical Chemistry* 2014;69(9):817-844.
971. Brandt SD, Elliott SP, Kavanagh PV, Dempster NM, Meyer MR, Maurer HH, Nichols DE. Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. *Rapid Communications in Mass Spectrometry* 2015;29(7):573-584.
972. Fowler F, Huang L. Rapid identification of designer drugs with NMR spectroscopy. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHED-272.
973. Hashimoto N. Toxicology and management of designer drugs. *Igaku no Ayumi* 2015;254(2):167-171.
974. Li L, Lurie IS. Regioisomeric and enantiomeric analyses of 24 designer cathinones and phenethylamines using ultra high performance liquid chromatography and capillary electrophoresis with added cyclodextrins. *Forensic Science International* 2015;254:148-157.
975. Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. *Forensic Toxicology* 2015: Ahead of Print.
976. Regester LE, Chmiel JD, Holler JM, Vorce SP, Levine B, Bosy TZ. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits. *Journal of Analytical Toxicology* 2015;39(2):144-151.
977. Stankova M, Jandera P. Dual retention mechanism in two-dimensional LC separations of barbiturates, sulfonamides, nucleic bases and nucleosides on polymethacrylate zwitterionic monolithic micro-columns. *Chromatographia* 2016: Ahead of Print.
978. Andriolo DSM, da Cunha LH, Santana AS, Sampaio ME, Valenzuela VdCT, Duarte MGR, Garcia EdF. Investigation on the occurrence of anorexigens, benzodiazepines and antidepressants in the weight-loss phytotherapy formulations. *Revista do Instituto Adolfo*

Lutz 2012;71(1):148-152.

979. Haneef J, Shaharyar M, Husain A, Rashid M, Mishra R, Siddique NA, Pal M. Analytical methods for the detection of undeclared synthetic drugs in traditional herbal medicines as adulterants. *Drug Testing and Analysis* 2013;5(8):607-613.
980. Monakhova YB, Kuballa T, Loebell-Behrends S, Maixner S, Kohl-Himmelseher M, Ruge W, Lachenmeier DW. Standardless 1H NMR determination of pharmacologically active substances in dietary supplements and medicines that have been illegally traded over the internet. *Drug Testing and Analysis* 2013;5(6):400-411.
981. Cho S-H, Park HJ, Lee JH, Kim HJ, Cho S, Yoon C-Y, Kim WS. Monitoring of 35 illegally added steroid compounds in foods and dietary supplements. *Food Additives & Contaminants, Part A: Chemistry, Analysis, Control, Exposure & Risk Assessment* 2014;31(9):1470-1475.
982. Kim HJ, Lee JH, Park HJ, Cho S-H, Cho S, Kim WS. Monitoring of 29 weight loss compounds in foods and dietary supplements by LC-MS/MS. *Food Additives & Contaminants, Part A: Chemistry, Analysis, Control, Exposure & Risk Assessment* 2014;31(5):777-783.
983. Moreira APL, Martini M, Carvalho LM. Capillary electrophoretic methods for the screening and determination of pharmacologic adulterants in herbal-based pharmaceutical formulations. *Electrophoresis* 2014;35(21-22):3212-3230.
984. Pan X-h. Rapid identification of 22 drugs illegally added into sleep-improving health foods by ultra performance liquid chromatography/time-of-flight mass spectrometry method. *Shipin Anquan Zhiliang Jiance Xuebao* 2014;5(5):1524-1532.
985. Choi JY, Heo S, Yoo GJ, Park S-K, Yoon C-Y, Baek SY. Development and validation of an LC-MS/MS method for the simultaneous analysis of 28 specific narcotic adulterants used in dietary supplements. *Food Additives & Contaminants, Part A: Chemistry, Analysis, Control, Exposure & Risk Assessment* 2015: Ahead of Print.
986. Jia C, Zhang Y, Chen L, Min C, Gu B. Analysis of chemicals illegally added into sedative-hypnotic health foods by UPLC-ESI-Q-TOF/MS. *Zhongguo Yaoshi* 2015;18(7):1129-1132,1135.
987. Lu L, Gong X, Tan L. Fast screening of 24 sedative hypnotics illegally added in

- improving sleep health foods by high performance liquid chromatography-ion trap mass spectrometry. *Sepe* 2015;33(3):256-266.
988. Ou B-l, Zhang H-w, Xu H-x. UPLC-MS/MS determination of 36 chemicals added into traditional Chinese medicines and health care products. *Yaowu Fenxi Zazhi* 2013;33(12):2141-2147.
989. Quan Q-b, Wang J-f, Li N, Li J-q, Chen J-q. Substitute reference substance and secondary mass spectral libraries for rapid screening of sedative hypnotic drugs illegally added in Chinese patent drugs and health products. *Yaowu Fenxi Zazhi* 2015;35(1):154-160.
990. Ranjitha D, Sudha K. Alkaloids in foods. *International Journal of Pharmaceutical, Chemical and Biological Sciences* 2015;5(4):896-906.
991. Viana C, Zemolin GM, Muller LS, Dal Molin TR, Seiffert H, de Carvalho LM. Liquid chromatographic determination of caffeine and adrenergic stimulants in food supplements sold in Brazilian e-commerce for weight loss and physical fitness. *Food Additives & Contaminants, Part A* 2015: Ahead of Print.
992. Xu S, Jin P-f, Xu Q-l, Lu X-c, He X-r. Advances in the chemical substances illegally adulterated in traditional Chinese medicines and health foods. *Zhongguo Xinyao Zazhi* 2015;24(16):1843-1850.
993. Black C, Haughey SA, Chevallier OP, Galvin-King P, Elliott CT. A comprehensive strategy to detect the fraudulent adulteration of herbs: The oregano approach. *Food Chemistry* 2016;210:551-557.
994. Liu Y, Ding T, Liao X-q, Shen C-y, Jiang S, Lu C, Gui Q-w, Liu H, Fei X-q, Wu B, Zhang R, Wang Y, Ji M-q, Wang X-l, Huang Z-q. Direct determination of 42 chemical drugs illegally added in herbal medicines and dietary supplement by high performance liquid chromatography-quadrupole/electrostatic field orbitrap high resolution mass spectrometry. *Fenxi Huaxue* 2016;44(3):423-429.
995. Pawar RS, Grundel E. Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs). *Drug Testing and Analysis* 2016: Ahead of Print.
996. Sisco E, Dake J. Detection of low molecular weight adulterants in beverages by direct

- analysis in real time mass spectrometry. *Analytical Methods* 2016;8(14):2971-2978.
997. Skalicka-Wozniak K, Georgiev MI, Orhan IE. Adulteration of herbal sexual enhancers and slimmers: The wish for better sexual well-being and perfect body can be risky. *Food and Chemical Toxicology* 2016: Ahead of Print.
998. Maldaner AO, Schmidt LL, Locatelli MAF, Jardim WF, Sodre FF, Almeida FV, Pereira CEB, Silva CM. Estimating cocaine consumption in the Brazilian Federal District (FD) by sewage analysis. *Journal of the Brazilian Chemical Society* 2012;23(5):861-867.
999. Castiglioni S, Bijlsma L, Covaci A, Emke E, Hernandez F, Reid M, Ort C, Thomas KV, van Nuijs ALN, de Voogt P, Zuccato E. Evaluation of uncertainties associated with the determination of community drug use through the measurement of sewage drug biomarkers. *Environmental Science & Technology* 2013;47(3):1452-1460.
1000. Chen C, Kostakis C, Irvine RJ, White JM. Increases in use of novel synthetic stimulants are not directly linked to decreased use of 3,4-methylenedioxy-N-methylamphetamine (MDMA). *Forensic Science International* 2013;231(1-3):278-283.
1001. Feitosa RS, Sodre FF, Maldaner AO. Drugs of abuse in waters and wastewaters: Occurrence, analytical determination and forensic applications. *Quimica Nova* 2013;36(2):291-305.
1002. Fenech C, Nolan K, Rock L, Morrissey A. An SPE LC-MS/MS method for the analysis of human and veterinary chemical markers within surface waters: An environmental forensics application. *Environmental Pollution* 2013;181:250-256.
1003. Fontanals N, Borrull F, Marce RM. On-line weak cationic mixed-mode solid-phase extraction coupled to liquid chromatography - mass spectrometry to determine illicit drugs at low concentration levels from environmental waters. *Journal of Chromatography A* 2013;1286:16-21.
1004. Mwenesongole EM, Gautam L, Hall SW, Waterhouse JW, Cole MD. Simultaneous detection of controlled substances in waste water. *Analytical Methods* 2013;5(13):3248-3254.
1005. Pascual Aguilar JA, Andreu V, Vazquez P, Pico Y. Presence and spatial distribution of emerging contaminants (drugs of abuse) in protected agroecological systems (L'Albufera de Valencia Coastal Wetland, Spain). *Environmental Earth Sciences* 2013: Ahead of

Print.

1006. Vuori E, Happonen M, Gergov M, Nenonen T, Jarvinen A, Ketola RA, Vahala R. Wastewater analysis reveals regional variability in exposure to abused drugs and opioids in Finland. *Science of the Total Environment* 2013: Ahead of Print.
1007. Al-Qaim FF, Abdullah MP, Othman MR. Multi-residue analysis method for analysis of pharmaceuticals using liquid chromatography-time of flight/mass spectrometry (LC-TOF/MS) in water sample. *AIP Conference Proceedings* 2014: Ahead of Print.
1008. Andres-Costa MJ, Rubio-Lopez N, Morales Suarez-Varela M, Pico Y. Occurrence and removal of drugs of abuse in wastewater treatment plants of Valencia (Spain). *Environmental Pollution* 2014;194:152-162.
1009. Baker DR, Barron L, Kasprzyk-Hordern B. Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part A: Chemical analysis and drug use estimates. *Science of the Total Environment* 2014;487:629-641.
1010. Been F, Rossi L, Ort C, Rudaz S, Delemont O, Esseiva P. Population normalization with ammonium in wastewater-based epidemiology: Application to illicit drug monitoring. *Environmental Science & Technology* 2014;48(14):8162-8169.
1011. Biavardi E, Federici S, Tudisco C, Menozzi D, Massera C, Sottini A, Condorelli GG, Bergese P, Dalcanale E. Cavitand-grafted silicon microcantilevers as a universal probe for illicit and designer drugs in water. *Angewandte Chemie, International Edition* 2014;53(35):9183-9188.
1012. Bijlsma L, Beltran E, Boix C, Sancho JV, Hernandez F. Improvements in analytical methodology for the determination of frequently consumed illicit drugs in urban wastewater. *Analytical and Bioanalytical Chemistry* 2014;406(17):4261-4272.
1013. Bletsou AA, Psoma AK, Gago Ferrero P, Thomaidis NS. Targeted determination of 1525 micropollutants and transformation products in wastewater by liquid chromatography quadrupole-time-of-flight mass spectrometry with an accurate-mass database. *Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ENVR-553.*
1014. Boleda MR, Alechaga E, Moyano E, Galceran MT, Ventura F. Survey of the occurrence of pharmaceuticals in Spanish finished drinking waters. *Environmental Science and*

Pollution Research 2014;21(18):10917-10939.

1015. Borova VL, Maragou NC, Gago-Ferrero P, Pistos C, Thomaidis NS. Highly sensitive determination of 68 psychoactive pharmaceuticals, illicit drugs, and related human metabolites in wastewater by liquid chromatography-tandem mass spectrometry. *Analytical and Bioanalytical Chemistry* 2014;406(17):4273-4285.
1016. Botero-Coy AM, Bijlsma L, Bade R, Ibanez M, Bustos MC, Rincon RJ, Moncayo A, Sancho JV, Hernandez F. Screening of illicit and licit drugs in waters from Colombia making use of liquid chromatography-hybrid quadrupole-time-of-flight mass spectrometry. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ENVR-722.
1017. Carmona E, Andreu V, Pico Y. Occurrence of acidic pharmaceuticals and personal care products in Turia River Basin: From waste to drinking water. *Science of the Total Environment* 2014;484:53-63.
1018. Castiglioni S, Griffiths P, Kasprzyk-Hordern B, Me A, Thomas KV. Special issue. Testing the waters: A selection of papers from the first international multidisciplinary conference on detecting illicit drugs in wastewater. *Science of the Total Environment* 2014;487:611-612.
1019. Damien DA, Thomas N, Helene P, Sara K, Yves L. First evaluation of illicit and licit drug consumption based on wastewater analysis in Fort de France urban area (Martinique, Caribbean), a transit area for drug smuggling. *Science of the Total Environment* 2014;490:970-978.
1020. El-Didamony AM, Khater HM, Ali II. New sensitive bromatometric assay methods for the determination of four analgesic drugs in pharmaceutical formulations and biological fluids. *Journal of Pharmaceutical Education and Research* 2013;4(1):54-63.
1021. Evans SE, Kasprzyk-Hordern B. Applications of chiral chromatography coupled with mass spectrometry in the analysis of chiral pharmaceuticals in the environment. *Trends in Environmental Analytical Chemistry* 2014;1:e34-e51.
1022. Fedorova G, Randak T, Golovko O, Kodes V, Grabicova K, Grabic R. A passive sampling method for detecting analgesics, psycholeptics, antidepressants and illicit drugs in aquatic environments in the Czech Republic. *Science of the Total Environment* 2014;487:681-687.

1023. Fontanals N, Miralles N, Abdullah N, Davies A, Gilart N, Cormack PAG. Evaluation of strong cation-exchange polymers for the determination of drugs by solid-phase extraction - liquid chromatography-tandem mass spectrometry. *Journal of Chromatography A* 2014;1343:55-62.
1024. Frederic O, Yves P. Pharmaceuticals in hospital wastewater: Their ecotoxicity and contribution to the environmental hazard of the effluent. *Chemosphere* 2014;115:31-39.
1025. Greenhagen AM, Lenczewski ME, Carroll M. Natural attenuation of pharmaceuticals and an illicit drug in a laboratory column experiment. *Chemosphere* 2014;115:13-19.
1026. Hernandez F, Ibanez M, Bade R, Bijlsma L, Sancho JV. Investigation of pharmaceuticals and illicit drugs in waters by liquid chromatography-high-resolution mass spectrometry. *TrAC, Trends in Analytical Chemistry* 2014;63:140-157.
1027. Heuett NV, Ramirez CE, Batchu SR, Gardinali P. Communal assessment of drugs of abuse and identification of their transformation products by online SPE-LC-HRMS. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ENVR-860.
1028. Jones HE, Hickman M, Kasprzyk-Hordern B, Welton NJ, Baker DR, Ades AE. Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part B: Placing back-calculations in a formal statistical framework. *Science of the Total Environment* 2014;487:642-650.
1029. Jones-Lepp T. Occurrence, effects, and methods for antibiotics and illicit drugs in the environment. *Pharmaceutical Accumulation in the Environment* 2014:43-63.
1030. Khan U, van Nuijs ALN, Li J, Maho W, Du P, Li K, Hou L, Zhang J, Meng X, Li X, Covaci A. Application of a sewage-based approach to assess the use of ten illicit drugs in four Chinese megacities. *Science of the Total Environment* 2014;487:710-721.
1031. Kim I, Tanaka H. International management trend of pharmaceuticals and personal care products (PPCPs) in water environment. *Yosui to Haisui* 2014;56(6):421-429.
1032. Lambropoulou DA, Evgenidou E. Transformation products of illicit drugs. *Transformation Products of Emerging Contaminants in the Environment* 2014;2:493-523.
1033. Li J, Hou L, Du P, Yang J, Li K, Xu Z, Wang C, Zhang H, Li X. Estimation of

- amphetamine and methamphetamine uses in Beijing through sewage-based analysis. *Science of the Total Environment* 2014;490:724-732.
1034. Lv M, Sun Q, Hu A, Hou L, Li J, Cai X, Yu C-P. Pharmaceuticals and personal care products in a mesoscale subtropical watershed and their application as sewage markers. *Journal of Hazardous Materials* 2014;280:696-705.
1035. Mackul'ak T, Skubak J, Grabic R, Drtil M, Bodik I. Comparison of illicit drug use in three selected towns in Slovakia by wastewater analysis. *Urban Water Journal* 2014: Ahead of Print.
1036. Masia A, Campo J, Blasco C, Pico Y. Ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry to identify contaminants in water: An insight on environmental forensics. *Journal of Chromatography A* 2014;1345:86-97.
1037. Mastroianni N, Lopez de Alda M, Barcelo D. Analysis of ethyl sulfate in raw wastewater for estimation of alcohol consumption and its correlation with drugs of abuse in the city of Barcelona. *Journal of Chromatography A* 2014;1360:93-99.
1038. Meffe R, de Bustamante I. Emerging organic contaminants in surface water and groundwater: A first overview of the situation in Italy. *Science of the Total Environment* 2014;481:280-295.
1039. Nowicki P, Klos J, Kokot ZJ. Amphetamines in wastewater of the city Poznan (Poland). Estimation of drug abuse. *Acta Poloniae Pharmaceutica* 2014;71(1):25-33.
1040. Prichard J, Hall W, de Voogt P, Zuccato E. Sewage epidemiology and illicit drug research: The development of ethical research guidelines. *Science of the Total Environment* 2014;472:550-555.
1041. Racamonde I, Rodil R, Quintana JB, Villaverde-de-Saa E, Cela R. Determination of benzodiazepines, related pharmaceuticals and metabolites in water by solid-phase extraction and liquid-chromatography-tandem mass spectrometry. *Journal of Chromatography A* 2014;1352:69-79.
1042. Reid MJ, Baz-Lomba JA, Ryu Y, Thomas KV. Using biomarkers in wastewater to monitor community drug use: A conceptual approach for dealing with new psychoactive substances. *Science of the Total Environment* 2014;487:651-658.

1043. Robles-Molina J, Lara-Ortega FJ, Gilbert-Lopez B, Garcia-Reyes JF, Molina-Diaz A. Multi-residue method for the determination of over 400 priority and emerging pollutants in water and wastewater by solid-phase extraction and liquid chromatography - time-of-flight mass spectrometry. *Journal of Chromatography A* 2014;1350:30-43.
1044. Rodayan A, Majewsky M, Yargeau V. Impact of approach used to determine removal levels of drugs of abuse during wastewater treatment. *Science of the Total Environment* 2014;487:731-739.
1045. Thomas KV, Araujo da Silva FM, Langford KH, Leao de Souza AD, Nizzeto L, Waichman AV. Screening for selected human pharmaceuticals and cocaine in the urban streams of Manaus, Amazonas, Brazil. *Journal of the American Water Resources Association* 2014;50(2):302-308.
1046. Zhou H, Zhang Q, Wang X, Zhang Q, Ma L, Zhan Y. Systematic screening of common wastewater-marking pharmaceuticals in urban aquatic environments: Implications for environmental risk control. *Environmental Science and Pollution Research* 2014;21(11):7113-7129.
1047. Acuna V, von Schiller D, Garcia-Galan MJ, Rodriguez-Mozaz S, Corominas L, Petrovic M, Poch M, Barcelo D, Sabater S. Occurrence and in-stream attenuation of wastewater-derived pharmaceuticals in Iberian rivers. *Science of the Total Environment* 2015;503-504:133-141.
1048. Arbelaez P, Borrull F, Pocurull E, Marce RM. Liquid chromatography-tandem mass spectrometry to determine sedative hypnotic drugs in river water and wastewater. *International Journal of Environmental Analytical Chemistry* 2015;95(8):669-684.
1049. Bade R, Rousis NI, Bijlsma L, Gracia-Lor E, Castiglioni S, Sancho JV, Hernandez F. Screening of pharmaceuticals and illicit drugs in wastewater and surface waters of Spain and Italy by high resolution mass spectrometry using UHPLC-QTOF MS and LC-LTQ-Orbitrap MS. *Analytical and Bioanalytical Chemistry* 2015: Ahead of Print.
1050. Been F, Benaglia L, Lucia S, Gervasoni J-P, Esseiva P, Delemont O. Data triangulation in the context of opioids monitoring via wastewater analyses. *Drug and Alcohol Dependence* 2015: Ahead of Print.
1051. Boix C, Ibanez M, Sancho JV, Rambla J, Aranda JL, Ballester S, Hernandez F. Fast determination of 40 drugs in water using large volume direct injection liquid

- chromatography - tandem mass spectrometry. *Talanta* 2015;131:719-727.
1052. Borova VL, Gago-Ferrero P, Pistos C, Thomaidis NS. Multi-residue determination of 10 selected new psychoactive substances in wastewater samples by liquid chromatography-tandem mass spectrometry. *Talanta* 2015;144:592-603.
1053. Castiglioni S, Borsotti A, Senta I, Zuccato E. Wastewater analysis to monitor spatial and temporal patterns of use of two synthetic recreational drugs, ketamine and mephedrone, in Italy. *Environmental Science & Technology* 2015;49(9):5563-5570.
1054. Du P, Li K, Li J, Xu Z, Fu X, Yang J, Zhang H, Li X. Methamphetamine and ketamine use in major Chinese cities, a nationwide reconnaissance through sewage-based epidemiology. *Water Research* 2015;84:76-84.
1055. Gosetti F, Mazzucco E, Gennaro MC, Marengo E. Contaminants in water: Non-target UHPLC/MS analysis. *Environmental Chemistry Letters* 2015: Ahead of Print.
1056. Hapeshi E, Gros M, Lopez-Serna R, Boleda M-R, Ventura F, Petrovic M, Barcelo D, Fatta-Kassinos D. Licit and illicit drugs in urban wastewater in Cyprus. *Clean: Soil, Air, Water* 2015: Ahead of Print.
1057. Hernandez F, Ibanez M, Botero-Coy A-M, Bade R, Bustos-Lopez MC, Rincon J, Moncayo A, Bijlsma L. LC-QTOF MS screening of more than 1,000 licit and illicit drugs and their metabolites in wastewater and surface waters from the area of Bogota, Colombia. *Analytical and Bioanalytical Chemistry* 2015: Ahead of Print.
1058. Heuett NV, Ramirez CE, Fernandez A, Gardinali PR. Analysis of drugs of abuse by online SPE-LC high resolution mass spectrometry: Communal assessment of consumption. *Science of the Total Environment* 2015;511:319-330.
1059. Hernandez F, Sancho JV, Ibanez M, Portoles T. Advancing towards universal screening for organic micro-pollutants in waters by combined use of GC and LC coupled to HRMS. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ENVR-215.
1060. Hernandez F, Ibanez M, Portoles T, Cervera MI, Sancho JV, Lopez FJ. Advancing towards universal screening for organic pollutants in waters. *Journal of Hazardous Materials* 2015;282:86-95.

1061. Heuett NV, Batchu SR, Gardinali PR. Understanding the magnitude of emergent contaminant releases through target screening and metabolite identification using high resolution mass spectrometry: Illicit drugs in raw sewage influents. *Journal of Hazardous Materials* 2015;282:41-50.
1062. Jiang J-J, Lee C-L, Brimblecombe P, Vydrova L, Fang M-D. Source contributions and mass loadings for chemicals of emerging concern: Chemometric application of pharmacosignature in different aquatic systems. *Environmental Pollution* 2015: Ahead of Print.
1063. Kinyua J, Covaci A, Maho W, McCall A-K, Neels H, van Nuijs ALN. Sewage-based epidemiology in monitoring the use of new psychoactive substances: Validation and application of an analytical method using LC-MS/MS. *Drug Testing and Analysis* 2015: Ahead of Print.
1064. Lai FY, Anuj S, Bruno R, Carter S, Gartner C, Hall W, Kirkbride KP, Mueller JF, O'Brien JW, Prichard J, Thai PK, Ort C. Systematic and day-to-day effects of chemical-derived population estimates on wastewater-based drug epidemiology. *Environmental Science & Technology* 2015;49(2):999-1008.
1065. Mackulak T, Mosny M, Grabic R, Golovko O, Koba O, Birosova L. Fenton-like reaction: A possible way to efficiently remove illicit drugs and pharmaceuticals from wastewater. *Environmental Toxicology and Pharmacology* 2015;39(2):483-488.
1066. Meyer MR, Vollerthun T, Hasselbach R. Prevalence and distribution patterns of amphetamine and methamphetamine consumption in a federal state in southwestern Germany using wastewater analysis. *Drug and Alcohol Dependence* 2015: Ahead of Print.
1067. Mueller JF, Oh J-E. The first application of wastewater-based drug epidemiology in five South Korean cities. *Science of the Total Environment* 2015: Ahead of Print.
1068. Petrie B, Camacho-Munoz D, Castrignano E, Evans S, Kasprzyk-Hordern B. Chiral liquid chromatography coupled with tandem mass spectrometry for environmental analysis of pharmacologically active compounds. *LC-GC Europe* 2015;28(3):151-152.
1069. Prunyn MR, Gardinali PR. Detection of designer drugs and relevant metabolites in raw sewage samples using high resolution mass spectrometry. *Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ANYL-77.*

1070. Rodayan A, Afana S, Segura PA, Sultana T, Metcalfe CD, Yargeau V. Linking drugs of abuse in wastewater to contamination of surface and drinking water. *Environmental Toxicology and Chemistry* 2015: Ahead of Print.
1071. Rodriguez-Alvarez T, Racamonde I, Gonzalez-Marino I, Borsotti A, Rodil R, Rodriguez I, Zuccato E, Quintana JB, Castiglioni S. Alcohol and cocaine co-consumption in two European cities assessed by wastewater analysis. *Science of the Total Environment* 2015;536:91-98.
1072. Salvatore S, Bramness JG, Reid MJ, Thomas KV, Harman C, Roeislien J. Wastewater-based epidemiology of stimulant drugs: Functional data analysis compared to traditional statistical methods. *PLoS One* 2015;10(9):e0138669/1-e0138669/14.
1073. Senta I, Krizman I, Ahel M, Terzic S. Multiresidual analysis of emerging amphetamine-like psychoactive substances in wastewater and river water. *Journal of Chromatography A* 2015: Ahead of Print.
1074. Tschärke BJ, Chen C, Gerber JP, White JM. Trends in stimulant use in Australia: A comparison of wastewater analysis and population surveys. *Science of the Total Environment* 2015;536:331-337.
1075. Voloshenko-Rossin A, Gasser G, Cohen K, Gun J, Cumbal-Flores L, Parra-Morales W, Sarabia F, Ojeda F, Lev O. Emerging pollutants in the Esmeraldas watershed in Ecuador: Discharge and attenuation of emerging organic pollutants along the San Pedro-Guayllabamba-Esmeraldas rivers. *Environmental Science: Processes & Impacts* 2015;17(1):41-53.
1076. Zuccato E, Castiglioni S, Senta I, Borsotti A, Genetti B, Andreotti A, Pieretti G, Serpelloni G. Population surveys compared with wastewater analysis for monitoring illicit drug consumption in Italy in 2010-2014. *Drug and Alcohol Dependence* 2016: Ahead of Print.
1077. Aalizadeh R, Thomaidis NS, Bletsou AA, Gago-Ferrero P. Quantitative structure-retention relationship models to support nontarget high-resolution mass spectrometric screening of emerging contaminants in environmental samples. *Journal of Chemical Information and Modeling* 2016: Ahead of Print.
1078. Alygizakis NA, Gago-Ferrero P, Borova VL, Pavlidou A, Hatzianestis I, Thomaidis NS. Occurrence and spatial distribution of 158 pharmaceuticals, drugs of abuse and related

- metabolites in offshore seawater. *Science of the Total Environment* 2016;541:1097-1105.
1079. Baena-Nogueras RM, Pintado-Herrera MG, Gonzalez-Mazo E, Lara-Martin PA. Determination of pharmaceuticals in coastal systems using solid phase extraction (SPE) followed by ultra performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS). *Current Analytical Chemistry* 2016;12(3):183-201.
1080. Banta-Green CJ, Brewer AJ, Ort C, Helsel DR, Williams JR, Field JA. Using wastewater-based epidemiology to estimate drug consumption - Statistical analyses and data presentation. *Science of the Total Environment* 2016: Ahead of Print.
1081. Been F, Esseiva P, Delemont O. Analysis of illicit drugs in wastewater - Is there an added value for law enforcement? *Forensic Science International* 2016;266:215-221.
1082. Been F, Lai FY, Kinyua J, Covaci A, van Nuijs ALN. Profiles and changes in stimulant use in Belgium in the period of 2011-2015. *Science of the Total Environment* 2016: Ahead of Print.
1083. Brieudef V, Lardy-Fontan S, Lalere B, Vaslin-Reimann S, Budzinski H. Validation and uncertainties evaluation of an isotope dilution-SPE-LC-MS/MS for the quantification of drug residues in surface waters. *Talanta* 2016;146:138-147.
1084. Bujak R, Gadzala-Kopciuch R, Nowaczyk A, Raczak-Gutknecht J, Kordalewska M, Struck-Lewicka W, Markuszewski MJ, Buszewski B. Selective determination of cocaine and its metabolite benzoylecgonine in environmental samples by newly developed sorbent materials. *Talanta* 2016;146:401-409.
1085. Castrignano E, Lubben A, Kasprzyk-Hordern B. Enantiomeric profiling of chiral drug biomarkers in wastewater with the usage of chiral liquid chromatography coupled with tandem mass spectrometry. *Journal of Chromatography A* 2016;1438:84-99.
1086. Concheiro-Guisan M, Jacox A, Wetzel J, Cheng S-Y. Quantitative analysis of licit & illicit drugs in river & wastewater samples. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-22.
1087. Depaolini AR, Fattore E, Cappelli F, Pellegrino R, Castiglioni S, Zuccato E, Fanelli R, Davoli E. Source discrimination of drug residues in wastewater: The case of salbutamol.

1088. Gatidou G, Kinyua J, van Nuijs ALN, Gracia-Lor E, Castiglioni S, Covaci A, Stasinakis AS. Drugs of abuse and alcohol consumption among different groups of population on the Greek Island of Lesbos through sewage-based epidemiology. *Science of the Total Environment* 2016;563-564:633-640.
1089. Geme G, Wood L. Screening for drugs of abuse in the waste water in a small college town in Southern Arkansas. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: ENVR-520.
1090. Gonzalez-Marino I, Gracia-Lor E, Bagnati R, Martins CPB, Zuccato E, Castiglioni S. Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry. *Analytical and Bioanalytical Chemistry* 2016: Ahead of Print.
1091. Humphries MA, Bruno R, Lai FY, Thai PK, Holland BR, O'Brien JW, Ort C, Mueller JF. Evaluation of monitoring schemes for wastewater-based epidemiology to identify drug use trends using cocaine, methamphetamine, MDMA and methadone. *Environmental Science & Technology* 2016: Ahead of Print.
1092. Kankaanpaa A, Ariniemi K, Heinonen M, Kuoppasalmi K, Gunnar T. Current trends in Finnish drug abuse: Wastewater based epidemiology combined with other national indicators. *Science of the Total Environment* 2016: Ahead of Print.
1093. Klupczynska A, Dereziński P, Krysztofiak J, Kokot ZJ. Estimation of drug abuse in 9 Polish cities by wastewater analysis. *Forensic Science International* 2016;260:14-21.
1094. Krizman I, Senta I, Ahel M, Terzic S. Wastewater-based assessment of regional and temporal consumption patterns of illicit drugs and therapeutic opioids in Croatia. *Science of the Total Environment* 2016;566-567:454-462.
1095. Lai FY, O'Brien J, Bruno R, Hall W, Prichard J, Kirkbride P, Gartner C, Thai P, Carter S, Lloyd B, Burns L, Mueller J. Spatial variations in the consumption of illicit stimulant drugs across Australia: A nationwide application of wastewater-based epidemiology. *Science of the Total Environment* 2016: Ahead of Print.
1096. Lai FY, O'Brien JW, Thai PK, Hall W, Chan G, Bruno R, Ort C, Prichard J, Carter S, Anuj S, Kirkbride KP, Gartner C, Humphries M, Mueller JF. Cocaine, MDMA and

- methamphetamine residues in wastewater: Consumption trends (2009-2015) in South East Queensland, Australia. *Science of the Total Environment* 2016: Ahead of Print.
1097. Li K, Du P, Xu Z, Gao T, Li X. Occurrence of illicit drugs in surface waters in China. *Environmental Pollution* 2016;213:395-402.
1098. Mackulak T, Birosova L, Bodik I, Grabic R, Takacova A, Smolinska M, Hanusova A, Hives J, Gal M. Zerovalent iron and iron(VI): Effective means for the removal of psychoactive pharmaceuticals and illicit drugs from wastewaters. *Science of the Total Environment* 2016;539:420-426.
1099. Mastroianni N, Bleda MJ, Lopez de Alda M, Barcelo D. Occurrence of drugs of abuse in surface water from four Spanish river basins: Spatial and temporal variations and environmental risk assessment. *Journal of Hazardous Materials* 2016;316:134-142.
1100. McCall A-K, Bade R, Kinyua J, Lai FY, Thai PK, Covaci A, Bijlsma L, van Nuijs ALN, Ort C. Critical review on the stability of illicit drugs in sewers and wastewater samples. *Water Research* 2016;88:933-947.
1101. Mendoza A, Zonja B, Mastroianni N, Negreira N, Lopez de Alda M, Perez S, Barcelo D, Gil A, Valcarcel Y. Drugs of abuse, cytostatic drugs and iodinated contrast media in tap water from the Madrid region (central Spain): A case study to analyse their occurrence and human health risk characterization. *Environment International* 2016;86:107-118.
1102. Parker W, Boles T. Effects of time delay between sample collection and extraction of wastewater samples for amphetamine and opioid analysis. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-784.
1103. Pereira CDS, Maranhão LA, Cortez FS, Pusceddu FH, Santos AR, Ribeiro DA, Cesar A, Guimaraes LL. Occurrence of pharmaceuticals and cocaine in a Brazilian coastal zone. *Science of the Total Environment* 2016;548-549:148-154.
1104. Reynolds S. Detection and quantification of various opioid compounds in urban wastewater by utilization of liquid chromatography-tandem mass spectrometry. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: ENVR-387.
1105. Tschärke BJ, Chen C, Gerber JP, White JM. Temporal trends in drug use in Adelaide,

South Australia by wastewater analysis. *Science of the Total Environment* 2016;565:384-391.

1106. Vial G, Foy G. Determination of illicit drug metabolites in wastewater by liquid chromatography mass spectroscopy. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-674.
1107. Wang D-G, Zheng Q-D, Wang X-P, Du J, Tian C-G, Wang Z, Ge L-K. Illicit drugs and their metabolites in 36 rivers that drain into the Bohai Sea and north Yellow Sea, north China. *Environmental Science and Pollution Research* 2016: Ahead of Print.
1108. Yang Z, Castrignano E, Estrela P, Frost CG, Kasprzyk-Hordern B. Community sewage sensors towards evaluation of drug use trends: Detection of cocaine in wastewater with DNA-directed immobilization aptamer sensors. *Scientific Reports* 2016;6:21024.
1109. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radomska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. *Forensic Science International* 2013;233(1-3):416-422.
1110. Wilkins C, Sheridan J, Adams P, Russell B, Ram S, Newcombe D. The new psychoactive substances regime in New Zealand: A different approach to regulation. *Journal of Psychopharmacology* 2013;27(7):584-589.
1111. Burns L, Roxburgh A, Matthews A, Bruno R, Lenton S, Van Buskirk J. The rise of new psychoactive substance use in Australia. *Drug Testing and Analysis* 2014;6(7-8):846-849.
1112. Duffert A. Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective. *Drug Testing and Analysis* 2014;6(7-8):876-878.
1113. Gine CV, Espinosa IF, Vilamala MV. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon - NPS as adulterants of controlled drugs. *Drug Testing and Analysis* 2014;6(7-8):819-824.
1114. Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R, Wood DM, Dargan

- PI. Current European data collection on emergency department presentations with acute recreational drug toxicity: Gaps and national variations. *Clinical Toxicology* 2014;52(10):1005-1012.
1115. Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: Mislabeling and sale as bath salts, spice, and research chemicals. *Deutsches Ärzteblatt International* 2014;111(9):139-147.
1116. Kavanagh PV, Power JD. New psychoactive substances legislation in Ireland - Perspectives from academia. *Drug Testing and Analysis* 2014;6(7-8):884-891.
1117. Lowry S, Bradley M, Jalenak W. Identifying synthetic designer drugs using FT-IR, Raman, and GC-IR. *Spectroscopy* 2014;29(Suppl.):26-32,38.
1118. Rapaka RS, Purohit V, Schnur P, Rutter J. Emerging trends in the abuse of designer drugs and their catastrophic health effects: Update on chemistry, pharmacology, toxicology and addiction potential. *Life Sciences* 2014;97(1)1.
1119. Sullivan JA. New and emerging drugs. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-213.
1120. Tsujikawa K, Yamamuro T, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H. Application of a portable near infrared spectrometer for presumptive identification of psychoactive drugs. *Forensic Science International* 2014;242:162-171.
1121. Wilkins C. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing. *Drug Testing and Analysis* 2014;6(7-8):868-875.
1122. Zamengo L, Frison G, Bettin C, Sciarrone R. Understanding the risks associated with the use of new psychoactive substances (NPS): High variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. *Toxicology Letters* 2014;229(1):220-228.
1123. Alechaga E, Moyano E, Galceran MT. Wide-range screening of psychoactive substances by FIA-HRMS: Identification strategies. *Analytical and Bioanalytical Chemistry* 2015: Ahead of Print.

1124. Armenta S, Garrigues S, de la Guardia M, Brassier J, Alcalà M, Blanco M, Perez-Alfonso C, Galipienso N. Detection and characterization of emerging psychoactive substances by ion mobility spectrometry. *Drug Testing and Analysis* 2015;7(4):280-289.
1125. Chavan S, Roy V. Designer drugs: A review. *World Journal of Pharmacy and Pharmaceutical Sciences* 2015;4(8):297-336.
1126. Crews BO, Petrie MS. Recent trends in designer drug abuse. *Clinical Chemistry* 2015;61(7):1000-1001.
1127. Gwak S, Almirall JR. Rapid screening of 35 new psychoactive substances by ion mobility spectrometry (IMS) and direct analysis in real time (DART) coupled to quadrupole time-of-flight mass spectrometry (QTOF-MS). *Drug Testing and Analysis* 2015: Ahead of Print.
1128. Kurihara M. In silico study on prediction of bioactivity for regulation of new designer drugs. *Nippon Yakurigaku Zasshi* 2015;146(6):315-320.
1129. Lee WWY, Silverson VAD, Jones LE, Ho YC, Fletcher NC, McNaul M, Peters KL, Speers SJ, Bell SEJ. Surface-enhanced Raman spectroscopy of novel psychoactive substances using polymer-stabilized Ag nanoparticle aggregates. *Chemical Communications* 2015: Ahead of Print.
1130. Smith JP, Sutcliffe OB, Banks CE. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). *Analyst* 2015;140(15):4932-4948.
1131. Tetley J, Crean C. New psychoactive substances: Catalysing a shift in forensic science practice? *Philosophical Transactions of the Royal Society, B: Biological Sciences* 2015;370(1674):1-4.
1132. Zawilska JB, Andrzejczak D. Next generation of novel psychoactive substances on the horizon - A complex problem to face. *Drug and Alcohol Dependence* 2015: Ahead of Print.
1133. Coulon P, Gorji A. Tightrope or slackline? The neuroscience of psychoactive substances. *Trends in Pharmacological Sciences* 2016: Ahead of Print.
1134. Gebel Berg E. Designer drug detective work. *ACS Central Science* 2016: Ahead of Print.

1135. Jones LE, Stewart A, Peters KL, McNaul M, Speers SJ, Fletcher NC, Bell SEJ. Infrared and Raman screening of seized novel psychoactive substances: A large scale study of >200 samples. *Analyst* 2016;141(3):902-909.
1136. Meyer MR, Maurer HH. Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today? *Analytica Chimica Acta* 2016;927:13-20.
1137. Risoluti R, Materazzi S, Gregori A, Ripani L. Early detection of emerging street drugs by near infrared spectroscopy and chemometrics. *Talanta* 2016;153:407-413.
1138. Rychert M, Wilkins C. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties. *Drug Testing and Analysis* 2016:Ahead of Print.
1139. Schifano F, Papanti GD, Orsolini L, Corkery JM. Novel psychoactive substances: The pharmacology of stimulants and hallucinogens. *Expert Review of Clinical Pharmacology* 2016:Ahead of Print.
1140. Shimane T, Funada M. Understanding and responding to the new wave of substance abuse: Law-evading drugs and prescription drug abuse. *Yakugaku Zasshi* 2016;136(1):63-64.
1141. Vikingsson S, Green H. Putting designer drugs back in Pandora's box: Analytical challenges and metabolite identification. *Clinical Chemistry* 2016;62(1):4-5.
1142. Gross M. Drugs prohibition is criminals' gain, neuroscience's loss. *Current Biology* 2013;23(14):R585-R588.
1143. Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. *Drug Testing and Analysis* 2014;6(7-8):614-632.
1144. Cimpoi C, Hosu A. TLC of anxiolytics and sedatives. *Chromatographic Science Series* 2014;106(Thin Layer Chromatography in Drug Analysis):279-322.
1145. Yan M-Z, Chang Q, Zhong Y, Xiao B-X, Feng L, Cao F-R, Pan R-L, Zhang Z-S, Liao Y-H, Liu X-M. Lotus leaf alkaloid extract displays sedative-hypnotic and anxiolytic effects through GABAA Receptor. *Journal of Agricultural and Food Chemistry* 2015;63(42):9277-9285.

1146. Bell SEJ, Stewart SP, Speers SJ. Raman spectroscopy of drugs of abuse. *Infrared and Raman Spectroscopy in Forensic Science* 2012:317-337.
1147. Buckley K, Matousek P. Non-invasive detection of illicit drugs using spatially offset Raman spectroscopy. *Infrared and Raman Spectroscopy in Forensic Science* 2012:351-356.
1148. Burnett AD, Cunningham JE, Davies AG, Dean P, Linfield EH. Terahertz frequency spectroscopy and its potential for security applications. *Infrared and Raman Spectroscopy in Forensic Science* 2012:295-314.
1149. Faulds K, Smith WE. Detection of drugs of abuse using surface enhanced Raman scattering. *Infrared and Raman Spectroscopy in Forensic Science* 2012:357-366.
1150. Hargreaves MD. Drugs of abuse-application of handheld FT-IR and Raman spectrometers. *Infrared and Raman Spectroscopy in Forensic Science* 2012:339-349.
1151. Lurie IS. UHPLC and UHPLC-MS for the analysis of seized drugs. *RSC Chromatography Monographs* 2012;16(UHPLC in Life Sciences):316-336.
1152. Thevis M, Volmer DA. Recent instrumental progress in mass spectrometry: Advancing resolution, accuracy, and speed of drug detection. *Drug Testing and Analysis* 2012;4(3-4):242-245.
1153. Broseus J, Debrus B, Delemont O, Rudaz S, Esseiva P. Study of common database feeding with results coming from different analytical methods in the framework of illicit drugs chemical profiling. *Forensic Science International* 2013: Ahead of Print.
1154. Clemons K, Dake J, Sisco E, Verbeck GF 4th. Trace analysis of energetic materials via direct analyte-probed nanoextraction coupled to direct analysis in real time mass spectrometry. *Forensic Science International* 2013;231(1-3):98-101.
1155. Cletus B, Olds W, Fredericks PM, Jaatinen E, Izake EL. Real-time detection of concealed chemical hazards under ambient light conditions using Raman spectroscopy. *Journal of Forensic Sciences* 2013;58(4):1008-1014.
1156. Demoranville LT, Brewer TM. Ambient pressure thermal desorption ionization mass spectrometry for the analysis of substances of forensic interest. *Analyst* 2013;138(18):5332-5337.

1157. Feng N, Lu Y, Jiang J, Chen J-h, Zhao J-p, Xie W-d. Rapid screening of 73 toxic and harmful substances in foods by ultra performance liquid chromatography-mass spectrometry with QuEChERS. *Shipin Kexue (Beijing, China)* 2013;34(16):214-220.
1158. Hasegawa T, Takahashi K, Saijo M, Fukiwake T, Motoki Y. Current situation and issues for analyzing illegal drug products. *Yakugaku Zasshi* 2013;133(1):7-11.
1159. Holness H, Almirall J. Speciation effects of solvent chemistry on the analysis of drugs and explosives by electrospray ion mobility mass spectrometry. *International Journal for Ion Mobility Spectrometry* 2013;16(3):237-246.
1160. Inoue H, Tsujikawa K, Iwata Y. Analysis of law-evading and illegal drugs in scientific investigation. *Medical Technology (Tokyo, Japan)* 2013;41(11):1166-1172.
1161. Masetto de Gaitani C, De Oliveira ARM, Bonato PS. Capillary electromigration techniques for the analysis of drugs and metabolites in biological matrices: A critical appraisal. *Capillary Electrophoresis and Microchip Capillary Electrophoresis* 2013:229-245.
1162. Minami T, Esipenko NA, Akdeniz A, Zhang B, Isaacs L, Anzenbacher P. Multianalyte sensing of addictive over-the-counter (OTC) drugs. *Journal of the American Chemical Society* 2013;135(40):15238-15243.
1163. Oestman P, Ketola RA, Ojanperae I. Application of electrospray ionization product ion spectra for identification with atmospheric pressure matrix-assisted laser desorption / ionization mass spectrometry - A case study with seized drugs. *Drug Testing and Analysis* 2013;5(2):68-73.
1164. Rameev B, Mozzhukhin G, Aktas B. Magnetic resonance detection of explosives and illicit materials. *Applied Magnetic Resonance* 2012;43(4):463-467.
1165. Thevis M, Kuuranne T, Geyer H, Schaenzer W. Annual banned-substance review: Analytical approaches in human sports drug testing. *Drug Testing and Analysis* 2013: Ahead of Print.
1166. Thomas BF, Pollard GT, Grabenauer M. Analytical surveillance of emerging drugs of abuse and drug formulations. *Life Sciences* 2013;92(8-9):512-519.
1167. Ali EMA, Edwards HGM. Screening of textiles for contraband drugs using portable

- Raman spectroscopy and chemometrics. *Journal of Raman Spectroscopy* 2014;45(3):253-258.
1168. Heinle A, Cipoletti M. Effectiveness of various spectroscopic methods in the analysis of drug mixtures. Abstracts, 45th Central Regional Meeting of the American Chemical Society, Pittsburgh, PA, United States, October 29-November 1, 2014: CERMACS-447.
1169. Kennedy JH, Wiseman JM. Screening of drugs of abuse using the Velox 360 paper spray system. *LC-GC North America* 2014;(Suppl.):36.
1170. Lu X-h, Yang T. Application of HPLC in detection of abused drugs. *Weiliang Yuansu Yu Jiankang Yanjiu* 2014;31(3):58,65.
1171. Meyer MR. Trends in analyzing emerging drugs of abuse, from seized samples to body samples. *Analytical and Bioanalytical Chemistry* 2014;406(25):6105-6110.
1172. Nelson D, O'Donnell D. Raman and surface enhanced Raman spectroscopy of designer drugs known as "bath salts". Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014: CHED-352.
1173. Pourmand A, Armstrong P, Mazer-Amirshahi M, Shokoohi H. The evolving high: New designer drugs of abuse. *Human & Experimental Toxicology* 2014;33(10):993-999.
1174. Wang Q, Jia Q, Yan L, Xia S, Ma P. Quantitative structure-toxicity relationship of the aquatic toxicity for various narcotic pollutants using the norm indexes. *Chemosphere* 2014;108:383-387.
1175. Bell S, Nida C. Pyrolysis of drugs of abuse: A comprehensive review. *Drug Testing and Analysis* 2015: Ahead of Print.
1176. Cody RB, Musah R, Lesiak A, Shepard J. "Pick your poison": Recent developments in the analysis of natural and "unnatural" drugs of abuse by DART-MS. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: ANYL-247.
1177. Fontanez A, Berk JR. Determination and use of diazonium ions for the presumptive testing of narcotics containing an activated aromatic ring. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHED-1323.

1178. Fujii H, Waters B, Hara K, Kashiwagi M, Matsusue A, Takayama M, Kubo S-i. Direct heating headspace solid-phase microextraction for the screening of illicit drugs. *Forensic Toxicology* 2015;33(1):61-68.
1179. He L. Identification of abused drugs using gas chromatography coupled with Fourier transform infrared spectroscopy. *Huaxue Shiji* 2015;37(4):328-330.
1180. Jha SK, Hayashi K, Yadava RDS. Drugs of abuse and their detection methodologies: Contribution of chemical sensor. *Current Organic Chemistry* 2015;19(12):1191-1201.
1181. Mackulak T, Stanova AV, Gal M, Hives J, Grabic R, Tichy J. Determination of illicit drugs and their metabolites contamination on banknotes. *Monatshefte fuer Chemie* 2015: Ahead of Print.
1182. Molnar B, Molnar-Perl I. The role of alkylsilyl derivatization techniques in the analysis of illicit drugs by gas chromatography. *Microchemical Journal* 2015;118:101-109.
1183. Weiss JA, Mohr S, Schmid MG. Indirect chiral separation of new recreational drugs by gas chromatography-mass spectrometry using trifluoroacetyl-L-prolyl chloride as chiral derivatization reagent. *Chirality* 2015;27(3):211-215.
1184. Brunt TM, Nagy C, Buecheli A, Martins D, Ugarte M, Beduwe C, Ventura Vilamala M. Drug testing in Europe: Monitoring results of the Trans European Drug Information (TEDI) project. *Drug Testing and Analysis* 2016: Ahead of Print.
1185. Fletcher CM, Sleeman R. Rapid identification of seized controlled substances and related compounds by tandem mass spectrometry without chromatography. *Rapid Communications in Mass Spectrometry* 2016;30(7):908-916.
1186. Li F, Beck R, Tice J, Shrader S, Musselman B. Screening of drugs of abuse using DART-MS and in-source CID reverse library search. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-440.
1187. Lin DL, Wang SM, Wu CH, Chen BG, Liu RH. Chemical derivatization for forensic drug analysis by GC- and LC-MS. *Forensic Science Review* 2016;28(1):17-35.
1188. Odoardi S, Romolo FS, Strano-Rossi S. A snapshot on NPS in Italy: Distribution of drugs in seized materials analysed in an Italian forensic laboratory in the period

- 2013-2015. *Forensic Science International* 2016;265:116-120.
1189. Kwok K, Taylor LS. Raman spectroscopy for the analysis of counterfeit tablets. *Infrared and Raman Spectroscopy in Forensic Science* 2012:561-572.
1190. Bajema E, Barstis T, Lieberman M. Catching the Counterfeits. *Chemistry & Industry* 2013;77(1):28-30.
1191. Deconinck E, Sacre P-Y, Courselle P, De Beer JO. Chromatography in the detection and characterization of illegal pharmaceutical preparations. *Journal of Chromatographic Science* 2013;51(8):791-806.
1192. Degardin K, Roggo Y, Margot P. Understanding and fighting the medicine counterfeit market. *Journal of Pharmaceutical and Biomedical Analysis* 2014;87:167-175.
1193. Ferreira CR, Wu L, Vogt FG, Bornancini ER, Cooks RG. Fiducial markers for distribution of drug and excipient on tablet surfaces by multimodal desorption electrospray ionization - mass spectrometry (DESI-MS) imaging. *Analytical Letters* 2013: Ahead of Print.
1194. Lu F, Weng X, Chai Y, Yang Y, Yu Y, Duan G. A novel identification system for counterfeit drugs based on portable Raman spectroscopy. *Chemometrics and Intelligent Laboratory Systems* 2013;127:63-69.
1195. Michelet A, Boiret M, Lemhachheche F, Malec L, Tfayli A, Ziemons E. Use of Raman spectrometry [sic] in the pharmaceutical field. *STP Pharma Pratiques* 2013;23(2):97-117.
1196. Patlevic P, Dorko F, Svorc Jr P, Vaskova J, Vasko L. Counterfeit drugs - How to reveal them? *Chemicke Listy* 2013;107(1):37-43.
1197. Been F, Roggo Y, Degardin K, Esseiva P. Providing a forensic approach for fighting against counterfeit medicines. *Spectra Analyse* 2014;43(298):51-62.
1198. Easter JL, Steiner RR. Pharmaceutical identifier confirmation via DART-TOF. *Forensic Science International* 2014;240:9-20.
1199. Nikam UA, Jadhav AV, Salunkhe VR, Magdum CS. An overview of pharmaceutical process validation of solid dosage form. *Current Pharma Research* 2013;3(2):824-835.

1200. Dégardin K, Roggo Y, Margot P. Forensic intelligence for medicine anticounterfeiting. *Forensic Science International* 2015;248:15-32.
1201. Dégardin K, Roggo Y. Counterfeit analysis strategy illustrated by a case study. *Drug Testing and Analysis* 2016;8(3-4):388-397.
1202. Krakowska B, Custers D, Deconinck E, Daszykowski M. Chemometrics and the identification of counterfeit medicines - A review. *Journal of Pharmaceutical and Biomedical Analysis* 2016:Ahead of Print.
1203. Kumar B, Baldi A. The challenge of counterfeit drugs: A comprehensive review on prevalence, detection and preventive measures. *Current Drug Safety* 2016;11(2):112-120.
1204. Iwata Y. Scientific investigation and analytical chemistry (3). Forensic drug analysis. *Bunseki* 2014;(3):113-119.
1205. Yan S, Zhang Q. Advances in drug detection technology. *Shanghai Huagong* 2014;39(4):12-16.
1206. Aturki Z, Rocco A, Fanali S. Forensic drugs analysis: A review of miniaturized separation techniques. *LC-GC Europe* 2015;28(1):18-25.
1207. Rubiano C, St. Firmin J, Coticone SR. The effect of benzene ring substituents on the mechanism of Duquenois Levine (DL) test for cannabinoid detection. *Journal of Chemical and Pharmaceutical Research* 2014;6(6):1261-1264.
1208. Weaver A, Lieberman M. Paper analytical devices for detection of low-quality pharmaceuticals. *Proceedings of SPIE* 2014;8976(Microfluidics, BioMEMS, and Medical Microsystems XII):89760H/1-89760H/6.
1209. Cuypers E, Bonneure A-J, Tytgat J. The use of presumptive color tests for new psychoactive substances. *Drug Testing and Analysis* 2015:Ahead of Print.
1210. Pack BW, Montgomery LL, Hetrick EM. Modernization of physical appearance and solution color tests using quantitative tristimulus colorimetry: Advantages, harmonization, and validation strategies. *Journal of Pharmaceutical Sciences* 2015:Ahead of Print.

1211. Laberke PJ, Fornaro J, Kim S-k, Blum S, Augsburg M, Alkadhi H, Wildermuth S, Hausmann R, Leschka S. Dual-energy CT behavior of heroin, cocaine, and typical adulterants. *Forensic Science, Medicine, and Pathology* 2015: Ahead of Print.
1212. Sica G, Guida F, Bocchini G, Iaselli F, Iadevito I, Scaglione M. Imaging of drug smuggling by body packing. *Seminars in Ultrasound, CT and MRI* 2015;36(1):39-47.
1213. Franco M, Jasionowska R. Quick single run capillary zone electrophoresis determination of active ingredients and preservatives in pharmaceutical products. *American Journal of Analytical Chemistry* 2013;4(3):117-124.
1214. Jac P, Scriba GKE. Recent advances in electrodriven enantioseparations. *Journal of Separation Science* 2013;36(1):52-74.
1215. Albals D, Hendrickx A, Clincke L, Chankvetadze B, Heyden YV, Mangelings D. A chiral separation strategy for acidic drugs in capillary electrochromatography using both chlorinated and nonchlorinated polysaccharide-based selectors. *Electrophoresis* 2014;35(19):2807-2818.
1216. McCord B, Editor. *Forensic Analysis. Electrophoresis* 2014;35(21-22):262 pp.
1217. Sieradzka E, Witt K, Milnerowicz H. The application of capillary electrophoresis techniques in toxicological analysis. *Biomedical Chromatography* 2014;28(11):1507-1513.
1218. Sundari PJP, Sireesha MS. Review on capillary electrophoresis - diode array detection. *Inventi Impact: Pharm Analysis & Quality Assurance* 2014;(1):16-26.
1219. Posch TN, Puetz M, Martin N, Huhn C. Electromigrative separation techniques in forensic science: Combining selectivity, sensitivity, and robustness. *Analytical and Bioanalytical Chemistry* 2015;407(1):23-58.
1220. Groves Carlin M, Dean JR. *Forensic Applications of Gas Chromatography*. 2013; CRC Press, Boca Raton, FL, 186 pp.
1221. Sampat A, Lopatka M, Sjerps M, Vivo-Truyols G, Schoenmakers P, van Asten A. Forensic potential of comprehensive two-dimensional gas chromatography. *TrAC, Trends in Analytical Chemistry* 2016;80:345-363.

1222. Schmidt ML, Snow NH. Making the case for QuEChERS - gas chromatography of drugs. *TrAC, Trends in Analytical Chemistry* 2016;75:49-56.
1223. Nelson MP, Basta A, Patil R, Klueva O, Treado PJ. Development of a handheld widefield hyperspectral imaging (HSI) sensor for standoff detection of explosive, chemical and narcotic residues. *Proceedings of SPIE* 2013;8726(Next-Generation Spectroscopic Technologies VI):872605/1-872605/9.
1224. Zhang R, Yin L, Jin S. Application of infrared spectral imaging in drug quality control. *Zhongguo Yaoshi* 2013;27(6):635-638.
1225. Lanzarotta A. Analysis of forensic casework utilizing infrared spectroscopic imaging. *Sensors* 2016;16(3):278-Unknown (page range not provided).
1226. Pederson CG, Friedrich DM, Hsiung C, von Gunten M, O'Brien NA, Ramaker H-J, van Sprang E, Dreischor M. Pocket-size near-infrared spectrometer for narcotic materials identification. *Proceedings of SPIE* 2014;9101(Next-Generation Spectroscopic Technologies VII):910100/1-910100/11.
1227. Jackson DS. Ion chromatographic analysis of pharmaceuticals for authenticity and adulteration. *Applications of Ion Chromatography for Pharmaceutical and Biological Products* 2012:247-257.
1228. Barron L, Gilchrist E. Ion chromatography-mass spectrometry: A review of recent technologies and applications in forensic and environmental explosives analysis. *Analytica Chimica Acta* 2014;806:27-54.
1229. Roscioli KM, Tufariello JA, Zhang X, Li SX, Goetz GH, Cheng G, Siems WF, Hill HH. Desorption electrospray ionization (DESI) with atmospheric pressure ion mobility spectrometry for drug detection. *Analyst* 2014;139(7):1740-1750.
1230. Goyal S, Thorson MR, Gong Y, Zhang GGZ, Kenis PJA. Microfluidic platforms for solid form screening of pharmaceuticals. *International Conference on Miniaturized Systems for Chemistry and Life Sciences, 15th, Seattle, WA, United States, Oct. 2-6, 2011*:2089-2091.
1231. Al-Hetlani E. Forensic drug analysis and microfluidics. *Electrophoresis* 2013;34(9-10):1262-72.

1232. Gracioso Martins AM, Glass NR, Harrison S, Rezk AR, Porter NA, Carpenter PD, Du Plessis J, Friend JR, Yeo LY. Toward complete miniaturisation of flow injection analysis systems: Microfluidic enhancement of chemiluminescent detection. *Analytical Chemistry* 2014;86(21):10812-10819.
1233. Andola HC. Good laboratory practices for high performance liquid chromatography (HPLC): An overview. *International Research Journal of Pharmaceutical & Applied Sciences* 2012;2(1):46-52.
1234. Chinchole R, Hatre PM, Desai U, Chavan R. Recent applications of hyphenated liquid chromatography techniques in forensic toxicology: A review. *International Journal of Pharmaceutical Sciences Review and Research* 2012;14(1):57-63.
1235. Gorynski K, Bojko B, Nowaczyk A, Bucinski A, Pawliszyn J, Kaliszan R. Quantitative structure-retention relationships models for prediction of high performance liquid chromatography retention time of small molecules: Endogenous metabolites and banned compounds. *Analytica Chimica Acta* 2013;797:13-19.
1236. Geryk R, Kalikova K, Vozka J, Tesarova E. Immobilized polysaccharide-based stationary phases for enantioseparation in normal versus reversed phase HPLC. *Chromatographia* 2014: Ahead of Print.
1237. Plotka JM, Biziuk M, Morrison C, Namiesnik J. Pharmaceutical and forensic drug applications of chiral supercritical fluid chromatography. *TrAC, Trends in Analytical Chemistry* 2014;56:74-89.
1238. Zuo Y, Zhou S, Zuo R, Shi T, Yang Y, Henegan P. Hydrophilic interaction liquid chromatography: Fundamentals and applications. *High-Performance Liquid Chromatography (HPLC)* 2014:1-21.
1239. Cook DW, Rutan SC, Stoll DR, Carr PW. Two dimensional assisted liquid chromatography - A chemometric approach to improve accuracy and precision of quantitation in liquid chromatography using 2D separation, dual detectors, and multivariate curve resolution. *Analytica Chimica Acta* 2015;859:87-95.
1240. Kubik L, Struck-Lewicka W, Kaliszan R, Wiczling P. Simultaneous determination of hydrophobicity and dissociation constant for a large set of compounds by gradient reverse phase high performance liquid chromatography-mass spectrometry technique. *Journal of Chromatography A* 2015;1416:31-37.

1241. Wang L, Zheng J, Gong X, Hartman R, Antonucci V. Efficient HPLC method development using structure-based database search, physico-chemical prediction and chromatographic simulation. *Journal of Pharmaceutical and Biomedical Analysis* 2015;104:49-54.
1242. Appulage DK, Wang EH, Carroll F, Schug KA. Automated screening of reversed phase stationary phases for small-molecule separations using liquid chromatography with mass spectrometry. *Journal of Separation Science* 2016;39(9):1638-1647.
1243. Jeong LN, Sajulga R, Forte SG, Stoll DR, Rutan SC. Simulation of elution profiles in liquid chromatography - I: Gradient elution conditions, and with mismatched injection and mobile phase solvents. *Journal of Chromatography A* 2016: Ahead of Print.
1244. Roesner P. *Mass Spectra of Designer Drugs* 2012. Wiley-VCH, Weinheim, Germany, 350 pp.
1245. Forbes TP, Brewer TM, Gillen G. Desorption electro-flow focusing ionization of explosives and narcotics for ambient pressure mass spectrometry. *Analyst* 2013;138(19):5665-5673.
1246. Gross JH. Direct analysis in real time - A critical review on DART-MS. *Analytical and Bioanalytical Chemistry* 2013: Ahead of Print.
1247. Kandiah M, Urban PL. Advances in ultrasensitive mass spectrometry of organic molecules. *Chemical Society Reviews* 2013;42(12):5299-5322.
1248. Li L-P, Feng B-S, Yang J-W, Chang C-L, Bai Y, Liu H-W. Applications of ambient mass spectrometry in high-throughput screening. *Analyst* 2013;138(11):3097-3103.
1249. McGee E, MacDonald S, McGibbon GA, Moser A. An evaluation of standardized software for processing GC/MS data from different vendors' instruments in a forensic laboratory. *Journal of Forensic Sciences* 2013;58(3):764-766.
1250. Minohata T, Kudo K, Usui K, Shima N, Katagi M, Ikeda N, Tsuchihashi H, Suzuki K. The application of ultra-fast triple quadrupole LC-MS/MS to forensic analysis. *Shimadzu Hyoron* 2013;70(3/4):149-156.
1251. Morelato M, Beavis A, Kirkbride P, Roux C. Forensic applications of desorption electrospray ionisation mass spectrometry (DESI-MS). *Forensic Science International*

2013;226(1-3):10-21.

1252. Oberacher H, Whitley G, Berger B, Weinmann W. Testing an alternative search algorithm for compound identification with the Wiley Registry of Tandem Mass Spectral Data, MSforID. *Journal of Mass Spectrometry* 2013;48(4):497-504.
1253. Trimpin S, Inutan ED. Matrix assisted ionization in vacuum, a sensitive and widely applicable ionization method for mass spectrometry. *Journal of the American Society for Mass Spectrometry* 2013;24(5):722-732.
1254. Lesiak AD, Shepard JRE. Recent advances in forensic drug analysis by DART-MS. *Bioanalysis* 2014;6(6):819-842.
1255. Guinan T, Kirkbride P, Pigou PE, Ronci M, Kobus H, Voelcker NH. Surface-assisted laser desorption ionization mass spectrometry techniques for application in forensics. *Mass Spectrometry Reviews* 2015;34(6):627-640.
1256. Hoffmann WD, Jackson GP. Forensic mass spectrometry. *Annual Review of Analytical Chemistry* 2015;8:419-440.
1257. Kawase K, Kadokami K. Examination of wide use target screening system for GC/MS. *Bunseki Kagaku* 2015;64(1):43-50.
1258. Kulyk DS, Miller CF, Badu-Tawiah AK. Reactive charged droplets for reduction of matrix effects in electrospray ionization mass spectrometry. *Analytical Chemistry* 2015;87(21):10988-10994.
1259. Mandra VJ, Kouskoura MG, Markopoulou CK. Using the partial least squares method to model the electrospray ionization response produced by small pharmaceutical molecules in positive mode. *Rapid Communications in Mass Spectrometry* 2015;29(18):1661-1675.
1260. Smyth WF, McClean S, Massaro CF, Smyth TJ, Brooks P, Robledo VR. Characterization of synthetic and natural product pharmaceuticals by functional group analysis using electrospray ionization-ion trap mass spectrometry: A mini-review. *Analytical Letters* 2015;48(17):2661-2675.
1261. Williams AJ, Tkachenko V, Pshenichnov A. Using online chemistry databases to facilitate structure identification in mass spectral data. *Abstracts of Papers, 249th ACS*

National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: ANYL-45.

1262. Yuan C, Chen D, Wang S. Drug confirmation by mass spectrometry: Identification criteria and complicating factors. *Clinica Chimica Acta* 2015;438:119-125.
1263. Correa DN, Santos JM, Eberlin LS, Eberlin MN, Teunissen SF. Forensic chemistry and ambient mass spectrometry: A perfect couple destined for a happy marriage? *Analytical Chemistry* 2016: Ahead of Print.
1264. Gross JH. Direct analysis in real time - A critical review on DART-MS. *Analytical and Bioanalytical Chemistry* 2014;406(1):63-80.
1265. Li L, Zhao G. Determination of trace palladium in chemical bulk drug by ICP-MS with microwave digestion. *Zhongguo Wuji Fenxi Huaxue* 2016;6(1):6-9.
1266. Pavlovich MJ, Musselman B, Hall AB. Direct analysis in real time - mass spectrometry (DART-MS) in forensic and security applications. *Mass Spectrometry Reviews* 2016;(volume and page range not provided).
1267. Cheng Y-q, Li M-c, Ji S-g. Research progress on liquid phase micro-extraction (LPME), and its application in analysis of Chinese traditional medicines. *Zhongguo Yaofang* 2013;24(15):1431-1433.
1268. Kokosa JM. Advances in solvent-microextraction techniques. *TrAC, Trends in Analytical Chemistry* 2013: Ahead of Print.
1269. Kataoka H. SPME techniques for biomedical analysis. *Bioanalysis* 2015;7(17):2135-2144.
1270. Fang L, Deng J, Yang Y, Wang X, Chen B, Liu H, Zhou H, Ouyang G, Luan T. Coupling solid-phase microextraction with ambient mass spectrometry: Strategies and applications. *TrAC, Trends in Analytical Chemistry* 2016: Ahead of Print.
1271. He Y. Application of microextraction to forensic toxicology analysis. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-23.
1272. Montesano C, Sergi M. Microextraction techniques in illicit drug testing: Present and

- future. *Bioanalysis* 2016;8(9):863-866.
1273. Elie LE, Baron MG, Croxton RS, Elie MP. Investigation into the suitability of capillary tubes for microcrystalline testing. *Drug Testing and Analysis* 2013;5(7):573-580.
1274. Bunaciu AA, Fleschin S, Aboul-Enein HY. Infrared microspectroscopy applications - Review. *Current Analytical Chemistry* 2014;10(1):132-139.
1275. Lanzarotta A. Approximating the detection limit of an infrared spectroscopic imaging microscope operating in an attenuated total reflection (ATR) modality: Theoretical and empirical results for an instrument using a linear array detector and a 1.5 millimeter germanium hemisphere internal reflection element. *Applied Spectroscopy* 2015;69(2):205-214.
1276. Remaud GS, Bussy U, Lees M, Thomas F, Desmurs J-R, Jamin E, Silvestre V, Akoka S. NMR spectrometry isotopic fingerprinting: A tool for the manufacturer for tracking active pharmaceutical ingredients from starting materials to final medicines. *European Journal of Pharmaceutical Sciences* 2013;48(3):464-473.
1277. Gama LA, Merlo BB, Lacerda V, Romao W, Neto AC. No-deuterium proton NMR (No-D NMR): A simple, fast and powerful method for analyses of illegal drugs. *Microchemical Journal* 2015;118:12-18.
1278. Sudzukovic N, Puchner C, Brecker L. Crime-scene NMR laboratory - On the trail of molecules. *Nachrichten aus der Chemie* 2016;64(5):585-586.
1279. Schoenberger T, Menges S, Bernstein MA, Perez M, Seoane F, Sykora S, Cobas C. Improving the performance of high-precision qNMR measurements by a double integration procedure in practical cases. *Analytical Chemistry* 2016;88(7):3836-3843.
1280. Singh S, Roy R. The application of absolute quantitative <sup>1</sup>H NMR spectroscopy in drug discovery and development. *Expert Opinion on Drug Discovery* 2016;11(7):695-706.
1281. Heyler RA, Carriere JTA, Havermeier F. THz-Raman accessing molecular structure with Raman spectroscopy for enhanced chemical identification, analysis and monitoring. *Proceedings of SPIE* 2013;8726(Next-Generation Spectroscopic Technologies VD):87260J/1-87260J/7.
1282. Kim HM, Park HS, Cho Y, Jin SM, Lee KT, Jung YM, Suh YD. Noninvasive deep

- Raman detection with 2D correlation analysis. *Journal of Molecular Structure* 2014;1069:223-228.
1283. Muehlethaler C, Leona M, Lombardi JR. Review of surface enhanced Raman scattering applications in forensic science. *Analytical Chemistry* 2016;88(1):152-169.
1284. Khimchenko SV, Eksperiandova LP. Colorimetric and stochastic assessment of the visual limit of color perception for visual colorimetric analysis. *Journal of Analytical Chemistry* 2014;69(4):322-326.
1285. Sreenivasulu M, Murthy VR. Molecular electron ionization cross-section and  $\lambda_{\max}$  in the studies of activities of alkaloids. *International Journal of Pharma and Bio Sciences* 2014;5(2):147-154.
1286. Bratuz N, Javorsek D, Tomc HG. Defining optimal conditions of colors in 3D space in dependence on gamma values, illumination, and background color. *Journal of Imaging Science and Technology* 2015;59(4):1-11.
1287. Parmar A, Sharma S. Derivative UV-Vis absorption spectra as an invigorated spectrophotometric method for spectral resolution and quantitative analysis: Theoretical aspects and analytical applications: A review. *TrAC, Trends in Analytical Chemistry* 2016;77:44-53.
1288. *Stable Isotope Forensics: An Introduction to the Forensic Application of Stable Isotope Analysis*. Meier-Augenstein W, Editor, Wiley-Blackwell: Ames, Iowa, 2011.
1289. Benson SJ. Forensic applications of isotope ratio mass spectrometry. *Mass Spectrometry Handbook* 2012:341-372.
1290. Carter JF, Fry B. Ensuring the reliability of stable isotope ratio data - Beyond the principle of identical treatment. *Analytical and Bioanalytical Chemistry* 2013;405(9):2799-2814.
1291. Eiler JM. The isotopic anatomies of molecules and minerals. *Annual Review of Earth and Planetary Sciences* 2013;41:411-441.
1292. Magdas DA, Cristea G, Bot A, Mirel V. The use of carbon stable isotope ratios in drugs characterization. *AIP Conference Proceedings* 2013;1565(Processes in Isotopes and Molecules):282-284.

1293. Terzer S, Wassenaar LI, Araguas-Araguas LJ, Aggarwal PK. Global isoscapes for  $\delta^{18}\text{O}$  and  $\delta^2\text{H}$  in precipitation: Improved prediction using regionalized climatic regression models. *Hydrology and Earth System Sciences* 2013;17(11):4713-4728.
1294. Landwehr JM, Coplen TB, Stewart DW. Spatial, seasonal, and source variability in the stable oxygen and hydrogen isotopic composition of tap waters throughout the USA. *Hydrological Processes* 2014;28(21):5382-5422.
1295. Delavau C, Chun KP, Stadnyk T, Birks SJ, Welker JM. North American precipitation isotope ( $\delta^{18}\text{O}$ ) zones revealed in time series modeling across Canada and northern United States. *Water Resources Research* 2015;51(2):1284-1299.
1296. Dunn PJH, Hai L, Malinovsky D, Goenaga-Infante H. Simple spreadsheet templates for the determination of the measurement uncertainty of stable isotope ratio delta values. *Rapid Communications in Mass Spectrometry* 2015;29(22):2184-2186.
1297. Gentile N, Siegwolf RT, Esseiva P, Doyle S, Zollinger K, Delémont O. Isotope ratio mass spectrometry as a tool for source inference in forensic science: A critical review. *Forensic Science International* 2015;251:139-158.
1298. Desfontaine V, Veuthey J-L, Guillarme D. Evaluation of innovative stationary phase ligand chemistries and analytical conditions for the analysis of basic drugs by supercritical fluid chromatography. *Journal of Chromatography A* 2016;1438:244-253.
1299. Milojkovic-Opsenica D, Ristivojevic P, Andric F, Trifkovic J. Planar chromatographic systems in pattern recognition and fingerprint analysis. *Chromatographia* 2013;76(19-20):1239-1247.
1300. Chalmers JM, Edwards HGM, Hargreaves MD. Vibrational spectroscopy techniques: Basics and instrumentation. *Infrared and Raman Spectroscopy in Forensic Science* 2012:9-44.
1301. Chalmers JM, Edwards HGM, Hargreaves MD. Vibrational spectroscopy sampling techniques. *Infrared and Raman Spectroscopy in Forensic Science* 2012:45-86.
1302. Li Y, Liu P, Du H, Li Z, Liu J, Yu D, Li M. Marginal Fisher analysis-based feature extraction for identification of drug and explosive concealed by body packing. *Analytical Methods* 2013;5(22):6331-6337.

1303. Guna RN, Vyas JM, Ramkishan A, Agrawal YK. Metal ion sensors for trace determination of metals in drugs and pharmaceuticals. *Reviews in Analytical Chemistry* 2012;31(3-4):193-199.
1304. Bystritsky VM, Zubarev EV, Krasnoperov AV, Porohovoi SY, Rapatskii VL, Rogov YN, Sadovskii AB, Salamatin AV, Salmin RA, Slepnev VM, Andreev EI. Gamma detectors in explosives and narcotics detection systems. *Physics of Particles and Nuclei Letters* 2013;10(6):566-572.
1305. Lisowski P, Zarzycki PK. Microfluidic paper-based analytical devices ( $\mu$ PADs) and micro total analysis systems ( $\mu$ TAS): Development, applications and future trends. *Chromatographia* 2013;76:1201-1214.
1306. Szente L, Szeman J. Cyclodextrins in analytical chemistry: Utility of host-guest type molecular recognition. *Analytical Chemistry* 2013: Ahead of Print.
1307. Adcock JL, Barnett NW, Barrow CJ, Francis PS. Advances in the use of acidic potassium permanganate as a chemiluminescence reagent: A review. *Analytica Chimica Acta* 2014;807:9-28.
1308. Cameron RP, Yao AM, Barnett SM. Diffraction gratings for chiral molecules and their applications. *Journal of Physical Chemistry A* 2014;118(19):3472-3478.
1309. Woltmann E, Meyer H, Weigel D, Pritzke H, Posch TN, Kler PA, Schuermann K, Roscher J, Huhn C. Applicability of UV laser-induced solid-state fluorescence spectroscopy for characterization of solid dosage forms. *Analytical and Bioanalytical Chemistry* 2014;406(25):6347-6362.
1310. Aturki Z, Rocco A, Fanali S. Forensic drugs analysis: A review of miniaturized separation techniques. *LC-GC North America* 2015;33(10):786-795.
1311. Bell S, Nida C. Pyrolysis of drugs of abuse: A comprehensive review. *Drug Testing and Analysis* 2015;7(6):445-456.
1312. Cardell C, Guerra I. An overview of emerging hyphenated SEM-EDX and Raman spectroscopy systems: Applications in life, environmental and materials sciences. *TrAC, Trends in Analytical Chemistry* 2015: Ahead of Print.
1313. Kubán P, Hauser PC. Contactless conductivity detection for analytical techniques -

- Developments from 2012 to 2014. *Electrophoresis* 2015;36(1):195-211.
1314. Armstrong DW. Enhanced performance separations: Smaller, faster, more complex samples. *Analytical Chemistry* 2016;88(11):5561.
1315. Yadav NR. Prescription drug abuse and need of abuse deterrent formulations: An overview. *American Journal of PharmTech Research* 2013;3(3):153-169.
1316. Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. Development and impact of prescription opioid abuse deterrent formulation technologies. *Drug and Alcohol Dependence* 2014;138:1-6.
1317. Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. *Current Medical Research and Opinion* 2014;30(8):1589-1598.
1318. Schweighardt AE, Juba KM. Extended-release hydrocodone: The devil in disguise or just misunderstood? *Annals of Pharmacotherapy* 2014;48(10):1362-1365.
1319. Sellers EM, Shram MJ, Schoedel KA. The US FDA draft guidance for developing abuse-deterrent opioid analgesics: 2014 and beyond. *Pharmaceutical Medicine (Cham, Switzerland)* 2014;28(6):317-327.
1320. Tzschentke TM. Where do we stand in the field of anti-abuse drug discovery? *Expert Opinion on Drug Discovery* 2014;9(11):1255-1258.
1321. Victorri-Vigneau C, Collin C, Messina-Gourlot C, Raffournier C, Mallaret M, Besse J, Courne M-A, Richard N, Sebille V, Arnaud P. Designing a tool allowing for a standardized assessment of resistance to drug diversion. *Expert Opinion on Drug Delivery* 2014;11(7):995-1004.
1322. Meng L-p, Wang G-p, Yi B-x. Advance in the R&D of abuse-deterrent opioid analgesics. *Zhongguo Xinyao Zazhi* 2015;24(18):2110-2114,2121.
1323. Nguyen V, Raffa RB, Taylor R, Pergolizzi JV Jr. The role of abuse-deterrent formulations in countering opioid misuse and abuse. *Journal of Clinical Pharmacy and Therapeutics* 2015;40(6):629-634.
1324. Simon K, Worthy SL, Barnes MC, Tarbell B. Abuse-deterrent formulations:

Transitioning the pharmaceutical market to improve public health and safety.  
*Therapeutic Advances in Drug Safety* 2015;6(2):67-79.

1325. Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: Differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. *Pain* 2016;157(6):1232-1238.
1326. Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: A review and assessment of the potential impact of abuse-deterrent formulations. *Postgraduate Medicine* 2016;128(1):85-96.
1327. Gudin JA, Nalamachu SR. An overview of prodrug technology and its application for developing abuse-deterrent opioids. *Postgraduate Medicine* 2016;128(1):97-105.
1328. Vadivelu N, Schermer E, Kodumudi G, Berger JM. The clinical applications of extended-release abuse-deterrent opioids. *CNS Drugs* 2016;30(7):637-646.
1329. Xu X, Gupta A, Al-Ghabeish M, Calderon SN, Khan MA. Risk based in vitro performance assessment of extended release abuse deterrent formulations. *International Journal of Pharmaceutics* 2016;500(1-2):255-267.
1330. Koenka IJ, Mai TD, Hauser PC, Saiz J. Simultaneous separation of cations and anions in capillary electrophoresis - Recent applications. *Analytical Methods* 2016: Ahead of Print.
1331. Cho KT, Richardson MM, Kirkbride KP, McNevin D, Nelson M, Pianca D, Roffey P, Gahan ME. Recovery and identification of bacterial DNA from illicit drugs. *Forensic Science International* 2014;235:78-85.
1332. Griffith DJ, MacKintosh CL, Inverarity D. Staphylococcus aureus bacteraemia associated with injected new psychoactive substances. *Epidemiology and Infection* 2016;144(6):1257-1266.
1333. Kuiper I. Microbial forensics: Next-generation sequencing as catalyst. The use of new sequencing technologies to analyze whole microbial communities could become a powerful tool for forensic and criminal investigations. *EMBO Reports* 2016: Ahead of Print.
1334. Jezierski T, Adamkiewicz E, Walczak M, Sobczynska M, Gorecka-Bruzda A, Ensminger J, Papet E. Efficacy of drug detection by fully-trained police dogs varies by breed, training level, type of drug and search environment. *Forensic Science International*

2014;237:112-118.

1335. Wang D-w, Liu J-y, Liu G-q. Treatment and prevention of acute poisoning for sniffer dogs caused by new-type narcotics. *Zhongguo Shouyi Zazhi* 2014;50(9):97-99.
1336. Furton KG, Caraballo NI, Cerreta MM, Holness HK. Advances in the use of odour as forensic evidence through optimizing and standardizing instruments and canines. *Philosophical Transactions of the Royal Society of London. Series B. Biological Sciences* 2015;370(1674):(Page range not provided).
1337. Al-Obaidi TA, Fletcher SM. Management of clandestine drug laboratories: Need for evidence-based environmental health policies. *Environmental Health and Preventive Medicine* 2014;19(1):1-11.
1338. Kates LN, Knapp CW, Keenan HE. Acute and chronic environmental effects of clandestine methamphetamine waste. *Science of the Total Environment* 2014;493:781-788.
1339. Pal R, Megharaj M, Kirkbride KP, Naidu R. Adsorption and desorption characteristics of methamphetamine, 3,4-methylenedioxymethamphetamine, and pseudoephedrine in soils. *Environmental Science and Pollution Research* 2014: Ahead of Print.
1340. Van Hout MC. Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. *Drug Testing and Analysis* 2014;6(7-8):778-787.
1341. Mach PM, McBride EM, Sasiene ZJ, Brigance KR, Kennard SK, Wright KC, Verbeck GF. Vehicle-mounted portable mass spectrometry system for the covert detection via spatial analysis of clandestine methamphetamine laboratories. *Analytical Chemistry* 2015: Ahead of Print.
1342. Oudejans L, O'Kelly J, Evans AS, Wyrzykowska-Ceradini B, Touati A, Tabor D, Snyder EG. Decontamination of personal protective equipment and related materials contaminated with toxic industrial chemicals and chemical warfare agent surrogates. *Journal of Environmental Chemical Engineering* 2016;4(3):2745-2753.
1343. Blessy M, Patel RD, Prajapati PN, Agrawal Yk. Development of forced degradation and stability indicating studies of drugs. *Journal of Pharmaceutical Analysis* 2014;4(3):159-165.

1344. Maggio RM, Calvo NL, Vignaduzzo SE, Kaufman TS. Pharmaceutical impurities and degradation products: Uses and applications of NMR techniques. *Journal of Pharmaceutical and Biomedical Analysis* 2014;101:102-122.
1345. He J-m, Zheng Y-j, Gao Y, Zhang R-p, Wang H-q, Zeper A. A rapid resolution liquid chromatography-collision energy correlated mass spectrometric method for analysis of degradation products from drugs. *Fenxi Huaxue* 2015;43(4):479-483.
1346. Quinn C, Orr P, Rybolt T, Symes S. Stability-indicating UPLC-MS/MS assay for 1960's era pharmaceuticals in dosage forms. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-400.
1347. Frederick KA. Using forensic science to teach method development in the undergraduate analytical laboratory. *Analytical and Bioanalytical Chemistry* 2013: Ahead of Print.
1348. Ravgiala RR, Weisburd S, Sleeper R, Martinez A, Rozkiewicz D, Whitesides GM, Hollar KA. Using paper-based diagnostics with high school students to model forensic investigation and colorimetric analysis. *Journal of Chemical Education* 2013: Ahead of Print.
1349. Ahrenkiel L, Worm-Leonhard M. Offering a forensic science camp to introduce and engage high school students in interdisciplinary science topics. *Journal of Chemical Education* 2014;91(3):340-344.
1350. Boerner LK, Burks R, Hartings M, Jones C, Shanks K, Stemwedel JD, VanAlphen B. Combatting chemophobia: Speaking science to distrust and engaging with empathy, online, and face-to-face. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: CINF-68.
1351. Davis BA. Chemistry and crime: Educating non-science majors for citizenship. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: CHED-422.
1352. Donavant BW. Forensic praxis: Real learning, real world, real jobs. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-97.
1353. Marriott K-S. Forensic science: A theory for everything. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-585.

1354. McGill J. Birth and evolution of a forensic chemistry program (and a forensic chemist). Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-586.
1355. Meyer AF, Knutson CM, Finkenstaedt-Quinn SA, Gruba SM, Meyer BM, Thompson JW, Maurer-Jones MA, Halderman S, Tillman AS, DeStefano L, Haynes CL. Activities for middle school students to sleuth a chemistry "whodunit" and investigate the scientific method. *Journal of Chemical Education* 2014;91(3):410-413.
1356. Montgomery R. Forensic science: There is chemistry involved. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-584.
1357. Rouse BD, Schneider RL, Smith ET. Presumptive and confirmatory tests using analogs of illicit drugs: An undergraduate instrumental methods exercise. *Chemical Educator* 2014;19:70-72.
1358. Scott KD. Utilizing the "CSI Effect" in chemistry instruction. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-582.
1359. Starr T, Schoch W, Wallace-Duckworth D. Forensic science education: Beyond the college classroom. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-95.
1360. Triplett J. Toward a better partnership: Advancing researcher/practitioner partnerships in a post-NAS forensic world. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-212.
1361. Vance DE. FEPAC accreditation for forensic science programs. Abstracts, 66th Southeast Regional Meeting of the American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-96.
1362. Wouters K. Careers in chemistry: Forensics. Abstracts, 70th Southwest Regional Meeting of the American Chemical Society, Fort Worth, TX, United States, November 19-22, 2014: SWRM-224.
1363. Zuidema DR. Using The Poisoner's Handbook in conjunction with teaching a first-term general/organic/biochemistry course. Abstracts, 66th Southeast Regional Meeting of the

American Chemical Society, Nashville, TN, United States, October 16-19, 2014: SERMACS-456.

1364. Champion KE, Teesson M, Newton NC. Development of a universal internet-based prevention program for ecstasy and new psychoactive substances. *Open Journal of Preventive Medicine* 2015;5(1):23-30.
1365. Kloosterman A, Mapes A, Geradts Z, van Eijk E, Koper C, van den Berg J, Verheij S, van der Steen M, van Asten A. The interface between forensic science and technology: How technology could cause a paradigm shift in the role of forensic institutes in the criminal justice system. *Philosophical Transactions of the Royal Society, B: Biological Sciences* 2015;370(1674):1-10.
1366. Wallace Duckworth D. Case study review of a problem based learning approach used to educate and train young forensic scientists through the use of six sigma investigative tools. Abstracts of Papers, 250th ACS National Meeting & Exposition, Boston, MA, United States, August 16-20, 2015: CHED-481.
1367. Contakes SM. Misconduct at the lab? A performance task case study for teaching data analysis and critical thinking. *Journal of Chemical Education* 2016;93(2):314-317.
1368. Kraus H, Blackburn M, Rohan M, Railing M. Using "Drug of the Week" to educate chemistry students about prescription drugs and their abuse. Abstracts of Papers, 251st ACS National Meeting & Exposition, San Diego, CA, United States, March 13-17, 2016: CHED-774.
1369. Redden PA, Held M, Patel G. A novel way to create a crime scene for forensic chemistry. Abstracts, 44th Middle Atlantic Regional Meeting of the American Chemical Society, Riverdale, NY, United States, June 9-12, 2016: MARM-404.
1370. Dinis-Oliveira RJ. Heterogeneous and homogeneous immunoassays for drug analysis. *Bioanalysis* 2014;6(21):2877-2896.
1371. Krasowski MD, Ekins S. Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays. *Journal of Cheminformatics* 2014;6:22/1-22/13.
1372. Pranathi Reddy S, Swathi E, Jyothisri S, Siddartha Reddy T, Monica P, Sowjanya T. Detection techniques for eliminating pharmaceutical impurities: Focus on genotoxic

- impurities. *Journal of Scientific Research in Pharmacy* 2012;1(1):1-9.
1373. Kallam V, Nissankararao S, Bhimavarapu R, Renuka K, Silpa JN, Sravanthi SL. Retrospect of impurity profiling - An industry perspective. *International Journal of Inventions in Pharmaceutical Sciences* 2013;1(2):89-98.
1374. Landge AK, Deshmukh VK, Chaudhari SR. Impurities in pharmaceuticals - A review. *Current Pharma Research* 2013;4(1):1105-1116.
1375. Li S, Wang W, Tang H, Chen K, Yang J, He L, Ye H, Peng A, Chen L. Comparison of counter-current chromatography and preparative high performance liquid chromatography applied to separating minor impurities in drug preparations. *Journal of Chromatography A* 2014;1344:51-58.
1376. Chen X-y, Li Y-f, Lin X-y, Fan Y-d, Huang F-y, Jin C-d. Advances in researches on analysis of impurities in chemical drugs by LC-MS technology. *Xiandai Yaowu Yu Linchuang* 2014;29(6):696-700.
1377. Jadhav GP, Kasture VS, Pawar SS, Vadgaonkar AR, Lodha AP, Tuse SK, Kajale HR, Borbane SA. Drug impurity profiling: A scientific approach. *Journal of Pharmacy Research (Mohali, India)* 2014;8(6):696-706.
1378. Kamboj S, Kamboj N, Rawal RK, Thakkar A, Bhardwaj TR. A compendium of techniques for the analysis of pharmaceutical impurities. *Current Pharmaceutical Analysis* 2014;10(2):145-160.
1379. Prajapati P, Agrawal YK. Analysis and impurity identification in pharmaceuticals. *Reviews in Analytical Chemistry* 2014;33(2):123-133.
1380. Sharangi G, Lewits P, Appelblad P, Herzig B. Monograph modernization and impurity profiling methods for pharmaceutical drugs per current United States Pharmacopoeia guidelines. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ANYL-240.
1381. Galea C, Mangelings D, Heyden YV. Method development for impurity profiling in SFC: The selection of a dissimilar set of stationary phases. *Journal of Pharmaceutical and Biomedical Analysis* 2015: Ahead of Print.
1382. Holm R, Elder DP. Analytical advances in pharmaceutical impurity profiling. *European*

Journal of Pharmaceutical Sciences 2015: Ahead of Print.

1383. Hu C-q. Current situation and trend in impurity profiling of chemical drugs. *Zhongguo Xinyao Zazhi* 2015;24(15):1727-1734.
1384. Lemasson E, Bertin S, Hennig P, Boiteux H, Lesellier E, West C. Development of an achiral supercritical fluid chromatography method with ultraviolet absorbance and mass spectrometric detection for impurity profiling of drug candidates. Part I: Optimization of mobile phase composition. *Journal of Chromatography A* 2015;1408:217-226.
1385. Lemasson E, Bertin S, Hennig P, Boiteux H, Lesellier E, West C. Development of an achiral supercritical fluid chromatography method with ultraviolet absorbance and mass spectrometric detection for impurity profiling of drug candidates. Part II. Selection of an orthogonal set of stationary phases. *Journal of Chromatography A* 2015;1408:227-235.
1386. Murugan GLB. Profiling of impurities in pharmaceutical formulations. *International Journal of Pharmaceutical Sciences and Research* 2015;6(7):2709-2712.
1387. Stella GM, Geetha K, Ajitha A, Rao VUM. A review on impurity profiling. *European Journal of Biomedical and Pharmaceutical Sciences* 2015;2(5):646-659.
1388. Yue Y, Luo X, Zhong W, Hou W. Advances in researches on impurities in chemical drugs. *Yaoxue Jinzhan* 2015;39(7):533-539.
1389. Galea C, West C, Mangelings D, Vander Heyden Y. Is the solvation parameter model or its adaptations adequate to account for ionic interactions when characterizing stationary phases for drug impurity profiling with supercritical fluid chromatography? *Analytica Chimica Acta* 2016: Ahead of Print.
1390. van Amsterdam J, Nabben T, van den Brink W. Recreational nitrous oxide use: Prevalence and risks. *Regulatory Toxicology and Pharmacology* 2015: Ahead of Print.
1391. Witkowski MR, Carrabba MW. Examination of counterfeit pharmaceutical labels. *Infrared and Raman Spectroscopy in Forensic Science* 2012:573-582.
1392. Gan Y, Yin L, Shi X. A preliminary study on the influence of common drug packaging materials on nondestructive detecting by Raman spectrometry. *Zhongguo Yaoshi (Beijing, China)* 2013;27(12):1281-1284.

1393. McCabe KR, Tulleners FA, Braun JV, Currie G, Gorecho EN 3rd. A quantitative analysis of torn and cut duct tape physical end matching. *Journal of Forensic Sciences* 2013;58(Suppl 1):S34-S42.
1394. Pereira TMC, Junior JAQ, Ortiz RS, Rocha WFC, Endringer DC, Filgueiras PR, Poppi RJ, Romao W. Viagra and Cialis blister packaging fingerprinting using Fourier transform infrared spectroscopy (FTIR) allied with chemometric methods. *Analytical Methods* 2014;6(8):2722-2728.
1395. Zhang Y, Yu J, Xie M-x. Identification methods of stamp impressions. *Lihua Jianyan, Huaxue Fence* 2014;50(11):1470-1475.
1396. Hu X, Song J. DSC's application in the aspect of drug packaging. *Heilongjiang Yiyao* 2015;28(1):29-30.
1397. Jin H, Wang D, Hu K, Yu H. Determination of ethylene dichloride in drug packaging material of polyethylene dichloride by headspace GC-ECD. *Zhongguo Xiandai Yingyong Yaoxue* 2015;32(7):838-840.
1398. Calderon SN, Klein M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. *Neuropharmacology* 2014;87,:97-103.
1399. Pope SA, Erickson MS. Measurement of molecular structural similarity. Abstracts of Papers, 247th ACS National Meeting & Exposition, Dallas, TX, United States, March 16-20, 2014: CHED-1232.
1400. Smith L, Erickson MS. In search of objective measures of molecular structural similarity. Abstracts of Papers, 249th ACS National Meeting & Exposition, Denver, CO, United States, March 22-26, 2015: CHED-1152.
1401. Schaffer M, Groger T, Putz M, Zimmermann R. Forensic profiling of sassafras oils based on comprehensive two-dimensional gas chromatography. *Forensic Science International* 2013;229(1-3):108-115.
1402. Kavita G, Jaskaran S, Shukla SK. Drug of abuse: Precursor chemicals. *Research Journal of Chemical Sciences* 2015;5(5):89-91.
1403. Saputri FA, Mutakin M, Lestari K, Levita J. Determination of safrole in ethanol extract of nutmeg (*Myristica fragrans* Houtt) using reversed-phase high performance liquid

- chromatography. *International Journal of Chemistry* 2014;6(3):14-20.
1404. Zamengo L, Bettin C, Frison G, Gregio M, Sciarrone R. Drugs WorkBook (DWB): A tool for the analysis of illicit drugs in seized materials. *Science & Justice* 2013, Ahead of Print.
1405. Bovens M, Csesztregi T, Franc A, Nagy J, Dujourdy L. Sampling of illicit drugs for quantitative analysis - Part II. Study of particle size and its influence on mass reduction. *Forensic Science International* 2013: Ahead of Print.
1406. Csesztregi T, Bovens M, Dujourdy L, Franc A, Nagy J. Sampling of illicit drugs for quantitative analysis - Part III: Sampling plans and sample preparations. *Forensic Science International* 2014;241:212-219.
1407. Dujourdy L, Csesztregi T, Bovens M, Franc A, Nagy J. Sampling of illicit drugs for quantitative analysis. Part I: Heterogeneity study of illicit drugs in Europe. *Forensic Science International* 2013;231(1-3):249-256.
1408. Leitch O, Anderson A, Kirkbride KP, Lennard C. Biological organisms as volatile compound detectors: A review. *Forensic Science International* 2013;232(1-3):92-103.
1409. Hernandez PT, Naik AJT, Newton EJ, Hailes SMV, Parkin IP. Assessing the potential of metal oxide semiconducting gas sensors for illicit drug detection markers. *Journal of Materials Chemistry A: Materials for Energy and Sustainability* 2014;2(23):8952-8960.
1410. Olson D, Rains G. Use of a parasitic wasp as a biosensor. *Biosensors* 2014;4(2):150-160.
1411. Yanez-Sedeno P, Agui L, Villalonga R, Pingarron JM. Biosensors in forensic analysis. A review. *Analytica Chimica Acta* 2014;823:1-19.
1412. Schott M, Klein B, Vilcinskas A. Detection of illicit drugs by trained honeybees (*Apis mellifera*). *PLoS One* 2015;10(6):e0128528.
1413. Murray RC. Forensic examination of soils. *Forensic Chemistry Handbook* 2012:109-130.
1414. Woods B, Kirkbride KP, Lennard C, Robertson J. Soil examination for a forensic trace evidence laboratory - Part 2: Elemental analysis. *Forensic Science International*

- 2014;245:195-201.
1415. Woods B, Lennard C, Kirkbride KP, Robertson J. Soil examination for a forensic trace evidence laboratory - Part 1: Spectroscopic techniques. *Forensic Science International* 2014;245:187-194.
1416. Woods B, Lennard C, Kirkbride KP, Robertson J. Soil examination for a forensic trace evidence laboratory - Part 3: A proposed protocol for the effective triage and management of soil examinations. *Forensic Science International* 2016;262:46-55.
1417. Beck F, Guignard R, Legleye S. Does computer survey technology improve reports on alcohol and illicit drug use in the general population? A comparison between two surveys with different data collection modes in France. *PLoS One* 2014;9(1):e85810/1-e85810/11.
1418. Burns L, Roxburgh A, Bruno R, Van Buskirk J. Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. *Drug Testing and Analysis* 2014;6(7-8):840-845.
1419. Nizar H, Dargan PI, Wood DM. Using internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance 4-methylaminorex and 4,4'-dimethylaminorex. *Journal of Medical Toxicology* 2014:Ahead of Print.
1420. Singh I, Bard I, Jackson J. Robust resilience and substantial interest: A survey of pharmacological cognitive enhancement among university students in the UK and Ireland. *PLoS One* 2014;9(10):e105969/1-e105969/12.
1421. Ledberg A. The interest in eight new psychoactive substances before and after scheduling. *Drug and Alcohol Dependence* 2015:Ahead of Print.
1422. Taylor D, Bowden SG, Knorr R, Wilson DR, Proudfoot J, Dunlop AE. The Pistoia Alliance Controlled Substance Compliance Service Project: From start to finish. *Drug Discovery Today* 2015;20(2):175-180.
1423. Weber C, Kamber M, Lentillon-Kaestner V, Krug O, Thevis M. Seizures of doping substances at the Swiss Border - A descriptive investigation. *Forensic Science International* 2015;257:359-368.
1424. Jakubowski MJ, Beltis KJ, Drennan PM, Pindzola BA. Forensic collection of trace

- chemicals from diverse surfaces with strippable coatings. *Analyst* 2013;138(21):6398-6403.
1425. Jayaprakash PT. Practical relevance of pattern uniqueness in forensic science. *Forensic Science International* 2013:Ahead of Print.
1426. Bialonska A. From molecular recognition to racemic resolution by fractional crystallization of diastereomeric salts. *Wiadomosci Chemiczne* 2014;68(5-6):545-562.
1427. Frink LA, Weatherly CA, Armstrong DW. Water determination in active pharmaceutical ingredients using ionic liquid headspace gas chromatography and two different detection protocols. *Journal of Pharmaceutical and Biomedical Analysis* 2014;94:111-117.
1428. Heard D, Bobashev GV, Morris RJ. Reducing the complexity of an agent-based local heroin market model. *PLoS One* 2014;9(7):e102263/1-e102263/10.
1429. Suzuki Y. Scientific investigation and analytical chemistry (2). Examination trace physical evidence, artificial materials. *Bunseki* 2014;(2):63-68.
1430. Williams AJ, Tkachenko V, Pshenichnov A. Using an online database of chemical compounds for the purpose of structure identification. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, August 10-14, 2014: ANYL-354.
1431. Baechler S, Morelato M, Ribaux O, Beavis A, Tahtouh M, Kirkbride KP, Esseiva P, Margot P, Roux C. Forensic intelligence framework. Part II: Study of the main generic building blocks and challenges through the examples of illicit drugs and false identity documents monitoring. *Forensic Science International* 2015;250:44-52.
1432. Daveluy A, Geniaux H, Eiden C, Boucher A, Chenaf C, Deheul S, Spadari M, Gerardin M, Miremont-Salame G, Haramburu F. Illicit drugs or medicines taken by parachuting. *Fundamental & Clinical Pharmacology* 2015:Ahead of Print.
1433. Grantham NS, Reich BJ, Pacifici K, Laber EB, Menninger HL, Henley JB, Barberan A, Leff JW, Fierer N, Dunn RR. Fungi identify the geographic origin of dust samples. *PLoS One* 2015;10(4):e0122605/1-e0122605/13.
1434. Varlet V, Farsalinos K, Augsburger M, Thomas A, Etter J-F. Toxicity assessment of refill liquids for electronic cigarettes. *International Journal of Environmental Research*

and Public Health 2015;12(5):4796-4815.

\* \* \* \* \*